This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory and immune system disorders. Additionally, this invention relates to the use such compounds as probes for the localization of C5a receptors.

Background of the Invention C5a, a 74 amino acid peptide, is generated in the complement cascade by the cleavage of the complement protein C5 by the complement C5 convertase enzyme.

C5a has both anaphylatoxic (e. g., bronchoconstricting and vascular spasmogenic) and chemotactic effects. Therefore, it is active in engendering both the vascular and cellular phases of inflammatory responses. Because it is a plasma protein and, therefore, generally almost instantly available at a site of an inciting stimulus, it is a key mediator in terms of initiating the complex series of events that results in augmentation and amplification of an initial inflammatory stimulus. The anaphylatoxic and chemotactic effects of the C5a peptide are believed to be mediated through its interation with the C5a receptor (CD88 antigen), a 52 kD membrane bound G-protein coupled receptor (GPCR). C5a is a potent chemoattractant for polymorphonuclear leukocytes, bringing neutrophils, basophils, eosinophils and monocytes to sites of inflammation and/or cellular injury. C5a is one of the most potent chemotactic agents known for a wide variety of inflammatory cell types. C5a also"primes"or prepares neutrophils for various antibacterial functions, e. g., phagocytosis. Additionally, C5a stimulates the release of inflammatory mediators (e. g., histamines, TNF-ot, IL-1, IL-6, IL-8, prostaglandins, and leukotrienes) and the release of lysosomal enzymes and other cytotoxic components from granulocytes.

Among its other actions, C5a also promotes the production of activated oxygen radicals and the contraction of smooth muscle.

Considerable experimental evidence implicates increased levels of C5a in a number of autoimmune diseases and inflammatory and related disorders.

Antagonists that block the binding of C5a to its receptor or other agents, including inverse agonists, which modulate signal transduction associated with C5a-receptor interactions, can inhibit the pathogenic events, including chemotaxis, associated with anaphylatoxin activity contributing to such inflammatory and autoimmune conditions. Despite many attempts, no one has previously been able to provide any small molecule (less than 700 Daltons MW, or amu) non-peptide, non- peptidomimetic, non-peptoid, C5a antagonist that is essentially free of agonist activity at the C5a receptor and that exhibits a binding affinity for the C5a receptor of less than 1 micromolar, and preferably less than 100 nanomolar.

Description of Related Art Certain modified C5a peptides (i. e., modifications of C5a) have been identified as partial C5a antagonists and have been shown to block a number of C5a mediated actions including neutrophil chemotaxis, neutropenia and superoxide formation.

Various C5a peptidomimetic compounds have also been reported as modulating C5a activity, including cyclic peptoids (a peptoid is a peptidomimetic compound comprising an oligomeric assemblage of naturally occurring amino acids that have been N-substituted). Typically these C5a modulatory compounds exhibit a molecular weight greater than 500 Daltons, and generally greater than 700 Daltons.

SUMMARY OF THE INVENTION The present invention provides novel compounds that are small molecule C5a receptor antagonists that are non-peptide, non-peptidomimetic, and are preferably free of C5a receptor agonist activity, which compounds exhibit high affinity for the C5a receptor, i. e., an affinity constant for binding to the C5a receptor of less than 1 micromolar. Highly preferred compounds exhibit very high affinity for the C5a receptor, i. e., an affinity constant for binding to the C5a receptor of less than 100 nanomolar. Preferred compounds are C5a receptor antagonists (including inverse agonists). Preferred antagonists exhibit an antagonist EC50 (which as usd herein includes ICso) of less than 1 micromolar, preferably less than 100 nanomolar, in an assay of C5a mediated chemotaxis. Preferred C5a receptors are mammalian, preferably primate receptors, including human C5a receptors, and may either be cloned, recombinantly expressed receptors or naturally expressed receptors. In certain preferred embodiments, compounds of the invention exhibit an affinity for human C5a receptors that is higher than for rodent C5a receptors, preferably at least five times higher, more preferably ten times higher.

The compounds of the present invention do not interact with dopamine receptors with even moderate affinity, i. e., they do not bind to dopamine receptors with Ki values of less than 100 micromolar. Preferred compounds of the invention do not bind to any naturally occurring receptors other than C5a receptors with high affinity, and preferably they do not bind to any naturally occurring receptors other than C5a receptors with even moderate affinity.

In certain embodiments these compounds also possess one or more, and preferably two or more, three or more, four or more, or all of the following properties in that they are : 1) multi-aryl in structure (having a plurality of un-fused or fused aryl groups), 2) heteroaryl in structure, 3) orally available in vivo (such that a sub- lethal or preferably a pharmaceutically acceptable oral dose can provide a detectable in vivo effect such as a reduction of C5a-induced neutropenia), 4) comprised of fewer than four, preferably fewer than three, or fewer than two, or no amide bonds, and 5) capable of inhibiting leukocyte chemotaxis at nanomolar concentrations and preferably at sub-nanomolar concentrations.

In a highly preferred aspect, the invention provides non-peptidic, non- peptidomimetic, low molecular weight compounds that act as high affinity antagonists of the human C5a receptor. Specifically exemplified representative compounds include, but are not limited to optionally substituted arylimidazoles (i. e. imidazoles having one or more ring substituents of optionally substituted carbocyclic aryl or optionally substituted heteroaryl), optionally substituted arylpyridyls (i. e. pyridyls having one or more ring substituents of optionally substituted carbocyclic aryl or optionally substituted heteroaryl), optionally substituted aryl-substituted cycloalkylimidazoles (i. e. cycloalkylimidazoles having one or more ring substituents of optionally substituted carbocyclic aryl or optionally substituted heteroaryl), optionally substituted arylpyrazoles (i. e. pyrazoles having one or more ring substituents of optionally substituted carbocyclic aryl or optionally substituted heteroaryl), optionally substituted benzimidazoles, optionally substituted aryl-substituted tetrahydroisoquinolines (i. e. tetrahydroisoquinolines having one or more ring substituents of optionally substituted carbocyclic aryl or optionally substituted heteroaryl), and optionally substituted biaryl carboxamides (i. e. a carboxamide that has one or more optionally substituted bi-carboxylic aryl or heteroaryl substituents). Novel intermediates useful for synthesizing compounds of the invention are also provided.

Preferred compounds of the invention are compounds of Formula I, shown below, that bind specifically, and preferably with high affinity, to C5a receptors.

The invention also provides pharmaceutical compositions comprising compounds of the invention, including those of Formula I, including otppinally substituted arylimidazoles, optionally substituted arylpyridyls, optionally substituted aryl-substituted cycloalkylimidazoles, optionally substituted arylpyrazoles, optionally substituted benzimidazoles, optionally substituted aryl- substituted tetrahydroisoquinolines, and optionally substituted biaryl carboxamides.

The C5a receptor antagonist compounds described herein are particularly useful in the treatment of C5a-mediated inflammation, e. g., inflammation associated with various inflammatory and immune system disorders. The invention further comprises a method of treating a patient in need of such anti-inflammatory treatment or immune treatment an effective amount of a compound of the invention, e. g. an amount of a compound of the invention sufficient to yield a plasma concentration of the compound (or its active metabolite, if a pro-drug) high enough to inhibit white blood cell (e. g., neutrophil) chemotaxis in vitro. Treatment of humans, domesticated companion animals (pets) or livestock animals suffering such conditions with an effective amount of a compound of the invention is contemplated by the invention. For treating non-human animals of any particular species, a compound exhibiting high affinity for the C5a receptor of that particular species is preferred.

In a separate aspect, the invention provides methods of using compounds of the invention as positive controls in assays for receptor activity and using appropriately labeled compounds of the invention as probes for the localization of receptors, particularly C5a receptors, e. g., in tissue sections (e. g., via autoradiography) or in vivo (e. g., via positron emission tomography, PET, or single positron emission computed tomography, SPECT, scanning and imaging).

The invention provides compounds and compositions that are useful as inhibitors of C5a-mediated chemotaxis (e. g., they may be used as standards in assays of such chemotaxis). The invention additionally comprises methods of inhibiting C5a-mediated cellular chemotaxis, preferably leukocyte (e. g., neutrophil) chemotaxis. These methods comprise contacting white blood cells, particularly primate white blood cells, especially human white blood cells, with one or more compounds of the invention. Preferably the concentration is sufficient to inhibit chemotaxis of white blood cells in an in vitro chemotaxis assay, so that the levels of chemotaxis observed in a control assay (e. g., one to which a compound of the invention has not been added) are significantly higher (significantly here measured as ps0. 05 using a conventional parametric statistical analysis method such as a student's T-test) than the levels observed in an assay to which a compound of the invention has been added.

Accordingly, a broad aspect of the invention is directed to non-peptidic organic (carbon-containing) molecules, having a molecular mass of less than 700 amu, that exhibit C5a antagonist activity or C5a inverse agonist activity with an ECso of less than 500 nM in an assay of C5a mediated leukocyte chemotaxis.

More particularly the invention includes compounds of Formula I, Formula I wherein: AR1 and AR2 are independently carbocyclic aryl or heteroaryl ; LIP represents an alkyl, carbocyclic aryl, heteroaryl, or arylalkyl ; A is oxygen or nitrogen; di represents the distance between A and the geometric center of AR1 and is between 3 and 6 angstroms in at least one energetically accessible conformer of the compound; d2 represents the distance between A and the geometric center of AR2 and is between 5 and 10 angstroms in at least one energetically accessible conformer of the compound; and d3 represents the distance between A and the nearest atom of LIP and is between 3 and 6 angstroms in at least one energetically accessible conformer of the compound. Preferred compounds of Formula I exhibit antagonist (including inverse agonist) activity at C5a Receptors, and essentially no or little agonist activity at this receptor. Preferably such compounds contain one or more heteroaryl rings.

Preferred compounds of the invention exhibit good activity in standard in vitro C5 receptor mediated chemotaxis assay, specifically the assay as specified in Example 12, which follows and is defined below. Alternative preferred assays include the calcium mobilization assay. Preferred compounds of the invention exhibit an ECso of about 500 nM or less in such a standard C5a mediated chemotaxis assay, more preferably an ECso of about 200 nM or less in such a standard C5a mediated chemotaxis assay, still more preferably an ECso of about 100,50,25 and 10 nM in such a standard C5a mediated chemotaxis assay, even more preferably an ECso of about 5 nM in such a standard C5a mediated chemotaxis assay.

The invention includes additional methods such as methods for localizing C5a recerptors in tissue section samples, comprising cotacting a tissue sample with detectably labelled one or more compounds of the invention that are preferably detectably labeled, optionally washing the contacted tissue sample, and detecting the bound compound associated with the tissue sample. Suitable detectable labels include e. g. l25I, tritium, 32p, 99Tc or the like. A variety of detection methods could be employed include single emission photono computed tomography ("SPECT").

Other aspects of the invention are discussed infra.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is the sequence of SEQ ID NO-1.

DETAILED DESCRIPTION OF THE INVENTION Preferred compounds of the invention include carbon-containing molecules that comprise: i) having a molecular mass of less than 700 amu; ii) that is nonpeptidic; iii) that exhibits C5a antagonist activity or C5a inverse agonist activity with an ECso of less than 500 nM in an assay of C5a mediated leukocyte chemotaxis ; and iv) exhibits less than 10% intrinsic agonist activity in an assay of leukocyte chemotaxis.

Among such compounds, particularly preferred are those that contain one or more heteroaryl and/or carbocyclic rings. For example, preferred are compounds of the following formula: AR1 and AR2 are independently optionally substituted carbocyclic aryl or optionally substituted heteroaryl; LIP represents an optionally substituted alkyl, optionally substituted carbocyclic aryl, optionally substituted heteroaryl, or optionally substituted arylalkyl ; A is oxygen or nitrogen; dl represents the distance between A and the geometric center of AR1 and is between 3 and 6 angstroms in at least one energetically accessible conformer of the compound; d2 represents the distance between A and the geometric center of AR2 and is between 5 and 10 angstroms in at least one energetically accessible conformer of the compound; and d3 represents the distance between A and the nearest atom of LIP and is between 3 and 6 angstroms in at least one energetically accessible conformer of the compound.

Preferred compounds of the invention also include heterocycles of the following formula II : II or a pharmaceutically acceptable salt thereof, wherein the compound exhibits an ECso of luM or less in an assay of C5a mediated chemotaxis, wherein: the ring system represented by is a 5 to 7 membered heterocycle that may be either aromatic or partially unsaturated; X is N, C, or CR7, wherein R7 is hydrogen, hydroxy, halogen, amino, cyano, nitro, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted mono-or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted (cycloalkyl) alkyl ; Y is N or CH ; n is 0, 1, or 2 ; m is 0, 1, or 2 ; R and RI are independently chosen from hydrogen, hydroxy, halogen, amino, cyano, nitro, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted mono-or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl) alkyl, optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; R2, R3, R3A, R5, and R6 are independently selected from hydrogen, hydroxy, halogen, amino, cyano, nitro, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted mono-or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, and optionally substituted (cycloalkyl) alkyl; When n is 0, Ri and R3 may be joined to form a cycloalkyl or heterocycloalkyl ring, each of which may be optionally substituted; When n is 1, R and R3 may be joined to form a cycloalkyl or heterocycloalkyl ring, each of which may be optionally substituted; R4 is alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl each of which may be optionally substituted; or R4 is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; and Ari and Ar2 are independently optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms.

Preferred compounds of the above Formula II include those compounds wherein: R and Ri are independendently selected from i) hydrogen, halogen, hydroxy, amino, alkoxy, mono-or dialkylamino, cyano, nitro, haloalkyl, and ii) alkyl, alkenyl, alkynyl, cycloalkyl, and (cycloalkyl) alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono-or dialkylamino, iii) phenyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono-or dialkylamino ; R2, R3, R3A, R5, and R6 are independently selected from i) hydrogen, halogen, hydroxy, amino, alkoxy, mono-or dialkylamino, cyano, nitro, haloalkyl, and ii) alkyl, alkenyl, alkynyl, cycloalkyl, and (cycloalkyl) alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono-or dialkylamino ; R7 is hydrogen, hydroxy, halogen, amino, cyano, nitro, or haloalkyl, or R7 is alkoxy, mono-or dialkylamino, alkyl, alkenyl, alkynyl or (cycloalkyl) alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono-or dialkylamino; When n is 0, Ri and R3 may be joined to form a cycloalkyl or heterocycloalkyl ring, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, mono-or dialkylamino; When n is 1, R and R3 may be joined to form a cycloalkyl or heterocycloalkyl ring, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono-or dialkylamino ; R4 is alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono-or dialkylamino; or R4 is phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, mono-or dialkylamino, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or dialkylaminocarbonyl, N-alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, and 1-piperidyl; or R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono-or dialkylamino ; and Arl and Ar2 are independently chosen from i) phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, mono-or dialkylamino, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or dialkylaminocarbonyl, N-alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, and 1-piperidyl, and ii) bicyclic oxygen-containing groups of the formula: wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono-or dialkylamino.

Additional preferred compounds of the above formula II include those wherein R and Ri are independently selected from i) hydrogen, halogen, hydroxy, amino, Cl-C6 alkoxy, mono-or di (Cl- C6) alkylamino, cyano, nitro, haloalkyl, and ii) Cl-C8 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and (C3- C8) cycloalkyl) Cl-C3 alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono-or di (Cl- C6) alkylamino, iii) phenyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C8 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cl-C6 alkoxy, amino, and mono-or di (Ci-C6) alkylamino ; When n is 0, Ri and R3 may be joined to form a C3-C8 cycloalkyl or C3-C8 heterocycloalkyl ring, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cl-C6 alkoxy, amino, mono-or di (Cl- C6) alkylamino ; When n is 1, R and R3 may be joined to form a C3-C8 cycloalkyl or C3-C8 heterocycloalkyl ring, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cl-C6 alkoxy, amino, and mono-or di (Cl- C6)alkylamino; R2, R3, R3A, Rs, and R6 are independently selected from i) hydrogen, halogen, hydroxy, amino, C1-C6 alkoxy, mono-or di (Cl- C6) alkylamino, cyano, nitro, haloalkyl, and ii) C1-C8 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and (C3-C8 cycloalkyl) C1-C3 alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkoxy, amino, mono-or di (Cl- C6) alkylamino ; R7 is hydrogen, hydroxy, halogen, amino, cyano, nitro, or haloalkyl, R7 is alkoxy, mono-or di (Ci-C6) alkylamino, Cl-C6 alkyl, C2-C6alkenyl, C2-C6 alkynyl or (C3-C8cycloalkyl) C1-C3alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkoxy, amino, and mono-or di (C1-C6) alkylamino ; R4 is C1-C8 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, (C3-C8 cycloalkyl) Cl-C3 alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cl-C6 alkoxy, amino, and mono-or di (C1- C6) alkylamino ; or R4 is phenyl, phenyl (Ci-C4) alkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-C6 alkyl, Ca-Ce alkenyl, C2-C6 alkynyl, Cl-C6 alkoxy, amino, mono-or di (Ci-C6) alkylamino, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N- (Cl-C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, and 1- piperidyl; or R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl, Ca-Ce alkenyl, C2-C6 alkynyl, Cl-C6 alkoxy, amino, and mono-or di (Cl- C6) alkylamino ; and Arl and Ar2 are independently chosen from phenyl, phenyl (Cl-C4) alkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl, C2-C6 alkenyl, Ca-Ce alkynyl, Cl-C6 alkoxy, amino, mono-or di (Ci-C6) alkylamino, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N- (Ci- C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, and 1-piperidyl ; and ii) bicyclic oxygen-containing groups of the formula: wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (Cl- C6) alkylamino.

Still additional preferred compounds of the aboveformula II include those compounds of the following fomula: and additionally include those compounds of the following formula: m is 0, 1, or 2 ; Ri is chosen from hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono-or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl) alkyl, optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; R2, R3, R3A, Rs, and R6 are independently selected from hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono-or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, and optionally substituted (cycloalkyl) alkyl ; R4 is alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl each of which may be optionally substituted; or R4 is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; and Ar, and Ar2 are independently optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms.

Additional preferred compounds of the above formula II include those compounds of the following formula: wherein: Ri is hydrogen, Cl-C7 alkyl, halogen or phenyl optionally substituted with Cl-C6 alkyl, Ci-Ce alkoxy, halogen, hydroxy, amino, or mono-or di (Ci-C6) alkylamino; R2 is Ci-Ca alkyl or Cs-Cs cycloalkyl ; and R3 is hydrogen or Cl-C7 alkyl.

Additional preferred compounds of the above formula II include those compounds of the following formula: wherein: Arl is phenyl, phenylalkyl, thienyl, imidazolyl, pyridyl, pyrimidyl, benzodioxinyl, benzodioxolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, Cz-Ce alkenyl, C2-C6 alkynyl, Cl-C6 alkoxy, amino, mono-or di (Cl- C6)alkylamino; Ar2 is defined as in Claim 2; Ri is hydrogen, C1-C7 alkyl, halogen or phenyl optionally substituted with C1-C6 alkyl, Cl-C6 alkoxy, halogen, hydroxy, amino, or mono-or di (Cl-C6) alkylamino; R2 is Cl-Cs alkyl or Cs-Cs cycloalkyl ; and R3 is hydrogen or C1-C7 alkyl ; and R4 is Ci-Cs alkyl, C3-Cs cycloalkyl, or (Cs-Cs cycloalkyl) Cl-C3 alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cl-C6 alkoxy, amino, and mono-or di (Cl-C6) alkylamino.

Additional preferred compounds of the above formula II include those compounds of the following formula: wherein: Arl is phenyl, phenylalkyl, thienyl, imidazolyl, pyridyl, pyrimidyl, benzodioxinyl, benzodioxolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, amino, mono-or di (Cl- C6) alkylamino ; Ar2 is defined as in Claim 4; Rl is hydrogen, Cl-C7 alkyl, halogen or phenyl optionally substituted with Cl-C6 alkyl, C1-C6 alkoxy, halogen, hydroxy, amino, or mono-or di (Cl-C6) alkylamino; R2 is Ci-Cs alkyl or Cs-Cs cycloalkyl ; and R3 is hydrogen or Cl-C7 alkyl ; and R4 is phenyl, phenyl (Ci-C4) alkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl, C2-C6 alkenyl, Ca-Ce alkynyl, C1-C6 alkoxy, amino, mono-or di (Ci-C6) alkylamino; or R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, amino, and mono-or di (Cl- C6) alkylamino.

Additional preferred compounds of the above formula II include those compounds of the following formula: wherein: Arl is phenyl, phenylalkyl, thienyl, or pyridyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Ci-C6) alkylamino; Ar2 is defined as in formula II; Ri is hydrogen, methyl, ethyl, or optionally substituted phenyl; R2 is Cs-Cs alkyl or Cs-Cg cycloalkyl ; and R3 is hydrogen or methyl; and R4 is Ci-Cs alkyl, C3-C8 cycloalkyl, or (C3-C8 cycloalkyl) C1-C3 alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, Ca-Ce alkynyl, C1-C6 alkoxy, amino, and mono-or di (C1-C6) alkylamino.

Additional preferred compounds of the above formula II include those of the followingformula: wherein: Arl is phenyl, phenylalkyl, thienyl, or pyridyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Cl-C6) alkylamino ; Ar2 is defined as in Claim 4; Ri is hydrogen, methyl, ethyl, or phenyl; R2 is C3-C8 alkyl or Cs-Cs cycloalkyl ; and R3 is hydrogen or methyl; and R4 is phenyl, phenyl (Cl-C4) alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo [b] thiophenyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2- C6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Ci-C6) alkylamino; or R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (Cl- C6) alkylamino.

Still additional preferred compounds of the above formula Ii include of the following formula: wherein: Arl is phenyl, phenylalkyl, thienyl, or pyridyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cl-C6 alkoxy, amino, mono-or di (C1-C6) alkylamino; Ar2 is chosen from phenyl, phenyl (Ci-Ca) alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, and quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl, C2-C6 alkenyl, C2- C6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Cl-C6) alkylamino, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl- C6) alkylaminocarbonyl, N-(C1-C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1- pyrrolidinyl, and 1-piperidyl ; or Ar2 is a bicyclic oxygen-containing groups of the formula: wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cl-C6 alkoxy, amino, and mono-or di (Cl- C6)alkylamino; Ri is hydrogen, methyl, ethyl, or phenyl; R2 is C3-C8 alkyl or C3-C8 cycloalkyl ; and R3 is hydrogen or methyl; and R4 is Cl-C8 alkyl, C3-C8 cycloalkyl, or (C3-C8 cycloalkyl) Cl-C3 alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cl-C6 alkoxy, amino, and mono-or di (Cl-C6) alkylamino.

Still further preferred compounds of the above formula II include those of the followingformula: wherein: Arl is phenyl, phenyl (Ci-C4) alkyl, thienyl, or pyridyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, amino, mono-or di (Cl-C6) alkylamino; Ar2 is chosen from phenyl, phenyl (Ci-C4) alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, and quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, Ca- C6 alkynyl, C1-C6 alkoxy, amino, mono-or di (Cl-C6) alkylamino, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl- C6) alkylaminocarbonyl, N-(C1-C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1- pyrrolidinyl, and 1-piperidyl ; or Ar2 is a bicyclic oxygen-containing groups of the formula: wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cl-C6 alkoxy, amino, and mono-or di (Cl- C6) alkylamino ; Ri is hydrogen, methyl, ethyl, or phenyl; R2 is C3-C8 alkyl or C3-Cs cycloalkyl ; and R3 is hydrogen or methyl; and R4 is phenyl, phenyl (Ci-Ca) alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo [b] thiophenyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, Ca-Ce alkenyl, C2- C6 alkynyl, Cl-C6 alkoxy, amino, mono-or di (Cl-C6) alkylamino ; or R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl, Ca-Ce alkenyl, C2-C6 alkynyl, Cl-C6 alkoxy, amino, and mono-or di (Ci- C6) alkylamino.

Preferred compounds of the invention also include those of the following formula III: or a pharmaceutically acceptable salt thereof, wherein: Arl is phenyl, phenyl (Cl-C4) alkyl, thienyl, or pyridyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (C1-C6) alkylamino ; Ar2 is a bicyclic oxygen-containing groups of the formula: wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (C1- C6) alkylamino ; Ri is selected from i) hydrogen, halogen, hydroxy, amino, Cl-C6 alkoxy, mono-or di (Cl- C6) alkylamino, cyano, nitro, haloalkyl, and ii) C1-Cs alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and (C3- C8) cycloalkyl) Cl-C3 alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono-or di (Ci- C6) alkylamino; or Ri is selected from phenyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C8 alkyl, Ca-Ce alkenyl, Ca-Ce alkynyl, Ci-Ce alkoxy, amino, and mono-or di (Cl- C6) alkylamino ; R2 and R3 are independently selected from i) hydrogen, halogen, hydroxy, amino, Ci-Ce alkoxy, mono-or di (Cl- C6) alkylamino, cyano, nitro, haloalkyl, and ii) Ci-C8 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and (C3-Cs cycloalkyl) Cl-C3 alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkoxy, amino, mono-or di (C1- C6) alkylamino; and R4 is C1-C8 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, 3-C8 cycloalkyl, (C3-Cs cycloalkyl) Cl- C3 alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cl-C6 alkoxy, amino, and mono-or di (Cl- C6) alkylamino; or R4 is phenyl, phenyl (CI-C4) alkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, amino, mono-or di (Cl-C6) alkylamino, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N- (Ci-C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, and 1- piperidyl; or R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, Ca-Ce alkenyl, C2-C6 alkynyl, Cl-C6 alkoxy, amino, and mono-or di (Cl-C6) alkylamino.

Preferred compounds of the above formula III include those wherein: Ri is hydrogen, methyl, ethyl, or phenyl; R2 is Cg-Cg alkyl or C3-C8 cycloalkyl ; R3 is hydrogen or methyl; and R4 is C1-C8 alkyl, C2-C6 alkenyl, Ca-Ce alkynyl, C3-C8 cycloalkyl, (C3-C8 cycloalkyl) C1- C3 alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl, C2-C6 alkenyl, C2- C6 alkynyl, C1-C6 alkoxy, amino, and mono-or di (Cl-C6) alkylamino.

Additional preferred compounds of formula III include those wherein: Ri is hydrogen, methyl, ethyl, or phenyl; R2 is C3-C8 alkyl or C3-Cs cycloalkyl ; R3 is hydrogen or methyl; and R4 C1-C8 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, (C3-C89 cycloalkyl) C1- C3 alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl, C2-C6 alkenyl, C2- C6 alkynyl, C1-C6 alkoxy, amino, and mono-or di (Cl-C6) alkylamino.

Still additional preferred compounds of formula III above include those wherein: Ri is hydrogen, methyl, ethyl, or phenyl; R2 is C3-C8 alkyl or C3-C8 cycloalkyl ; R3 is hydrogen or methyl; and phenyl, phenyl (Cl-C4) alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo [b] thiophenyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, Ca-Ce alkynyl, C1-C6 alkoxy, amino, mono-or di (Cl-C6) alkylamino.

Preferred compounds of formula III above also include those wherein: Ri is hydrogen, methyl, ethyl, or phenyl; R2 is C3-C8 alkyl or C3-C8 cycloalkyl ; R3 is hydrogen or methyl; and R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (Cl- Ce) alkylamino.

The invention also includes compounds of the following formula IV: or a pharmaceutically acceptable salt thereof, wherein: n is an integer from 0 to 3; and R2 is hydrogen or alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl, or haloalkyl, each or which may be substituted or unsubstituted; R4 is hydrogen or alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl, haloalkyl, each or which may be substituted or unsubstituted; or R4 is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 hetero atoms, R3 and R3A are the same or different and represent hydrogen or alkyl ; or R3 and R3A, taken together with the carbon atom to which they are attached, form a cycloalkyl ring; R5 and R6 are the same or different and represent hydrogen, halogen, hydroxy, alkyl, or alkoxy; or R, and R6, taken together with the carbon atom to which they are attached form a cycloalkyl ring; R5a and R6a are the same or different, and are independently selected at each occurrence from hydrogen, halogen, hydroxy, alkyl, and alkoxy ; R7 represents hydrogen or alkyl ; Arl and Ar2 are independently optionally substituted carbocyclic aryl, optionally substituted arylalkyl, or an optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 hetero atoms.

Also preferred are compounds of that formula IV above (such preferred compounds referred to as compounds of formula IV-A) wherein n, R3, R3A, R5, R6, R5a, Pea, and R7 are as defined in that formula IV, and R2 is hydrogen or alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl, or haloalkyl, each or which unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluormethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono-or dialkylamino; R4 is hydrogen or alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino and mono-or dialkylamino, R4 is phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, mono-or dialkylamino, aminoalkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or dialkylaminocarbonyl, N- alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl and- XRg, wherein X and RB are as defined below; or R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono-or dialkylamino; Arl and Ar2 are independently chosen from i) phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, mono-or dialkylamino, aminoalkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or dialkylaminocarbonyl, N- alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl and- XRB, wherein X and RB are as defined below;, and ii) bicyclic oxygen-containing groups of the formula: wherein Rs represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono-or dialkylamino; X is independently selected at each occurrence from the group consisting of-CH2-,- CHRc-,-O-,-S (O) m-,-NH-,-NRc-,-C (=O) NH-,-C (=O) NRc-,-S (O) mNH-,-S (O) mNRc-, -NHC(=O)-, -NRcC(=O)-, -NHS(O)m-, -C(=O) NHS (O) m-, and-NRcS (O) m- (where m is 0,1, or 2); and Ra and Rc, which may be the same or different, are independently selected at each occurrence from the group consisting of : hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent (s) selected from: oxo, hydroxy,-O (alkyl),-NH (alkyl), - N (alkyl) (alkyl),-NHC (O) (alkyl),-N (alkyl) C (O) (alkyl),-NHS (O)x (alkyl),-S (O) x (alkyl),- S (O) xNH (alkyl),-S (O) xN (alkyl) (alkyl), (where x is 0, 1, or 2).

Also preferred are compounds of formula IV above wherein (such preferred compounds referred to as compounds of formula IV-B) n is defined as in formula IV above, and R3 and R3A are the same or different and represent hydrogen or Cl-C6 alkyl ; or R3 and R3A, taken together with the carbon atom to which they are attached, form a C3-8 cycloalkyl ring; R5 and R6 are the same or different and represent hydrogen, halogen, hydroxy, Ci-Ce alkyl, or Ci-Ce alkoxy; or R5 and R6, taken together with the carbon atom to which they are attached form a C3-8 cycloalkyl ring; R5a and R6b are the same or different, and are independently selected at each occurrence from hydrogen, halogen, hydroxy, Ci-Ce alkyl, and Ci-Ce alkoxy; R2 is hydrogen or C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalkyl, (C3-8 cycloalkyl) C1-3 alkyl, or Ci- C6 haloalkyl, each or which unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluormethyl, trifluoromethoxy, Cl-3 haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono-or di (Ci-C6) alkylamino; R4 is hydrogen or C1-8 alkyl, C2-8 alkenyl, 2-8 alkynyl, C3 8cycloalkyl, (C3-8 cycloalkyl) C1-4alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Cl-C6 alkoxy, amino and mono-or di (Ci-C6) alkylamino, R4 is phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-C6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Cl-C6) alkylamino, amino (Ci-C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N- ( Cl-C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl,- XRs, wherein X and RB are as defined below; or R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (Cl- C6) alkylamino ; Arl and Ar2 are independently chosen from i) phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, Cz-6 alkynyl, Ci-C6 alkoxy, amino, mono-or di (Cl-C6) alkylamino, amino (Cl-C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N- ( Cl-C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl, and-XRs, wherein X and RB are as defined below; and ii) bicyclic oxygen-containing groups of the formula: wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, C2-6 alkynyl, Cl-C6 alkoxy, amino, and mono-or di (Cl- C6)alkylamino; X is independently selected at each occurrence from the group consisting of-CH2-,- CHRc-,-0-,-S (O) m-,-NH-,-NRc-,-C (=O) NH-,-C (=O) NRc-,-S (O) NH-,-S (O) mNRc-, -NHC (=O)-, - NRcC (=O)-,-NHS (O) m-,-C (=O) NHS (O) m-, and-NRcS (O) m- (where m is 0,1, or 2); and RB and Rc, which may be the same or different, are independently selected at each occurrence from the group consisting of : hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent (s) selected from: oxo, hydroxy, -O (Ci-C6 alkyl),-NH (Ci-C6 alkyl), -N(C1-C6 alkyl)(C1-C6 alkyl), -NHC(O)(C1-C6 alkyl),-N(C1-C6 alkyl) C (O) (Ci-6 alkyl),-NHS (O) x (Cl-C6 alkyl),-S (O) x (Ci-C6 alkyl),- S (O) xNH (C1-C6 alkyl), -S (O) xN (Cl-C6 alkyl) ( Cl-C6 alkyl), (where x is 0,1, or 2).

Also preferred are compounds of formula IV above (such preferred referred to as compounds of formula IV-C) wherein n, R2, R3, R3A, Rs, R6, Rsa, Pea, and R7 are as defined in formula IV above, R4 is hydrogen or Cl-Cs alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8cycloalkyl, (C3-C8cycloalkyl) Cl-C4alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, Ca-Ce alkynyl, C1-C6 alkoxy, amino and mono-or di 9C1- C6) alkylamino, R4 is phenyl, naphthyl, thienyl, pyridyl, pyrimidyl, dihydrobenzofuranyl, furanyl, benzodioxanyl, indolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, amino, mono-or di (C1-C6) alkylamino, amino (Cl-C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N- (Ci- C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl,- XRB, wherein X and RB are as defined below; or R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (Cl- C6) alkylamino ; Arl is phenyl, thienyl, or pyridyl, pyrimidyl, dihydrobenzofuranyl, furanyl, benzodioxanyl, indolyl, each of which is unsubstituted or substituted with up to four substituents independently selected from: halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, amino, mono-or di (C1-C6 alkylamino, amino (Ci-C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (C1- C6) alkylaminocarbonyl, N- (CI-C6) alkylsulfonylaminocarbonyl, 1- azetidinyl, 1-pyrrolidinyl, 1-piperidyl, and-XRs, wherein X and RB are as defined below; Ar2 is phenyl, naphthyl, thienyl, pyridyl, pyrimidyl, dihydrobenzofuranyl, furanyl, benzodioxanyl, indolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (C1-C6) alkylamino, amino (C1-C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (C1-C6) alkylaminocarbonyl, N-(C1- C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl, and- XRB, wherein X and Rs are as defined below; or Ar2 is a bicyclic oxygen-containing group of the formula: wherein RA'represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (Cl- C6) alkylamino ; X is independently selected at each occurrence from the group consisting of-CH2-,- CHRc-,-O-,-S (O) m-,-NH-,-NRc-,-C (=O) NH-,-C (=O) NRc-,-S (O) mNH-,-S (O) mNRc-, -NHC(=O)-, -NRCC(=O)-, -NHS(O)m-, -C(=O) NHS (O) m-, and-NRcS (O) m- (where m is 0,1, or 2) ; and RB and Rc, which may be the same or different, are independently selected at each occurrence from the group consisting of : hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent (s) selected from: oxo, hydroxy, -O (Ci-Ce alkyl),-NH (Cl-C6 alkyl), - N (C1-C6 alkyl) (Cl-C6 alkyl),-NHC (O) (C1-C6 alkyl),-N (Cl-C6 alkyl) C (O) (Ci-C6 alkyl),-NHS (O) x (C1-C6 alkyl),-S (O) x (Cl-C6 alkyl),- S (O) xNH (Ci-Ce alkyl), -S (O) xN (C1-C6 alkyl) (C1-C6 alkyl), (where x is 0,1, or 2).

Further preferred are compounds of the above formula IV-C wherein: R3 and R4 are the same or different and represent hydrogen or methyl; R5 and R6 are the same or different and represent hydrogen or methyl; and Rsa and R6a are the same or different, and are independently selected at each occurrence from hydrogen and methyl.

Further preferred are compounds of the above formula IV-C wherein: R3 and R4 are hydrogen; R5 and R6 are the same or different and represent hydrogen or methyl; and Rsa and R6a are the same or different, and are independently selected at each occurrence from hydrogen and methyl.

Further preferred are compounds of the above formula IV-C wherein: or a pharmaceutically acceptable salt thereof, wherein: n is an integer from 0 to 3; and R2 is hydrogen or alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl, or haloalkyl, each or which may be substituted or unsubstituted; R4 is hydrogen or C1-Cs alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8cycloalkyl, (C3-C8cycloalkyl) Cl-C4alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino and mono-or di (C1- C6)alkylamino, R4 is phenyl, naphthyl, thienyl, pyridyl, pyrimidyl, dihydrobenzofuranyl, furanyl, benzodioxanyl, indolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, Ca-Ce alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, amino, mono-or di (Cl-C6) alkylamino, amino (C1-C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N- (Cl- C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl,- XRs, wherein X and RB are as defined below; or R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, amino, and mono-or di (C1- C6) alkylamino ; Ar2 is phenyl, naphthyl, thienyl, pyridyl, pyrimidyl, dihydrobenzofuranyl, furanyl, benzodioxanyl, indolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, Ca-Ce alkynyl, Ci-Ce alkoxy, amino, mono-or di (Cl-C6) alkylamino, amino (Ci-C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N-(C1- C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl, and- XRB, wherein X and RB are as defined below; or Ar2 is a bicyclic oxygen-containing group of the formula: wherein RA'represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (C1- C6) alkylamino ; X is independently selected at each occurrence from the group consisting of-CH2-,- CHRc-,-O-,-S (O)m-, -H-, -NRC-, -C(=O)NH-, -C(O)NRC-, -S(O)mNH-, -S(O)mNRC-, - NHC (=O)-, -NRcC (=O)-,-NHS (O) m-,-C (=O) NHS (O) m-, and-NRcS (O) m- (where m is 0,1, or 2); and RB and Rc, which may be the same or different, are independently selected at each occurrence from the group consisting of : hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent (s) selected from: oxo, hydroxy, -O (Ci-C6 alkyl),-NH (C1-C6 alkyl), - N (Ci-C6 alkyl) (Ci-C6 alkyl),-NHC (O) (Ci-C6 alkyl),-N (Ci-C6 alkyl)C(O)(C1-C6 alkyl), -NHS(O)x(C1-C6 alkyl), -S(O)x(C1-C6 alkyl), - S (O) NH (C1-C6 alkyl),-S (O) xN (C1-C6 alkyl) (C1-C6 alkyl), (where x is 0,1, or2).

Rs and R6 are the same or different and represent hydrogen or methyl; Rsa and R6a are the same or different, and are independently chosen at each occurrence from hydrogen and methyl; and Rx represents up to four substituents independently chosen from hydrogen, halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (C1-C6) alkylamino, and amino (Cl-C6) alkoxy.

Further preferred are compounds of the above formula IV-C wherein: or a pharmaceutically acceptable salt thereof, wherein: n is an integer from 0 to 3; and R4 is hydrogen or Cl-C$ alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Cs-Cscycloalkyl, (C3-C8cycloalkyl) C1-C4alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, amino and mono-or di (Cl- C6) alkylamino, R4 is phenyl, naphthyl, thienyl, pyridyl, pyrimidyl, dihydrobenzofuranyl, furanyl, benzodioxanyl, indolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (C1-C6) alkylamino, amino (C1-C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N- (Ci- C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl,- XRs, wherein X and RB are as defined below; or R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, amino, and mono-or di (Cl- C6)alkylamino; Ar2 is phenyl, naphthyl, thienyl, pyridyl, pyrimidyl, dihydrobenzofuranyl, furanyl, benzodioxanyl, indolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Cl-C6) alkylamino, amino (Cl-C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (C1-C6) alkylaminocarbonyl, N- (Cl- C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl, and- XRs, wherein X and RB are as defined below; or Ar2 is a bicyclic oxygen-containing group of the formula: wherein RA'represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (C1- C6) alkylamino ; X is independently selected at each occurrence from the group consisting of-CH2-,- CHRc-,-O-,-S (O) m-,-NH-,-NRc-,-C (=O) NH-,-C (=O) NRc-,-S (O) mNH-, -S(O)mNRC-, -NHC(=O)-, -NRcC (=O)-,-NHS (O) m-,-C (=O) NHS (O) m-, and-NRcS (O) m- (where m is 0,1, or 2); and RB and Rc, which may be the same or different, are independently selected at each occurrence from the group consisting of : hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent (s) selected from: oxo, hydroxy,-O (Ci-Ce alkyl),-NH (Ci-Ce alkyl), - N (Ci-C6 alkyl) (C1-C6 alkyl),-NHC (O) (Ci-Ce alkyl),-N (C1-C6 alkyl) C (O) (C1-C6 alkyl),-NHS (O) x (C1-C6 alkyl), -S(O)x(C1-C6 alkyl),- S (O) xNH (C1-C6 alkyl),-S (O) N (Ci-C6 alkyl) (C1-C6 alkyl), (where x is 0,1, or 2).

R2 is C3-C8 straight or branched chain alkyl, C2-C8 alkenyl, or C2-C8 alkynyl; Rs and R6 are the same or different and represent hydrogen or methyl; Rsa and R6a are the same or different, and are independently chosen at each occurrence from hydrogen and methyl; and Rx represents up to four substituents independently chosen from hydrogen, halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Cl-C6) alkylamino, and amino (Cl-C6) alkoxy.

Further preferred are compounds of the above formula IV-C wherein: Ar2, Rx, and n are as defined in formula IV-C, or a pharmaceutically acceptable salt thereof, wherein: R2 is C3-C8 straight or branched chain alkyl, C2-C8 alkenyl, or C2-C8 alkynyl; and R4 is Cl-C8 straight or branched chain alkyl, C2-C8 alkenyl, or Ca-Cg alkynyl.

Further preferred are compounds of the above formula IV-C, or a pharmaceutically acceptable salt thereof, wherein: R2 is Cs-Cs straight or branched chain alkyl, C2-C8 alkenyl, or C2-C8 alkynyl; R4 is phenyl, which may be unsubstituted or substituted with: Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cg-Cs cycloalkyi, (Cg-Cg cycloalkyl) Ci-C4 alkyl, haloalkyl, Ci-Ce alkoxy, halogen, hydroxy, amino, or mono-or di (C1-C6) alkylamino; or R4 is a bicyclic oxygen containing group of the formula: wherein RA is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, (C3-C8cycloalkyl) C1-C4 alkyl, haloalkyl, alkoxy, halogen, hydroxy, amino, or mono-or di (C1-C6) alkylamino ; Ar2 is phenyl which is unsubstituted or optionally substituted or substituted with up to four groups independently selected from: halogen, Ci-C alkyl, C1-C7 alkoxy, cyano, amino, mono-or di (Cl- C6) alkylamino, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or dialkylaminocarbonyl, N- alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl, 1-morpholino, nitro, hydroxy, acetoxy, trifluoromethyl, and trifluoromethoxy or-XRs, wherein X and RB are as defined for formula IV-C; or Ar2 is a bicyclic oxygen-containing group of the formula: wherein RA, RA', and n are as defined in formula IV-C.

Also preferred are compounds of formula IV-C as specified above, wherein: n is an integer from 0 to 3; R2 is C3-Cs straight or branched chain alkyl, C2-C8 alkenyl, or C2-Cs alkynyl; R4 is Ci-Cs straight or branched chain alkyl, C2-C8 alkenyl, or C2-C8 alkynyl; Ar2 is a bicyclic oxygen containing group of the formula: wherein RA'represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (Cl- C6) alkylamino.

Additional preferred compounds include those of the following formula V: wherein: n is an integer from 0 to 3; R3 and R3A are the same or different and represent hydrogen, halogen, hydroxy, alkyl, or alkoxy; or R3 and R3A, taken together with the carbon atom to which they are attached, form a cycloalkyl ring; R5 and R6 are the same or different and represent hydrogen, halogen, hydroxy, alkyl, or alkoxy; or R, and R6, taken together with the carbon atom to which they are attached form a cycloalkyl ring; and R5A and R6A are the same or different and represent hydrogen, halogen, hydroxy, alkyl, or alkoxy.

Preferred compounds of formula V include those compounds wherein: R3 and R3A are the same or different and represent hydrogen or Ci-Ce alkyl ; or R3 and R3A, taken together with the carbon atom to which they are attached, form a cycloalkyl ring of from three to six carbon atoms; R5 and R6 are the same or different and represent hydrogen, halogen, hydroxy, C1-C6 alkyl, or Ci-Ce alkoxy; or R5 and R6, taken together with the carbon atom to which they are attached form a cycloalkyl ring of from three to six carbon atoms; and R5A and R6A are the same or different and represent hydrogen, halogen, hydroxy, Ci- C6 alkyl, or Ci-Ce alkoxy.

Preferred compounds of formula V include thosae compounds wherein: R3 and R4 are hydrogen; and R5, R6, R5A, and R6A are the same or different and represent hydrogen or methyl.

The invention also includes compounds of the following formula VI: wherein: n is an integer from 0 to 3; R2 is alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl, or haloalkyl, each of which may be substituted or unsubstituted; R3 and R4 are the same or different and represent hydrogen or alkyl ; or R3 and R3a, taken together with the carbon atom to which they are attached, form a cycloalkyl ring; Rs and R6 are the same or different and represent hydrogen, halogen, hydroxy, alkyl, or alkoxy; or Rs and R6, taken together with the carbon atom to which they are attached, form a cycloalkyl ring; R5A and R6A are the same or different and represent hydrogen, halogen, hydroxy, alkyl, or alkoxy; and Arl is unsubstituted or substituted carbocyclic aryl, unsubstituted or substituted arylalkyl, or a unsubstituted or substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 hetero atoms.

Preferred compounds of formula VI include those compounds wherein: R2 is Cl-C8 straight or branched chain alkyl, C2-C8 alkenyl, Cz-Cs alkynyl, Cs-Cs cycloalkyl, C2-C8 (cycloalkyl) Ci-Ca. alkyl, or Ci-Cs haloalkyl ; R3 and Rsa are the same or different and represent hydrogen or C1-C6 alkyl ; or R3 and Rsa, taken together with the carbon atom to which they are attached, form a cycloalkyl ring of from three to six carbon atoms; and Rs and R6 are the same or different and represent hydrogen, halogen, hydroxy, C1-C6 alkyl, or C1-C6 alkoxy; or Rs and R6, taken together with the carbon atom to which they are attached form a cycloalkyl ring of from three to six carbon atoms; R5A and R6A are the same or different and represent hydrogen, halogen, hydroxy, Ci- C6 alkyl, or Ci-Ce alkoxy; Arl is phenyl, thienyl, or pyridyl, pyrimidyl, dihydrobenzofuranyl, furanyl, benzodioxanyl, indolyl, each of which is unsubstituted or substituted with up to four substituents independently selected from: halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, amino, mono-or di (Cl-C6) alkylamino, amino (C1-C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl- C6) alkylaminocarbonyl, N-(C1-C6) alkylsulfonylaminocarbonyl, 1- azetidinyl, 1-pyrrolidinyl, 1-piperidyl, and-XRs, wherein X and Rs are as defined below; X is independently selected at each occurrence from the group consisting of-CH2-,- CHRc-,-O-,-S (O) m,-NH-,-NRc-,-C (=O) NH-,-C (=O) NRc-,-S (O) mNH-,- S (O) mNRc-,-NHC (=O)-,-NRcC (=O)-,-NHS (O) m-,-C (=O) NHS (O) m-, and- NRcS (O) m- (where m is 0,1, or 2); and Ra and RC, which may be the same or different, are independently selected at each occurrence from the group consisting of : hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent (s) selected from: oxo, hydroxy,-O (C1-C6 alkyl),-NH (Ci-Ce alkyl), -N(C1-C6 alkyl)(C1-C6 alkl), -NHC(O)(C1-C6 alkyl), -N(C1-C6 alkyl) C (O) (C1-C6 alkyl),-NHS (O)x(C1-C6 alkyl), -S(O)x(C1-C6 alkyl),- S (O) XNH (C1-C6 alkyl),-S (O) XN (C1-C6 alkyl) (C1-C6 alkyl), (where x is 0,1, or 2).

Preferred compounds of the above formula VI include those of the following formula: wherein: n is 0, 1, or 2 : R2 is C3-C8 straight or branched chain alkyl, C2-C8 alkenyl, or C2-C8 alkynyl; Rs, R6, RsA, and R6A are the same or different and represent hydrogen or methyl; and Rx represents up to four substituents independently chosen from hydrogen, halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Cl-C6 alkoxy, amino, mono-or di (Cl-C6) alkylamino, and amino (C1-C6) alkoxy.

The invention also includes compounds of the following formula VII: n is an integer from 0 to 3; and Ra is alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl, haloalkyl, each or which may be substituted or unsubstituted; R3 and R3A are the same or different and represent hydrogen or alkyl ; or R3 and R3a, taken together with the carbon atom to which they are attached, form a cycloalkylring; R5 and R6 are the same or different and represent hydrogen or alkyl ; or R5 and R6, taken together with the carbon atom to which they are attached, form a cycloalkylring; Rsa and R6a are the same or different, and are independently selected at each occurrence from hydrogen, halogen, hydroxy, alkyl, and alkoxy ; R7 represents hydrogen or alkyl ; and Arl is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, or an optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 hetero atoms.

Preferred compounds of formula VII include those of the following formula: wherein: n is an integer from 0 to 3; Ra is C3-C8 straight or branched chain alkyl, Cs-Cs alkenyl, or C2-C8 alkynyl; R5, R6, R5A, and R6A are the same or different and represent hydrogen or methyl; and Rx represents up to four substituents independently chosen from hydrogen, halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C8 alkenyl, Ca-Cs alkynyl, Ci-Ce alkoxy, amino, mono-or di (Cl-C6) alkylamino, and amino (Ci-C6) alkoxy.

The invention also includes methods of syntesis of compounds of the invention. In particular, the invention includes methods to synthesis compounds of the following formula VIII : wherein: n is an integer from 0 to 3; and R2 is hydrogen or alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl, or haloalkyl, each or which may be substituted or unsubstituted; R4 is hydrogen or alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl, haloalkyl, each or which may be substituted or unsubstituted; or R4 is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 hetero atoms, R3 and R3A are the same or different and represent hydrogen or alkyl ; or R3 and R3A, taken together with the carbon atom to which they are attached, form a cycloalkyl ring; Rs and R6 are the same or different and represent hydrogen, halogen, hydroxy, alkyl, or alkoxy; or R5 and R6, taken together with the carbon atom to which they are attached form a cycloalkylring; Rsa and R6a are the same or different, and are independently selected at each occurrence from hydrogen, halogen, hydroxy, alkyl, and alkoxy; R7 represents hydrogen or alkyl ; Arl and Ar2 are independently optionally substituted carbocyclic aryl, optionally substituted arylalkyl, or an optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 hetero atoms. the process comprising: reacting a compound of the formula: wherein Y is halogen or sulfonate ester, in a suitable solvent in the presence of a suitable base, with a secondary amine of the formula: In that synthetic method, preferred are compounds (referred to as compounds of formula VIII-A) wherein n and Y are as defined above for formula VIII; R3 and R3A are the same or different and represent hydrogen or Ci-Ce alkyl ; or R3 and R3A, taken together with the carbon atom to which they are attached, form a C3-8 cycloalkylring; R5 and R6 are the same or different and represent hydrogen, halogen, hydroxy, Ci-Ce alkyl, or Ci-Ce alkoxy; or R5 and R6, taken together with the carbon atom to which they are attached form a C3-8 cycloalkyl ring; R5a and R6a are the same or different, and are independently selected at each occurrence from hydrogen, halogen, hydroxy, Ci-Ce alkyl, and Cl-C6 alkoxy; R2 is hydrogen or C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalkyl, (C3 s cycloalkyl) C1-3 alkyl, or C1- C6 haloalkyl, each or which unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluormethyl, trifluoromethoxy, Ci-3 haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono-or di (C1-C6) alkylamino; R4 is hydrogen or C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8cycloalkyl, (C3-s cycloalkyl) Cz-4alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-6 alkenyl, 2-6 alkynyl, Ci-Ce alkoxy, amino and mono-or di (Cl-C6) alkylamino, R4 is phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Cl-C6) alkylamino, amino (Ci-Cs) alkoxy, carboxylic acid, esters of Cl-C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl, XRs, wherein X and RB are as defined below; or R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, 2-6 alkenyl, C2-6 alkynyl, Ci-C6 alkoxy, amino, and mono-or di (Cl- C6)alkylamino; Arl and Ar2 are independently chosen from i) phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2 6 alkenyl, C2-6 alkynyl, CmC6 alkoxy, amino, mono-or di (Cl-C6) alkylamino, amino (Ci-C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N- ( Cl-C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl, and-XRB, wherein X and Ra are as defined below; and ii) bicyclic oxygen-containing groups of the formula: wherein Rs represents 0 to 3 groups selected from halogen, nitro, cyano, C2-6 alkenyl, C2-6 alkynyl, Ci-C6 alkoxy, amino, and mono-or di (Cl- Ce) alkylamino ; X is independently selected at each occurrence from the group consisting of-CH2-,- CHRc-,-O-,-S (O) m,-NH-,-NRc-,-C (=O) NH-,-C (=O) NRc-,-S (O) mNH-,-S (O) mNRc-, -NHC (=O)-, - NRcC (=O)-,-NHS (O) m-, =C (=O) NHS (O) m-, and-NRcS (O) m- (where m is 0,1, or 2); and RB and Rc, which may be the same or different, are independently selected at each occurrence from the group consisting of : hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent (s) selected from: oxo, hydroxy, -O (C1-C6 alkyl),-NH (Ci-C6 alkyl), -N(C1-C6 alkyl) (C1-C6 alkyl),-NHC (O) (C1-C6 alkyl),-N (Ci-C6 alkyl) C (O) (Cl-6 alkyl),- NHS (O) x (Ci-C6 alkyl),-S (O) x (Ci-C6 alkyl),-S (O) xNH (Cl-C6 alkyl),-S (O) xN (Ci-C6 alkyl) ( Ci-Ce alkyl), (where x is 0,1, or 2).

The invention also includes compounds of the above formula VIII and VIII-A, and pharmaceutically acceptable salts of such compounds.

The invention also provides compounds of the following formula IX: or a pharmaceutically acceptable salt ethereof, wherein: m is 0, 1, or 2; R is hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono- or optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl) alkyl ; or R is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; Ri, R2, R3, R3A, Rs, and R6 are independently selected from hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono-or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, and optionally substituted (cycloalkyl) alkyl ; R4 is alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl each of which may be optionally substituted; or R4 is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; and Arl and Ar2 are independently optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms.

Preferred compounds of formula IX include those of the following formula IX- A: wherein Arl, Ar2, R, Ri, R2, R3, and R4 are for formula IX above.

Preferred compounds of formula IX-A above include those wherein: i) hydrogen, halogen, hydroxy, amino, alkoxy, mono-or dialkylamino, cyano, nitro, haloalkyl, and ii) alkyl, alkenyl, alkynyl, cycloalkyl, and (cycloalkyl) alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono-or dialkylamino ; or R is selected from phenyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono-or dialkylamino; and Ri, R2, and R3 are independently selected from i) hydrogen, halogen, hydroxy, amino, alkoxy, mono-or dialkylamino, cyano, nitro, haloalkyl, and ii) alkyl, alkenyl, alkynyl, cycloalkyl, and (cycloalkyl) alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono-or dialkylamino; R4 is hydrogen or alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino and mono-or dialkylamino, R4 is phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, mono-or dialkylamino, aminoalkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or dialkylaminocarbonyl, N- alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl,-XRB, wherein X and RB are as defined below; or R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono-or dialkylamino; Arl and Ar2 are independently chosen from i) phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [b) thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, mono-or dialkylamino, aminoalkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or dialkylaminocarbonyl, N- alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl, and- ii) bicyclic oxygen-containing groups of the formula: wherein Rs represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono-or dialkylamino ; X is independently selected at each occurrence from the group consisting of-CH2-,- CHRc-,-O-,-S (O) m-, -NH-, -NRc-, -C(=O) NH-,-C (=O) NRc-,-S (O) mNH-,-S (O) mNRc-, -NHC(=O)-, -NRcC (=O)-,-NHS (O) m-,-C (=O) NHS (O) m-, and-NRcS (O) m- (where m is 0,1, or 2); and RB and Rc, which may be the same or different, are independently selected at each occurrence from the group consisting of : hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent (s) selected from: oxo, hydroxy,-O (alkyl),-NH (alkyl), - N (alkyl) (alkyl),-NHC (O) (alkyl),-N (alkyl) C (O) (alkyl),-NHS (O) x (Cl-C6 alkyl),-S (O) x (alkyl),-S (O) xNH (alkyl),-S (O) xN (alkyl) (alkyl), (where x is 0,1, or 2).

Additional preferred compounds of formula IX-A include those wherein: Ri, R2, and R3 are independently selected from i) hydrogen, halogen, hydroxy, amino, Ci-Ce alkoxy, mono-or di (Cl- C6) alkylamino, cyano, nitro, haloalkyl, and ii) C1-C8 alkyl, Ca-Ce alkenyl, C2-C6 alkynyl, Cs-Cs cycloalkyl, and (C3-Cs cycloalkyl) Cl-C3 alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkoxy, amino, mono-or di (Cl- C6)alkylamino; R is selected from i) hydrogen, halogen, hydroxy, amino, Ci-Ce alkoxy, mono-or di (Cl- C6) alkylamino, cyano, nitro, haloalkyl, and ii) C1-C8 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and (C3- C8) cycloalkyl) Ci-C3 alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono-or di (Cl- C6) alkylamino; or R is selected from phenyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C8 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (Cl- C6)alkylamino; R4 is hydrogen or C1-8 alkyl, C2-8 alkenyl, 2-3 alkynyl, C3-8cycloalkyl, (C3-8 cycloalkyl) C1-4alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-Ce alkoxy, amino and mono-or di (Ci-C6) alkylamino, R4 is phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, 2-6 alkenyl, 2-6 alkynyl, C1-C6 alkoxy, amino, mono-or di (Cl-C6) alkylamino, amino (C1-C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N- ( C1-C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl,- XRB, wherein X and RB are as defined below; or R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, 2-6 alkenyl, C2-6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (Cl- C6) alkylamino ; and Ari and Ara are independently chosen from i) phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [b]thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, 2-5 alkynyl, C1-C6 alkoxy, amino, mono-or di (Cl-C6) alkylamino, amino (Cl-C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N- ( Cl-C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl, and-XRB, wherein X and Rs are as defined below; and wherein Rs represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-C6 alkoxy, amino, and mono-or di (Cl- C6) alkylamino ; X is independently selected at each occurrence from the group consisting of -CH2-, - CHRc-, -O-, -S(O)m-, -NH-, -NRC-, -C(=O) NH-,-C (=O) NRC-, -S(O)mNH-, -S(O)mNRC-, -NHC(=O)-, -NRCC(=O)-, -NHS9O)m-, -C(=O) NHS (O) m-, and-NRcS (O) m- (where m is 0,1, or 2); and RB and RC, which may be the same or different, are independently selected at each occurrence from the group consisting of : hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent (s) selected from: oxo, hydroxy, -O (C1-C6 alkyl),-NH (Ci-C6 alkyl), - N (Ci-C6 alkyl) (Ci-C6 alkyl),-NHC (O) (C1-C6 alkyl),-N (Cl-C6 alkyl) C(O)(C1-6 alkyl), -NHS(O)x(C1-C6 alkyl), -S(O)x(C1-C6 alkyl), - S (O) NH (C1-C6 alkyl),-S (O) xN (Cl-C6 alkyl) (C1-C6 alkyl), (where x is 0,1, or 2).

Additional preferred compounds of formula IX-A above include those wherein: R is hydrogen, halogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-Cs cycloalkyl, (C3-C8cycloalkyl)C1-C3alkyl, C1-C8 alkoxy, or Cl-C8 haloalkyl, or R is a phenyl which may be substituted by up to five substituents independently chosen from C1-Cs alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 alkoxy, halogen, cyano, carboxylic acid, hydroxy, acetoxy, nitro, amino, mono or di (C1- C6) alkylamino, aminocarbonyl, sulfonamido, mono or di (Ci-C6) alkylsulfonamido, 3,4-methylenedioxy, 3, 4-(1, 2-ethylene) dioxy, trifluoromethyl or trifluoromethoxy ; Ri is hydrogen, Cl-Cs alkyl, Ca-Cs alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl (Cs- C8cycloalkyl) Cl-alkyl or Ci-Cs haloalkyl ; R2 is Cl-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 cycloalkyl or (Cs- C8cycloalkyl)C1-C3alkyl or Cl-C8 haloalkyl ; R3 is hydrogen, C1-8 alkyl, C2-Cs alkenyl, or C2-C8 alkynyl; R4 is C1-8 alkyl, Cs-Cs cycloalkyl, or (C3-C8 cycloalkyl) C1-Cs alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, amino, and mono-or di (Cl-C6) alkylamino; or R4 is phenyl, phenyl (Ci-C4) alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo [b] thiophenyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2- C6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (C1-C6) alkylamino; or R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, amino, and mono-or di (Cl-C6) alkylamino; and Arl and Ar2 are independently chosen from phenyl, phenyl (C1-C4) alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, and quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, amino, mono-or di (Cl-C6) alkylamino, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N- (Ci- C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, and 1-piperidyl, and bicyclic oxygen-containing groups of the formula: wherein Rs represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-C6 alkoxy, amino, and mono-or di (Cl- C6)alkylamino.

Still additional preferred compounds of formula IX-A include those compounds wherein: R is hydrogen, halogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Ca cycloalkyl, (C3-C8cycloalkyl)C1-C3alkyl, C1-C8 alkoxy, or Cl-C8 haloalkyl, or R is a phenyl which may be substituted by up to five substituents independently chosen from C1-C8 alkyl, Cz-Cs alkenyl, C2-C8 alkynyl, Cl-C8 alkoxy, halogen, cyano, carboxylic acid, hydroxy, acetoxy, nitro, amino, mono or di (C1- C6) alkylamino, aminocarbonyl, sulfonamido, mono or di (Cl-C6) alkylsulfonamido, 3,4-methylenedioxy, 3,4- (1,2-ethylene) dioxy, trifluoromethyl or trifluoromethoxy ; Rl is hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl (C3- C8cycloalkyl) Ci-Csalkyl or Ci-Cs haloalkyl ; R2 is Cl-Cs alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 cycloalkyl or (C3-C8 cycloalkyl) Cl-C3alkyl or C1-C8 haloalkyl ; R3 is hydrogen, C1-C8 alkyl, C2-C8 alkenyl, or C2-C8 alkynyl; R4 is Cl-C$ alkyl, C3-C8 cycloalkyl, or (C3-C8 cycloalkyl) C1-Cs alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, Ca-Ce alkynyl, C1-C6 alkoxy, amino, and mono-or di (Cl-C6) alkylamino; or R4 is phenyl, phenyl (Cl-C4) alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo [b] thiophenyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2- C6 alkynyl, Cl-C6 alkoxy, amino, mono-or di (Ci-C6) alkylamino; or R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, Ca-Ce alkenyl, Ca-Ce alkynyl, Ci-C6 alkoxy, amino, and mono-or di (Cl-C6) alkylamino; Arl is phenyl, thienyl, or pyridyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Cl- C6) alkylamino; and Ar2 is phenyl, phenyl (Cl-C4) alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, and quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl, C2-C6 alkenyl, C2- C6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Cl-C6) alkylamino, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl- C6) alkylaminocarbonyl, N- (Ci-C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1- pyrrolidinyl, and 1-piperidyl, or Ar2 is a bicyclic oxygen-containing group of the formula: wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, amino, and mono-or di (C1- C6) alkylamino.

Still further preferred compounds of formula IX above include those wherein R is hydrogen, halogen, methyl, ethyl, methoxy, ethoxy, trifluoromethyl, or phenyl; Ri is hydrogen, methyl or ethyl; R2 is C3-C6 alkyl ; R3 is hydrogen, methyl or ethyl; R4 is Cl-Ce alkyl, Cs-Cs cycloalkyl, or (Cs-Cs cycloalkyl) C1-C3 alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, Ca-Ce alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (Cl-C6) alkylamino; or R4 is phenyl, phenyl (C1-C4) alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo [b] thiophenyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2- C6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (C1-C6) alkylamino; or R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (Cl-C6) alkylamino; Arl is phenyl, thienyl, or pyridyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Cl- C6) alkylamino; and Ar2 is phenyl, phenyl (Cl-C4) alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, and quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2- C6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Cl-C6) alkylamino; Ar2 is a bicyclic oxygen-containing group of the formula: wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (Cl-C6) alkylamino.

The invention also include compounds of the following formula X: wherein: m is 0, 1, or 2 ; R is hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono-or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl) alkyl ; or R is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; Ri, R2, R3, R3A, R5, and R6 are independently selected from hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono-or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, and optionally substituted (cycloalkyl) alkyl; R4 is alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl each of which may be optionally substituted; or R4 is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; and Ari and Ar2 are independently optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms.

Preferred compounds of formula X include those of the following formula X- A : wherein Arl, R, Ri, R2, R3, R4 are as defined for formula X above.

Additional preferred compounds of formula X include those wherein: Ri, R2, and R3 are independently selected from i) hydrogen, halogen, hydroxy, amino, Ci-Ce alkoxy, mono-or di (Cl- C6) alkylamino, cyano, nitro, haloalkyl, and ii) Ci-Cs alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and (C3-C8 cycloalkyl) C1-Cs alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkoxy, amino, mono-or di (Cl- C6) alkylamino ; R is selected from i) hydrogen, halogen, hydroxy, amino, Ci-Ce alkoxy; mono-or di (Cl- C6) alkylamino, cyano, nitro, haloalkyl, and ii) Cl-Ca alkyl, Ca-Ce alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and (Cs- C8) cycloalkyl) Ci-Ca alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono-or di (Cl- C6) alkylamino ; or R is selected from phenyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-Cs alkyl, C2-C6 alkenyl, Ca-Ce alkynyl, Ci-Ce alkoxy, amino, and mono-or di (Cl- C6) alkylamino ; R4 is hydrogen or C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8cycloalkyl, (C3-8 cycloalkyl) C1-4alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, 2-6 alkenyl, 2-6 alkynyl, Ci-Ce alkoxy, amino and mono-or di (Cl-C6) alkylamino, R4 is phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, 2-6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Ci-C6) alkylamino, amino (C1-C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N- ( Cl-C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl,- XRB, wherein X and RB are as defined below; or R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (Cl- C6) alkylamino ; and Arl and Ar2 are independently chosen from i) phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (C1-C6) alkylamino, amino (Cl-C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N- ( Cl-C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl, and-XRB, wherein X and Rs are as defined below; and ii) bicyclic oxygen-containing groups of the formula: wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (C1- C6)alkylamino; X is independently selected at each occurrence from the group consisting of-CH2-,- CHRC-, -O-, -S(O)m-, -NH-, -NRC-, -C(-O) NH-,-C (=O) NRc-,-S (O) mNH-,-S (O) mNRc-, - NHC (=O)-, -NRCC(=O)-, -NHS(O) m-,-C (=O) NHS (O) m-, and-NRcS (O) m- (where m is 0,1, or 2); and RB and Rc, which may be the same or different, are independently selected at each occurrence from the group consisting of : hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent (s) selected from: oxo, hydroxy,-O (Ci-C6 alkyl),-NH (C1-C6 alkyl), -N(C1-C6 alkyl)(C1-C6 alkyl), -NHC(O)(C1-C6 alkyl), -N(C1-C6 alkyl) C (O) (Cl-6 alkyl),- NHS (O)x(C1-C6 alkyl), -S(O)x(C1-C6 alkyl), -S(O)xNH(C1-C6 alkyl), -S(O)xN(C1-C6 alkyl) ( Ci-C6 alkyl), (where x is 0,1, or 2).

Additional preferred compounds of formula X above include those wherein: R is hydrogen, halogen, methyl, ethyl, methoxy, ethoxy, trifluoromethyl, or phenyl; Ri is hydrogen, methyl or ethyl; R2 is C3-C6 alkyl ; R3 is hydrogen, methyl or ethyl; R4 is Cl-Ce alkyl, C3-C8 cycloalkyl, or (C3-C8 cycloalkyl) CI-C3 alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, Ca-Ce alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (Cl-C6) alkylamino ; or R4 is phenyl, phenyl (Ci-C4) alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo [b] thiophenyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2- C6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Ci-C6) alkylamino; or R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, Ca-Ce alkynyl, C1-C6 alkoxy, amino, and mono-or di (Cl-C6) alkylamino; and Arl is phenyl, thienyl, or pyridyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, Ca-Ce alkynyl, Ci-Ce alkoxy, amino, mono-or di (Cl- C6) alkylamino.

The invention also includes compounds of the following formula XI: or pharmaceutically acceptable salt thereof, wherein: n is 0, 1, or 2 ; R is chosen from hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono-or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl) alkyl, optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; Ra, R3, R3A, R5, and R6 are independently selected from hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono-or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, and optionally substituted (cycloalkyl) alkyl ; R and R3 may be joined to form an optionally substituted saturated carbocylic ring of from 5 to 8 members or an optionally substituted heterocyclic ring of from 5 to 8 members; R4 is alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl each of which may be optionally substituted; or R4 is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; and Arl and Ar2 are independently optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms.

The invention further includes compounds of the following formula XII: or a pharmaceutically acceptable salt thereof, wherein: R is chosen from hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono-or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl) alkyl, optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; Ra and R3 are independently selected from hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono-or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, and optionally substituted (cycloalkyl) alkyl ; R and R3 may be joined to form an optionally substituted carbocylic ring of from 5 to 8 members or an optionally substituted heterocyclic ring of from 5 ro 8 members; R4 is alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl each of which may be optionally substituted; or R4 is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; and Ari and Ar2 are independently optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms.

Preferred compounds of formula XII above include wherein R and Rs are not joined.

Also preferred are compounds of formula XII wherein: R is selected from i) hydrogen, halogen, hydroxy, amino, alkoxy, mono-or dialkylamino, cyano, nitro, haloalkyl, and ii) alkyl, alkenyl, alkynyl, cycloalkyl, and (cycloalkyl) alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono-or dialkylamino, iii) phenyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, each of which may be substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono-or dialkylamino ; R2 and R3 are independently selected from i) hydrogen, halogen, hydroxy, amino, alkoxy, mono-or dialkylamino, cyano, nitro, haloalkyl, and ii) alkyl, alkenyl, alkynyl, cycloalkyl, and (cycloalkyl) alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono-or dialkylamino ; R4 is hydrogen or alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino and mono-or dialkylamino, R4 is phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, mono-or dialkylamino, aminoalkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or dialkylaminocarbonyl, N- alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl and- XRB, wherein X and RB are as defined below; or R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono-or dialkylamino; Arl and Ar2 are independently chosen from i) phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, mono-or dialkylamino, aminoalkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or dialkylaminocarbonyl, N- alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl and- XRs, wherein X and RB are as defined below;, and ii) bicyclic oxygen-containing groups of the formula: wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono-or dialkylamino ; X is independently selected at each occurrence from the group consisting of-CH2-,- CHRc-,-O-,-S (O) m-,-NH-,-NRc-,-C (=O) NH-,-C (=O) NRc-,-S (O) mNH-,-S (O) mNRc-, -NHC(=O)-, - NRcC (=O)-,-NHS (O) m-,-C (=O) NHS (O) m-, and-NRcS (O)m- (where m is 0,1, or 2); and RB and Rc, which may be the same or different, are independently selected at each occurrence from the group consisting of : hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent (s) selected from: oxo, hydroxy,-O (alkyl),-NH (alkyl), - N (alkyl) (alkyl),-NHC (O) (alkyl),-N (alkyl) C (O) (alkyl),-NHS (O) x (alkyl),-S (O) x (alkyl),- S (O) xNH (alkyl),-S (O) xN (alkyl) (alkyl), (where x is 0, 1, or 2).

Additional preferred compounds of formula XII include those wherein: R is selected from i) hydrogen, halogen, hydroxy, amino, Ci-Ce alkoxy, mono-or di (Cl- C6) alkylamino, cyano, nitro, haloalkyl, and ii) Cl-Cs alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and (C3- Cs) cycloalkyl) C1-Cs alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono-or di (Cl- C6)alkylamino, iii) phenyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-Cs alkyl, Ca-Ce alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (Cl-C6) alkylamino ; R2 and R3 are independently selected from i) hydrogen, halogen, hydroxy, amino, C1-C6 alkoxy, mono-or di (Cl- C6) alkylamino, cyano, nitro, haloalkyl, and ii) C1-Cs alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and (C3-Cs cycloalkyl) Ci-Cs alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkoxy, amino, mono-or di (Cl- C6)alkylamino; R4 is hydrogen or CI-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8cycloalkyl, (C3-8 cycloalkyl)C1-4alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-C6 alkoxy, amino and mono-or di (Cl-C6) alkylamino, R4 is phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, 2-6 alkenyl, C2-6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Cl-C6) alkylamino, amino (Cl-C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Ci-C6) alkylaminocarbonyl, N- ( Cl-C6) alkylsulfonylaminocarbonyl, I-azetidinyl, 1-pyrrolidinyl, 1-piperidyl,- XRB, wherein X and RB are as defined below; or R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-C6 alkoxy, amino, and mono-or di (Cl- C6) alkylamino ; Arl and Ar2 are independently chosen from i) phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [dlisoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Ci-C6) alkylamino, amino (Ci-C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N- ( Cl-C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl, and-XRB, wherein X and RB are as defined below; and ii) bicyclic oxygen-containing groups of the formula: wherein Ra represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, 2-6 alkynyl, Ci-C6 alkoxy, amino, and mono-or di (Ci- C6) alkylamino ; X is independently selected at each occurrence from the group consisting of-CH2-,- CHRc-, O-, -S(O)m-, -NH-, -NRc-, -C(=O) NH-,-C (=O) NRc-, -S(O)mNH-, -S(O)mNRc-, -NHC(=O)-, -NRcC (=O)-,-NHS (O) m-,-C (=O) NHS (O) m-, and-NRcS (O) m- (where m is 0,1, or 2); and RB and Rc, which may be the same or different, are independently selected at each occurrence from the group consisting of : hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent (s) selected from: oxo, hydroxy, -O (C1-C6 alkyl),-NH (C1-C6 alkyl), -N(C1-C6 alkyl) (C1-C6 alkyl),-NHC (O) (C1-C6 alkyl),-N (C1-C6 alkyl) C (O) (C1-C6 alkyl), -NHS(O)x(C1-C6 alkyl), -S(O)x(C1-C6 alkyl), - S (O) xNH (Ci-Ce alkyl), -S (O) xN (Ci-C6 alkyl) ( Ci-C6 alkyl), (where x is 0,1, or 2).

Also preferred are compounds of formula XII wherein: R is hydrogen, halogen, hydroxy, C1-C6 alkoxy, haloalkyl, C1-Cs alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and (C3-C8) cycloalkyl) C1-Cs alkyl, or R is phenyl substituted with up to five groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Cs alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (Cl-C6) alkylamino, aminocarbonyl, sufonamido, mono or di (C1- C6) alkylsulfonamido, 3,4-methylenedioxy, and 3, 4-(1, 2-ethylene) dioxy; Ra is selected from Ci-Cg alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, (C3-C8 cycloalkyl) Ci-C3 alkyl and haloalkyl ; R3 is hydrogen C1-Cs alkyl, C2-C6 alkenyl, C2-C6 alkynyl; R4 is C1-C8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8cyaloalkyl, (C3-C8 cyaloalkyl)C1-4alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, 2-6 alkenyl, C2-6 alkynyl, Ci-Ce alkoxy, amino and mono-or di (Cl-C6) alkylamino, R4 is phenyl, phenyl (Cl-C4) alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, chromanyl, dihydrobenzofuranyl, naphthyl, indolyl, indanyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, each of which may be substituted with up to five groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, 2-6 alkenyl, 2-5 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Cl-C6) alkylamino, amino (Cl-C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N- (Cl- C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl, R4 is a bicyclic oxygen-containing group of the formula: wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl, C2-6 alkenyl, 2-6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (C1- C6) alkylamino ; Arl and Ar2 are independently chosen from i) phenyl, phenyl (Cl-C4) alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, chromanyl, dihydrobenzofuranyl, naphthyl, indolyl, indanyl, benzo [b]thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, and benz [d] isoxazolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-C6 alkoxy, amino, mono-or di (Ci-C6) alkylamino, amino (Cl- C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N-(C1-C6) alkylsulfonylaminocarbonyl, 1- azetidinyl, 1-pyrrolidinyl, 1-piperidyl; or ii) bicyclic oxygen-containing groups of the formula: wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-C6 alkoxy, amino, and mono-or di (Cl-C6) alkylamino.

Also preferred are compounds of formula XII wherein: R, R2, R3, R4, and Ar2 are as defined in formula XII ; Arl is phenyl with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-C6 alkoxy, amino, mono-or di (Cl- C6) alkylamino, and amino (C1-C6) alkoxy.

Also preferred are compounds of formula XII wherein: R, R2, and R3 are as defined in formula XII; Arl is phenyl with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Cl- C6) alkylamino, and amino (Cl-C6) alkoxy; R4 is C3-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8cycloalkyl, (C3-C8 cycloalkyl)C1- C4alkyl, C1-Cs haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Cl-C6 alkoxy, amino and mono-or di (Cl- C6)alkylamino, R4 is phenyl, phenyl (Cl-C4) alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, chromanyl, dihydrobenzofuranyl, naphthyl, indolyl, indanyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-C6 alkoxy, amino, mono-or di (Cl-C6) alkylamino, amino (Cl- C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N- (Cl-C6) alkylsulfonylaminocarbonyl, 1- azetidinyl, 1-pyrrolidinyl, 1-piperidyl ; Ar2 is phenyl, phenyl (Ci-C4) alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, chromanyl, dihydrobenzofuranyl, naphthyl, indolyl, indanyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, or benz [d] isoxazolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Cl-C6) alkylamino, amino (Cl- C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Ci-C6) alkylaminocarbonyl, N-(C1-C6) alkylsulfonylaminocarbonyl, 1- azetidinyl, 1-pyrrolidinyl, 1-piperidyl ; or Ar2 is bicyclic oxygen-containing groups of the formula : wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, 2-6 alkenyl, C2-6 alkynyl, Cl-C6 alkoxy, amino, and mono-or di (Cl-C6) alkylamino.

Also preferred are compounds of formula XII wherein: R is hydrogen, C1-Cs alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, or (C3- Cs) cycloalkyl) C1-Cs alkyl, or R is phenyl substituted with up to five groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-Ca alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cl-C6 alkoxy, amino, and mono-or di (Cl-C6) alkylamino, aminocarbonyl, sufonamido, mono or di (Cl- C6) alkylsulfonamido, 3,4-methylenedioxy, and 3, 4-(1, 2-ethylene) dioxy; R2 is C3-C6 alkyl ; R3 is hydrogen, methyl, or ethyl; R4 is Cs-Cs alkyl, C2-Cs alkenyl, C2-C8 alkynyl, C3-C8cyclalkyl, (C3-C8 cycloalkyl)C1- C4alkyl, C1-C8 haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-C6 alkoxy, amino and mono-or di (Cl- Ce) alkylamino, R4 is phenyl, phenyl (Ci-C4) alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, chromanyl, dihydrobenzofuranyl, naphthyl, indolyl, indanyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Ci-C6) alkylamino, amino (C1- C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (C1-C6) alkylaminocarbonyl, N- (CI-C6) alkylsulfonylaminocarbonyl, 1- azetidinyl, 1-pyrrolidinyl, 1-piperidyl ; Ari is phenyl with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Cl- C6) alkylamino, and amino (Cl-C6) alkoxy ; Ar2 is phenyl, phenyl (Cl-C4) alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, chromanyl, dihydrobenzofuranyl, naphthyl, indolyl, indanyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, or benz [d]isoxazolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-C6 alkoxy, amino, mono-or di (Cl-C6) alkylamino, amino (Cl- C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N-(C1-C6)alkylsulfonylaminocarbonyl, 1- azetidinyl, 1-pyrrolidinyl, 1-piperidyl ; or Ar2 is bicyclic oxygen-containing groups of the formula : wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-C6 alkoxy, amino, and mono-or di (Cl-C6) alkylamino.

Also preferred are compounds of formula XII wherein: R is hydrogen, C1-C8 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, or (C3- C8) cycloalkyl) C1-C3 alkyl, or phenyl; R2 is C3-C6 alkyl ; R3 is hydrogen, methyl, or ethyl; R4 is C3-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8cycloalkyl, (C3-8 cycloalkyl) C1- C4alkyl, C1-C8 haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, 2-6 alkynyl, C1-C6 alkoxy, amino and mono-or di (C1- C6)alkylamino ; Arl is phenyl with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, 2-6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Cl- C6) alkylamino, and amino (Ci-Ce) alkoxy; and Ar2 is phenyl, phenyl (Cl-C4) alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, chromanyl, dihydrobenzofuranyl, naphthyl, indolyl, indanyl, benzo [b]thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, or benz [d] isoxazolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2- C6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (C1-C6) alkylamino, amino (C1- C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N- (Ci-C6) alkylsulfonylaminocarbonyl, 1- azetidinyl, 1-pyrrolidinyl, 1-piperidyl; or Ar2 is bicyclic oxygen-containing groups of the formula: wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (Cl-C6) alkylamino.

Also preferred are compounds of formula XII wherein: R is hydrogen, C1-C8 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, or (C3- C8) cycloalkyl) C1-C3 alkyl, or phenyl; R2 is C3-C6 alkyl ; R3 is hydrogen, methyl, or ethyl; R4 is phenyl, phenyl (Cl-C4) alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, chromanyl, dihydrobenzofuranyl, naphthyl, indolyl, indanyl, benzo [b] thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz [d] isoxazolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Cl-C6) alkylamino, amino (C1- C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N- (Cl-C6) alkylsulfonylaminocarbonyl, 1- azetidinyl, 1-pyrrolidinyl, 1-piperidyl; Arl is phenyl with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Cl-C6 alkoxy, amino, mono-or di (C1- C6) alkylamino, and amino (C1-C6) alkoxy; Ar2 is phenyl, phenyl (Ci-C4) alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, chromanyl, dihydrobenzofuranyl, naphthyl, indolyl, indanyl, benzo [b]thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, or benz [d] isoxazolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, 2-6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (C1-C6) alkylamino, amino (Cl- C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N- (Ci-C6) alkylsulfonylaminocarbonyl, 1- azetidinyl, 1-pyrrolidinyl, 1-piperidyl ; or Ar2 is bicyclic oxygen-containing groups of the formula : wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, 2-6 alkenyl, 2-5 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (Cl-C6) alkylamino.

The invention also includes compounds of the following formula XIII : or a pharmaceutically acceptable salt thereof, wherein: n is 1, 2, or 3 m represents a carbon chain that may be substituted with hydrogen, halogen, cyano, nitro amino, mono or dialkyl amino, alkenyl, alkynyl, alkoxy, trifluoromethyl, trifluoromethoxy, straight or branched chain alkyl, or cycloalkyl, and n is 1,2, or 3; Ari, Ar2, and Ar3 are independently optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; and Ri represents up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, alkoxy, acetoxy, mono-or dialkylamino, cyano, nitro, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl, hydroxy carbonyl (COOH), aminocarbonyl (CONH2), mono or dialkylaminocarbonyl, sulfonamido, and mono or dialkylsulfonamido.

Also preferred are compounds of formula XIII wherein n, m, and Ri are defined as for formula XIII above; Arl and Ar3 are independently chosen from phenyl, pyridyl, and pyrimidinyl each of which is optionally optionally substituted or substituted with up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, Ci-Ce alkoxy, acetoxy, mono-or di (Cl-C6) alkylamino, cyano, nitro, C1-C6 haloalkyl, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, (C3-C8cycloalkyl) Cl-C3alkyl, hydroxy carbonyl (COOH), aminocarbonyl (CONH2), mono or di (Cl-C6) alkylaminocarbonyl, sulfonamido, 3,4-methylenedioxy, ethylenedioxy, and mono or di (Cl-C6) alkylsulfonamido; and Ar2 represents suberanyl, indanyl, tetrhydronaphtyl, or indolyl, each of which is optionally optionally substituted or substituted with up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, Ci-C6 alkoxy, acetoxy, mono-or di (Ci-C6) alkylamino, cyano, nitro, Ci-Ce haloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cs-C8 cycloalkyl, (Cs-Cscycloalkyl) Cl-C3alkyl, hydroxy carbonyl (COOH), aminocarbonyl (CONH2), mono or di (C1-C6) alkylaminocarbonyl, sulfonamido, 3,4-methylenedioxy, ethylenedioxy, and mono or di (Ci-C6) alkylsulfonamido.

Also preferred are compounds of formula XIII above wherein: Ri, R3, and Rs each represent up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, Ci-Ce alkoxy, acetoxy, mono-or di (Cl-C6) alkylamino, cyano, nitro, Ci-Ce haloalkyl, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, (Cs-Cacycloalkyl) C1-C3 alkyl, hydroxy carbonyl (COOH), aminocarbonyl (CONH2), mono or di (C1-C6) alkylaminocarbonyl, sulfonamido, and mono or di (C1- C6) alkylsulfonamido ; and represents suberanyl, indanyl, tetrhydronaphtyl, or indolyl, each of which is optionally optionally substituted or substituted with up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, C1-C6 alkoxy, acetoxy, mono-or di (C1-C6) alkylamino, cyano, nitro, Ci-Ce haloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cs-Cs cycloalkyl, (C3-Cscycloalkyl) Cl-C3alkyl, hydroxy carbonyl (COOH), aminocarbonyl (CONH2), mono or di (Cl-C6) alkylaminocarbonyl, sulfonamido, 3,4- methylenedioxy, ethylenedioxy, and mono or di (Cl-C6) alkylsulfonamido.

The invention also includes compounds of the followinf formula XIV: or a pharmaceutically acceptable salt, thereof, wherein: R represents up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, alkoxy, acetoxy, mono-or dialkylamino, cyano, nitro, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl, hydroxy carbonyl (COOH), aminocarbonyl (CONH2), mono or di (Ci-C6) alkylaminocarbonyl, sulfonamido, 3,4-methylenedioxy, ethylenedioxy, and mono or dialkylsulfonamido; Ri is alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl each of which may be optionally substituted; or Ri is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkyl, or an optionally substituted heteroalicyclic or heteroalicyclicalkyl group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; and Ari and Ar2 are independently optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, or an optionally substituted heteroalicyclic or heteroalicyclicalkyl group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms.

Preferred compounds of formula XIV include those (referred to herein as compounds of formula XIV-A) wherein R represents up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, Ci-Ce alkoxy, acetoxy, mono-or di (Cl-C6) alkylamino, cyano, nitro, C1- C6 haloalkyl, Cl-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3 C8 cycloalkyl, (C3- C8 cycloalkyl) C1-C3 alkyl, hydroxy carbonyl (COOH), aminocarbonyl (CONH2), mono or di (Cl-C6) alkylaminocarbonyl, sulfonamido, 3,4-methylenedioxy, ethylenedioxy, and mono or di (Cl-C6) alkylsulfonamido; Ri is C1-C8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8cycloalkyl, (C3-8 cycloalkyl)C1-4alkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-Ce alkoxy, amino and mono-or di (Cl-C6) alkylamino, or Ri is phenyl, phenylalkyl, chromanyl, chromanylalkyl, imidazolyl, imidazolylalkyl, pyridyl, pyridylalkyl, pyrimidyl, pyrimdylalkyl, pyrazinyl, pyrazinylalkyl, indolyl, indolylalkyl, indanyl, indanylalkyl, benzodioxolylalkyl, or benzodioxolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-6 alkenyl, 2-6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Ci-C6) alkylamino, amino (Ci-C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (C1-C6) alkylaminocarbonyl, N-(C1- C6) alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, and 1-piperidyl; Arl is chosen from phenyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, thiophenyl, and pyridyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, C2-6 alkyl, C1-C6 alkoxy, amino, mono-or di (Cl-C6) alkylamino, amino (Cl-C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (C1-C6) alkylaminocarbonyl, and N- (Ci- C6) alkylsulfonylaminocarbonyl ; and Ar2 is chosen from phenyl, phenylalkyl, chromanyl, chromanylalkyl, pyrrolyl, pyrrolylalkyl, furanyl, furanylalkyl, thienyl, thienylalkyl, pyridyl, pyridylalkyl, pyrimidyl, pyrimidylalkyl, pyrazinyl, pyrazinylalkyl, benzimidazolyl, benzimidazolylalkyl, imidazopyrdinyl, imidazopyrdinylalkyl, naphthyl, napthylalkyl, indolyl, indolylalkyl, indanyl, indanylalkyl, benzofuranyl, benzofuranylalkyl, benzodioxinyl, benzodioxinylalkyl, benzodioxolyl, benzodioxolylalkyl, quinolinyl, quinolinylalkyl, isoquinolinyl, isoquinolinylalkyl, each of which may be optionally substituted or substituted with up to four groups independently selected from: halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, 2-6 alkenyl, C2-6 alkynyl, C1-C6 alkoxy, amino, mono-or di (Ci-C6) alkylamino, mono-or di (C1-C6) alkylamino (Cl- C6) alkyl, amino (Ci-C6) alkoxy, Ci-C6 alkoxyC1-C6 alkyl, Ci-Ce alkoxyCl-C6 alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di (Cl-C6) alkylaminocarbonyl, N-(C1- C6) alkylsulfonylaminocarbonyl, benzyl (which may be unsubstituted or substituted with one or more substituents independently chosen from halogen, C1-C6alkyl, and Cl- C6alkoxy), -C1-C6 alkylNR2R3 or -C1-C6alkoxy NR2R3 wherein the point of attachment to Ar2 is at the C1-C6 alkyl or C1-C6 alkoxy, and R2 and R3 are hydrogen, or straight or branched chain alkyl and are optionally substituted with halogen, hydroxy, or C1-C6 alkoxy and R2 and R3 may be taken together with the nitrogen to which they are attached to form a heterocycloalkyl group.

Preferred compopunds of formula XIV-A include those wherein: wherein: Ar2 is as defined in Claim in formula XIV-A ; Rx represents up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, C1-C6 alkoxy, acetoxy, mono-or di (Cl-C6) alkylamino, cyano, nitro, Ci-C6 haloalkyl, Ci-Ce alkyl, C2-C6 alkenyl, and C2-C6 alkynyl; and Ri is C1-C6alkyl, C3-C8cycloalkyl, (C3-C8 cycloalkyl) Cl-C4alkyl, phenyl, phenyl- C6alkyl, chromanyl, chromanylCl-C6alkyl, imidazolyl, imidazolylCi-C6alkyl , pyridyl, pyridylCi-C6alkyl, pyrimidyl, pyrimidylCl-C6alkyl, pyrazinyl, pyrazinylC1-C6alkyl, indolyl, indolylCl-C6alkyl, indanyl, indanylCl-C6alkyl, benzodioxolyl, or benzodioxoylC1-C6alkyl each or which may be unsubstituted or substituted with up to 4 substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-C6 alkoxy, amino and mono-or di (C1-C6) alkylamino.

Additional preferred compounds of formula XIV-A includes those of the followingformula: wherein: Rx represents up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, C1-C6 alkoxy substituted with 0-2 R2, acetoxy, mono-or di (Ci-C6) alkylamino, cyano, nitro, Ci-Ce haloalkyl, C1-C6 alkyl, C2-C6 alkenyl, and C2-C6 alkynyl; Ri is phenyl, phenylCl-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl(C1-C4 alkyl), naphthyl, napthylCl-C6alkyl, indanyl, indanylCl-C6 alkyl, benzodioxolanyl, or benzodioxolanylCl-C6 alkyl, each of which may be substituted by up to 4 groups chosen from halogen, hydroxy, amino, Ci-Ce alkoxy, acetoxy, mono- or di (Cl-C6) alkylamino, cyano, nitro, C1-C6 haloalkyl, Ci-Ce alkyl ; and Ar2 represents phenyl, benzyl, indanyl, indanyl-CH2-, benzodioxolanyl, or benzodioxolanyl-CH2- ; each of which is substituted by up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, C1-C6 alkoxy, acetoxy, mono-or di (Cl-C6) alkylamino, cyano, nitro, Ci-Ce haloalkyl, Ci-Ce alkyl, C2-C6 alkenyl, and C2-6 alkynyl.

Additional preferred compounds of formula XIV includes those wherein: Ar2 is as defined for formula XIV ; R represents up to 4 groups independently chosen from hydrogen, halogen, amino, C1-C6 alkoxy, Ci-Ce alkyl, trifluoromethyl, and trifluoromethoxy ; Ri is phenyl, benzyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl(C1-C4 alkyl), naphthyl, naphthyl-CH2-, indanyl, indandyl-CH2-, benzodioxolanyl-CH2-, or benzodioxolanyl, each of which may be substituted by up to 4 groups chosen from halogen, hydroxy, amino, C1-C6 alkoxy, acetoxy, mono-or di (Cl- C6) alkylamino, cyano, nitro, Ci-Ce haloalkyl, C1-C6 alkyl ; and Arl is chosen from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, thiophenyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, trifluoromethyl, trifluoromethoxy, Cl-C6 alkoxy, C1-C6 alkyl, and amino.

Also preferred are compounds of the formula XIV above wherein: R represents up to 4 groups independently chosen from hydrogen, halogen, amino, Ci-Ce alkoxy, Ci-Ce alkyl, trifluoromethyl, and trifluoromethoxy ; Ri is benzyl which is unsubstituted or substituted by up to 4 groups chosen from halogen, hydroxy, amino, Ci-Ce alkoxy, acetoxy, mono-or di (Cl- C6) alkylamino, cyano, nitro, Ci-Ce haloalkyl, Ci-Ce alkyl ; Arl is chosen from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, thiophenyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, trifluoromethyl, trifluoromethoxy, Ci-C6 alkoxy, Ci-Ce alkyl, and amino; and Ar2 is chosen from phenyl, benzyl, indolyl, indolyl-CH2-, indanyl, indanyl-CHa-, chromanyl, chromanyl-CH2-, benzofuranyl, benzofuranyl-CH2-, benzodioxinyl, benzodioxinyl-CH2-, benzodioxolyl-CH2-, and benzodioxolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from: halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-Ce alkoxy, amino, and mono-or di (CI-C6) alkylamino.

Preferred compounds of formula XIV also include thos eof the following formula IV-B: m is 0,1,2, or 3, and represents a carbon chain which is optionally substituted with methyl, ethyl, methoxy, ethoxy, hydoxy, halogen, or amino; R represents up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, Cl-C6alkyl, C2-C6 alkenyl, C1-C6alkynyl, Ci-Ce alkoxy, acetoxy, mono- or di (Ci-C6) alkylamino ; Rx and Ry each represent up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, Ci-Ce alkoxy, acetoxy, mono-or di (Cl- C6) alkylamino, cyano, nitro, C1-C6 haloalkyl, Ci-Ce alkyl, C2-C6 alkenyl, and C2-C6 alkynyl; and Ri and R4 are independently selected from C1-C6alkyl, C3-C8cycloalkyl, (C3-C8 cycloalkyl) Ci-C4alkyl, phenyl, phenylCi-C6alkyl, pyridyl, and pyridyl- C6alkyl, each or which may be unsubstituted or substituted with up to 4 substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-6 alkenyl, 2-6 alkynyl, C1-C6 alkoxy, amino and mono-or di (Cl-C6) alkylamino.

The invention also provides compounds of the following formula XV: or a pharmaceutically acceptable salt thereof, wherein; m is 0,1,2, or 3, and represents a carbon chain which is optionally substituted with methyl, ethyl, methoxy, ethoxy, hydoxy, halogen, or amino ; n is 0,1,2, or 3, and represents a carbon chain which is optionally substituted with methyl, ethyl, methoxy, ethoxy, hydoxy, halogen, or amino; R represents up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, alkoxy, acetoxy, mono-or dialkylamino, cyano, nitro, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, and (cycloalkyl) alkyl; R2 is i) hydrogen, halogen, hydroxy, amino, alkoxy, mono-or dialkylamino, cyano, nitro, haloalkyl, and ii) alkyl, alkenyl, alkynyl, cycloalkyl, and (cycloalkyl) alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, mono-or dialkylamino; and Arl and Ara are independently optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkyl, or an optionally substituted heteroalicyclic or heteroalicyclicalkyl group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms.

Preferred compounds of formula XV include those of the following formula: m is 1 and represents a carbon chain which is unsubstituted; n is 1 and represents a carbon chain which is unsubstituted; R represents up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, Ci-Ce alkoxy, acetoxy, mono-or di (Cl-C6) alkylamino, cyano, nitro, Cl- C6 haloalkyl, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C2-C6 cycloalkyl, and (C3-Cs cycloalkyl) C1-C4 alkyl ; R2 is C3-Cs alkyl or Cs-Cs cycloalkyl ; Arl and Ar2 are independently chosen from phenyl, phenyl (Ci-C4) alkyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, pyridyl, pyrimidyl, and pyrazinyl, each of which may be unsubstituted or optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, amino, mono-or di (Ci-C6) alkylamino.

Compounds of the invention may have one or more asymmetric centers or planes. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms (racemates), by asymmetric synthesis, or by synthesis from optically active starting materials. Resolution of the racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral HPLC column. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral (enantiomeric and diastereomeric), and racemic forms, as well as all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated.

Some compounds of the invention may exist as tautomers. Unless otherwise specified any description or claim of one tautomeric form is intended to encompass the other tautomer.

Specifically preferred compounds include those shown in the FIGS. 1 through 6. In those figures, the substituent X depicts the moiety linkage to the base compound whose strucutre is shown at the top of each Figure.

Addiional preferred compounds of the invention include the following (compounds structures are shown directly above the compound chemical name in many instances): 1- (1-butyl)-2-phenyl-5- (N, N-di [3,4-methylenedioxyphenyl methyl) aminomethylimidazole; 1-(1-butyl)-2-phenyl-5-(1-[N-{3, 4-methylenedioxyphenylmethyl}-N- phenylmethyl] amino) ethylimidazole; 1-Butyl-2-phenyl-4-bromo-5-(N-phenylmethyl-N-[1-butyl]) amino- methylimidazole; 1- (1-Butyl)-2-phenyl-4-methyl-5- (N- [3,4-methylenedioxyphenyl-methyl]-N- phenylmethyl) aminomethylimidazole; 1- (l-Butyl)-2- (4-fluorophenyl)-5- (N- [1, 4-benzodioxan-6-yl] methyl-N- phenylmethyl) aminomethylimidazole; 1- (1-Butyl)-2- (4-fluorophenyl)-5- (N- [3,4-methylenedioxyphenylmethyl]-N- phenylmethyl) aminomethylimidazole; l- (l-Butyl)-2- (4-Quorophenyl)-5- (N- [l, 4-benzodioxan-6-yl] methyl-N- phenylmethyl) aminomethylimidazole; 1- (1-Butyl)-2- (4-fluorophenyl)-5- (N- [3, 4-methylenedioxyphenylmethyl]-N- phenylmethyl)aminomethylimidazole; 1- (l-Butyl)-2- (2-fluorophenyl)-5- (N- [1, 4-benzodioxan-6-ylmethyl]-N- phenylmethyl) amino- methylimidazole ; 1- (1-Butyl)-2- (2-methoxyphenyl)-5- (N- [naphtha-2-ylmethyl]-N- phenylmethyl) amino-methylimidazole ; 1-(1-Butyl)-2-(2-methoxyphenyl)-5-(N-[3,4-methylenedioxyphen ylmethyl]-N- phenylmethyl) aminomethylimidazole; 1- (1-Butyl)-2- (2-methoxyphenyl)-5- (N, N-di [3,4-methylenedioxyphenylmethyl]) aminomethylimidazole ; 1- (l-Butyl)-2- (2-methoxyphenyl)-5- (N- [4-dimethylaminophenylmethyl]-N- phenylmethyl)aminomethylimidazole; 1-(1-Butyl)-2-(2-methylphenyl)-5-(N-[3, 4-methylenedioxyphenylmethyl]-N- phenylmethyl) aminomethylimidazole; 1- (1-Butyl)-2- (4-fluorophenyl)-5- (N, N-di [3,4- methylenedioxyphenylmethyl]) amino- methylimidazole ; 1- (1-Butyl)-2- (2-methylphenyl)-5- (N, N-di [3,4- methylenedioxyphenylmethyl]) amino-methylimidazole ; 1-(1-Butyl)-2-(3-fluorophenyl)-5-(N-[naphth-2-ylmethyl]-N- phenylmethyl) amino methylimidazole; 1- (l-Butyl)-2- (3-fluorophenyl)-5- (N- [3, 4-methylenedioxyphenylmethyl]-N- phenylmethyl)aminomethylimidazole; 1- (1-Butyl)-2- (3-fluorophenyl)-5- (N, N-di [3,4- methylenedioxyphenylmethyl]) amino-methylimidazole ; 1- (1-Butyl)-2- (3-methoxyphenyl)-5- (N- [3, 4-methylenedioxyphenylmethyl]-N- phenylmethyl)-aminomethylimidazole; 1- (1-Butyl)-2-phenyl-5- {1- (N- [3, 4-methylenedioxyphenylmethyl]-N- phenylmethyl) amino} ethylimidazole; 1-(1-Pentyl)-2-phenyl-5-(N-[indol-5-ylmethyl]-N-phenylmethyl ) aminomethylimidazole; Bis-benzo [1, 3] dioxol-5-ylmethyl- (3-butyl-2, 5-diphenyl-3H-imidazol-4-ylmethyl)-amine Benzo [1, 3] dioxol-5-ylmethyl-benzyl- [3-butyl-5- (4-methoxy-phenyl)-2-phenyl-3H-imidazol-4-ylmethyl]- amine 4-({Benzyl-[1-(3-butyl-2,5-diphenyl-3H-imidazol-4-yl)-ethyl] -emino}-methyl)-benzamide 4- { [Benzyl- (3-butyl-2, 5-diphenyl-3H-imidazol-4-ylmethyl)-amino]-methyl}-3-chloro- phenol 4-({[1-(3-Butyl-2-phenyl-3H-imidazol-4-yl)-pentyl]-cyclohexy lmethyl-amino}-methyl)- phenol 4- { [Benzyl- (3-butyl-2, 5-diphenyl-3H-imidazol-4-ylmethyl)-amino]-methyl}-benzamide 1- (1-Propyl)-2-phenyl-5- (N- [indol-5-ylmethyl]-N-phenylmethyl) aminomethylimidazole; 1- (1-Butyl)-2-phenyl-5-(N-[1-(S)-phenylethyl]-N- phenylmethyl)aminomethylimidazole; 1-(1-Butyl)-2-phenyl-5-(N-[1-(R)-phenylethyl]-N- phenylmethyl) aminomethylimidazole ; 1- (1-Butyl)-2-phenyl-5- (N- [3, 4-methylenedioxyphenylmethyl]-N- [3, 4- dichlorophenyl] methyl) aminomethylimidazole; 1-(1-Butyl)-2-phenyl-5-(N, N-di [3,4-methylenedioxyphenylmethyl]) aminomethylimidazole; 1- (1-Butyl)-2-phenyl-5- (N- [3, 4-methylenedioxyphenylmethyl]-N- [3, 4- methoxyphenylmethyl])-aminomethylimidazole ; 1- (1-Butyl)-2-phenyl-5- (N- [3, 4-methylenedioxyphenylmethyl]-N- [4- {1- propyl} phenylmethyl]) aminomethylimidazole; 1-(1-Butyl)-2-phenyl-5-(N-[3,4-methylenedioxyphenylmethyl]-N -[3, 4- dichlorophenylethyl]) aminomethylimidazole; 1- (l-Butyl)-2-phenyl-5- (N- [3,4-methylenedioxyphenyl] methyl-N- [4- nitrophenylmethyl]) aminomethylimidazole ; 1-(1-Butyl)-2-phenyl-5-(N-[3, 4-methylenedioxyphenylmethyl]-N- [4-{1- propyloxy} phenylmethyl]) aminomethylimidazole; 1- (l-Butyl)-2-phenyl-5- (N- [3, 4-methylenedioxyphenylmethyl]-N- [quinol-6- ylmethyl])-aminomethylimidazole; 1- (l-Butyl)-2-phenyl-5- (N- [3, 4-methylenedioxyphenylmethyl]-N- [2, 3- dichlorophenylmethyl])-aminomethylimidazole ; 1- (1-Butyl)-2-phenyl-5- (N- [3, 4-methylenedioxyphenylmethyl]-N- [3, 4- dimethylphenylmethyl])-aminomethylimidazole; 1- (l-Butyl)-2-phenyl-5- (N- [3, 4-methylenedioxyphenyl] methyl-N- [indan-2-yl])- aminomethylimidazole; 1- (l-Butyl)-2-phenyl-5- (N- [3, 4-methylenedioxyphenylmethyl]-N- [2- phenylethyl]) amino-methylimidazole; 1- (l-Propyl)-2-phenyl-5- (N- [ 1, 4-benzodioxan-6-ylmethyl]-N- phenylmethyl)aminomethyl-imidazole; 1- (1-Butyl)-2-phenyl-S- (N- [3, 4-methylenedioxyphenylmethyl]-N- phenylmethyl) aminomethyl-imidazole ; 1-(1-Butyl)-2-phenyl-5-(N- [3,4-methylenedioxyphenylmethyl]-N- ethyl)aminomethylimidazole; 1-(1-Butyl)-2-phenyl-5- (N- [3,4-methylenedioxyphenylmethyl]-N-[1- propyls)aminomethyl-imidazole; 1- (I-Butyl)-2-phenyl-5- (N- [3, 4-methylenedioxyphenylmethyl]-N- [l- butyl]) aminomethyl-imidazole ; 1- (1-Butyl)-2-phenyl-5- (N- [3, 4-methylenedioxyphenylmethyl]-N- cycloheptylmethyl) amino-methylimidazole ; 1- (1-Butyl)-2-phenyl-5- (N- [3, 4-methylenedioxyphenylmethyl]-N- isobutyl) aminomethyl-imidazole ; 1- (1-Butyl)-2-phenyl-5- (N- [3, 4-methylenedioxyphenylmethyl]-N- [2- cyclopentylethyl]) amino-methylimidazole; 1- (1-Butyl)-2-phenyl-5- (N- [3, 4-methylenedioxyphenylmethyl]-N- [3- cyclopentylpropyl]) amino-methylimidazole; 1- (1-Butyl)-2-phenyl-5- (N- [3,4-methylenedioxyphenylmethyl]-N-[1-n- octyl])aminomethyl-imidazole; 1-(1-Butyl)-2-phenyl-5-9N- [3,4-methylenedioxyphenylmethyl]-N- cyclopropylmethyl)amino-methylimidazole; 1- (l-Butyl)-2-phenyl-5- (N- [3, 4-methylenedioxyphenylmethyl]-N- cyclopentylmethyl)amino-methylimidazole; 1- (l-Butyl)-2-phenyl-5- (N- [3, 4-methylenedioxyphenylmethyl]-N- cyclohexylmethyl)amino-methylimidazole; 1- (l-Butyl)-2-phenyl-5- (N- [3, 4-methylenedioxyphenylmethyl]-N- [t- amyl]) aminomethylimidazole ; 1-(1-Butyl)-2-phenyl-5-(N-[3,4-methylenedioxyphenylmethyl]-N -[1-{3-, methyl} butyl)] amino-methylimidazole ; 1-(1-Butyl)-2-phenyl-5-(N-[3,4-methylenedioxyphenylmethyl]-N -[1-{2, 2- dimethyl} butyl]) aminomethylimidazole ; 1- (l-Butyl)-2-phenyl-5- (N- [3, 4-methylenedioxyphenylmethyl]-N- methyl)aminomethylimidazole; 1-(1-Butyl)-2-phenyl-5-(N- [3,4-methylenedioxyphenylmethyl]-N- [2- thiophenylmethyl]) amino-methylimidazole ; 1-(1-Butyl)-2-phenyl-5-(N- [3,4-methylenedioxyphenylmethyl]-N- [indol-5- ylmethyl])amino-methylimidazole; l- (l-Butyl)-2-phenyl-5- (N- [3, 4-methylenedioxyphenylmethyl]-N- [ {l-methylindol-5- yl} methyl]) aminomethylimidazole ; 1- (1-Butyl)-2-phenyl-5- (N- [3, 4-methylenedioxyphenyl] methyl-N- [4-hydroxy-2- chlorophenyl]-methyl) aminomethylimidazole ; 1-(1-Butyl)-2-(3-fluorophenyl)-5-(1-[N-(2-chloro-4-hydroxyph enyl}methyl-N- phenylmethyl]) aminoethylimidazole; 1- (l-Butyl)-2-phenyl-5- (N- [3, 4-methylenedioxyphenyl] methyl-N- [2, 3- dihydrobenzo [b] furan-5-yl] methyl) aminomethylimidazole ; 1-Butyl-2-(4-fluorophenyl)-5-(1-[N-[3,4-methylenedioxyphenyl }methyl-N- phenylmethyl]-amino) ethylimidazole; 1- (l-Butyl)-2- (2-thienyl)-5- (N- [3, 4-methylenedioxyphenyl] methyl-N-phenylmethyl] aminomethylimidazole; 1-(1-Butyl)-2-phenyl-5-(N-[3, 4,5-trimethoxyphenylmethyl]-N-phenylmethyl) amino- methylimidazole; 1- (l-Butyl)-2-phenyl-5- (N-phenylmethyl-N- [3, 4- dimethoxyphenylmethyl]) aminomethyl-imidazole; 1- (1-Butyl)-2-phenyl-5- (N- [4-dimethylaminophenylmethyl]-N- phenylmethyl)aminomethyl-imidazole; 1- (1-Butyl)-2-phenyl-5- (N- [4-methylaminophenylmethyl]-N- phenylmethyl)aminomethyl-imidazole; 1- (1-Butyl)-2-phenyl-5- (N- [3-methyl-4-aminophenylmethyl]-N- phenylmethyl)aminomethyl-imidazole); 1- (1-Butyl)-2-phenyl-5- (N- [2, 3-dichlorophenylmethyl]-N- phenylmethyl)aminomethylimidazole; 1-(1-Butyl)-2-phenyl-5-(N-[3, 4-dichlorophenylmethyl]-N- phenylmethyl)aminomethylimidazole; 1-(1-Butyl)-2-phenyl-5-(N- [3,4-difluorophenylmethyl]-N- phenylmethyl) aminomethylimidazole ; 1- (l-Butyl)-2-phenyl-5- (N- (benzo [b] thiophen-5-ylmethyl)-N- phenylmethyl) aminomethyl-imidazole ; l- (l-Butyl)-2-phenyl-5- (N- [4-ethoxyphenylmethyl]-N- phenylmethyl)aminomethylimidazole; 1- (l-Butyl)-2-phenyl-4-bromo-5- (N-phenylmethyl-N- [l-butyl]) aminomethylimidazole ; 1- (1-Butyl)-2-phenyl-5- (N- [4-methoxyphenylmethyl]-N- phenylmethyl) aminomethylimidazole ; 1-(1-Butyl)-2-phenyl-5-(N-[6-chloro-3, 4-methylenedioxyphenylmethyl]-N- phenylmethyl)-aminomethylimidazole; 1- (1-Butyl)-2-phenyl-5- (N- [2,3-dichlorophenylmethyl]-N-[1- butyl])aminomethylimidazole; 1- (1-Butyl)-2-phenyl-5- (N- [3-methoxyphenylmethyl]-N- phenylmethyl) aminomethylimidazole; 1-(1-Butyl)-2-phenyl-5-(N-[2-chloro-4-fluorophenylmethyl]-N- phenylmethyl) aminomethyl-imidazole ; 1-(1-Butyl)-2-phenyl-4-bromo-5-(N- [2,3-dichlorophenylmethyl]-N-[1- butyl])aminomethyl-imidazole; 1-(1-Butyl)-2-phenyl-5-(N-[2, 6-dichlorophenylmethyl]-N- phenylmethyl)aminomethylimidazole; 1- (1-Butyl)-2-phenyl-5- (N- [2-chloro-4-hydroxyphenylmethyl]-N- phenylmethyl) aminomethyl-imidazole ; 1-(1-Butyl)-2-phenyl-4-chloro-5-(N-phenylmethyl-N-[1-butyl]) aminomethylimidazole; 4- { [Benzyl- (3-butyl-2, 5-diphenyl-3H-imidazol-4-ylmethyl)-aminol-methyl}-2-methyl- phenol 4-{[(3-Butyl-2,5-diphenyl-3H-imidazol-4-ylmethyl)-cyclohexyl methyl-amino]-methyl}-2- methyl-phenol (3-Butyl-2,5-diphenyl-3H-imidazol-4-ylmethyl)-(2,5-difluoro- benzyl)-(4-methoxy-benzyl)- amine Benzo [1, 3] dioxol-5-ylmethyl-butyl-[3-butyl-2-(2-methoxy-phenyl)-5-phen yl-3H-imidazol-4-yl methyl]-amine 4- ({Benzyl-[3-butyl-2-(2-methoxy-phenyl)-5-phenyl-3H-imidazol- 4-ylmethyl]-amino}-methyl)- benzenesulfonamide Benzo [1, 3] dioxol-5-ylmethyl-benzyl- [3-butyl-2- (2-methoxy-phenyl)-5-phenyl-3H-imidazol-4-yl methyl]-amine 4- ( {Butyl- [3-butyl-2- (3-methoxy-phenyl)-5-phenyl-3H-imidazol-4-ylmethyl]-amino}-m ethyl )-3-chloro- phenol 4- { [ (3-Butyl-2,5-diphenyl-3H-imidazol-4-ylmethyl)- (4-methoxy-benzyl)-amino]-methyl}-benzoic acid 4-({Benzyl-[3-butyl-2-(3-methoxy-phenyl)-5-phenyl-3H-imidazo l-4-ylmethyl]-amino}-methyl)-3-chloro- phenol Benzol, 3] dioxol-5-ylmethyl-benzyl- [l- (3-butyl-2, 5-diphenyl-3H-imidazol-4-yl)-pentyl]-amine Benzo [1, 3] dioxol-5-ylmethyl-benzyl- [1- (3-butyl-2, 5-diphenyl-3H-imidazol-4-yl)-ethyl]-amine 4-{[Butyl-(3-butyl-2,5-diphenyl-3H-imidazol-4-ylmethyl)-amin o]-methyl}-benzamide Benzoyl, 3] dioxol-5-ylmethyl-benzyl- [3-butyl-5- (4-fluoro-phenyl)-2-phenyl-3H-imidazol-4-ylmet hyl]- amine 3-{[Benzyl-(3-butyl-2,5-diphenyl-3H-imidazol-4-ylmethyl)-ami no]-methyl}-phenol 4-{[Butyl-(3-butyl-5-tert-butyl-2-phenyl-3H-imnidazol-4-ylme thyl}-amino]-methyl}-benzamide Benzyl- (3-butyl-2, 5-diphenyl-3H-imidazol-4-ylmethyl)- (2, 3-dihydro-benzo[1, 4] dioxin-6-ylmethyl)-amm (3-Butyl-2,5-diphenyl-3H-imidazol-4-ylmethyl}-(2,5-difluoro- benzyl}-{4-methoxy-benzyl)-amine (3-Butyl-2,5-diphenyl-3H-imidazol-4-ylmethyl)- (2, 6-dichloro-benzyl)- (4-methoxy-benzyl)- amine 4- { [Benzyl- (3-butyl-2, 5-diphenyl-3H-imidazol-4-ylmethyl)-amino]-methyl}-2, 6-dimethyl-phenol 4-({[3-Butyl-5-(4-methoxy-phenyl)-2-phenyl-3H-imidazol-4-ylm ethyl]-cyclohexylmethyl-amino}-methyl)- 2,6-dimethyl-phenol [3-Butyl-5- (4-methoxy-phenyl)-2-phenyl-3H-imidazol-4-ylmethyl]-cyclohex ylmethyl- (2, 3-dihydro-benzo furan-5-ylmethyl)-amine 4- { [Butyl- (3-butyl-2, 5-diphenyl-3H-imidazol-4-ylmethyl)-amino]-methyl}-2, 6-dimethyl-phenol 4-({Butyl-[1-(3-butyl-2,5-diphenyl-3H-imidazol-4-yl)-ethyl]- amino}-methyl)-2, 6-dimethyl-phenol 4-{[93-Butyl-2,5-diphenyl-3H-imidazol-4-ylmethyl)-(4-dimethy lamino-benzyl)-amino]-methyl} -benzoic acid 4-{5-[(Bis-benzo[1, 3] dioxol-5-ylmethyl-amino)-methyl]-2, 4-diphenyl-imidazol-1-yl}-butyric acid ethyl ester 4-{5-[(Bis-benzo[1, 3] dioxol-5-ylmethyl-amino)-methyl]-2,4-diphenyl-imidazol-1-yl} -butan-1-o 1 (4-{[(3-Butyl-2,5-diphenyl-3H-imidazol-4-ylmethyl)-cyclohexy lmethyl-amino]-methyl}-phenyl)- dimethyl-amine 1- (1-Butyl)-2-phenyl-5- (N- [4- { 1-pyrrolidinyl} phenylmethyl]-N- phenylmethyl)aminomethyl-imidazole; 1- (. 1-Butyl)-2-phenyl-5- (N- [4-diethylaminophenylmethyl]-N- phenylmethyl)aminomethyl-imidazole; 1- (1-Butyl)-2-phenyl-5- (N- [pyridin-2-ylmethyl]-N- phenylmethyl) aminomethylimidazole; 1-(1-Butyl)-2-phenyl-5-(N-[pyridin-3-ylmethyl]-N- phenylmethyl) aminomethylimidazole ; 1-(1-Butyl)-2-phenyl-5-(N-[pyridin-4-ylmethyl]-N- phenylmethyl)aminomethylimidazole; 1-(1-Butyl)-2-phenyl-5-(N-[2-fluoro-6-chlorophenylmethyl]-N- phenylmethyl) aminomethyl-imidazole) ; 1-(1-Butyl)-2-phenyl-5-(N-[2,4-dichlorophenylmethyl]-N-pheny lmethyl) aminomethyl- imidazole); 1- (1-Butyl)-2-phenyl-5- (N- [4-chlorophenylmethyl]-N- phenylmethyl) aminomethylimidazole; 1- (1-Butyl)-2-phenyl-5- (N- [4-hydroxyphenylmethyl]-N- phenylmethyl)aminomethylimidazole; 1-(1-Butyl)-2-phenyl-5-(N-[4-trifluoromethoxyphenylmethyl]-N - phenylmethyl) aminomethyl-imidazole) ; 1-(1-Butyl)-2-phenyl-5-(N-[2-chloro-3, 4-dimethoxyphenylmethyl]-N- phenylmethyl) amino-methylimidazole); 1- (1-Butyl)-2-phenyl-5- (N- [4-nitrophenylmethyl]-N- phenylmethyl)aminomethylimidazole; 1-(1-Butyl)-2-phenyl-5-(N-[4-aminophenylmethyl]-N- phenylmethyl)aminomethylimidazole; 1- (1-Butyl)-2, 4-diphenyl-5- (N-phenylmethyl-N- [ I-butyl]) aminomethylimidazole; 1- (l-Butyl)-2-phenyl-5- (N- [2-aminopyridin-5-ylmethyl]-N- phenylmethyl)aminomethyl-imidazole 1-(1-Butyl)-2-phenyl-5-(N-[2, 3-dihydrobenzo [b] furan-5-ylmethyl]-N- phenylmethyl) amino-methylimidazole ; 1-(1-Butyl)-2-phenyl-5-(N-[2-chloro-4-hydroxyphenylmethyl]-N -[1- butyl]) aminomethyl-imidazole) 1-(1-Butyl)-2-phenyl-4-methyl-5-(N-phenylmethyl-N-[1-butyl]) aminomethylimidazole; 1- (1-Butyl)-2- (4-fluorophenyl)-5- (N- [2-chloro-4-hydroxyphenylmethyl]-N- phenylmethyl)-aminomethylimidazole ; 1- (1-Butyl)-2- (3-fluorophenyl)-5- (N- [2-chloro-4-hydroxyphenylmethyl]-N- phenylmethyl)-aminomethylimidazole ; 1- (1-Butyl)-2- (3-fluorophenyl)-5- (N- [2,3-dichlorophenylmethyl]-N- phenylmethyl)amino-methylimidazole; 1- (1-Butyl)-2- (3-fluorophenyl)-5- (N- [4-dimethylaminophenylmethyl]-N- phenylmethyl) amino-methylimidazole; 1- (1-Butyl)-2- (3-fluorophenyl)-5- (N- [4-{1-pyrrolidinyl} phenylmethyl]-N- phenylmethyl) amino-methylimidazole; 1-(1-Butyl)-2-(3-chlorophenyl)-5-(1-[N-(2-chloro-4-hydroxyph enylmethyl}-N- phenylmethyl] amino) ethylimidazole; 1-(1-Butyl)-2-phenyl-5-(N-[indol-5-ylmethyl]-N-phenylmethyl) aminomethylimidazole; 1-(1-Butyl)-2-(4-fluorophenyl)-5-(1-N, N-di [3, 4- methylenedioxyphenylmethyl] amino) ethylimidazole ; 2- { [5- ( {Butyl [ (1-butyl-2, 4-diphenylimidazol-5-yl) methyl] amino} methyl)-2- pyridyl] amino} ethan-l-ol ; As discussed above, preferred compounds of the invention exhibit good activity in standard in vitro C5 receptor mediated chemotaxis assay, specifically the assay as specified in Example 12, which follows. References herein to"standard in vitro C5 receptor mediated chemotaxis assay"are inteided to refer to that protocol as defined in Example 12 which follows. Preferred compounds of the invention exhibit an ECso of about 100 uM or less in such a standard C5a mediated chemotaxis assay, more preferably an ECSO of about 10 I1M or less in such a standard C5a mediated chemotaxis assay, still more preferably an ECso of about 1 uM in such a standard C5a mediated chemotaxis assay, even more preferably an ECso of about 0.1 M in such a standard C5a mediated chemotaxis assay.

Additional assays suitable for determining the effects of small molecule compounds on C5a receptor binding and receptor modulatory activity, as well as assays suitable for measuring their effects on C5a-induced neutropenia in vivo, can be found in the published literature, for example in US patent 5,807,824, which is incorporated herein by reference for its disclosure in this regard in Examples 6-9, columns 19-23, as well as for its discussion of complement and inflammation at columns 1-2. Those of skill in the art will recognize that such assays can be readily adapted to the use of cells or animals of different species as deemed appropriate.

In one aspect of the invention, one or more compounds of the invention, preferably in solution in a pharmaceutically acceptable carrier as a pharmaceutical preparation, is used to perfuse a donor organ prior to transplantation of the organ into a recipient patient. Such perfusion is preferably carried out using a solution comprising an concentration of the compound of the invention that is an effective amount sufficient to inhibit C5a mediated effects in vitro or in vivo. Such perfusion preferably reduces the severity or frequency of one or more of the inflammatory sequelae following organ transplantation when compared to that occurring in control (including, without restriction, historical control) transplant recipients who have received transplants of donor organs that have not been so perfused.

Definitions In certain situations, the compounds of of the invention may contain one or more asymmetric elements such as stereogenic centers, stereogenic axes and the like, e. g. asymmetric carbon atoms, so that the compounds can exist in different stereoisomeric forms. These compounds can be, for example, racemates or optically active forms. For compounds with two or more asymmetric elements, these compounds can additionally be mixtures of diastereomers. In these situations, the single enantiomers, i. e., optically active forms, can be obtained by asymmetric synthesis, synthesis from optically pure precursors or by resolution of the racemates. Resolution of the racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral HPLC column.

The term"substituted", as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valence is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i. e., =0), then 2 hydrogens on the atom are replaced. Keto substituents are not present on aromatic moieties. The present invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example, and without limitation, isotopes of hydrogen include tritium and deuterium and isotopes of carbon include"C, i3C, and 14C.

When any variable occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R*, then said group may optionally be substituted with up to two R* groups and R* at each occurrence is selected independently from the definition of R*. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

As indicated herein, various substituents of the compounds of the present invention and various formulae set forth herein are"optionally substituted", including, e. g., Arl, Ar2, R, Ri, R2, R3, R3A, R4, Rs, R6, R7, RA, RA', RB, and Rc. When substituted, those substituents may be substituted at one or more of any of the available positions, typically 1,2,3, or 4 positions, by one or more suitable groups such as those disclosed herein.

Suitable groups or"substituted"moities of compounds of the invention include e. g., halogen such as fluoro, chloro, bromo or iodo; cyano; hydroxyl; nitro; azido; alkanoyl such as a Cl-6 alkanoyl group such as acyl and the like ; carboxamido; alkyl groups including those groups having 1 to about 12 carbon atoms, or 1,2,3,4,5, or 6 carbon atoms; alkenyl and alkynyl groups including groups having one or more unsaturated linkages and from 2 to about 12 carbon, or 2,3,4,5 or 6 carbon atoms; alkoxy groups having those having one or more oxygen linkages and from 1 to about 12 carbon atoms, or 1,2,3,4,5 or 6 carbon atoms; aryloxy such as phenoxy; alkylthio groups including those moieties having one or more thioether linkages and from 1 to about 12 carbon atoms, or 1,2,3,4,5 or 6 carbon atoms; alkylsulfinyl groups including those moieties having one or more sulfinyl linkages and from 1 to about 12 carbon atoms, or 1,2,3,4,5, or 6 carbon atoms; alkylsulfonyl groups including those moieties having one or more sulfonyl linkages and from 1 to about 12 carbon atoms, or 1,2,3,4,5, or 6 carbon atoms; aminoalkyl groups such as groups having one or more N atoms and from 1 to about 12 carbon atoms, or 1,2,3,4,5 or 6 carbon atoms; carbocyclic aryl having 6 or more carbons, particularly phenyl (e. g. an Ar group being a substituted or unsubstituted biphenyl moiety); arylalkyl having 1 to 3 separate or fused rings and from 6 to about 18 carbon ring atoms, with benzyl being a preferred group; aralkoxy having 1 to 3 separate or fused rings and from 6 to about 18 carbon ring atoms, with 0-benzyl being a preferred group; or a heteroaromatic or heteroalicyclic group having 1 to 3 separate or fused rings with 3 to about 8 members per ring and one or more N, O or S atoms, e. g. coumarinyl, quinolinyl, pyridyl, pyrazinyl, pyrimidyl, furyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, indolyl, benzofuranyl, benzothiazolyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, morpholino and pyrrolidinyl.

As used herein,"alkyl"is intended to include both branched and straight- chain saturated aliphatic hydrocarbon groups, having the specified number of carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n- propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl. Preferred alkyl groups are Cl-C8 and C1 6 alkyl groups. Especially preferred alkyl groups are methyl, ethyl, propyl, butyl, 3-pentyl. The term Ci-6 alkyl as used herein includes alkyl groups consisting of 1 to 6 carbon atoms, which may contain a cyclopropyl moiety.

Suitable examples are methyl or ethyl.

"Cycloalkyl"is intended to include saturated ring groups, having the specified number of carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl and brigded or caged saturated ring groups such as norbornane or adamantane and the like.

In the term" (C3-6 cycloalkyl) Cl-4 alkyl", as defined above, the point of attachment is on the alkyl group. This term encompasses, but is not limited to, cyclopropylmethyl, cyclohexylmethyl and cyclohexylethyl.

"Alkenyl"is intended to include hydrocarbon chains of either a straight or branched configuration comprising one or more unsaturated carbon-carbon bonds, which may occur in any stable point along the chain, such as ethenyl and propenyl.

"Alkynyl"is intended to include hydrocarbon chains of either a straight or branched configuration comprising one or more triple carbon-carbon bonds that may occur in any stable point along the chain, such as ethynyl and propynyl.

"Haloalkyl"is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen (for example-C" (Xi) wi (H2v+1-#(wl)) where v = 1 to 3; Xi = F (i=l), Cl (i=2), Br (i=3), I (i=4) and SwiS2v+1). Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl.

"Alkoxy"represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, 2- butoxy, t-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, n- hexoxy, 2-hexoxy, 3-hexoxy, and 3-methylpentoxy.

As used herein, the term"carbocyclic aryl"indicates aromatic groups containing only carbon in the aromatic ring. Such aromatic groups may be further substituted with carbon or non-carbon atoms or groups. Typical carbocyclic aryl groups contain 1 to 3 separate of fused rings and from 6 to about 18 ring atoms, without heteroatoms as ring members. Specifically preferred carbocyclic aryl groups include phenyl, napthyl, including 1-naphthyl and 2-naphthyl, and acenaphthyl.

By the term"energetically accessible conformer"is meant any conformer of a compound that falls within about a 15 Kcal/mol window above the lowest energy conformation (as for example that found in a monte carlo or systematic confirmational search) by using MM2, MM3, or MMFF force fields as implemented in molecular modeling software such as MacroModel v 7.0, Schrödinger, Inc., Portland, Oregon United Stats and Jersey City, New Jersey, United States, http :/lwww. schrodinger. com or the like.

Peptidomimetic compounds are generally compounds with"chemical structures derived from bioactive peptides which imitate natural molecules" (Murray Goodman and Seonggu Ro,"Peptidomimetics for Drug Design"chapter twenty in Burger's Medicinal Chemistry and Drug Discovery, Volume 1 : Principles and Practice, Manfred E. Wolff, ed. John Wiley & Sons, Inc., NY, 1995, pp. 801- 861.) As used herein and in the claims, the term peptidomimetic additionally comprises peptoid compounds, which are compounds that comprise oligomers of N- substituted natural amino acids, and the term further comprises any compound having more than two amide bonds.

As used herein, the terms"heteroaryl"and-"heteroalicyclic"group are intended to indicate a stable 5-to 7-membered monocyclic or bicyclic or 7-to 10- membered bicyclic heterocyclic ring which is saturated, partially unsaturated or unsaturated (aromatic), and which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, 0 and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The term heteroaryl indicates that the group contains at least 1 aromatic ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. A nitrogen in the heterocycle may optionally be quaternized.

It is preferred that when the total number of S and 0 atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and 0 atoms in the heterocycle is not more than 1,2, or 3, more typically 1 or 2. It is preferred that the total number of S and O atoms in the aromatic heterocycle is not more than 1.

Examples of heteroaryl groups and other heterocycles include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, NH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H, 6H-1, 5,2-dithiazinyl, dihydrofuro [2,3-b] tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl ;- 1, 2,5oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1, 2,5-thiadiazinyl, 1,2,3- thiadiazolyl, 1, 2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1, 3,4thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, and xanthenyl.

Preferred heteroaryl groups include, but are not limited to, pyridinyl, pyrimidinyl, furanyl, and thienyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.

The term"halogen"indicates fluorine, chlorine, bromine, or iodine.

The term"pharmaceutically acceptable salts"includes, but is not limited to non-toxic salts with inorganic acids such as hydrochloride, sulfate, phosphate, diphosphate, hydrobromide, and nitrite or salts with an organic acids such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, 2-hydroxyethylsulfonate, salicylate and stearate. Similarly, pharmaceutically acceptable cations include, but are not limited to sodium, potassium, calcium, aluminum, lithium and ammonium. The present invention also encompasses the prodrugs of the compounds disclosed.

Examples of bicyclic oxygen containing groups of the formula: (RA may also be indicated Ra) include the following: Methods of Treating Patients The present invention provides methods of treating patients suffering from diseases or disorders involving pathologic activation of C5a receptors. Such diseases and disorders may include the following.

Such disorders that may be autoimmune in nature and are suitable for treatment in accordance with the present invention include e. g. rheumatoid arthritis, systemic lupus erythematosus (and associated glomerulonephritis), psoriasis, Crohn's disease, vasculitis, irritable bowel syndrome, dermatomyositis, multiple sclerosis, bronchial asthma, pemphigus, pemphigoid, scleroderma, myasthenia gravis, autoimmune hemolytic and thrombocytopenic states, Goodpasture's syndrome (and associated glomerulonephritis and pulmonary hemorrhage), and immunovasculitis. Such inflammatory and related conditions include neutropenia, sepsis, septic shock, Alzheimer's disease, stroke, inflammation associated with severe burns, lung injury, myocardial infarction, coronary thrombosis, vascular occlusion, post-surgical vascular reocclusion, artherosclerosis, traumatic central nervous system injury and ischemic heart disease, and ischemia- reperfusion injury, as well as acute (adult) respiratory distress syndrome (ARDS), systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), tissue graft rejection, and hyperacute rejection of transplanted organs. Also included are pathologic sequellae associated with insulin-dependent diabetes mellitus (including diabetic retinopathy), lupus nephropathy, Heyman nephritis, membranous nephritis and other forms of glomerulonephritis, contact sensitivity responses, and inflammation resulting from contact of blood with artificial surfaces that can cause complement activation, as occurs, for example, during extracorporeal circulation of blood (e. g., during hemodialysis or via a heart- lung machine, for example, in association with vascular surgery such as coronary artery bypass grafting or heart valve replacement) such as extracorporeal post- dialysis syndrome, or in association with contact with other artificial vessel or container surfaces (e. g., ventricular assist devices, artificial heart machines, transfusion tubing, blood storage bags, plasmapheresis, plateletpheresis, and the like).

Treatment methods of the invention include in general administration to a patient a therapeutically effective amount of one or more compounds of the invention. Suitable patients include those subjects suffering from or susceptible to (i. e. propylactic treatment) a disorder or disease identified herein. Typical patients for treatment in accordance with the invention include mammals, particularly primates, especially humans. Other suitable subjects include domesticated companion animals such as a dog, cat, horse, and the like, or a livestock animal such as cattle, pig, sheep and the like.

Pharmaceutical Preparations The compounds of the invention may be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. Oral administration in the form of a pill, capsule, elixir, syrup, lozenge, troche, or the like is particularly preferred. The term parenteral as used herein includes injections and the like, such as subcutaneous, intradermal, intravascular (e. g., intravenous), intramuscular, intrasternal, spinal, intrathecal, and like injection or infusion techniques, with subcutaneous, intramuscular and intravascular injections or infusions being preferred. In addition, there is provided a pharmaceutical formulation comprising a compound of the invention and a pharmaceutically acceptable carrier. One or more compounds of the invention may be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or adjuvants and if desired other active ingredients.

The pharmaceutical compositions containing compounds of the invention may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.

Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.

Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monosterate or glyceryl distearate may be employed.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.

Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti- oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.

Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

Pharmaceutical compositions of the invention may also be in the form of oil- in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.

Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monoleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monoleate. The emulsions may also contain sweetening and flavoring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono-or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

The compounds of the invention may also be administered in the form of suppositories e. g., for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

Compounds of the invention may be administered parenterally, preferably in a sterile non-toxic, pyrogen-free medium. The drug, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle.

Advantageously, adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.

Dosage levels of the order of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment or preventions of conditions involving pathogenic C5a activity, particularly those disorders list in the "background of the invention"section (about 0.5 mg to about 7 g per patient per day). The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient.

Frequency of dosage may also vary depending on the compound used and the particular disease treated. However, for treatment of most disorders, a dosage regimen of 4 times daily, three times daily, or less is preferred, with a dosage regimen of once daily or 2 times daily being particularly preferred.

It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination (i. e., other drugs being administered to the patient), the severity of the particular disease undergoing therapy, and other factors, including the judgment of the prescribing medical practitioner.

Preferred compounds of the invention will have favorable pharmacological properties. Such properties include, but are not limited to bioavailability (e. g., oral bioavailibilty, preferably high enough to permit oral administration of doses of less than 2 grams, preferably of less than or equal to one gram), low toxicity, low serum protein binding and desirable in vitro and iri vivo half-lifes. Distribution in the body to sites of complement activity is also desirable, e. g., compounds used to treat CNS disorders will preferably penetrate the blood brain barrier, while low brain levels of compounds used to treat periphereal disorders are typically preferred.

Assays may be used to predict these desirable pharmacological properties.

Assays used to predict bioavailability include transport across human intestinal cell monolayers, including Caco-2 cell monolayers. Toxicity to cultured hepatocyctes may be used to predict compound toxicity. Penetration of the blood brain barrier of a compound in humans may be predicted from the brain levels of the compound in laboratory animals given the compound intravenously.

Serum protein binding may be predicted from albumin binding assays. Such assays are described in a review by Oravcova, et al. (Journal of Chromatography B (1996) volume 677, pages 1-27).

Compound half-life is inversely proportional to the frequency of dosage required for the effective administration of a compound. In vivo half-lifes of compounds may be predicted, e. g., from assays of microsomal half-life as described by Kuhnz and Gieschen (Drug Metabolism and Disposition, (1998) volume 26, pages 1120-1127).

Preparation of compounds Representative methods for preparing the compounds of the invention are shown in the following Schemes. Schemes 1 and 2 show the preparation of arylimidazole compounds. Scheme 1 illustrates the preparation of arylimidazole compounds where Rl is hydrogen or halogen. Scheme 2 represents of the preparation of aryl imidazole compounds where Rl is alkyl. Within Schemes 1 and 2 the variables Arl, Ar2, Ri, R2, R3 and R4 # are defined as above for Formula I.

Schemel. Synthesis of 1-Alkyl-2-aryl-5-aminomethylimidazoles As shown in Scheme 1, an appropriately substituted arylnitrile 10 is converted to the imidate 11 via treatment with hydrogen chloride gas in methanol followed by subsequent treatment with base to release the free base. Amidine 12 is prepared from 11 by treatment with a primary amine. 2-Arylimidazole-4-carboxaldehyde 13 is prepared from 12 by one of several methods described in the chemical literature, for instance, by treatment with 2-bromo-3-isopropoxyacrolein in the presence of base. See, for example, J. Org, Chem., 62: 8449 (Shilcrat et al., 1997).

Aldehyde 13 can then be transformed into hydroxymethylimidazole 14 either by reduction (for cases where R4 is hydrogen) or by treatment with the appropriate organometallic (for cases where R4 is C1-C6 alkyl). The hydroxy group of 14 is converted to either a halogen or sulfonate ester leaving group. Treatment of this intermediate with an appropriate secondary amine in the presence of base provides 2-aryl-4-aminomethylimidazole 15. Alternatively, the aminoalkyl functionality of 15 may be elaborated by sequential amination-acylation-reduction steps. In situations where Ri is a halogen, it may be prepared from 15 (Ri=H) by treatment with the molecular halogen, a halosuccinimide or the like.

As shown in Scheme 2, an appropriately substituted 2-aryl-4- substitutedimidazole 20 can be N-alkylated by treatment with base such as sodium hydride and an alkyl halide or alkylsulfonate ester to provide the trisubstituted imidazole 21. Hydroxymethylation of 21 under the conditions of the Mannich reaction provides hydroxymethylimidazole 22. In examples where R3 is alkyl, hydroxymethyl derivative 24 is prepared from 22 by oxidation to aldehyde 23 and subsequent treatment with an appropriate organometallic reagent such as an alkyl lithium or Grignard reagent. Conversion of 22 or 24 to the, desired 2-aryl-S- aminomethylimidazoles is carried out by conversion of the hydroxymethyl to a halogen or sulfonate ester leaving group followed by treatment with a secondary amine. Alternatively, the aminoalkyl functionality of the 2-aryl-5- aminomethylimidazole product may be elaborated by sequential amination- acylation-reduction steps. Scheme 2. Synthesis of 2-Arylimidazoles Where R2 is alkyl : N R N Base _ /'HCHO N,-S Ri Base N RI HCHO N Ri R2X N Acettc acid H R2 R2 20 21 22 Where R3 is alkyl : N RI N RI Mon02 N 22 > N CHO I R2 R2 3 23 23 Where R3 is hydrogen N Ri R4 22 30 N N N I R3 Ar2 The 2-aryl-4-substitutedimidazole 20 may be prepared by methods described in the chemical literature, for instance, via condensation of an arylamidine with a halomethyl or hydroxymethyl ketone.

Cycloalkylimidazoles An illustration of the preparation of compounds of the Cycloalkylimidazole compounds of the present invention is given in Scheme 3. Within Scheme 3 the variables n, Arl, Ar2, R2, R3, R3a, R4, Rs, R6, R5a, Rua, R7 and X are defined previously.

Scheme 3. Preparation of Cyctoalkytimidazoles R3a R5 R nu (CR5aCR6a) n Me0 Ar N H + R2 Br Br 30 31 if R3a Rg R6 Jure ruz (CR5aCR6a) n N 1 0 Arl N au1 R3a Rs R s # R3--\ / (CRsacR6a) n N R7 1 Compound 33 X= OH Art N Compound 34 X = halogen or sulphonate ester R2 R3a R5 R6 'R P5 ? F R L-Rs 3a R, (CR5aCR6a) n N i/' N Arl N (\-Ar2 R2 As shown in Scheme 3, an appropriately substituted arylamidine 30 is condensed with an appropriately substituted 2-halo-3-alkoxyenone 31 to provide a 2-aryl-4,5- cycloalkylimidazole 32. The ketone functionality of 32 can be either reduced (R7 = H) or treated with an appropriate organometallic (for cases where R7 is alkyl) to give the cyclic alcohol 33. Compounds of general formula 34 can be prepared from 33 by one of several methods described in the chemical literature, for instance, by treatment with thionyl chloride or by treatment with an alkyl or arylsulphonyl chloride in the presence of base.

Compounds of formula 34 can then be transformed into compounds of general Formula 35 by direct treatment with the appropriate secondary amine.

Alternatively, the X functionality of 34 may be transformed into a tertiary amine in a stepwise manner. In this case, 34 would be treated with a primary amine to provide an intermediate secondary amine. This, in turn, could be alkylated to give cycloalkylimidazole compounds of the invention.

Pyridines An illustration of the preparation of pyridine compounds of the present invention is given in Scheme 4. Those having skill in the art will recognize that the starting materials may be varied and additional steps employed to produce compounds encompassed by the present invention. Within Scheme 4 the variables Ari, Ar2, R, Ri, R2, R3, and R4 are defined as previously described.

Scheme 4. Preparation of Aryl pyridines As shown in Scheme 4, an appropriately substituted 4-phenyloxazole 40 is condensed with an appropriately substituted maleic acid to provide a 2- phenylisonicotinic acid 41. The carboxylic acid functionality of 41 can be reduced directly to the primary alcohol (43, R3 = H) or converted by methods known to the art to an intermediate aldehyde 42 and subsequently treated with the appropriate organometallic (for cases where R3 is alkyl) to give a secondary alcohol 43.

Compounds of general formula 44 can be prepared from 43 by one of several methods described in the chemical literature, for instance, by initial treatment with thionyl chloride or with an alkyl or arylsulphonyl chloride in the presence of base, followed by subsequent condensation with a primary amine. Compounds of formula 44 can then be transformed into compounds of formula 45 by direct treatment with the appropriate alkylating agent or, alternatively, by reductive alkylation.

Alternatively, the tertiary amine functionality of formula 45 may be realized directly from compounds of formula 43 by initial treatment with thionyl chloride or with an alkyl or arylsulphonyl chloride in the presence of base, followed by subsequent condensation with a secondary amine.

Pyrazoles An illustration of the preparation of arylpyrazole compounds of the present invention is given in Scheme 5. Within Scheme 5 the variables Arl, Ar2, Ri, R2, R3, and R4 are defined as previously described.

Scheme 5. Preparation of Arvlpyrazoles As shown in Scheme 5, an appropriately substituted phenylhydrazine adduct 50 is condensed with an appropriately substituted α-ketoester 51, in the presence of a Lewis acid, preferably ZnClz, with heating at 50-200 oC, preferably at 125 oc to provide a 1-phenylpyrazole ester 52. The carboxylic acid functionality of 52 can be reduced directly to the primary alcohol (53, R3 = H) or converted by methods known to the art to an intermediate aldehyde and subsequently treated with the appropriate the appropriate organometallic (for cases where R3 is alkyl) to give a secondary alcohol 53. Compounds of general formula 54, where LG represents a leaving group, can be prepared from 53 by one of several methods described in the chemical literature, for instance, by initial treatment with thionyl chloride or with an alkyl or arylsulphonyl chloride in the presence of base, followed by subsequent condensation with a primary amine. Compounds of formula 54 can then be transformed into compounds of formula 58 by sequential treatment with the appropriate primary amine followed by direct alkylation or reductive alkylation of the intermediate secondary amine. Alternatively, the tertiary amine functionality of formula 58 may be realized directly from compounds of formula 53 by initial treatment with thionyl chloride or with an alkyl or arylsulphonyl chloride in the presence of base, followed by subsequent condensation with a secondary amine.

An alternative route to the preparation of compounds of Formula 58 from the 1-phenylpyrazole ester 52 may be realized by hydrolysis of 52 to a carboxylic acid of general structure 56, followed by amide formation to provide 57 and, finally, reduction of the amide functionality to the tertiary amine of 58 (R3=H).

Scheme 6. Preparation of 2-(1-arv1-1, 2, 3s4-tetrahydroiso quinolin-2-sl) acetamides and bicyclic of other ring sizes fun=0. 1, 2, 3, etc) The 2- (1, 2,3,4-tetrahydroisoquinolin-2-yl) acetamides of general formula 62 of the present invention may be prepared according to the procedure described graphically in Scheme 6, wherein a compound of general Formula 60, prepared according to literature procedures, (for example: Scully, Frank E., Jr.; Schlager, John J. Synthesis of dihydroisoquinolines and 1-substituted tetrahydroisoquinolines. Heterocycles (1982), 19 (4), 653-6 or Shinohara, Tatsumi; Takeda, Akira; Toda, Jun; Terasawa, Noriyo; Sano, Takehiro. A highly efficient synthesis of 1-methyl-, 1-benzyl-, and l-phenyl-1, 2,3,4- tetrahydroisoquinolines by a modified Pummerer reaction. Heterocycles (1997), 46: 555-566.) is combined (in an appropiate solvent in the presence of an organic or inorganic base) with an appropriately substituted acetamid derivative possessing a leaving group X at its 2 position. For example, X may be halogen, alkyl or aryl sulfonate, or polyfluoroalkylsulfonate. Acetamides of general Formula 61 may be prepared via condensation of the appropriate secondary amine with a 2- haloacetylhalide (such as 2-chloroacaetyl chloride) in the presence of base.

Alternatively acetamides of general formula 61 can be prepared by condensation of the appropriate secondary amine with either a 2-(alkylsulfonylester) acetic acid or 2- (arylsulfonylester) acetic acid in the pressence of an coupling agent such as CDI or the like.

Within Scheme 6, Ri, R2, R3, R4 and R5 may be the same or different and are chosen from hydrogen, halogen, Ci-Ce alkyl, Cl-C6 alkoxy, hydroxy, trifluoromethyl, trifluoromethoxyl, cyano, nitro, hydroxy carbonyl (COOH), aminocarbonyl (CONH2), mono or dialkylaminocarbonyl, sulfonamido, mono or dialkylsulfonamido, amino, mono-or di-alkylamino, aceto, acetoxy or 3,4-methylenedioxy or ethylenedioxy. The term n refers to an integer from 1 to 3. R6 may be Cl-Cg straight or branched chain alkyl, benzyl (substituted or unsubstituted), phenylethyl (substituted or unsubstituted), phenylpropyl (substituted or unsubstituted), or may be cycloalkyl fused with an aromatic group such as 1,2,3,4-tetrahydronaphthyl, 1-or 2-indanyl or suberanyl.

Scheme 7. Preparation of Ortho Biarvlamides zers 3 R2 R4 I-SOC12 or R2 R4 CDI OH 2, g5R61Vg R NR5R6 x ol 1 I I x o "X 0 70 71 Suzuki or Stille R3 coupling R1 sI < nI NR5R6 R, NR5R6 au Ar 0 72 The preparation of the ortho biarylamides of the present invention may be carried out via a series of chemical transformations similar to those displayed graphically in Scheme 7. An individual skilled in the art may find modifications of one or several of the synthetic steps described herein without diverting significantly from the overall synthetic scheme.

Thus, as shown, the synthetic route begins with a benzoic acid of general structure 70 possessing a group X at the ortho position. This X group may be iodine, bromine, chlorine, sulfonate ester or polyfluoroalkylsulfonate ester. The benzoic acid may also be substituted by up to four independently chosen substitutents represented by the variables Rl-R4. Examples of suitable substituents include hydrogen, chlorine, fluorine, cyano, Cl-C6 straight or branched chain alkyl, Cl-C6 straight or branched chain alkoxy, trifluoromethyl, trifluoromethoxy, nitro, amino, mono or dialkyl amino, sulfonamido, mono or dialkylsulfonamido, alkylthio e. g. methylthio, alkylsulfoxide, alkylsulfone, acetyl, acetoxy, alkoxycarbonyl (COOAlkyl) or dialkylaminocarbonyl (CON [alkyl] 2). Additionally, two adjacent groups (i. e Ri and R2, or R2 and R3 or R3 and R4) may be taken together with a chain of from 3 to 5 methylene carbons to form a alkyl ring of from five to seven carbons fused to the benzoic acid moiety. Additionally, two adjacent groups (i. e Ri and R2, or R2 and R3 or R3 and R4) may be taken together with an alkyloxy chain, for example OCHzO or OCH2CH20 to form an oxygen-containing moiety (in this example methylenedioxy or ethylenedioxy, respectively) fused to the benzoic acid.

This benzoic acid is then activated by conversion to an acid chloride with thionyl chloride, oxalyl chloride or the like. Alternatively, it may be activated by treatment with carbonyldiimidazole or a similar agent. The activated benzoic acid is then treated with an appropriate secondary amine in the presence of base to provide a tertiary amide of general structure 71.

Amide 71 is then converted to the biaryl structure 72 through the use of aryl coupling reactions know in the chemical literature. Examples of such reactions are the Stille reaction where an aryl trialkyltin reagent is coupled to an appropriate aryl in the presence of a catalyst such as palladium or nickel; or a Suzuki reaction where a arylboronic acid is coupled to an appropriate aryl in the presence of a nickel or palladium catalyst in the presence of base.

The group"Ar"of General structure 72 may be a phenyl which may be substituted with up to five additional independently chosen substitutents, e. g. hydrogen, halogen, cyano, Cl-C6 straight or branched chain alkyl, C1-C6 straight or branched chain alkoxy, trifluoromethyl, trifluoromethoxy, nitro, amino, mono or dialkyl amino, sulfonamido, mono or dialkylsulfonamido, alkylthio e. g. methylthio, alkylsulfoxide, alkylsulfone, acetyl, acetoxy, hydroxycarbonyl (COOH), alkoxycarbonyl (COOAlkyl), aminocarbonyl (CONH2), monoalkylaminocarbonyl, dialkylaminocarbonyl (CON [alkyl] 2, methylenedioxy or ethylenedioxy.

The Ar of General Structure 72 may also represent a heteroaryl group such as 1-or 2-thienyl or 1-or 2-furanyl. Such a heteroaryl group which may be additionally substituted by up to three independently chosen substituents, such as hydrogen, halogen, cyano, Ci-Ce straight or branched chain alkyl, Ci-Ce straight or branched chain alkoxy, trifluoromethyl, trifluoromethoxy, dialkyl amino, sulfonamido, mono or dialkylsulfonamido, alkylthio e. g. methylthio, alkylsulfoxide, alkylsulfone, acetyl, acetoxy, hydroxycarbonyl (COOH), alkoxycarbonyl (COOAlkyl), aminocarbonyl (CONH2), monoalkylcarbonyl, dialkylaminocarbonyl (CON [alkyl] 2.

Scheme 8. General Preparation of Azaaryl benzamides The preparation of 2-imidazolyl, 2-pyrrazolyl and 2- (1, 2,4)-triazolyl benzamides begins with an appropriately substituted benzonitrile derivative having a leaving group X at the position ortho to the carboxylic acid functionality. Most commonly this group would be a fluorine or chlorine group. This benzonitrile may be optionally substituted or additionally substituted by up to four substituents (R1-R4) which may be the same or different (examples of such substituents are: hydrogen, halogen, cyano, Ci-Ce straight or branched chain alkyl, Ci-Ce straight or branched chain alkoxy, trifluoromethyl, trifluoromethoxy, nitro, amino, mono or dialkyl amino, sulfonamido, mono or dialkylsulfonamido, methylthio, alkylsulfoxide, alkylsulfone, acetyl, acetoxy, alkoxycarbonyl (COOAlkyl) or dialkylaminocarbonyl (CON [alkyl] 2).

The benzonitrile 73 is mixed with the azaheterocycle 74 (wherein A and B may be either nitrogen or carbon with the caveat that both A and B not be carbon.

R5 and R6 may be the same as those groups described for Rl-R4.) This condensation may be carried out either in a single phase system in an appropriate solvent and base, or in a two-phase manner using a phase transfer catalyst.

2-Azaheterocyclicbenzonitrile 75 is the hydrolyzed to the corresponding benzoic acid 76 via means common to the chemical literature, for instance mineral acid.

The benzoic acid 76 is then activated via thionyl chloride, CDI or other means known to the chemical literature and condensed with an appropriately substituted secondary amine toprovide the desired final products 77.

EXAMPLES The general methods given in Schemes 1 to 8 above for the preparation of compounds of the present invention are further illustrated by the following examples. Specifically, the methods given in Schemes 1 and 2 for the preparation of aryl imidazoles are illustrated by Examples 1-4, shown below. An example of the method shown in Scheme 3 for the preparation of cycloalkylimidazoles is given in example 5, and example of the method shown in Scheme 4 for the preparation of arylpyridines is given in example 6, and an example of the method shown in Scheme 5 for the preparation of arylpyrazoles is given in example 7. The method shown by Scheme 6 for the preparations of 2- (1-Aryl-1, 2,3,4-tetrahydroisoquinolin-2- yl) acetamides is further illustrated in example 8. The methods shown in Schemes 7 and 8 for the preparation of ortho biarylamides and azaarylamides, respectively, are exemplified in Examples 9 and 10. Unless otherwise specified all starting materials and reagents are of standard commercial grade, and are used without further purification, or are readily prepared from such materials by routine methods. Those skilled in the art of organic synthesis will recognize that starting materials and reaction conditions may be varied to achieve the desired end product.

Example 1. Preparation of an arylimidazole compound: l-(l-butyl)-2-phenvl-5-(N. N- di [3, 4-methvlenedioxvphenyl methyl]) aminomethvlimidazole (Compound 106).

N- (n-butyl)-benzamidine (101). To a solution of methyl benzimidate hydrochloride (12 g, 0.07 mole) in dimethylformamide (DMF, 20 mL) is added 7 ml of triethylamine at 0 °C. After 2 h the reaction is filtered to remove triethylamine hydrochloride. To the filtrate is added 3.68 g of 1-butylamine and the mixture is heated to 60 °C for 6 h. After cooling the mixture is partitioned between ethyl acetate and water. The organic layer is washed with brine, dried over sodium sulfate and concentrated to provide 13.28 g of the amidine as a yellow oil. IH NMR (400 MHz, CDCIs) 8 7.55 (m, 2H), 7.4 (m, 3H), 3.37 (bm, 2H), 1. 62 (m, 2H), 1. 42 (m, 2H), 0.95 (t, J = 7 Hz, 3H).

1- (l-Butyl)-2-phenylimidazole-5-carboxaldehyde (102). To a solution of 101 (13.28 g) and 2-bromo-3-isopropoxyacrolein (22 g) in chloroform (150 ml) is added potassium carbonate (15.5 g) and water (19 ml). The mixture is stirred at room temperature overnight. The aqueous layer is discarded and the organic layer is washed with water (3X 100 mL), dried (Na2S04) and concentrated. The residue is purified via flash chromatography (5% MeOH/CHC13) to provide the desired imidazole carboxaldehyde as a pale yellow oil (21.55 g). IH NMR (400 MHz, CDC13) 8 9.75 (s, 1H), 7.90 (s, 1H), 7.55 (m, 2H), 7.45 (m, 3H), 4.38 (t, J = 8Hz, 2H), 1.75 (m, 2H), 1.22 (m, 2H), 0.91 (t, J = 7 Hz, 3H).

Representative preparation of a 1-Alkyl-2-aryl-4-aminomethylimidazole : 1-(1-Butyl)-2-phenyl-5-(N,N-di[3,4-methylendioxyphenylmethyl ]) aminomethylimidazole) 1- (l-Butyl)-2-phenyl-5-hydroxymethylimidazole (103). Aldehyde 102 is dissolved in methanol (150 mL). Sodium borohydride (3 g) is added in portions.

After the addition was complete, the reaction is diluted with water and concentrated.

The residue is dissolved in ethyl acetate, washed with brine, dried (Na2SO4) and concentrated. The product is purified by flash chromatography on silica gel (5% MeOH/CHCls) to give 4.17 g of 103 as a cream colored solid. lH-NMR (400 MHz, CDCl3) : 8 0.79 (3H, t, d=7.4), 1.18 (2H, m, d=7.4), 1.60 (2H, m, d=7.6), 4.03 (2H, dd, d=7. 6), 4.56 (2H, s), 6.84 (1H, s), 7.39-7.50 (3H, m), 7.50-7.53 (2H, m). l- (l-Butyl)-2-phenyl-5- (N- [3, 4- methylenedioxyphenylmethyl]) aminomethylimidazole (104).

Hydroxymethylimidazole 103 (0.82 g) is dissolved in chloroform (10 ml) and treated with thionyl chloride (1 ml). The solution is heated to 50 °C for 30 min, cooled and evaporated. The residue is washed with benzene and evaporated to give the intermediate chloromethyl hydrochloride as a white powder which is taken up in acetonitrile (30 mL). This is added dropwise to a solution of piperonylamine (5 ml) in acetonitrile (10 mL). The reaction is allowed to stand overnight and then evaporated. The residue is taken up in ethyl acetate and washed with water. The organic layer is dried (Na2SO4) and concentrated. Purification on silica gel (10% MeOH/CHCIs) provides the product as a pale yellow oil (0.91 g). 1H NMR (400 MHz, CDC1s) : 8 0.79 (3H, t, d=7.4), 1.18 (2H, m, d=7.4), 1.56 (2H, m, d=7.4), 3.75 (4H, s), 4.04 (2H, dd, d=8), 5.92 (2H, s), 6.76 (2H, m), 6.84 (lH, s), 6.97 (1H, s), 7.38-7.44 (3H, m), 7.53-7.56 (2H, m).

1- (1-Butyl)-2-phenyl-5- (N- [3, 4-methylenedioxyphenyl methyl]-N- (3, 4- methylenedioxyphenylcarboxyl) aminomethylimidazole (105). Compound 104 (160 mg, 0.44 mmol) is dissolved in chloroform (5 ml, pentene stabilized) and treated sequentially with piperonyloyl chloride (100 mg) and triethylamine (1 ml). The mixture is stirred at room temperature overnight. The solution is concentrated and the residue taken up in ethyl acetate. The organic is washed with water, dried (Na2SO4) and concentrated. Purification by preparative thin layer chromatography (5% MeOH/CHCl3) provides compound 105 as a pale yellow oil (240 mg). 1H-NMR (400 MHz, CDC13) : 8 0.75 (3H, br), 1.16 (2H, br), 1.49 (2H, br), 4.01 (2H, br), 4.54 (2H, br), 4.68 (2H, br), 5.97 (2H, s), 5.99 (2H, s), 6.66 (2H, d, d=7.2), 6.80 (2H, t, d=8), 6.98-7.02 (2H, m), 7.40-7.47 (3H, m), 7.56 (2H, d, d=6.8).

1- (1-Butyl)-2-phenyl-5- (N, N-di [3,4-methylenedioxy phenylmethyl])- aminomethylimidazole (106). Amide 105 (215 mg) in tetrahydrofuran (THF, 3 ml) is added dropwise to a solution of alane (1 M in THF, 2 ml) and the resulting solution is stirred for 2.5 h at room temperature. A solution of sodium hydroxide (15% NaOH, 1 ml) is added and the mixture is extracted with chloroform. The organic extracts are dried (Na2SO4) and concentrated. Purification by preparative thin layer chromatography (10% MeOH/CHCIs) provided compound 106 as a colorless oil (115 mg). 1H-NMR (400 MHz, CDC1s) : 8 0.70 (3H, t, d=7.6), 0.98 (2H, m, d=7.6), 1.30 (2H, m), 3.44 (4H, s), 3.52 (2H, s), 3.98 (2H, dd, d=8), 5.92 (4H, s), 6.74 (4H, s), 6.69 (2H, s), 7.02 (1H, s), 7.36-7.42 (3H, m), 7.54 (2H, dd, d=1.4,6.6). The hydrochloride salt (m. p. 187-190 °C) was prepared in isopropanol.

Example 2. Preparation of 1-(1-butyl)-2-phenyl-5-(1-[N-[3, 4- methvlenedioxyphenylmethyl}-N-phenvlmethyl] ethylimidazole (Compound 108).

1-Butyl-2-phenyl-5-91-hydroxyethyl) imidazole (107). A solution of aldehyde 102 (230 mg) in diethyl ether (30 mL) is placed in a separatory funnel and treated with a solution of Preparation of 1- (1-Butyl)-2-phenyl-5- (1- [N- [ {3, 4-methylendioxyphenylmethyl]}- N- aminoethylimidazole) methyl lithium (1. 4 M in THF, 1.5 ml). After 10 min, the solution is washed with ammonium chloride solution (1 M, 20 ml), dried (Na2S04) and concentrated. The resulting dark oil is purified by preparative TLC (10% MeOH/CHCl3) to provide compound 107 as a colorless oil (180 mg). 1H NMR (400 MHz, CDC13) 8 7.56 (d, J = 2 Hz, 2H), 7.4 (m, 3H), 7.01 (s, 1H), 4.86 (q, J = 7 Hz, 1H), 4.18 (m, 1H), 4.0 (m, 1H), 1.63 (d, J = 6.6 Hz, 3H), 1.63 (m, 2H), 1.23 (m, 2H), 0.81 (t, J = 7 Hz, 3H). l-Butyl-2-phenyl-5- (N- [3, 4-methylenedioxyphenyl]-N- phenylmethyl) aminoethylimidazole (108). A solution of compound 107 (80 mg) in chloroform (10 ml) is treated with thionyl chloride (1 ml) and heated to 50 °C for 30 min. The solution is then concentrated, diluted with chloroform and reconcentrated to provide the intermediate chloromethyl hydrochloride as an oil. This material is taken up in chloroform (5 ml) and treated sequentially with N-benzylpiperonylamine (80 mg) and triethylamine. After stirring overnight, the reaction is washed with saturated potassium carbonate solution, dried (Na2S04) and concentrated.

Purification by preparative thin layer chromatography (10% MeOH/CHCls) provides compound 108 as a colorless oil (62 mg).'H NMR (400 MHz, CDC1s) 8 7.46-7.43 (m, 1H), 7.2-7.3 (m, 9H), 6.74-6.86 (m, 4H), 5.94 (s, 2H), 4.82 (q, J = 6.8 Hz, 1H), 4.33 (m, 2H), 3. 78 (s, 2H), 3.53 (s, 2H), 1.83 (d, J = 6.8 Hz, 3H), 1.62-1.68 (m, 2H), 1.21 (q, J = 7.8 Hz, 2H), 0.82 (t, J = 7.8 Hz, 3H).

Example 3. Preparation of l-Butvl-2-phenyl-4-bromo-5- (N-phenvlmethyl-N- [l- butyl] amino-methylimidazole (Compound 110).

Preparation of 1- (1-Butyl)-2-phenyl-4-bromo-5- [N-phenylmethyl-N- [1-butyl]) aminomethylimidazole) l-Butyl-2-phenyl-5- (N-benzyl-N-butyl) aminomethylimidazole (109). A solution of compound 102 (115 mg) and N-butylbenzylamine (85 mg) in toluene (10 ml) is allowed to stand overnight. Treatment of the reaction with sodium borohydride (100 mg) and ethanol (2 mL) followed by aqueous workup and purification on silica gel (10% MeOH/CHCls) provides compound 109 as a colorless oil (35 mg).'H NMR (400 MHz, CDC13) 8 7.2-7.5 (m, 10H), 6.98 (s, 1H), 4.0 (t, J = 8 Hz, 2H), 3.55 (s, 2H), 3.52 (s, 2H), 2.42 (t, J = 8 Hz, 2H), 1. 2-1.55 (m, 6 H), 1.05 (m, 2H), 0.84 (t, J = 7 Hz, 3H), 0.72 (t, J = 7 Hz, 3H). l-Butyl-2-phenyl-4-bromo-5-(N-phenylmethyl-N-[l- butyl]) aminomethylimidazole (110). To a solution of 109 (30 mg) in acetonitrile (4 mL) was added N-bromosuccinimide (16 mg). The resulting mixture was heated to 60 °C and the progress of the reaction followed by TLC. The cooled reaction mixture was diluted with ethyl acetate and washed twice with water. Purification by preparative thin layer chromatography (10% MeOH/CHCls) provided compound 110 as a colorless oil (22 mg). IH NMR (400 MHz, CDCl3) 5 7.2-7.5 (m, 10 H), 3.98 (t, J = 8 Hz, 2H), 3.55 (s, 2H), 3.53 (s, 2H), 2.46 (t, J = 7 Hz, 2H), 1.52 (m, 2H), 1.3 (m, 4H), 0.98 (q, J = 7 Hz, 2H), 0.84 (t, J = 7 Hz, 3H), 0.70 (t, J = 7 Hz, 3H).

Example 4. Preparation of l- (l-Butyl)-2-phenyl-4-methvl-5- (N- [3, 4- methylenedioyphenyl-methyl]-N-phenylmethyl)aminomethylimidaz ole. (Compound 114).

1-Butyl-2-phenyl-4-methylimidazole (112). To a solution of 4-methyl-2- phenylimidazole (111, 15.8 g) in dimethylformamide (100 ml) is added sodium hydride (4.4 g, 60% in mineral oil) in small portions. After the addition is complete, the mixture was stirred for an additional 20 min and treated with l-iodobutane (18.8 g). The reaction is fitted with a reflux condensor and heated at 100 °C for 12 h. The cooled reaction mixture is partitioned between water (300 ml) and diethyl ether (300 ml). The organic layer is washed with water (3X 200 ml), dried (Na2SO4) and concentrated to provide 20.5 g of N-butylimidazoles. Analysis by 1H-NMR and GC-MS revealed mixture of l-butyl-2-phenyl-4-methylimidazole (112) and 1-butyl-2- phenyl-5-methylimidazole in a ratio of 11.5/1. The mixture was carried on to the next step without purification.

I-Butyl-2-phenyl-4-methyl-5-hydroxymethylimidazole (113). A solution of 112 (1 g) in acetic acid (10 mL) and 40% aqueous formaldehyde (2 mL) is refluxed for 14 h. The reaction is then concentrated and dried by repeated reconcentration with toluene. The residue is purified by column chromatography (10% MeOH/CHC13). The fractions are assayed by GC and those fractions uncontaminated by the isomeric hydroxymethylimidazole combined. Concentration of the combined fractions provides compound 113 (320 mg) as a pale yellow oil. 1H NMR (400 MHz, CDCl3) 8 7.4-7.6 (m, 6H), 4.61 (s, 2H, CH20H), 4.02 (t, J = 7 Hz, 2H, NCH2), 2.22 (s, 3H, Me), 1.63 (m, 2H, 1.25 (m, 2H), 0.81 (t, J = 7 Hz, 3H).

Preparation of 1- (1-Butyl)-2-phenyl-4-methyl-5- (N- [3, 4-methylenedioxyphenyl]-N-phenylmethyl) aminomethylimidazole 1-Butyl-2-phenyl-4-methyl-5- (N-benzyl-N-butyl) aminomethylimidazole (114).

Compound 114 (23 mg) is prepared from 113 (50 mg) in a method similar to that used to obtain compound 108.1H NMR (400 MHz, CDCls) 5 7.5-7.55 (m, 2H), 7.38- 7.42 (m, 3H), 7.23-7.30 (m, 5H), 3.95 (t, J = 7. 5 Hz, 2H), 3.55 (s, 2H), 3.53 (s, 2H), 2.40 (t, J = 7 Hz, 2H), 2.22 (s, 3H), 1.25-1.40 (m, 6H), 1.05 (m, 2H), 0.82 (t, J = 7 Hz, 3H). 0.70 (t, J = 7 Hz, 3H); MS (LCMS) m/e 390 (M++1) Example 5. Preparation of a cycloalkvlimidazole compound: 4-f[butyl (l-butyl-2- phenyl (4, 5, 6-trihvdrocvclopentat3 z2-d3imidazol-6-vl)) amino] methyll-3-chlorophenol N- (n-butyl)-benzamidine (120). To a solution of methyl benzimidate hydrochloride (12 g, 0.07 mole) in dimethylformamide (DMF, 20 mL) is added 7 ml of triethylamine at 0 °C. After 2 h the reaction is filtered to remove triethylamine hydrochloride. To the filtrate is added 3.68 g of 1-butylamine and the mixture is heated to 60 oC for 6 h. After cooling the mixture is partitioned between ethyl acetate and water. The organic layer is washed with brine, dried over sodium sulfate and concentrated to provide 13.28 g of the amidine as a yellow oil. 1H NMR (CDC13) 7.55 (m, 2H), 7.4 (m, 3H), 3.37 (bm, 2H), 1.62 (m, 2H), 1.42 (m, 2H), 0.95 (t, J = 7 Hz, 3H).

2-Bromo-3-methoxycyclopentenone (131) is prepared via the method of Curran et al JACS, vol 112, page 5601. To a suspension of 1,3-cyclopentanedione (10 g) in chloroform (700 ml) is added a N-bromosuccinimide (18.2 g). The mixture is refluxed for 2 h, cooled and concentrated. Methanol (700 mL) and p-toluenesulfonic acid (1 g) are added and the solution is refluxed overnight. The mixture is concentrated to 100 ml, diluted with methylene chloride (500 mL) and poured into water. The aqueous layer is discarded and the organic layer is washed with water (3 X 100 mL), dried (Na2SO4) and concentrated. The residue is crystallized from ethyl acetate to give 131 as tan crystals (1.67 g).

1-Butyl-2-phenyl-4, 5-dihydrocyclopenty [1, 2-d] imidazol-6-one (Compound 132). To a mixture of amidine 130 (3.52 g, 20 mmol) and enone 13 (4.58 g, 24 mmol) in chloroform (40 mL) and water (5 mL) was added solid potassium carbonate (3.32 g, 24 mmol). The resulting mixture is refluxed overnight. After cooling, the mixture is washed with water, dried (Na2SO4) and concentrated. Purification on silica gel eluting with 25% ethyl acetate/hexane gives the desired product 132 (3.0 g) LC-MS (M++1) : 255. 1H-NMR (o, CDC13) : 0.84 (t, J = 7. 6 Hz, 3H), 1.23 (dt, J = 7. 0,7.6 Hz, 2H), 1.81 (m, 2H), 2.95 (m, 4H), 4.13 (t, J = 7.6 Hz, 2H) 7.5-7.45 (m, 3H), 7.76-7.6 (m, 2H) ppm. l-Butyl-2-phenyl-4, 5-dihydrocyclopenty [1, 2-d] imidazol-6-ol (Compound 133). To a solution of 132 (2.68 g) in methanol (20 mL) is added sodium borohydride (1.5 equiv) and the mixture stirred overnight. The mixture is concentrated, diluted with chloroform and washed with 0.5 N NH4C1 solution. The organic layer is dried (Na2SO4) and concentrated to provide the desired product 133. LC-MS (M + 1) 257.

Butyl (l-butyl-2-phenyl-4, 5,6-trihydrocyclopentyl [3,2-d] imidazol-6-yl)) amine (Compound 135). Compound 133 (2 g) is dissolved in chloroform (20 mL) and thionyl chloride (5 mL) and the resulting solution is stirred at room temperature overnight. The solvent and excess thionyl chloride are evaporated and the crude chloride 134 was dissolved in n-butylamine (10 mL). After 2 h, the excess butylamine was evaporated, the residue dissolved in ethyl acetate and the organic solution washed with 5% NaOH solution and water. The organic layer was dried and concentrated. The organic residue is purified by column chromatography on silaica gel eluting with 10% CHsOH in CHC13 to provide the desired secondary amine 135 in 82% yield. LC-MS (M+1) 312 1H-NMR (chemical shift, CDCl3) : 0.83 (t, J = 7. 2 Hz, 3H), 0.9 (t, J = 7.2 Hz, 3H), 1.23 (q, J = 7.2 Hz, 2H), 1.35 (q, J = 7.2 Hz, 2H), 1.46 (m, 2H), 1.70 (m, 2H), 2.24 (m, 1H), 2. 55-2.66 (m, 4H), 2.73-2.80 (m, 2H), 3.97-4.04 (m, 2H), 4.30 (d, J = 5.6 Hz, 1H), 7.37-7.44 (m, 3H), 7.55-7.57 (m, 2H).

4- { [Butyl (l-butyl-2-phenyl (4,5,6-trihydrocyclopenta [3,2-d] imidazol-6- yl)) amino] methyl}-3-chlorophenol (Compound 5, Table 1). To a solution of compound 135 (50 mg) in 1, 2-dichloroethane (2 mL) and 2-chloro-4- hydroxybenzaldehyde (30 mg) is added sodium triacetoxyborohydride (100 mg). The resulting mixture is allowed to stir overnight. After washing with 0.5 ammonium chloride solution, the organic layer is dried (Na2SO4) and concentrated. Purification using preparative thin layer chromatography eluting with 5% CH30H/CHC13 provides the desired product 136 as an oil (21 mg). LC-MS (M+1) 452, (M-1) 450.

H-NMR (chemical shift, CDC1s) : 0.74 (t, J = 7.2 Hz, 3H), 0.83 (t, J = 7.2 Hz, 3H), 1.11 (q, J = 7.2 Hz, 2H), 1.21-1.33 (m, 2H), 1.41-1.51 (m, 4H), 2.34-2.44 (m, 3H), 2.51-2.57 (m, 1H), 2.60-2.67 (m, 1H), 2.69-2.75 (m, 1H), 3.38 (d, J = 7.6 Hz, 1H), 3.47 (d, J = 13.6 Hz, 1H), 3.65 (d, J = 13.6 Hz, 1H), 3.78-3.96 (m, 1H), 6.62 (dd, J = 8,2 Hz, 1H), 6.78 (d, J = 2 Hz, 1H), 7.07 (d, J = 8 Hz, 1H), 7.35-7.41 (m, 3H), 7.45- 7.48 (m, 2H).

Preparation of 4-{[Butyl(1-butyl-2-phenyl(4,5,6-trihydrocyclopenta [3,2-d]imidazol-6-yl))amino]methyl}-3-chlorophenol NH Me0 + -qu Br ' Br 130 131 N t r N 132 N Compound 133 X = OH Compound 134 X = Cl Compound 135 X = HNBU OH OH CI Compound 136 Example 6. Preparation of 2-phensl-4-(N, N-dit2H-Benzof3. 4-d]-1s3-dioxolan-5- ylmethylZamino) methyl-3-butvlpyridine 4-Phenyl-5-butyloxazole (140). A mixture of a-bromohexanophenone (25.5 g, 0.1 mole), ammonium formate (22 g, 0.35 mole) and formic acid (110 mL) was refluxed with stirring for 3 h. The reaction mixture was poured onto ice and made basic with 10 N NaOH and extracted with ether. The organic layer was washed with water, dried over sodium sulfate and concentrated. The crude product was purified by flash chromatography on silica gel eluting with 20% ethyl acetate in hexane. To provide the desired compound as an oil (8.3 g, 41 %) ; lH NMR (8, CDC13, 400 MHz) 7.55 (m, 2H), 7.40 (s, 1H), 7.34 (dd, J= 7,7 Hz, 2H), 7.22 (dd, J= 7,7 Hz, 1H), 2.74 (m, 2H), 1.6 (m, 2H), 1.30 (m, 2H), 0.84 (t, J= 7 Hz, 3H) ppm.

2-Phenyl-3-butylisonicotinic acid (141). A mixture of 4-phenyl-5-butyloxazole (12,5 g, 25 mmol) and maleic acid (3.5 g, 30 mmol) is heated at 100 oC for 30 min.

After cooling, the semisolid mass is triturated with ether and the solid collected by filtration. 1H NMR (S, CDC13, 400 MHz) 11. 68 (brs, 1H), 8.72 (d, J= 6.0 Hz, 1H), 7.73 (d, J= 5.6 Hz, 1H), 7.48-7.51 (m, 2H), 7.42-7.44 (m, 2H), 6.25 (s, 1H), 2.86 (d, J= 7.6 Hz, 2H), 1.36 (m, 2H), 1.11 (dt, J= 7.6,7.2 Hz, 2H), 0.68 (t, J= 7.6 Hz, 3H).

MS (M+1): 256, (M-1) 254.

2-Phenyl-4-hydroxymethyl-3-butylpyridine (142). 4 mL of a 1M solution of lithium aluminum hydride in tetrahydrofuran is added to a solution of 2-phenyl- 3-butylisonicotinic acid (13,510 mg, 2 mmol) in tetrahydrofuran (20 mL). The reaction is stirred overnight and then quenched with 5 mL of 15% aqueous NaOH.

The resulting mixture is extracted with ether, dried (Na2SO4) and concentrated to provide the desired hydroxymethylpyridine as an oil (470 mg). LC-MS (M+1) : 242 ; 1H NMR (, CDCLs) 8.35 (1H, d, J = 5.2 Hz), 7.30-7.39 (6H, m), 4.59 (2H, s), 2.43 (2H, t, J = 8.0 Hz), 1.23 (2H, m), 1.13 (2H, m), 0. 70 (3H, t, J = 7.2 Hz).

2-Phenyl-4-(N-{2H-benzo [3,4-d]-1,3-dioxolan-5-ylmethyl}) aminomethyl-3- butylpyridine (143). Thionyl chloride (200 mg, 1.67 mmol) is added to a solution of 2-phenyl-4-hydroxymethyl-3-butylpyridine (400 mg, 1.66 mmol) in pentene stabilized chloroform (8 mL) and the mixture is heated to 50 oC for 2 h. The resulting mixture is cooled, washed with saturated sodium bicarbonate solution, dried (Na2SO4) and concentrated. The resulting crude chloride is taken up in dimethylformamide (10 mL) and added dropwise to a refluxing solution of piperonylamine (1.0 g, 4 equiv) in dimethylformamide (30 mL) containing 3 g of powdered potassium carbonate. After the addition is complete, the resulting mixture is refluxed for an additional 3 h, cooled and partitioned between water (200 mL) and ether (100 mL). The ethereal layer is washed 2 times with water, dried (Na2SO4) and concentrated. The resulting material is purified by chromatography on silica eluting with 10% CH30H/CHC13 to give the desired secondary amine 15. LC- MS (M+1) : 375.3 ; 1H-NMR (o, CDC13) : 0.73 (3H, t, J = 7. 2 Hz), 1.15 (2H, m J = 7.2 Hz), 1.30 (2H, m), 2.58 (2H, t, J = 8. 0 Hz), 3.79 (2H, s), 3.83 (2H, s), 5.93 (2H, s), 6.75-6.82 (2H, m), 6.89 (1H, d, J = 1. 2 Hz), 7.36-7.42 (6H, m), 8.45 (1H, d, J = 4.8 Hz) ppm.

2-Phenyl-4- (N, N-dit2H-benzo [3,4-dl-1,3-dioxolan-5-ylmethyl}) aminomethyl-3- butylpyridine (144). To a solution of 14 (38 mg) in dichloroethane (5 mL) was added piperonal (30 mg). The resulting mixture was stirred for 3 h after which time sodium triacetoxyborohydride (150 mg) is added in one portion and the resulting mixture is stirred overnight. The reaction mixture was quenched with 10% ammonium hydroxide solution (5 ml). The organic layer is washed with water and extracted with 1N HC1 solution. The acidic extract is made basic with 1N NaOH solution and extracted with chloroform. The organic extract is dried (Na2SO4) and concentrated. The resulting oil is purified on preparative thin layer chromatography eluting with 10% CH30H/CHC13 to give the desired tertiary amine 144 as an oil (18 mg). LC-MS (M+1) : 509.4 ; 1H-NMR (8, CDC13) : 0.71 (3H, t, J = 7.2 Hz), 1.10 (2H, m, J = 7.2 Hz), 2.60 (2H, t, J = 8.0 Hz), 3.48 (4H, s), 3.58 (2H, s), 5.94 (4H, s), 6.75 (1H, d, J = 8.0 Hz), 6.80 (1H, dd, J = 0.8,8.0 Hz), 6.91 (1H, d, J = 0.8 Hz), 7.36-7.43 (5H, m), 7.56 (1H, d, J = 5.2 Hz), 8.47 (1H, d, J = 5.2 Hz) ppm.

Preparation of 2-Phenyl-4- (N, N-di {2H-benzo [3, 4-d]-1, 3-dioxolan-5-ylmethyl}) aminomethyl-3-butylpyridine I ¢4 COOH < 140 141 141 141/ 07 3 aOH N/ l. thionyl chloride ) p 1 2. piperonylamine K2C03 142' 143 0-\0-\ O/ o \ N I x N N \ reduction 144 ol Example 7. Preparation of an Arylpyrazole : 1,3-diphenvl-4-(N-{2H-benzo [34-d]-1. 3-dioxolan-5-vlmethyl$-N-butvlamino) methyl- 5-propvlpvrazole N'-Phenyl-N-phenylhydrazone (150). Benzaldehyde (9.81 g, 9.25 mmol) is added at 0-5 oC to a solution of phenyl hydrazine (10 g, 9.25 mmol) in ethanol (100 mL). A cream colored solid forms and the reaction mixture is allowed to stand for 2h. The solid is collected by filtration, washed with ice-cold ethanol and dried under vacuum to provide the desired compound, compound 150 (14.92 g); LC-MS m/z 197.2,1H NMR (8, CDCl3, 400 MHz) ppm.

Ethyl 1, 3-diphenyl-5-propylpyrazole-4-carboxylate (152). A mixture of 150 (5 g, 25.5 mmol) and ethyl butyrylacetate (20.2 g, 128 mmol) and a catalytic amount of zinc chloride is heated at 125 oC under an air atmosphere for 3h. The reaction vessel is fitted with a short path distillation head and excess ethyl butyrylacetate iss distilled away under vacuum. The resulting material is purified by column chromatography on silica eluting with 10% ethyl acetate in hexanes to provide the desired ester 152 as a yellow oil (6.39 g) which crystallizes upon standing. Recrystallization from diisopropyl ether provides a white solid. 1H NMR (6, CDCl3, 400 MHz) MS (M+1) : 335.2 1, 3-Diphenyl-4-hydroxymethyl-5-propylpyrazole (153). To a solution of ester 153 (670 mg, 2 mmol) in tetrahydrofuran (20 mL) is added 4 mL of a 1M solution of lithium aluminum hydride in tetrahydrofuran. The reaction is stirred overnight and then quenched with 5 mL of 15% aqueous NaOH. The resulting mixture is extracted with ether, dried (Na2SO4) and concentrated to provide the desired hydroxymethylpyrazole as an oil (505 mg). LC-MS (M+1) : 293.3 ; 1H NMR (8, CDCL3) 7.86 (dd, J= 8.4 Hz, 2H), 7.34-7.52 (m, 8H), 4. 65 (s, 2H), 2.72 (t, J= 8.0 Hz, 2H), 1. 52 (m, 2H), 0.87 (t, J= 7.6 Hz, 3H).

[ (1, 3-Diphenyl-5-propylpyrazol-4-yl) methyl] butylamine (154). To a solution of 18 (289 mg) in pentene stabilized chloroform (8 mL) is added thionyl chloride (1 mL) and the mixture heated to 60 oC for 2 h. The resulting mixture is cooled, washed with saturated sodium bicarbonate solution, dried (Na2S04) and concentrated. The resulting crude chloride is taken up in dimethylformamide (3 mL) and added dropwise to a solution of butylamine (1.0 g) in dimethylformamide (10 mL) containing 2 g of powdered potassium carbonate. After the addition is complete, the resulting mixture is stirred for an additional 3 h and partitioned between water (20 mL) and ether (10 mL). The ethereal layer is washed 2 times with water, dried (Na2SO4) and concentrated. The resulting material is purified by chromatography on silica eluting with 10% CH30H/CHC13 to give the desired secondary amine 155 (190 mg). LC-MS (M+1) : 348. 3; 1H-NMR (8, CDC1s) : 7.87 (dd, J= 8.0,1.6 Hz, 2H), 7.32-7.48 (m, 8H), 3.77 (s, 2H), 2.70 (m, 4H), 1.48 (m, 4H), 1.34 (m, 2H), 0.91 (t, J= 7.6 Hz, 3H), 0.87 (t, J= 7. 6 Hz, 3H) ppm.

1, 3-Diphenyl-4- (N- {2H-benzo [3,4-d]-1,3-dioxolan-5-ylmethyl}-N- butylamino) methyl-5-propylpyrazole (Compound 155). To a solution of 154 (35 mg) in dichloroethane (5 mL) is added piperonal (30 mg). The resulting mixture is stirred for 3 h after which time sodium triacetoxyborohydride (150 mg) is added in one portion and the resulting mixture is stirred overnight. The reaction mixture is quenched with 10% ammonium hydroxide solution (5 ml). The organic layer is washed with water and extracted with 1N HC1 solution. The acidic extract is made basic with 1N NaOH solution and extracted with chloroform. The organic extract is dried (Na2SO4) and concentrated. The resulting oil is purified on preparative thin layer chromatography eluting with 10% CH30H/CHC13 to give the desired tertiary amine (Compound 155) as an oil (24 mg). LC-MS (M+1) : 482.5 ; 1H-NMR (o, CDC13) : 7.87 (d, J = 7.2 Hz, 2H), 7.47 (d, J= 4.4 Hz, 4H), 7.33-7.43 (m, 4H), 6.77 (s, 1H), 6.70 (s, 2H), 5.92 (s, 2H), 3.56 (s, 2H), 3.42 (s, 2H), 2.74 (t, J = 8.0 Hz, 2H), 2.37 (t, J = 7.2 Hz, 2H), 1.42 (m, 4H), 1.21 (m, 2H), 0.83 (t, J = 7.6 Hz, 3H), 0.81 (t, J = 7.2 Hz, 3H) ppm.

Preparation of 1,3-Diphenyl-4-(N-{2H-benzo[3,4-d]-1,3-dioxolan-5-ylmethyl} -N-butylamino) N-butylamino)methyl-5-propylpyrazole Example 8. Svnthesis of N-(1-fluorobenzyl)-N-indan-2-yl-2-(6. 7-dimethoxv-1- phenyl-1, 2, 3, 4-tetrahydroisoquinolin-1-yl) acetamide (162). A mixture of 6, 7- dimethoxy-1-phenyl-1, 2,3,4-tetrahydroisoquinoline hydrochloride (160,153 mg, 0.5 mmol), N-(l-fluorobenzyl)-N-indan-2-yl-2-bromoacetamide (161,180 mg, 0.5 mmol) and potassium carbonate (500 mg) in acetonitrile is heated at 80 oC overnight. After cooling, the mixture is filtered and concentrated. The resulting residue is purified by column chromatography eluting with 5% methanol in chloroform to provide the title product (162) as a thick oil (215 mg, 78%). 1H NMR (CDC13) 6.8-7.3 (m, 14H), 6.60 (s, 1H), 6.05 (s, 1H), Example 9. Preparation of 4'Trifluoromethyl-biphenyl-2-carboxvlic acid benzo 3] 3]dioxol-5-ylmethyl-benzyl-amide (174). 1, l'-carbonyldiimidazole (175 mg) is added to a solution of 2-iodobenzoic acid (248 mg, 1 mmol) (170) in tetrahydrofuran (THF, 5 ml). The resulting mixture is stirred overnight at room temperature. A solution of N-3,4-methylenedioxybenzyl-N-benzylamine (241 mg, 1 equiv) (171) in THF (2 mL) is added and the resulting solution is stirred for 1 h, quenched with water and extracted with diethyl ether. The organic extracts are dried (Na2SO4) and concentrated. The residual material is taken up in dimethoxyethane (10 mL) and a catalytic amount (20 mg) of tetrakis (triphenylphosphine) palladium (0) is added. The resulting mixture is stirred under an argon atmosphere for 10 min and solid 4-trifluoromethyllphenylboronic acid (150 mg) is added in one portion. A second phase of 1N aqueous Na2SO4 is added and the mixture is warmed to 80 oC for 6 h under a argon atmosphere. The solution is cooled, diluted with water and ethyl acetate and filtered through a pad of celite. The organic phase is dried over sodium sulfate and concentrated.

Purification on silica eluting with 20% ethyl acetate in hexane provided the desired biphenylamide product (174) (410 mg). The proton NMR displays a doubled pattern commonly observed for amides which possess some rotational restriction about the amide nitrogen at room temperature. The ratio of the rotomers is approximately equal. 1H NMR (CDC13) 3. 50 and 3.62 (two doublets, J = X Hz, 1H), 3.72 and 3.83 (two doublets, J = X Hz, 1H), 4.10 and 4.18 (two doublets, J = X Hz, 1H), 5.09 and 5.16 (two doublets, J = x Hz, 1H), 5.95 (d, J = X Hz, 2H, OCH20), 6.30 (m, 1.5 H), 6.46 (d, J = 1 Hz, 0.5 Hz), 6.60 and 6.66 (two doublets, J = X Hz, 1H), 6.80 (bd, J = X Hz, 1H), 6.86 (m, 1H), 7.16-7.62 (m, 11 H). 1. CDI, THF OH . N OH 2. CS : xi NH 172 170 0 171 O/H) Z X 'O 1. I \ OJ CF3 2. Pd (PPh3) 4 , 3. NaZC03, dimethoxyethane o 174 CF3 4'-Trifluoromethyl-biphenyl-2-carboxylic acid benzo [1, 3] dioxol-5-ylmethyl-benzyl-amide Example 10. Preparation of N-Benzo [ls3] dioxol-5-ylmethyl-N-benzyl-2-pyra benzamide 2-Pvrazol-l-yl-benzonitrile Compound 177. A solution of 20 mmol of 2- fluorobezonitrile and 40 mmol of pyrrazole is mixed together in dimethylformaide with 1 equivalent of potassium hydroxide and a catalytic amount of 18-crown-6.

The mixture is stirred at room temperature overnight, quenched with water and ethyl acetate and extracted with ethyl acetate. The organic extract is washed repeatedly with 1 N NaOH solution. The organic layer is then diluted with ether and washed with 1N HC1 solution, dried and concentrated. 1H NMR (CDC13) 6.55 (t, J = 2 Hz, 1H), 7.42 (M, 1H), 7.65-7.82 m, 4H), 8.15 (d, J = 1 Hz, 1H).

2-Pyrazol-l-yl-benzoic acid, Compound 178. A solution of compound 177 in conc HC1 is refluxed overnight, cooled and concentrated. The product is precipitated by addition of 1 N NaOH until pH of 5-6, filtered and dried. 1H (CDC1s) 6.52 (t, J = 3 Hz, 1H), 7.40 (d, J = 8 Hz, 1H), 7.50 (t, J = 8 Hz, 1H) 7.62 (t, J = 8 hz, 1H), 7.81 (m, 2H), 8. 12 (d, J = 8 Hz, 1H).

N-Benzo [1, 31dioxol-5-ylmethvl-N-benzyl-2-pyrazol-1-yl-benzamide, Compound 179.1.1 equiv of carbonyl diimidazole is added to a solution of benzoic acid 178 (200 mg) in tetrahydrofuran (5 mL); the reaction is stirred at room temperaturte for 3 h. After this time N-piperonyl-N-benzylamine (0.25 g) is added in one portion.

After 30 min, the reaction is filtered, diluted with ether and washed with water. The organic layer is dried (Na2S04) and purified over column chromatography to provide the desired product (390 mg). The proton NMR displays a typically doubled pattern.

1H (CDC1s) 3.83 and 4.32 (two doublets, J = 16 Hz, 1H), 3.91 (two doublets, J = 8 Hz, 1H), 4.18 two doublets (J = 6 Hz, 1H), 5.0 and 5.1 (two doublets, J = 14 Hz, 1H), 5.93 and 5.98 (s and doublet, J = 2 Hz, 2H, OCH20), 6.35-6.40 (m, 2H), 6.51 (d, J = 4 Hz, 0.5 H), 6.4 (m, 1.5 H), 7.0-7.88 m, 15H). LC-MS 412.3 Example 11. Preparation of N-benzoyrl-N- 4-methoxvbenzvl)-N- (l-propyl-2- methyleno-7-azabenzimidazole 2-aminopropyl-3-nitropyridine 2-chloro-3-nitroaminopyridine (180) (5. 5 g, 35 mmol) is dissolved in 150 mL acetonitrile at room temperature. Propylamine (21 g, 350 mmol) is added dropwise and the reaction mixture is stirred for 5 hours at room temperature. The solvent and excess propylamine are removed in vacuo. The residue is dissolved in 150 mL ethyl acetate and washed once with 100 mL saturated NaHCOs solution and once with 100 mL brine. The organic layer is dried over MgS04, filtered, and the solvent removed in vacuo to afford 6.3 g of 2-aminopropyl-3-nitropyridine (181).

2-aminopropyl-3-aminopyridine.

2-aminopropyl-3-nitropyridine (171) (6.3 g, 35 mmol) is dissolved in 100 mL 1/1 ethyl acetate/ethanol in a Parr shaker bottle. Nitrogen is bubbled through the solution for 2 minutes followed by the addition of 10% Pd/C (500 mg). The suspension is hydrogenated on a Parr apparatus under 40 psi of H2 until hydrogen uptake ceased. The suspension is filtered through Celite and the solvent evaporated in vacuo to afford 5.3 g of the 2-aminopropyl-3-aminopyridine (182).

1-propyl-2-chloromethyl-7-azabenzimidazole 2-aminopropyl-3-aminopyridine (172) (5.3 g, 35 mmol) is dissolved in 100 mL CHC13 at room temperature. Ethyl chloromethylimidate hydrochloride (14 g, 89 mmol) is added followed by K2C03 (25 g, 180 mmol). The suspension was stirred vigorously at room temperature for 3 hours. The reaction mixture is filtered through Celite and the solvent removed in vacuo. The residue is passed through a short plug of silica gel eluting with ethyl acetate to afford 3.7 g of 1-propyl-2-chloromethyl-7- azabenzimidazole (183).

1-propyl-2- (4-methoxybenzylamino) methyl-7-azabenzimidazole.

4-Methoxybenzylamine (3.8 g, 27 mmol) is dissolved in 20 mL dry acetonitrile. 1- propyl-2-chloromethyl-7-azabenzimidazole (173) (940 mg, 4.5 mmol) dissolved in 4.5 mL acetonitrile is added dropwise. The mixture is stirred 10 hours at room temperature. The solvent is removed in vacuo and the residue dissolved in 20 mL ethyl acetate. This solution is washed once with 20 mL 1 N NaOH, once with 20 mL water, once with 20 mL 5% HOAc in water, then once with 5 N NaOH. The organic phase was dried over MgS04, filtered, then concentrated in vacuo. The product mixture is purified by flash chromatography eluting with ethyl acetate followed by 95/5/1 ethyl acetate/methanol/triethylamine to afford 850 mg of the 1-propyl-2- (4-methoxybenzylamino) methyl-7-azabenzimidazole (184).

N-benzoyl-N- (4-methoxybenzyl)-N- (l-propyl-2-methyleno-7-azabenzimidazole 1-propyl-2- (4-methoxybenzylamino) methyl-7-azabenzimidazole (174) (19 mg, 0.06 mmol) is dissolved in 0.6 mL toluene. Saturated sodium bicarbonate solution in water (0.3 mL) is added followed by benzoyl chloride (11 mg, 0.08 mmol). The reaction mixture is stirred at room temperature for 10 hours. It is then diluted with 5 mL ethyl acetate and transferred to a separatory funnel. The aqueous layer is removed and the organic phase washed once with 1N NaOH, once with 5 mL water, then and once with mL brine. The organic phase is dried over MgS04, filtered and the solvent removed in vacuo. The product is purified by preparatory tlc eluting with 1/1 ethyl acetate/hexanes to afford 20 mg of the desired compound (185). NMR 400 MHz (CDC13) 8.39 ppm (br d, 1 H), 8.15 ppm (br d, 1 H), 7.52 ppm (m, 1.5 H), 7.40 ppm (s, 1.5 H), 7.22 (m, 1 H), 7.18 ppm (br d, 1 H), 6.83 ppm, (d, J = 4 Hz, 2 H), 4.93 ppm (br s, 2 H), 4.71 ppm (br s, 1 H), 4.39 ppm (br s, 1 H), 3.79 ppm (s, 3 H), 1.89 ppm (br m, 2 H), 0.98 pp, (br t, 3 H).

Example 12 Assay for C5a Receptor Mediated Chemotaxis This assay is a standard assay of C5a receptor mediated chemotaxis.

Human promonocytic U937 cells or purified human or non-human neutrophilis are treated with dibutyryl cAMP for 48 hours prior to performing the assay. Human neutrophils or those from another mammalian species are used directly after isolation. The cells are pelleted and resuspended in culture media containing 0.1% fetal bovine serum (FBS) and 10 ug/ml calcein AM (a fluorescent dye). This suspension is then incubated at 37 °C for 30 minutes such that the cells take up the fluorescent dye. The suspension is then centrifuged briefly to pellet the cells, which are then resuspended in culture media containing 0.1% FBS at a concentration of approximately 3 x 106 cells/mL. Aliquots of this cell suspension are transferred to clean test tubes, which contain vehicle (1% DMSO) or varying concentrations of a compound of interest, and incubated at room temperature for at least 30 minutes. The chemotaxis assay is performed in ChemoTxTM 101-8,96 well plates (Neuro Probe, Inc. Gaitherburg, MD). The bottom wells of the plate are filled with medium containing 0-10 nM of C5a, preferably derived from the same species of mammal as are the neutrophils or other cells (e. g., human C5a for the human U937 cells). The top wells of the plate are filled with cell suspensions (compound or vehicle-treated). The plate is then placed in a tissue culture incubator for 60 minutes. The top surface of the plate is washed with PBS to remove excess cell suspension. The number of cells that have migrated into the bottom well is then determined using a fluorescence reader. Chemotaxis index (the ratio of migrated cells to total number of cells loaded) is then calculated for each compound concentration to determine an ICso value.

As a control to ensure that cells retain chemotactic ability in the presence of the compound of interest, the bottom wells of the plate may be filled with varying concentrations chemo-attractants that do not mediate chemotaxis via the C5a receptor, e. g. zymosan-activated serum (ZAS), N-formylmethionyl-leucyl- phenylalanine (FMLP) or leukotriene B4 (LTB4), rather than C5a, under which conditions the compounds of the invention preferably do not inhibit chemotaxis.

Preferred compounds of the invention exhibit ICso values of less than 1 uM in the above assay for C5a mediated chemotaxis.

Example 13 Determination of dopamine D4 receptor binding activity The following assay is a standard assay for determining the binding affinity of compounds to dopamine D4 receptors.

Pellets of Chinese hamster ovary (CHO) cells containing recombinantly expressing primate dopamine D receptors are used for the assays. The dopamine D4 receptor expression vector may be the pCD-PS vector described by Van Tol et al.

(Nature (1991) 358: 149-152). The sample is homogenized in 100 volumes (w/vol) of 0.05 M Tris HC1 buffer containing 120 mM NaCl, 5 mM MgCl2 and 1 mM EDTA at 4°C and pH 7.4. The sample is then centrifuged at 30,000 x g and resuspended and rehomogenized. The sample is then centrifuged as described and the final tissue sample is frozen until use. The tissue is resuspended 1: 20 (wt/vol) in 0.05 M Tris HCl buffer containing 120 mM NaCl.

Incubations for dopaminergic binding are carried out at 25°C and contain 0.4 ml of tissue sample, 0.1 nM 3H-YM 09151-2 (Nemonapride, cis-5-Chloro-2- methoxy-4- (methylamino)-N- (2-methyl-2- (phenylmethyl)-3-pyrrolidinyl) benzamide) and the compound of interest in a total incubation of 1.0 ml. Nonspecific binding is defined as that binding found in the presence of 1 uM spiperone; without further additions, nonspecific binding is less than 20% of total binding.

Example 14. Preparation of radiolabeled probe compounds of the invention The compounds of the invention are prepared as radiolabeled probes by carrying out their synthesis using precursors comprising at least one atom that is a radioisotope. The radioisotope is preferably selected from of at least one of carbon (preferably 14C), hydrogen (preferably 3H), sulfur (preferably 35S), or iodine (preferably 125I). Such radiolabeled probes are conveniently synthesized by a radioisotope supplier specializing in custom synthesis of radiolabeled probe compounds. Such suppliers include Amersham Corporation, Arlington Heights, IL; Cambridge Isotope Laboratories, Inc. Andover, MA; SRI International, Menlo Park, CA; Wizard Laboratories, West Sacramento, CA; ChemSyn Laboratories, Lexena, KS; American Radiolabeled Chemicals, Inc., St. Louis, MO; and Moravek Biochemicals Inc., Brea, CA.

Tritium labeled probe compounds are also conveniently prepared catalytically via platinum-catalyzed exchange in tritiated acetic acid, acid-catalyzed exchange in tritiated trifluoroacetic acid, or heterogeneous-catalyzed exchange with tritium gas.

Such preparations are also conveniently carried out as a custom radiolabeling by any of the suppliers listed in the preceding paragraph using the compound of the invention as substrate. In addition, certain precursors may be subjected to tritium- halogen exchange with tritium gas, tritium gas reduction of unsaturated bonds, or reduction using sodium borotritide, as appropriate.

Example 15 : Baculoviral Preparations (For C5a Expression) The human C5a (hC5a) receptor baculoviral expression vector was co- transfected along with BACULOGOLD DNA (BD PharMingen, San Diego, CA) into Sj9 cells. The S/9 cell culture supernatant was harvested three days post-transfection.

The recombinant virus-containing supernatant was serially diluted in Hink's TNM- FH insect medium (JRH Biosciences, Kansas City) supplemented Grace's salts and with 4. lmM L-Gln, 3.3 g/L LAH, 3.3 g/L ultrafiltered yeastolate and 10% heat- inactivated fetal bovine serum (hereinafter"insect medium") and plaque assayed for recombinant plaques. After four days, recombinant plaques were selected and harvested into 1 ml of insect medium for amplification. Each 1 ml volume of recombinant baculovirus (at passage 0) was used to infect a separate T25 flask containing 2 x 106 Sf9 cells in 5 mls of insect medium. After five days of incubation at 27°C, supernatant medium was harvested from each of the T25 infections for use as passage 1 inoculum.

Two of seven recombinant baculoviral clones were then chosen for a second round of amplification, using 1 ml of passage 1 stock to infect 1 x 108 cells in 100 ml of insect medium divided into 2 T175 flasks. Forty-eight hours post infection, passage 2 medium from each 100ml prep was harvested and plaque assayed for titer. The cell pellets from the second round of amplification were assayed by affinity binding as described below to verify recombinant receptor expression. A third round of amplification was then initiated using a multiplicity of infection of 0.1 to infect a liter of Sf9 cells. Forty hours post-infection the supernatant medium was harvested to yield passage 3 baculoviral stock.

The remaining cell pellet is assayed for affinity binding using the"Binding Assays" described by DeMartino et al., 1994, J. Biol. Chem. 269 #20, pp. 14446-14450 at page 14447, adapted as follows. Radioligand is 0.005-0.500nM [1251] C5a (human recombinant), New England Nuclear Corp., Boston, MA; the hC5a receptor- expressing baculoviral cells are used instead of 293 cells; the assay buffer contains 50 mM Hepes pH. 7.6,1 mM CaC12, 5 mM MgC12, 0.1% BSA, pH 7.4,0.1 mM bacitracin, and 100 KIU/ml aprotinin; filtration is carried out using GF/C WHATMAN filters (presoaked in 1.0% polyethyeneimine for 2 hours prior to use); and the filters are washed twice with 5 mLs cold binding buffer without BSA, bacitracin, or aprotinin.

Titer of the passage 3 baculoviral stock is determined by plaque assay and a multiplicity of infection, incubation time course, binding assay experiment is carried out to determine conditions for optimal receptor expression.

A multiplicity of infection of 0.1 and a 72-hour incubation were the best infection parameters found for hC5a receptor expression in up to 1-liter Sf9 cell infection cultures.

Example 16 : Baculoviral Infections Log-phase SJ9 cells (INVITROGEN Corp., Carlsbad CA), are infected with one or more stocks of recombinant baculovirus followed by culturing in insect medium at 27°C. Infections are carried out either only with virus directing the expression of the hC5a receptor or with this virus in combination with three G-protein subunit- expression virus stocks: 1) rat Gai2 G-protein-encoding virus stock (BIOSIGNAL &num V5J008), 2) bovine bl G-protein-encoding virus stock (BIOSIGNAL &num V5H012), and 3) human g2 G-protein-encoding virus stock (BIOSIGNAL &num V6B003), which may be obtained from BIOSIGNAL Inc., Montreal.

The infections are conveniently carried out at a multiplicity of infection of 0.1: 1.0: 0.5: 0.5. At 72 hours post-infection, a sample of cell suspension is analyzed for viability by trypan blue dye exclusion, and the remaining Sf9 cells are harvested via centrifugation (3000 rpm/10 minutes/4°C).

Example 17: Purified Recombinant Insect Cell Membranes SJ9 cell pellets are resuspended in homogenization buffer (10 mM HEPES, 250 mM sucrose, 0.5 yg/ml leupeptin, 2 yg/ml Aprotinin, 200 yam PMSF, and 2.5 mM EDTA, pH 7.4) and homogenized using a POLYTRON homogenizer (setting 5 for 30 seconds). The homogenate is centrifuged (536 x g/10 minutes/ 4°C) to pellet the nuclei. The supernatant containing isolated membranes is decanted to a clean centrifuge tube, centrifuged (48,000 X g/30 minutes, 4°C) and the resulting pellet resuspended in 30 ml homogenization buffer. This centrifugation and resuspension step is repeated twice. The final pellet is resuspended in ice cold Dulbecco's PBS containing 5 mM EDTA and stored in frozen aliquots at-80°C until needed. The protein concentration of the resulting membrane preparation (hereinafter"P2 membranes") is conveniently measured using a Bradford protein assay (Bio-Rad Laboratories, Hercules, CA). By this measure, a 1-liter culture of cells typically yields 100-150 mg of total membrane protein.

Example 18: Agonist-Induced GTP Binding Agonist-stimulated GTP-gamma35S binding ("GTP binding") activity can be used to identify agonist and antagonist compounds and to differentiate neutral antagonist compounds from those that possess inverse agonist activity. This activity can also be used to detect partial agonism mediated by antagonist compounds. A compound being analyzed in this assay is referred to herein as a"test compound." Agonist-stimulated GTP binding activity is measured as follows: Four independent baculoviral stocks (one directing the expression of the hC5a receptor and three directing the expression of each of the three subunits of a heterotrimeric G-protein) are used to infect a culture of Sgg cells as described in Example 16.

Agonist-stimulated GTP binding on purified membranes (prepared as described in Example 17) is assessed using hC5a (Sigma Chemical Co., St. Louis, Missouri, USA) as agonist in order to ascertain that the receptor/G-protein-alpha- beta-gamma combination (s) yield a functional response as measured by GTP binding.

P2 membranes are resuspended by Dounce homogenization (tight pestle) in GTP binding assay buffer (50 mM Tris pH 7.0,120 mM NaCl, 2 mM MgC12, 2 mM EGTA, 0.1% BSA, 0.1 mM bacitracin, 100KIU/mL aprotinin, 5 ! 1M GDP) and added to reaction tubes at a concentration of 30 ug protein/reaction tube. After adding increasing doses of the agonist hC5a at concentrations ranging from 10-12 M to 10-6 M, reactions are initiated by the addition of 100 pM GTP gamma S. In competition experiments, non-radiolabeled test compounds (e. g., compounds of the invention) are added to separate assays at concentrations ranging from 10-1° M to 10-5 M along with 10 nM hC5a to yield a final volume of 0.25 mL.

Neutral antagonists are those test compounds that reduce the C5a- stimulated GTP binding activity towards, but not below, baseline (the level of GTP bound by membranes in this assay in the absence of added C5a or other agonist and in the further absence of any test compound).

In contrast, in the absence of added C5a certain preferred compounds of the invention will reduce the GTP binding activity of the receptor-containing membranes below baseline, and are thus characterized as inverse agonists. If a test compound that displays antagonist activity does not reduce the GTP binding activity below baseline in the absence of the C5a agonist, it is characterized as a neutral antagonist.

An antagonist test compound elevates GTP binding activity above baseline in the absence of added hC5a in this GTP binding assay is characterized as having partial agonist activity. Preferred antagonist compounds of the invention do not elevate GTP binding activity under such conditions more than 10% above baseline, preferably not more than 5% above baseline, and most preferably not more than 2% above baseline.

Following a 60-minute incubation at room temperature, the reactions are terminated by vacuum filtration over GF/C filters (pre-soaked in wash buffer, 0. 1% BSA) followed by washing with ice-cold wash buffer (50 mM Tris pH 7.0,120mM NaCl). The amount of receptor-bound (and thereby membrane-bound) GTP gamma35S is determined by measuring the bound radioactivity, preferably by liquid scintillation spectrometry of the washed filters. Non-specific binding is determined using 10 mM GTP gamma 35S and typically represents less than 5 percent of total binding. Data is expressed as percent above basal (baseline). The results of these GTP binding experiments may be conveniently analyzed using SIGMAPLOT software (SPSS Inc., Chicago, Illinois, USA).

EXAMPLE 19 Calcium Mobilization Assays A. Response to C5a U937 cells are grown in differentiation media (1 mM dibutyl cAMP in RPMI 1640 medium containing 10% fetal bovine serum) for 48 hrs at 37 C then reseeded onto 96-well plates suitable for use in a FLIPRTM Plate Reader (Molecular Devices Corp., Sunnyvale CA). Cells are grown an additional 24 hours (to 70-90% confluence) before the assay. The cells are then washed once with Krebs Ringer solution. Fluo-3 calcium sensitive dye (Molecular Probes, Inc. Eugene, OR) is added to 10 ug/mL and incubated with the cells at room temperature for 1 to 2 hours. The 96 well plates are then washed to remove excess dye. Fluorescence responses, measured by excitation at 480 nM and emission at 530 nM, are monitored upon the addition of human C5a to the cells to a final concentration of 0.01-30.0 nM, using the FLIPRTM device (Molecular Devices). Differentiated U937 cells typically exhibit signals of 5,000-50,000 Arbitrary Fluorescent Light Units in response to agonist stimulation.

B. Assays for Determination of ATP Responses Differentiated U937 cells (prepared and tested as described above under"A.

Response to C5a") are stimulated by the addition of ATP (rather than C5a) to a final concentration of 0.01 to 30 uM. This stimulation typically triggers a signal of 1,000 to 12,000 arbitrary fluorescence light units. Certain preferred compounds of the invention produce less than a 10%, preferably less than a 5%, and most preferably less than a 2% alteration of this calcium mobilization signal when this control assay is carried out in the presence or absence of the compounds.

C. Assays for the Identification of Receptor Modulatory Agents : Antagonists and Agonists Those of skill in the art will recognize that the calcium mobilization assay described above may be readily adapted for identifying test compounds as having agonist or antagonist activity, at the human C5a receptor.

For example, in order to identify antagonist compounds, differentiated U937 cells are washed and incubated with Fluo-3 dye as described above. One hour prior to measuring the fluorescence signal, a subset of the cells is incubated with a 1 M concentration of at least one compound to be tested. The fluorescence response upon the subsequent addition of 0.3 nM (final concentration) human recombinant C5a is monitored using the FLIPRTM plate reader. Antagonist compounds elicit at least a 2-fold decrease in the fluorescence response relative to that measured in the presence of human C5a alone. Preferred antagonist compounds elicit at least a 5- fold, preferably at least a 10-fold, and more preferably at least a 20-fold decrease in the fluorescence response relative to that measured in the presence of human C5a alone. Agonist compounds elicit an increase in fluorescence without the addition of C5a, which increase will be at least partially blocked by a known C5a receptor antagonist.

Example 20. Assays to evaluate agonist activity of small molecule C5a receptor antagonists Preferred compounds of the invention are C5a receptor antagonists that do not possess significant (e. g., greater than 5%) agonist activity in any of the C5a mediated functional assays discussed herein. Specifically, this undesired agonist activity can be evaluated, for example, in the GTP binding assay of Example 18, by measuring small molecule mediated GTP binding in the absence of the natural agonist, C5a. Similarly, in a calcium mobilization assay e. g., that of Example 19, a small molecule compound can be directly assayed for the ability of the compound to stimulate calcium levels in the absence of the natural agonist, C5a. The preferred extent of C5a agonist activity exhibited by compounds of the invention is less than 10%, more preferably less than 5% and most preferably less than 2% of the response elicited by the natural agonist, C5a.

EXAMPLE 21. Expression of a C5a receptor A human C5a receptor cDNA was obtained by PCR using 1) a forward primer adding a Kozak ribosome binding site and 2) a reverse primer that added no additional sequence, and 3) an aliquot of a Stratagene Human Fetal Brain cDNA library as template. The sequence of the resulting PCR product is set forth as SEQ ID NO : 1. The PCR product was subcloned into the cloning vector pCR-Script AMP (STRATAGENE, La Jolla, CA) at the Srf I site. It was then excised using the restriction enzymes EcoRI and NotI and subcloned in the appropriate orientation for expression into the baculoviral expression vector pBacPAK 9 (CLONTECH, Palo Alto, CA) that had been digested with EcoRI and NotI.

As set forth in the tables appended hereto, R groups do not necessarily correlate with those R groups shown in the text of the specification or in the claims.

The following table 1 (204-313) is a list of preferred 1,2,5 substituted imidazoles of the present invention; The following table 2 (314-419) is a list of preferred 1,2,4,5 substituted imidazoles of the present invention; The following table 3 (420-421) is a list of preferred pyrazoles of the present invention; The following table 4 (422-423) is another list of preferred 1,2,4,5 substituted imidazoles of the present invention; The following table 5 (424-456) is a list of preferred amides of the present invention; and The following table 6 (457-458) is a list of preferred amides of the present invention.

Additional Aspects of Preferred Compounds of the Invention The most preferred compounds of the invention are suitable for pharmaceutical use in treating human patients. Accordingly, such preferred compounds do not exhibit single or multiple dose acute or long-term toxicity, mutagenicity (e. g., as determined in a bacterial reverse mutation assay such as an Ames test), teratogenicity, tumorogenicity, or the like, and rarely trigger adverse effects (side effects) when administered at therapeutically effective dosages. For example, preferred compounds of the invention will not prolong heart QT intervals (e. g., as determined by electrocardiography, e. g., in guinea pigs, minipigs or dogs).

Therapeutically effective doses or concentrations of such compounds do not cause liver enlargement when fed to or injected into laboratory animals (e. g., mice or rats) and do not promote the release of liver enzymes (e. g., ALT, LDH, or AST) from hepatocytes in vitro or in vivo.

Because side effects are often due to undesirable receptor activation or antagonism, preferred compounds of the invention exert their receptor-modulatory effects with high specificity. This means that they only bind to, activate, or inhibit the activity of certain receptors other than C5a receptors with affinity constants of greater than 100 nanomolar, preferably greater than 1 micromolar, more preferably greater than 10 micromolar and most preferably greater than 100 micromolar. Such receptors preferably are selected from neurotransmitter receptors such as alpha-or beta-adrenergic receptors, muscarinic receptors (particularly ml, m2, or m3 receptors), dopamine receptors, and metabotropic glutamate receptors; and also include histamine receptors and cytokine receptors, e. g., interleukin receptors, particularly IL-8 receptors. Such receptors may also include GABAA receptors, bioactive peptide receptors (other than C5a receptors, including NPY or VIP receptors), neurokinin receptors, bradykinin receptors, hormone receptors (e. g., CRF receptors, thyrotropin releasing hormone receptors, or melanocyte-concentrating hormone receptors).

Additionally, preferred compounds of the invention do not inhibit or induce microsomal cytochrome P450 enzyme activities, such as CYP1A2 activity, CYP2A6 activity, CYP2C9 activity, CYP2C19 activity, CYP2D6 activity, CYP2E1 activity, or CYP3A4 activity. Preferred compounds of the invention also do not exhibit cytotoxicity in vitro or in vivo, are not clastogenic, e. g., as determined using a mouse erythrocyte precursor cell micronucleus assay, an Ames micronucleus assay, a spiral micronucleus assay, or the like and do not induce sister chromatid exchange, e. g., in Chinese hamster ovary cells.

Highly preferred C5a receptor antagonist compounds of the invention also inhibit the occurrence of C5a-induced oxidative burst (OB) in inflammatory cells, e. g., neutrophil, as can be conveniently determined using an in vitro neutrophil OB assay.

Initial characterization of preferred compounds of the invention can be conveniently carried out using a C5a receptor binding assay or functional assay, such as set forth in the Examples, and may be expedited by applying such assays in a high throughput screening setting.

The following Tables depict further preferred compounds of the invention. In those Tables, the vriable X indicates the pouint of attachment of the specified moiety to the structure shown at the top of the Table. R3 Ri f12 R4 TABLE I RZ R4 TADLE 1 Xr X2 Sß XU5 _'. Xs X2 I \ X I x 4 N 1. 95 A48. 2G27 49. 303G lCKI.... __. ___. --.. _ _______. __... __. _. _. __. __. _.. .. _. ... _ w x X /\ N x 1. 9G 4G2. 2784 4G3. 3201 _ __ _ _ _. _ __. _.. _ _ _.... _. _.... _, _ .... _... x w \ 2 X5 t 1. 91 4G2. 2784 AG3. 241 202 .. _.. __. .. _ _ I _ _ _. _ __. __. _ _ _. __.. _ _ __. _. _ _ I X f L,'ALL x X2 / toc x' 203 , t3C 2.09 5J. 2U75 4G. 3053 x X2 xs Xi 30 t-i c" 22. 1 459. 2675 460. 2983 ...-X ; _ X2 ___. .... __. _. _. _ _ ___. ___....... _ __ _. zozo 2 () 5 : 1 4 2.04 467. 2573 4G8. 2888 . __ __ \___Xy___. ____X ? _... _... _ _.... _ _ X^ _.. _... _. _.. _. X5. _. _ __. _ _ _.. _ __. _-... _. _ ___.. __.. l \ o 2. 05' 401. 2729 402. 3052 . __ _\_ X X ? _____.. _. _. _.. ___.... _. _..... __... _.. . _ __... _.. ___ _.. _________. _____-_. _ __ __.. ____. __. , x X2 X, CH. X,' ? 1 3 2-467.2573 460.2805 i , r X4 20B 4 1. 96 453. 2416 454. 2695 11-1 x x 3 9, Z y ftt V x x 209 2 5 1. 9 375. 2675 376. 2897 __... _ 1. 9 375. 2¢75 37G. 2897 z I _ _ Xz ___/X5 zizi xi x 2 1-13C x __. \ X' X2 X _-_. r_.-_. y I i U 0 x T\ C)-L N oJ i CI-13 X N/ xi x2-o X ! l flac / O . X X' --21 ?.,. ,..-. ...... .. ............. ..,...'-9i. 69. 2729 470. 29t36 . _-__.. _ __ T. O 214'6.) b xi xr, \ Cull Cz 0 xi CH 0 o 2. OG 473. 3U42 474. 3346 xI x 2 X, ro 1 W X CI-I 21G 2. 03 445. 2729 446. 302 F x2 XF- xi 217H3c X4 . HaC Xn F x2 xs r x ? j, X5... _ __. _. _ ____ -0 i 2 » Hc x F x x2 x 219 3 c x4 '/\ , v-3c x X X' j-r c. y 220CI13 __. _.-. __. _ _ Xi CI-13 220 x 2 X4 22)). 78 430. 2784 439. 3) 3 xi Xs X, CI Is x/ 2222 1. 86 452. 294 453. 3306 I i I xi X2 xr, {XX PXk CL X. oo 224 v, 1. 99 459. 1DS1 4GO. 22G .......... x x xs CI-f3 X Uv0 224 S 1. 99 459. 1981 460. 220 "'. x," ---"--- / 1 Ci-1 2z," 3 U 1. I36 419, 2573 A20. 2 (367 xi X5 1 X CI-i3 ovo 226Gil 3 1. 79 406. 2416 406. 2684 -- I/ CI I Cf-13 X, o, o ?. 27 2. Oa 521.1637 522.2009 x o-X ! l t ¢Vr S"\ cl Ci-i3 x o 0 220 ... ... . 1... 5t3. 2G28 5<4. 295t . _ _. ___. _.-. _. _. XJ , J 3c'° x,, x ell3 X5\ cl J CPS . o xi cii3 x zu . 232....... -1.... .... .. . ? J477J739 47C. 202) X1'Ci-i3 CI CI /Xs xi X2 t % th i I w x N i 233 1. 98 462. 2704 463. 3 <35 \ 3 N X5-C} I S t 232 ; f S- 233 3 yt f"f"r' 1ci x. ; xi Cl CI-i3 zsa Cl-13ovo x,. 23G. ^-... __-. _-_ '3. __ _... _... _.,. __... _... _. _. _. __ _... _.. _ _ U. __.-______ __.. __. _ 2. 07 535. 1793 536. 2415 ( : I', 3 x J. _.-__. __- /f \r. 3/ X4 < X, \ CH o 0 I 3 f SxAlUll3 JxW { x x2 xr) 237 C ii 3c, x 2 xr, I w X1 1/,/_\ n3c x oJ "" ? -., c x^ Uli3cwÆxpl Sz 1 ojo S S 238 3 4 2 483_2522 484. 3027 239 1. f37 4D2. 3046 lti3. 3743 ZY t, X, FI, C |, _ 1-3 ? 4D2 3D4G X X2 X-i 0 xi 0 x 20. ° 00.. .l---. _ O 241--------- , 7. zyz S ; t ? U, J X, N-CI 13 xli 0 2. 01 2 J'"'2. <".......::. 242 oJC x, ° ISJ, 252 tSSjts N--CI-1 [2x, X, f2 n X59 H,, Csopv ? > Q J \ Sl-ctl I/HC X, t t, c :, :. .. _ _ _........,............... _.., I 1 1 xi F) cr 0 /'3. zx/8Y. 31s -3C Xn O. s, t3 X, i 02 | 03 X l I 244 l I | 6, 1. 90 1 616. 222 15t¢-201s xi I . 1 0 245 { 3 I . v 245 NC XA 2,91 467.273 dCt3.3030 x X4 0- x 0 \/'' '-'aC-0"X. 24G 2 511. 2471 512. 3024 X J (Q" ? \ f O -i3c xn aJ 2i7 1. 99 171. 2322 472. 2f336 /1 O -0 0 Ou "3 0 248 1. 98 515. 222 516. 2795 --- -........ ........ .......... 0 X, C r H. C X, n 2. 01 4d3. 2522 4f34. 300F3 fTT' ( // C X, 250 H3c X4, 0 2. 06 503. 2573 504. 3187 __...... _.. __/ _. _. _.. ____ X5. _. __. ___.. _-_. _. _.-__. ____. . _...- I/1 F,i v 'toc C X S 2r0 3 4 o 2.08 477. 258 478. 3242 X 1s3CVZ S b 2. 03 477. 253 X rv' 0 " x 262 J5 496.2838 97.33) 6 X,) Ci 1, xi 3-N O CIIJ 0 cl 1, CC 262 x 2 X4 1.95 496.2838 497.3316 253x 2 1. 93 496. 2838 497. 3374 /o a i, \ ' ___. .254 2 1. 99 439. 2624 440. 3063 + -- + +-# -e o -w i 1 S ! C 255 2 4 2 05 487. 2027 488. 258 x Gil 3 ci O x Cil 3 x 1 ¢y 1 t S Exct o x I ci-i3 x _ 25G. _. _. _- _X ? _. ___. _. _. __, X5. _. __. _.. _. _...-.. __. 2. 1. _ 443. iEi95 AAA. 2521 __ O X2 257 2 439. 2624 440. 3058 xi x 2 w C11 XJ - rn' Xg o9 cl-I3 1. 7f3 504. 2525 505. 3216 xi CH 3 c \/ r -on X x' zu1. 97 459. 2077 460, 287 . _ \ X. _- _CH3.. ______. _.. _. _... _... _..... _.... _. _. Ci.. _.. __. __.. _-_. _ ___. _.. _. _. _... r. _. _. ___. __... _. __ ,-'zu \ .-60-..--... ..-..-.-.-.-. -..-.... ...-....'.-..-.-. . 06 77739 78 ; 233 ) ps/\ \ v Y/ 261 2.06 4. B1.2034 462.2581 X ! i (y k u j x x 260 X2 x ci 477. 1739 478. 2339 | a Xsv Nrc' ri 262 ____. ___\ X'___ __Ct ___. _ _.... _... XS. _ =N cy. _. _... _. _. ?. 63 X2 x 1. 76 4n0. 3253 4£31. AOA3 D C {X C V 26d 2 x 265 CX Va ? XG\ R f, C {43 X Ct-13 X N--_- x x 264.., L.-. . ° .. -75 40. 247 4) 96t \bol-0 = C 1 2.01-.503.2339-504.2863 266X . S-..... ........., .........."....... 2.0 503.2339 504.2863 493. 2341 494. 2973 - r - kir- 267 x2 X4 2i 5aOH l l l x/ OH. ___267. -. _. . __. _ Xz _... ___.... _...... __. ___. X. _. _... _. ___..... y___... _ _ l. Sf3 a25. 2467 42G, 2948 .rr'3 XJ !-. _. ». xi C113 F aryl ? 69 X2 X4 Cl / TX, CHg/\ \ 2. osa 461. 2034 462. 255 x cli3 x, cn3 \/"W _ ci 70.. ...... LZ39J78 ; 2429 X *F . . x 2 X5 CH x o 0 271 3 2. 06 521. 1637522.2083 ... ------.--- cor cl-i3 2722. 02 479. 2573 480. 2964 gC Scll3 [ [x\O ( < \ X 273......... ,. .. 03 433729 434.3264 C !-13 o p r-k cl-i CH, X, o. JD 273 ci-I3 4 2. 03 433. 2729 434. 3264 Cl-l3 oo / CI-13 X oo __. \ X CI-i, j'4 5aNIs 9 275"1. 74 424.2627 425. 298 CFI x x1 3 N 276 XZ X 1. 9f3 451. 2369 t55. 2'l56 _-... __\. _X' _. Chl3. __ __... _ _. _. X J _ \/\/ C ! cl 277 X2 X^ 2. 09 495. 1G44 496. 227 277 L -" ---29 495JG. H4 436. 227 , ( Q q CH3 9 F X2 x 1. 86 470. 2846 471. 3502 ) a j'NCF . \/. 9 279Xz X 2. 07 496. 3002 497. 375 Æ » - » - * e # * S e ~ /\, CI" X, 1 xtl 2 t xsS cl CI'/ i !-13C X,, ci f-LC X 6 2. 02 501. 2183 52. 2 (374 xi w o 0 rY"'f' [li i 0 2833 4 O-J 2. 01 459. 2806 460. 3366 ..... .. J f"Y-o "C X, o. J 284 3 2 473. 3042 A74. 3661 xi x 2 H3c x 4 HC X \ I/ 2S5 265. 3144 466. 3706 x xi r 2 X4 xsI H3C X 23b z 0 X 2871. 93 503.27G4 504. 3394 2NNx X5 CI Y ( j288/*-' ""o"T'--.-.--.--- i CHg x. oo .-02-.. ...-... -. ., L................. 1. 99 59. 2886 460. 3446 X, X, H, C CH X CH. o'o HICX4 ci Cf-i3 I x 2 X ! i 289 X4 1. 99 459. 2BB6 460. 3446 .. X, X, cn/x CI-i, a w. < T\ 291..... _.... _... __.. _. __ _____... _.. _.. __.-.. _ . _ _-... _____... . _. __. _.... . _... X. __X2_.. _.. _....... _. y X 5 XI xxsW _q2 _ _ _.. CHa _.... _.. _. __. __ v _ __ _ 2 08 _ 475, 3199 476. 3839 ru Xi r- chl X,, ovo 1 t X 2. 11 473. 3G4Z X 293,. cFJa-xK x x X5 x \ x4 _.. _. 1-13C \ , J CJ, v v x CH. X, T\ .. __. __... _. ___ X ;..,. _Xz/ \ ,--L1-13C w 2. 05 467. 2573 A68. 2I31 . 29G,.. __ _.. _... _. . _ _. __... _ _ __... _.. . _. _ _... ____.. _.. _ _.. _..., ___. __.-_. ___ ____... __.. _-.. __ X Xa I XI / xix 2 X4 o X5 , X, CH/-'\/. po 299'*2. 02 451. 2624 452. 2890 299 298, 3 2. 05 467 2573 46B. 2849 &1 ¢ S (aX2 | 2. D2 451 2G24 j L77. @ Xi CH 3 x Oil . CI 2.02 477,19f33 478.22f39 g a < C 4 ' () c' x x F ''Ps/\ s\/\ (j S -f -" ' (/' Fuzz 302. _. ___ ___.... _. _. _. __.. _.. _.. _..... :-_______.... _-... 1. 9' 495. 2522 496. 3082 v v y xi X2 3 X5 CF13 ra0y _ \ X'X2 X/ ! XS __. _. ___ __ C !-13 F w CW3 X, oo 303. ... . -......... .,.-. . . 9529. 2377 530. 2964 X / F CH3 X. s oo , < Xg r--\ X Xs CI-i3 i X, 305 ci-13 4 2. 05 477. 2791 478. 3398 xi CH'i XIV 306 2 ) Cl ! ! () o = X5 _ /o-I i cl F X CI-13 X, 110>^.. sn7 2 4 1. 99 491. 214 492. 2748 \/ x 309, .............-.. ,.,.-../,....-...... - . . 1. 69 425. 2579 26. 3054 . ___ X'X2/O X J... __. _ 308 2. 6 1. 91 425. 2234 42G. 2757 1 x cl /X, x I CH X4 o o CH. 6. Jo 3119t3 d59. 198t 460. 2525 311 t CHa X, x5 I. 9G 45G. 19G1 xx 2 xs I X, q 3 oo 312............. .............. . ... 1. 99 45L2293/<52. 2a99 F Y 3 19 692529 470.3jJ 312..-. =.--.-..- x Cil 3 rr \/ X X 469.2529470.3111 3l3Cl-13 1-1ac% X3 X5 (j ' g2 x ) 5 "L ? S5<2. 33<5 513. 4124 -. ci, x 3 31 X2 X 315 F X2 X4 1. 78 512. 3315 513. 4124 . __.. _.. __.. \ _.. X. CH3 _. _... _. ______ _.. _.. _ _ _.. _ _. X.... __. __.. _____-.... __. _ _ __.-_.. __.- _.. __. .. ci 3 - CI-13 \/ !-13C 31G X XS 1. a1 432. 3253 433. 3902 __ _\ _ X'_Ch, 3 _. _. ____. _. _. _.. X^. _.... _-' c. _NC' _. ____. _.. __ ____ _...-_ _ __-. - CI-13 \ I F 1_! aC 317 X2 xi 1 1.83 450. 3159 451. 3883 X, X, X CH, c x x 2 X, N /yi C 3t9 Ch13 X4 Cl ovo _ _ _ _s _ _ _ _,,,, 1. 95 503. 1976 504. 25B2 rl : ; f 1 320 Ct-t3 X4 Cl O o J X ; $ _ 7_. | 53G 203G 53G. 2G33 | /Cf. l3 I/ 1 szo t3 x, c3 ..... ____. _... __ _ _ __....... _ _.. _... _ _.....-_. _. _1. 7. _ 535. 2030 536. 2G33 GI-13 x 4 0 , O'L o.) - . L.....-. . . . ...,. ...... ........ 1, 93 493.2729 94. 3207 321 1. 93 493. 2729 494. 3207 \ Cl 3 CUL F X2 x ! ir) X, X/ 323 2. 02 471. 2453 472.317 ,3 j r f-f f X /-"OH ci cl .-..-. ......... . (J X, '' r/\ a je \/ xi F r Xz X4 jft )--C", J'' x x 3261. 98 457. 2296 458. 2892 , OII ci X x' 327.. ............/...... .......-.. 0. 2642' ! 5P : 3 326 1. 97 457. 2296 458. 2943 - CI-t, i \ f X X* F 327 2 1. 67 449. 2642 450. 3473 / ciCI . 32a ___. _.... _. _... _ X ? ___. __.... _.. _.......,. X... __. ____ _... __... _. _. ____. 2. 1 475. 1957 476. 232 328 2 2. 1 475. 1957 476. 2632 /IIaC,,,, . 2. 02 4 23. 2G75 4 24. 3092 X4 TS"''< /y ! _IaC Xs..- . c F-xi x ol 0 x :, \/\/ r 330 351 X'X 1. 98 491. 214 A92. 2755 XI) cul i cri r- 331 F X2 X4 1. 98 491. 214 492. 2755 x ci-i x x 01-i U-CI-13 . _333__ _-_.-..-__. _. ______ ___.,. _..... . _. _____...... _ __....-___. 2. 02 547. 2635 54i1. 3262 __ X'X ?. X'/\--. __. ___. !-/ i ! x o-cv-i3 \ l 334 2. Otl 577. 172J 57D. 25 LC A L XLL I O Xs Cri-13 H.H ; C X, -% 1. 96 511. 2471 512. 298 xi X2 x 1 3 oit xi 336__ _--______. _ ''"''. X,------ C.-. OH' 1.95 517.2132 51 f1.2731 337 3 1-13C X5 . 2132 518. 2731 . _ __.. __ _ 2. 15 521. 3173 522. 3696 -.-.. _. _... _.. _ _ __. _.. _ ____. _. __. _... _. __.. ___ _. _ I o 33t3_..-__ _ __ H3C H3C X5 . -L---..-..-..----..-,-. .........,. .... ? JS52L3J73 522. 3696 J (J--_. _.. __-_.. /\ 339 _. H3C XA O _-.-_-_ ____-. _. ____... __. p- xi X2 Cil Oil x -, i O !-I /\ O-P a10 t 3C X ; X - 5 0 2. 05 1a7, 3563 4f313. 4303 \ X X7 I_3C o oi i /\ 341 X 0S X3 _ s _ __ _ ~...... __ _ _.. 1-13C-'''........ _...... _ _ _ 2. 08 5f5 3512 51G. 4047 iv g I g 'w-w-2. Of3 515. 3512 51. 4047 2 3 4. oit 3431 C F13C ? f i) IX, .-Xa X^. _.. __....... _. _... _..-__ ____. _. _. ___. _. _ __.... _. X ? T) / s Ei3c 343 o 345 1-1 3c ci. 13 X5 1. 94 433. 2729 434. 297 xi x XII 2 sn 2. 07 473. 3042 474. 3316 si x ruz 11 3c HgC \--/X- 346'2.01 459.2SOG 460.3174 _ . 1 o'i r H,? | S 347 IA 3c X5 348 H3C _ Cl-ls X5 / _. _ H3C CI-1 X w'1. 7 405. 278 406. 3116 349 X X 1. 96 445. 3093 446. 3387 . X, X'"H, C X, '' 2 X4 350 H3C X V V t-) f Y - 0'CH. rr'"\/''fy po x, xi 2. 04 489. 3355 490. 3575 xi x 2 1-13C X4 O-Cli, _ ,-'° xi 352 H3C X3 3522J5 529.3660 530.395) -aC v 3J'3C X3 353 11 3c x -- X ___. _...'-'3C X^. _ _. _. _.. _.. _...... \_. _y i... _. _-.. _.-_ _-. _.. I X6 Hic 354 3 3 [fr'"/'/"\-/°' - X7... _.. __. __ I_iC Xn... _.... .. _\__.-ol . ___.-_.... _ _ xi 355 H3C X rT''//*/" / X xx 1-1 ic X4 355 H 3c x3 xi 3j xi x 1-1 3c X4 cor )) 0'-- o 35 f3C X3 1 2. 00 539. 3140 540. 3187 _ 2 xi 359 3C Xa C 2. 04 505. 3304 506. 3531 2 3 O-Clk, X-P 0 \O xi f-t3C Xs 3G0 ..-... ___. __.. ____. _ 2. 8 J4J. 3a JA.. 39 ... __.. _.. _. _.... _.. X.... _. __.. _.. _. mt-_...... __..... __ _.--. _.. _. ___. XS 3G1'i3C __.. _-_. ..-___ ^ 2 4f33. 2522 4134. 2723 x x x Oil cii, )) ('- zo xi . . X, X, X. " Oit -o-c i, o xi I- ! 3C fY) -""' )) 0 " 1 / O x5 J 0" 363 2.0009.299j 90.3 < 92 X v r -/ b x x 2 1.-1 3c x 4 H 3c x 5 X t7n i ol 0 36s xi x 11 3c X4 Oil \ i v . _ _. 3C X5 _. __....... __ _.. _.. __. __.. xx X4...... ! A 5 A ; C ! 94_ ; 5113 ! 3995X23533 cor \O 0 " 3G7, x x X4 1. 0 435. 2522 43fi. 2069 oui-I /\ cl-i x 3.D t-3C X a/ -.. X' : i C _.. __........ _. _-_ _... _______.... _. _. ____.... _. _.. __-__. a X OI-i / OH 369 HaC .. _. _.. __.. _. ___.. _ _____.. _. _.. _ 1. 94 511. 31 J9 512. 35D3 _..-X ? _'.'3C _. oi. -___ _. _... ___... _-. _. _ ,/ Oli . 7n I fC X3 r'3 1. 72 477. 3365 47f3. 381G p A OH / OH 371'i3C xJ X __. __. _... s J7J... ..............., .. J.-SO, 5J3G6a Sj0) 061 x x c x 4 0 ;, s o_", 372 inc 372 li 30 x 2. 02 553. 3304 559. 3617 o 'o-cti, x-- 3733 3 cl-I3 373... ....,.. t. 9G 519. 3461 520. 332 520. 382 ,, 0 o-cn, xs 374 11 c xa H, C X - 2. 09-. 559. 3774- 560. 4091 _ ''~ H3C f----ç f _2-09 666 3774 660 4091 ! (o /-o H. C \==/ Xs 375 1. 92 497. 2679 490. 3003 . X, X X," 0 /\ o HLC \-/ 37G 2 503.3140 504.343 x x x 4 % 0 t H, C X Y x X X Cor I_I3C 377 _. _. _. _... _.. _... _ _... _.... _ _. _...... _..... _','3C_.. __.. ___. _-.. ___. _.. _. ___ --- xi*--w b-_ i / yi x 378 2 525. 3355 526. 3682 37f1. _. __. ____.... _.. _.... _.. _. __ _... _. ____. _ ___..... . __.. . __. _ ( () X-0 oit , xi 379'"OL 49L3512 92. 3073 37Y,", _. _............................ _..... _.. _. _ _. _. < f l \ Ugli x5. 125 5313025 532t5 380 xix X4 113C cl hic xs X xi x 4 Oit 3au I/X^ I//I _ OII xs 3ti3 HaC o Q 303__. ___.. _. _ cn, 1. Q6 4p3. 2522 484. 2405 , CX j V2 ; |X, J°ell, ; f 94 ! 5|721Zl6. 2035f __.. C' __.. \. __. Oli.. - HC''' x x2 0 X. . ...... .......... .'.,...-..-- off, x X. 1. 97 497. 267, 9 490. 2453 cru 3J', 3C U HsC ... _. _.... __.. _.... _... _.. __. _...-. _-. _ /I xs J o 306 HaC o 1. 95 511. 2471 512. 2275 x x 2 X4 CIO, H C /w x,2. 06 553. 2941 554., 307 _. __. _.. _ _. _.... x'_..... __.. __....- (ct,'__-__... ____. ____.- _ _... _. 388 3 (oxo / . oven, 3ro H3 CI-I 2.05 51 J, 3097 520.290G run, cil, li c X, 389 3 tC k 0 . 39 Ivi l, j3c, 2 lSxl 3 x Oil X, , 39, 0-c- ! llo-/ob, 76 469236, 5|79236,, 390 143C 390 '.3C 1 X ! i"-, q 391 li 3c ci i I x 391 3C cl Xl z f. YO), t ! J x J J'"T . 1. 88 503 1976 504. 1985 / o Ito 0 403. 2522 484. 2435 1. 89 497. 2314 490. 227 393 1 Oil 1-1 c 394 3 394 Oil x x 2 X, xi 396 11 3c cor 395 cor U r D Oit . _. __... _. _. __ H3C _.. ... on ...... .. ......................... . 396...,. 1. Q5 49. 2729 470. 2647 xi 0 397E13C 403. 2522 404. 24 x x 2 X4 3sn1q3C X3 U x oll. 1.07 531. 3825 532, 3688 x X2 li 3c 4 0 ) 2 fA 399x 5 0 /x-_ 5 399 H3C X 399 ..-2. 07 509.3042 5J 0, 2907 ........ .... ...., ...... ................ i x5 i 1_f aC Xa \ 1. J9 4iI1. 30J3 A (32. 3090 x x 2"; Z I 1C I C2 9f 1X4 fXsDA°ll I i < x x2 x 4------ X5 1 t4 C X ? ci not 2. 05 515.2703 516. 2676 402 f 3cX IxX X ° I I I 4 /t 402 3C X n! j j f x. '' o t r f- H C X 0 2. 01 481. 3093 482. 3063 ... _.. _'1i3.... _.. xn...... ..... __ _. ____. _. \__oc'I'__.. __.. _.. _. _. r___. ______. o 403 3C 2.03 523. 3199 524. 30fif3 E 3c x 404 V13c x 3 Xf, I .--2. 04 523. 3199. 524. 307. 4 Ix 2 li3 4 xr ex 405 1. 96 47&3199 4763t77 . X."X,"""0-),. X,'--- ; o,,------ i x, H. C X C) L /) 06""1. 79 447. 325 448. 3324 2 3 x 4 01-1 ',-oil xi H C X) --407 3 ci-i r' Pa f. ) r J'oH tLC X C) L 2. 02 401. 28 482. 2077 2 1-13 4 408 I-|3C X3 Cl-13 t-LC'X C) L 408 1-13C x3 cl-1 : 3 /s/% U J ffl 410 H3C X3 Cl-1t3 X5 4, 0 5 PO J 2. 01 4Q9. 3355 I90. 329G .. 411 H3C Xa 410 H3c x r,-- 3 ci-i3 X r r. J' GF 1 1'cl3 x 2 A96. 3224 zo c , xi X7 fTY'f' ?"'r'fiYr '--_. ___. xr - 1. ___ _. _.... _ H'C X3 CI-I, r 19 I 3719 xs i . cn, ""0 mus. H C F . a X w 2.1 515.3124 516.3123 jf) J J J "c.., xix 2 x 4 x 0'Cl-13 H C xy 416 3 __ x 0 0 3 Q '3C X3 2. 16 501. 3719 502. 3629 C113 I NCf 1 i, cX l le2cßX^2-T _ 2 46 1 4s2 as6N 41 t3 HaC X ;, W I 4 IU.. H3C X3 _..... 1 1 X Xa CI-1 X^ ; f, 420 H3C X3 x x2 x4 f r r''" xI x2 vi X4 X, N'ci i, x. ! x x2 X4 01. 1 nL. A ' _-_ I /Xs /O 421 2t L-.-. . .--..--.......--.--..-. ..... .... ... SJ4 5 < 5. 3512 516.3379 I . _ n22 HaC X ; CI 2 ci-i x 0 'cl Xi X3 , -X, X. 0 X f. VCH, 423113c H R3 /' N R5 R1 I H N R2 ..........,.. TABLE tA R3 is Huntessotherwis specified CMP tl R 1 R2 _ n3 iTl4 1q5,. _..-Rln. Time Cmd Mass I ! F lon O,, bs F J/H3C 2/'\ X5 424 2. 02 427. 2424 428. 2541 F) Y H3c 2 4 Xi 6CH3 425CH H 3c X4 xs jjj n r* Xz ') H. C x, '--/""==\ 3 \ l cH3 'X, H C h fH 427 3 2. 1 455. 2737 456. 2953 I ß | i 13C] N WX] X5 3 1 1 S , \ H3C/ X2 (4 5 X SL F Chez 2. 13 469. 2fi93 170. 3137 H3c 2 3toc 429 2. 02 485. 2479486.2833 CH3 Hc X4 X ! i CH _430.. _ _ ___ __. _..................... H C 3 _. ? 15,. 4B1. 3093 482. 332 0 2. 1 ___... _ _. _. xi 4. T 0 432 ovo 432 o., o C hic- 433 4 1. 91 431. 2573 432. 2898 0 " -'T, Hic 1-1 au .. _. X4 X5 __. _..-.. . __. ___. _ __. __. _.. _. __. _. _ _. _.. _-_. _ H3C X n3n 1. 92 433. 2729 43R. 3079 . 433 1. 91 431. 2573 432. 2898 Ç Ç H3C/4 f X5 434 O 192 433. 2729 434. 3079 : X 1 13C~ X2 vX4 X5 Ç 1 t_t3C/'u X ? XA X5 3Cr X CI-is T "==< ? H 3c 3C'__/I CH3 x 2. 04 433. 2729 434. 3079 '/'3C' i xi 437 si 0 - X-X4 _ _. __ _... _. _ Vs i37 X - W H3c~ 2 b 95 2. 04 401. 2831 402. 3126 43t3 x O )/- 2 \ r)- \/5 T / Py iC-,-r o x,'.,. I 1. 99 447. 2886 448. 329 H c x4 0 / x-CH3 440 3 1. 98 447.2886 448. 3293 i< <X Ii3C II C/- 11c ci 13 CII3 J 441. ____ __. _ _... _......... _....... _. __..,,, 1. 95__ 447. 2886 448. 3331 '..... 1.95 447086 448.3331 S/ f 1. 95 447. 2886 448. 3331 H3c x4 0 442 x2 CH3 CH3 x- CH3 Xz CH3 H3c 4 443 xi CH3 fl/-"X,/X, X ruz ?'CYP zu 3C x4 X J __.. _...... _. - -- x Ut 44, li H3C 0 0 1. 99 459. 2886 460. 3416 .. __.. xA _. _.... _. _. _.... _..... _ _.. _. __.. __.. H C 3 9Xi 2. 07 459. 2886 460. 3427 \ X2 X,XI HJC t i, c \ X1 Ç 2 SX4 X 5< 8 x 4 X5 H3C/ / H3c 449OJ 9 ! H2CX2 í ß . l 'H CXZ 3 I (J. h T h I/r H3C , X O 450x,. X5. ___ _ , 1 11 C- i H3c x x, ou HJ"3C ) =' S--\. =/ \/X2 0 /H3C rr Xs O --452 xi 1 2. 09_ 1529. 2729 530. 334 X H2C, r, 2 2. 09 5292729 53 S H3 c X4 X5 . S O \ X 453 2. 09 545. 2678 546. 3349 . ___. _ . \_____,.. _ _, _. _. X2.... _. _........ __X X'___ _... _. _. _.. _.. _. ___. ____ _.. _ i HJC 45, 1 xi 2. 02 423. 2675 424. 3183 _... _..... X _ X.. _. _.. __.... ______. _.... _.. _.. ___... _ 2,/\ x5 Ç 1|3CX2 X4 sX5 455 xi 2. 01 409. 2518 410.3021 X4 i Ç H3C i X4 X5 45 _ b-b 459, 07 460. 326 HJC / X Ç2. 07 459. 2675 a60. 326 . ___ _.. i__. _. __ _.. ___ H. CXz..,.. _ X^... o../_. \. ____. _X5_. __.. ____. __. .. _..... __. _ _. __. 3 xi 457 x \ 2 453. 2416 454. 3023 CH 3 X 3 x, \ CH3 459 2. 05 423. 2675 424. 318 X4 \ \ I_IaC/ X \ 5 x 460 xi 2. 11 473. 2831 474. 3436 1-1 ac X4 ' J-CH, han Xz C3 CHL 462 2.06 437.2831 438.3386 f \ X2 X4 x5 HaC 1 \ , X CH3 nas CH, , 63,...,.,........................,....,... .-.. .-.- _I. XZ. X. O X5 _. __. _ 64 /-.....,.. 11. .. 3831 474485 x x, n, O e 2. 03 467.2573 468. 3192 U13C 2. 04 423.2675 424.3211 ... _ X5 _. _ _... _.. _.. _ Ç i H3C 1-13C X 467 xi ; 2. 1 473. 2831 474. 3467 .......... y x2 0 468 X,. O 2. 02 467. 2573 468. 3Z27 3 l 9 F t 469 xi 0 1. 99 471. 2322 472-3021 _ _ ___.. ./ 3 X1 47 () F 2. 02 441. 258 442.3175 xi Si hic 471F 0 1, 98 471. 2322 472. 3026 .... 4 ?].... | _ _. _ __.....,,,,,,,,.,,,,.,, F,, _, t_,,, _ _, __, ____ _. 98_ 471. 2322 472. 3026 Hsc 1''' x w 47, X 2. 03 441. 258 442.3185 S 73 S 13Cx2 f \ 473 _.-........... 2. 01... 427424 428. 3031 _..... __.. _.. _. __ __..... _. _.... __. F X1 471 475xi 7 J -2. 07 477. 258 478. 3228 I 9 I H3C U 5 475 xi 475 x r I 9 J H3C 2 j | SX4 C X5 . __. __, _ _ 7. 99 471. 2322 472. 300E __. I _ _ __ __ __ _ _.. _. ___... ___. _. _ 2. 08 _ 437. 2831 438. 351 3 476.. ........ 2 52987'452. 3606 _. _..... ...... 2. 14 487. 2987 488. 3652 x H. C xi 78 ""2. 14 487. 2987 488. 3652 ___. ___. _... _. _...... ___..... _.. __. __ __ (H3CX2 Xs /\ :/ X A7f3 2.1 1 487.2987 48E3.3652 X ;- 143C 2 ----479 xi _ 479 xt C 0 2. 07 481. 2729 482. 3446 X x 3 \/CH3 4a. X1- ..-_. _. ___. _.. __-_ _ __. __.... _. _... CHa 2. 08 437. 2831 438. 346 ==/\y"cH, xi 4F31 X1 483c 2 X4 x 5 i 81 9 H3C2I,,,, 23, 5 451 ? 957 45 ? 62r \/ci-13 4f32 X Ct-13 xi ii 3c 0 x 483 si /CII 4f33 r _. __.-. ___. __.. _-. ___. __,... __ __.. _. CII . _.../. .. __. __.. X.. Xs 2. 06 481. 2729 482. 3413 \/CH3 4f31 /) 84'.......... 2. 09 437. 2831j438. 3447 11 3c /'Cli I inc 2.07 481.2729 482.3401 zu _'x2 T f CH '\===/\==/3 2. 09 451. 2987 452. 3614 . __. _. _____. ____ _. ____.. _.. _. __. _.. _.... _.. _. __ I ? H3c Hdlr x 2.ji X, j i X . _ _ _. __ ___. _. _ _....... 2. 08 437. 2831 438 3399 H C 0 H, C 0 2. 06 481. 2729 482. 3407 _ __ 2. 06 481. 2729 482. 3407 .-__.. _ _. ___. ___.. _. _.. _. __. _.. _.... _..... _ _.. .x \ 1-r.. 2. 11 451. 2987 452. 3647 _ _..... _. _ 2. 11 451. 2987, 452. 3647 Q Hz 490 xi CH3 490 X'. _-. __.. _ ___. _ _.. __... _ ! _. ____.. ; _.. H3C..... _. __-_-_. 2_O9_ 437. 2831 4'38'. 3419 __... ___ _. _ _. ____ chez 491 2. 14 487. 2987 488. 3654 1x 92 ''-'0 2. 07 481. 2729 482. 3416 492 X !' CH l =' 2. 7 1a1. 2729 Au32. 341G ----------------7 H C oxy CH. 493 2. 1 451. 2987 452. 3654 - - s 113C X4 X5 T'' Hic xi 2. 09 437. 2831 438. 3447 494X2 X4 X5 ] Ç | H3C | X4 E X yXs í I t 495 1. Ch13.... _. _ 2. 14 _ 487*2987 488. 3656 H3c 496 x, cíl, O __.. _ 2_7_ 4812729 482. 3421 .-_....... Hic 496 _ 4 X'J__ _. ___... _. _____.....,... __. _.. _... _ cn'___..... _.. .. _.--_ _ 2. 07 481_2729 4Ei2. 3421 Xd X5 /w. r HaC/\ \ l _o 4xi time f3c 498 xi CH3 2. 01 439. 2624 440. 3276 2] [43Cx2 \ | 9 \ X CH1 \ 2 01 1 439. 2624 0 441 j H3c 5 cl3 CH H 3c-0 ci 1, 0 1. 99 483. 2ru22 484 3252 ,.3c 2 x4 X ! i i L 3C H C x 4 x 5 H, C 0 H, C O H. C ,. X X J xi O H3C 502 H 3 1. 99 439. 2624 440. 332 5uz......................... _ _. ___ _ __. _. _. __. (i 3 i o/\ _I_\ _/ x2 _ O f X5 v i I s 9, H3c<X2 z X o<>xs 504 X, 0 1. 97 1 483. 2522 484. 3253 504 x c (fj H, C/-/'\ 3c 5 0 O /-_... X 506 1. . 99 439.2624 a40.3253 H C x4 X 5 3 0 X 507 2. 07 489. 278 490. 3-057 x 3 x5 H3c 4 0 PO X 508 1. 97 483. 2522 484. 3227 i 9 F H3C HJC 509" x 2. 07 155, 2737 456. 3386 509 CH3. __. _. _ __..... __. _. _...... _.. 508 1. g7 483. 2522 484. 3227 3 F X1 CH CH3 510 2. 06 441. 258 442. 3267 51t1 í | H3 206 441. 258 44 j j...-. H3C 511 X, Cl-J3 2. 11 491.2737 492.3441 ------------ ./'xZ o/_ r v X5 512 xi 0 2. 04' 485. 2479486.3185 \/Xz X, Ç 3c 2 v X X i 1-Is 513. 2 04 441. 25S 442. 3253 9 H3C<x2 a 3c-b t<X5 H3C i i'c 1 f I x 2 x 4 x 5 CH 3 .. _ _ 1-l3C \ 515xi F 2. 05 455. 2737 456, 3376 R . S « w w R. * * 4- -+ /3 '' 51 G X'2, 04 441. 258 442, 325 _ 516 _. _.'__ __..... _............ _. _ ~.. ? 04 _441. 258 44 ?. 325,, H. 3c'4 ""Cb-F '-t)- - X 517 i 2. 1 491.2737 492. 3412 I X1t j Fl3C~ Xz 0 1 W 4 ° [2 02] 435. 2479 \ 48E X H3c 2 -6 0-0 F 5 1 9 X, O 2.02 485. 2479 486. 3193 y xi 5 c o-2X5 T Ct 520 Cl 2.04 487. 2027 488. 2782 vi 3c 2 t/3 X 520cl-2. 12 493. 2285 494. 3027 o H3C<x2 X, a (<x5 , N X2,). O,, x W HSC U U 5212. 04 487. 2027 488. 2797 + ~ ~ * a s 0 * » 522 xi 2. 06 457. 2285 458. 2941 /s y ci /'./X2 X4 X. HIC CI 523 X 2.04 443.2128 444.2792 HaC CI X 524 2. 09 493. 2285 494. 3003 . _.. . _.. ___. ______. __,.... _=. ___^X2 XA O/\. _X5. __ __... __. ___... __.... _. c 525 xi 0 2. 03 487. 2027 488. 278 525 525 ''-02.03 487.2027 488.278 xz xs aC \ 5 ? 6. o,,,,,,,,, 2,, 489. 2228 490. 2792 XI 1-1 ac2 X4 F F \/ si 527 F 2, 02 445. 2329 446. 2807 _.. __... __.. _. ___.-_.. ___.. ____ _. _. _. ____ F 528 xi X y \/ *-----4---Æ 6 6-- » . X Ç S I 3C 1 gF 5 F 3C g ft) Hr* \/ V Y'"""'''i3"'= /_"_ X F F 2. x1 i. - x2 /. X5 Xi xi __. 531.. _.. _. _. _____________ _.. _. __.. ____.. _.... _. _. ____.. _. _. __. 2. 07_ 495. 2486 496. 2984 .-I ! CXz X"o/ X5 _ _ _..... __ 3 e_, 53 ? _ Xr 1. 99 tt39. 2228 490. 2794 .-----.-. H3C r 2. 08 495. 2486 496. 3038 xi- H30 534 X, 0 2 489.2228 490 2825 tTj '-/-- /\ x 4 xs i x,- -535. C (13 2. 14 465. 3144 466. 3682 F13C I 9 He 13 451. 2987 452. 3522 HJC X 537 xi C143 2. 19 501. 3144 502, 3722 Xi xi X, 0 , x _. . __ x.'-A 0 CH, H3C i r x W O 'cr r, 5302. 11 495. 2886 496. 3486 y HC 3 X X. ? J2 452987 452. 3553 X4 1-13cx 5 . /-- 540 Xt Y"/CH,' - ,-.. ..'. ..,.-.. ...."'° . . . ..... . .-.. -2886. 496. 3533 ........ _ _ __ n l C- 0 c. -C... ........ . ..' ! 53 : 278 454334 C C" -o'' <I'--'' . __52. _... X'__.. _.. , __ _.. _ - o 3 \-f1'/\=-/ cozy 1 513 __. ___ ___. _____. _ ___.. ____.... _. __......., 2_04 453. 278 454. 334 _. _. _. __. ___... _ _. _. ___. __..... _. __... _. _. __ con3 _./\ _. __X2. _. _..... _.. _. __.. _.... _. _. _.. __.. _....... _. _.. _ ___. __ xi i-con xi PO 2. 02 497.2679 498. 3338 . _-_ X, w/1'Xz/\ Xs 546""a'"2.1 503.2937 5043604 547 'c". 0 2.01 497.2679 498.336 546H3. _.. _ x fol3 5__ _.. _. X _. _... __,..... _. ___ C. . _ _.. _. __-. _. .. _.., _Z. ^_ 503. 2937 504. 3604 547 0 2. 01 497. 2679 498. 336 hl3C 0 5q __.. _x.'. _. __. ^_.. r_. _, _. _.. m'_.. _ _...... _. _... __ _. __. 2. 01_.. 497. 2679 498_336 )) J'C/)- O i H3C/\ \ -. I.. H CX2.. X, OCn3 X5'-_ V H3C U U 649xl 2. 02 467 2937 468. 3528 __. _. _.. __ \. _. _.. _. ____ 9- 549 xi 1. 99 467. 2573 468. 3251 H3c - JJ..,. _. __..'_., _.. ______.-_ _. _. _.... __... _.. _.... _.. _. _O_..... __. _ _ _99_. 67. 2573 4G8. 3251 \ H C/X2 X^, \ X _ y /\ _. _ _. _ ___ ~ * * * o /X2 / O/\ Xs H3C q, 1.97 197.2314 498.303 2 x4 x5 H3C S / X2 X4 X5 s 9 1M2CX2 S t\ A 553 H3c 2. 05 469. 2552 470. 3185 --*-* --s xi 555Ç 1 H3C | E Xs X5 _ ____. _ __. vu 30 L . 556 __ _x"__, ^..-__ _. _ _. __... _.. ___ ''S _ _. _... _. _.... _...... _.. ___... _. _... _2=3 __ d9g. 2293 500. 3005 / X2 X4 X5 HIC / /F xi 557 3 1. 99 471. 2686 47 3348 f)) U Q X X - HIC o xi H. C 558 H3c 1. 98 457. 2529 458. 3177 s--- * -s # Ç \ 113C \ F r X1 813C 2. 05 507. 2686 508 3, 424 X \/ x Zl, C'O 1. 96 501. 2428 502. 3192 3 1 Ç t H3C i t SX N X5 S r Xt Cl Z. 1 457. ? 28, 5,'458. 2933 559 "-2. 05 507. 2686 508. 3424 Xi 0 ...... . _... 5 _. _ _ H3C CH3 y Y \ H3c X4 x 5 Cl3 H Cz . \ ,.. _ __ ____. ___ _. x xi- I/ 3. r Cfla/ 563 X'_. _. _. _ ____. __. __.. ... ... r.... _.. ___. ______. _... 2. Oa, _. 501. 21 t33 502^2952 .---563 ci.. x cl O 2. 0B 50t. 2183 502. 2952 __.... x_ i H3C ci I 664 'r02. 04 505.1932 506. 2737 56i xi H3c 2 x4 X CH3 565 tCH3 2 17 465. 3144 466.3809 Z',/-x2 0--X., .. _.. _.... _____.. 5 fiv l 567 CH3 2.15 509. 3042 510. 3789 H3c X4 x X CH3 1 H3C X, 3 H . b X CHa 2. 14 465. 3144 466. 3795 X5 0 H3c 2--- - cit, zu 2. __... _. _.. _. Xi 0 X cn, HsC X Zci, O 570 '-c... 0 2.06 511. 2835 512 3632 .... zinc i-\ CHEZ O Chi3 571 3 2. 06 467.2937 468. 3609 H c X2 X4-- x 5 . . C (I 2. 12 517. 3093518.3871 .......... 0 X,cil, x s-s 143C x2 x4 X5 X, s row 2. i 483.2708 484.3423 Xs S1 i 2. 08 469. 2552 470. 3222 H3 cZ--,/"--x2 x 5 H C//xz X. Xs Y S j _ 2. 13 519. 2708 520. 3477 xr-0 xs _____.. __. _. _.. ___. _.. __. _......... _..... Ct. i3..... _. _ _. -.. _. __ _... _... __... _. __ s H GXZ i Q X 3 2. 06 513. 245 514. 3214 1-1 3c x45 F i p F F 578 xi 57t3 T 'tF _ _ _... _______. _. _ ____. _. _. __... ____ _ _.... _ < o r- x / [j J HgC / -/ ___ _ _ __ _ r X 580xi _.,.,,... _,....... _ _ __,........ _,.,. _. _ _2. 08_ _ 513. 2392 514 017 j H2C 2 is | o x X XsS F H3c x 5a 1 ^_ ___.. _____. __. __. _. _ _ __. _. _....... __. _.. _ F__. _.... _ 2 507. 2133 508. 2841 H3c Z-"//,-x2 X4x5 I ? F xi 2. 06 513. 2392 514. 3171 .... _ o_../\__. _ XQ X J F......... _. _. _.. <o r- 583 C Xg F 1. 98 507. 2133 508. 2f343 / x-0 X CI (, HaC zu 584 xi 2. 03 461. 2034 462. 2718 Hacx4 ci /han--_ x F //\ -'/== { H Cx' x4 x J -C [_--.. _.. _.. ______... _.. _... _. _ ___ y F xi 2. 01 505. 1932 506. 2769 xz ci I H3C 587 xi ci 2. 17 561. 1505 562. 2524 ____. __. __.. -. __. __.. ____. X2.... _.. _'j1C=O... _... Xn X5... _. _. _... ___. _. __.-. __... _.... _. _ _. H3c 2-v \/\ 0 1. 99 527. 2784 528. 3599 rTI/-"X,'C-o /< X,-. H30 /\ \/ Ç ! H3C | J X4XCI | X vXs .... S88.. ......... \..... ,. .......... JL99, 527.2784 528.3599 Ç H3C 1 13Cv X XsX 2 saa cl l o 1. 99 527. 2784 528. 3599 fq H Cz/X2 F/4 X59 v 3 h F z 59 X 2. 02 459. 2486 460. 326 I H3c, 2 x4 x5 590 xi F r\ r\ H3c 2 x 591 xi cul 469. 2552 470. 3206 X s--) \ 592 % cri-13 514. 321 _ ^ 2. OG 469. 2552 470. 3206 593 xi o\, 0 __ 59 ?. __... _. X____-_ cnt 'chug 5952. 07 533. 1904 534. 271 1. 97 511. 2471 512. 3246 /3 H3C 4 xi 0 __... _....... _ .. __ ^, 2 467. 2573 468. 3217 O Xi O C! /S 59 i Cf 3 2.07 533.1904 534.271 x x i H3CXz X X5 596 X, Br CH3 2. 09 501. 1779 502.2556 597 x, H3C X2 W CH3 t<X5 H. C',/\ 0-) /' 5 C/-' 2. 08 545. 1678 546. 25 42 r1 "X, "\., \ x- 598 uiac/0 Ctl3 /ci_ _\ O cry/ X o . __.... _.., _. _,,,.., _..... 3........., 2. 07 545. 1678 546. 1 213 . _. _. ___.. _. _... _. _. _. ___ ? H, C -C' x H C X4 X5 . _.... _,. _.,. __.. b. _,........ _. 205 597. 1991 598. 16 ----» --*--- * . _.-__ 602x, W CH3 O 601 10 C113 ...... 2. 05 597. 1991 598. 16 H3c X4 CH3 602 si 2. 04 455. 2395 456. 2075 3 603 2. 01 499.2293 500. 2002 x2 Br X4 x5 Hic o-ci y 0 604 CI-13 O 1. 9g 605. 1889 606. 17 f. 1/-"X,", c-o ' 5- 6D';2. 06 575. 1783 576. 16 i 3/\/\ 1 O f3r H 0 xi 0 /3 0. / X, 4x hic 0 ". "'' X, \ J i/HsC a/\ Ii3C oJ. I \/'1. X2. F X,. X5 t/HaC w/\ X O 608 xi 2 503.2384 504. 2233 0 6 * 0 #-w w e * -S- v . v nCH3 f H0) W r-k. C)-o Xu9o x, X2 A X 2. 1 559.2835 560.2635 __ __-_ _. _ _ O l \ X5 I I lEl3c~x2 I X X5 2. 1 593. 1539 594. 1388 Q " "' \ N'X2 X4 X5 "3" r x, o. Ç il2CX2 Ç cX4Xsx H3c/l \ o 612 1.......,., _ 1. 99 _ 467. 2573 468 2505 . _. . __\_... ________. __ _ . xz X... o/\ _. _... X..-... _... _. _... _... __.- 612 xi 0 1.99 467.2573 468.2505 /'"i3Cr S 1/ 5 i 613 x, tr, c O __.... __2. 02 _ 473. 2137 474. 20E _. _ X Xe-X5 7 /HsC H30 0 6M. 2-P3. 8729482.2651 *-A--# "gU \/--. 10 x, oJ H3c 3 X4 X5 616 0 2. 03 481. 2729 482. 2703 a Y 3 O W 2. 05 437. 2831 438. 2783 616Vs CH3 XA __ r x.- v-/ ' CrX2 -. . X4 X5 li3c 0/---/X4 X5 611) xi b--i 0 1. 98 483.2522 484. 2532 113C F X4 X5 si-0 _ O J 62 ? X H3C 2 n ! 2 07 1 495. 28861 49 ? 667 ! .. _........ _... _. __. _ _. __ 2 485. 2479 486. 2474 620' 2. 08 451. 2987 452. 2939 X5 si 621 1 X5 s. -v HC v X- r. //2 HC \/""A ) ( X2 CIl O 622 2. 08 451. 2987 452. 2961 X4 0 gChf3.. eX4-H0) W F, XcEls S-o 623 Xl X2 vCklo X5 g\ f--O i 623 xi ci la xs ! S H3C sX ! XsX | ! ..... ___ ____... __. __ _ _X Xa Xs z 624 H 3c x4 62n.. 3..... __. _ _. _. ____ _. _. _.. _. __ H3C z i l 0 1, gg 497. 2679 498. 2035 . _. _.. _. ____. _. _.... _.. _. _... _. _. __.. _. ___ _.. _62 _... _ _... _.. ___. _.. __. _ _... _... _.... _. _...... . _.. _____. _ x5. l x,3c 62b. _.. _.. _...... __.. .... _,.. 2 : Q 497. 279 d98 : 1985 <n 627..... _.,,. _ _ _ _ 2t02 511. 2835 _512. 236 X H c X o xi 2. 02 511. 2835 512. 236 ... _..... __... \. ____ __ _. H3 _. _.. _... _ __ H 3 x5 X4 X . -- 6282. 04 511.2835 512. 2421 ..- I HJC W zu o. o ÇCH9 X4 X5 629 2. 03 497. 2679 498. 233g 629 xi 0 2.03 497.2679 498.2339 CH x x H 3c 0 00 630 b-0 0 1. 98 513.2628 514. 2338 -+--0 -@ F e ffi 6--- + -* H3C i i, c y 631 xi 2. 11 545.3042 54G. 2813 rT/-"X tiC-o/'5\ o-ci-ii 0 0 0-ovo . oxo J/V) C'-o \ _. 2 5 OCfi3 6321. 99 539. 2784 540. 2627 n X2) H3C-oa <X5 . _..... _ cy X XS... _ / 634 H 3c 2. 11 1 545. 3042 546. 2994 XI I Ç ! HsC N j Ck X3) 634 X, ItJC-O 2. 11 545. 3042 546. 2994 X, x '". c-o Y- I IaC-O oU' 0 0 635 2. 01 539. 2784 540. 2756 /v' y X*- H3C F J F X4 hic xi 0 636 2. 06 547. 2447 548. 2516 __... _. .. \-____ __. ___... __.. _. __.. _ X_. _.... ___. __.. W 9 H, C. Cl xi Ci ) t < -Br Ber 638.........,, _, 2. 09_ 527.1936 528. 22 H3c Br X4 x 5 xi 639 X4 X5 H3c 5 y S 640 xi 1. 99 441. 2239 442. 2316 CX4 X9--- vic 2 641 xi 2. 09 491.2395 492. 2484 H3c 2 x4 x5 642 1. 97 485. 2137 486. 2251 H3C z 1 643 Xf.............,., _. _ _ 2 07_ 475. 2624 476 2701 j) t H f/- \ - Xa Xs I X'o 0 1. 95 469. 2365 470. 24a7 H3c---/-"-X2 x4 x5 ouzo H3C/' X2/5 / X ci, 64 ! 3 2. 11 521. 3042 522. 3236 X 3 646 xi H3c 2 1 0 (T x5 2. 01'463. 2987 464. 304 x 113c x4 1 1.-- /\ H3C// X _. _ bn n _.. _.. _ _ .. _. X....... o... _.. _.... _.. _. ____. ___ _. 2. 02^, 449 2831 450_2887 w 5 1. 99 493. 2729 494. 2809 I 50 J---I---2, 08 i 4532ss} 4s4 835 ; 649 x 1 hic 650 si ... _.. _..... __.. _. _... __ _... _.. _. __ ___... _..... hic 650 _. _... _. _. _... _.. _, _. _. __-_ _.. _... 2. 11 503. 2737'S04. 279 X/ O 2. 05 497. 2479 498. 2578 in 3c i-3c G52 2. 05 457. 2285 458.2423 cl4 5 floc . _,'O - J Ç H3C 4 yX5 H3c X ri _...... _.... _. _ _____. 2 : 1. 3__ 5. 3144, q66_33_ . _..... __. _ ___. _.. __. ___. _. _. _..... In-0 x2 XA-a x 2 X4 CH3 2. 1 509. 3042 510. 315 . _..... _. _.... _.. x. X, x2 Hic r-o b56 x . _ __... _ _....'. __. _.......... ___. _.... _. _ _.. ____ 2.04. _ 467.2937 468.3029 . _.. __..-_ x, X Hc H3C' 2 f iC J -1-x I xsX X1 O 2 02 511. 2835 512. 2963 / Q _XCH3 fx4 O 657 2.02 511.283512.2963 658--J2. 06 467. 2937 468. 3049 3J X p 1- 0) x4 XI 0-0 511. 2835 512.2961 /V X**-'-\ Y r 2. 07 481. 3093 482. 3199 -CH 3 x 0------- cli, 0 661 si 2 .... _. _ __ __-____.. _. ___. _. _., _.... _ : n, X5 2.05 525.2991 526.3086 .. _....... __. __. _..... __..,...... __.... _. _..... __. J _.. _..... _'2. 01 483. 2a86'4F34. 3b15 L c v xI r * 663 X- X4 X 5 hic H CX2.. __... X4 X5. _.. ___... ___. _...... _____ 3 X r- r-t= O MX W eY ; ; s f"S/""/==< o 3X^ \J 665 2. 16 535. 3199 536. 342 [ (J HgC \/J X/ A 1 H3c, X2 ci X4 X5 H3C / xi-je , o 666 667 2. 07 543. 2886 544. 3081 S) H2C X,, Xsx / x- i Br X4 xs hic - _... _.'_ _ X2. _. . _. X4 X5... __. __.. _______. _-. _ __ ____ 670 xt 0 E3r 6b9 H3CXz f3r 4 s i . l _ l o X \ Cf- (3 X, x 0 \ C-3 x-. _.... ____... 2. 19 549. 3355 550. 3612 b t2 ! 9 | CK13 !, 2. 13_ ! 549 33551 5s0 3512 ! Xi , 672 x xa---- p O-CH .-........... ...... CH3 x _.... cl3 y if ' ? '''" ' CH, o-ct i 0 CH3 X'X2/\ x5 0.- 674 XIII 1. 96 513. 2628 514. 2808 CH 3 X4 O-CH, x 75' 675 L. CFI3 X4 cul x 2 % 2. 03 517. 2132 518. 2341 CH3 x, ci o, 677 X'X2 o CI 1. 678 j 9 1 C g ell3 X4 Br 67I1 X'X2 XS 2. 09 501. 1779 502. 2102 671) x1 cl3 X 680 xi 2 X5 CII 2. 11 515. 1936 516. 229 08 |. f s X, f xs _. _... _. _.. XS __. _ ___ _. _. ____ ___,..... _. _...... __., -Gl. la X4 X X2 682 2. 15 551. 1936 552. 23 C H3 x5 CI 13 Xe 1 bo; s C-13ci-i3x I cni XZ x. si 2 68ex 0 _. _ __.... Cli3 X Xz si 6a5 Cl-13 sr X. __ _.... _ _. l X X2 xa /\ O I F Ç xi x r-6 X, 0 _8_ L iU /X HsC xi x5 03 2. 13 57. 3042 558. 3331 x2 x4 /X HC 0 ... S9 - x X5 690 x 1 2 1 2.07 535. 1484 53G. 1722 -w -----w - -*--e _ f9 i X'X2 l X I 'H3 X5 691 xi xy CH3 X5 X4 I 692' 2. 06 579. 1383 580. 1661 Cz 63" X2 xi 4 .. __693.. _.. _.... _.. _. ____. _ _____..... __. _ . _. _. _... _.. _____.. __ ___. _.. __.. _., ___. _ _ Cli x 69, 1 xi x 2. 07 _1,) 35-1484 536, 1789 4 9 ß H3 2 < | X5 1 g t [1 $ 1 208 {579. 1383 S 580 1851 1 693, x2XcEd2 X4<l o C, St1 L XzSJe'i] t S I x,/< 1 2 n7 S s3s s4 S s3 ; L t X x2 XC23 { {8 I xg Cfi3 X, 1 b95 X Xz \/X Y-/< x1 2 t) X2 xi b96, _.. ___.. _.. _____.. _. _. _ _. _.. __. _. _.. _........ a __....... ___.. _.. __ ? _5 _ 79. 1383 5f30. 16F35 697 0 CH3 X5 X2 A 1 b97 x x i 69n 2. 04 579. 1383 580. 1639 60,,., si 2 699 0 699 699 ci-i3 I) r ( r x X5 \ I \/ 7 0 TOJ"' F 5 f3r /--O 701 / (. r O 701 1 Xl J XS ! 702 {x 1 xf 1 f 9 I xFX 703 {Xt f xf t 2 Wr 4 xr 702 X Xz r Xs x x xr-6 7042 5 0 7X 2 ¢ < i H3CH | | XCI 4 xA 1 207 j 531 2089 53 j .--ci O \C-z 703 xi x2 x5 // \- "l y J--i x/ \/\/ 705 x X2 F Xs .. _ _... __. _ __. _________ __.. _. __. ____ __... X2.. X,. \... :.. 01 __. _. _. _.. _.... ___.. . _ _..... _. __. __.. _. __.. X H3C. / F/O _ _ci \ 70G X'2. 07 531. 2089 532. 2447 &> ; H3C+X2 ; S X {xA _ _-_o _ -J--, 11-0/'0 0 x X2 x 7U7 "T/ 7-/° \ o Ç 1-13 x, X A) 0 0 0 70 ?, 2 te, c X5 __. _ I. _. _ _... H3C x2 '-.,..... __. _.,. __. _ _....... _ __ _ f-lsC. / -...-..-... . LJ f/-*-'\ HJC xii- C X5 0 oJ 711 1. 97 437. 2479 438. 2693 x F Z-,//-X 2 4 X5 '"."Qo 3 t-I, iC oJ 1. 91 451. 2635 452. 293G z Xn Xs HJC C3 J ? i9 Xt t. 91 45i. G35 452. 2922 -. .... X, """""""'" (t" H, C-1- HaC CHa/ I g IH2C 1 | Ctf3 X J° 715 xi 0 2. 02 451. 2635 452. 2937 Hac Xi f H CX2 X4.--_ 3 71G 716 0 2 463, 2635 464. 2918 ..... __ _ _ _..... __. _.... _. ___... _.., _. _..... 2 __... ___...... v. __. x, X5.... ;"_, x.-.-d :. ____. __. _.. __. _... _... __. .. _, _.... __... __... _... _. . /", xi hic Y 717 xi 0 1. 98 465, 2791 466. 3056 F. '-. . .-..--, .-. ... F CH3 x o th H3C A 0 X-cl 1 718 x X6 1. 97 465. 2791 466. 3057 ... __. _. __. ___.... __.. _. _ _ _ X _... m_ Xd X5 _.... . x xz Cl H3c 3 x, D 711 xi 465. 279 < 466. 3067 c-3 c 113 0 ci 4 ci t X. 2 ch,./ F 2 3 x 4 x 5 a H3c/ I CH 3 J 721 xi 2. 06 465.2791 466.309 _ _ _X2.... x'X.. _ _. _ _.. _... ___. _.. ___ _. HJC 0 X, O 722 1. 99 477. 2791 478. 3101 723 Sd ; F@3CX2S'SX, 4tD 2. 06 1477. 2791147. 30921 f H CXz i i 3, 723 x 0 2. 06 477. 2791 478. 3092 X4 x 5 H3C. _ / .. ? 23..'<--'0. P6477; 27? 1 476; 3092 | 4 [H3C 2 C XX X. X-. HJC H 3c 2 cr 725'"03 912948 j49Z327 /-"X, o-'\ HJC 726" 2. 1 491. 2948 492. 3293 _ X _ _ oti Xe / /.-J X Xs oit x 1W, s xS 1 ìxX CH ì 0<ì \ / oll 0 x x, xs s 1 t x X2 x, ; HC X 'Nt< CN (o cri, H3C X, 1. 91 572, 2787573.3109 1043 x CH, 'W I x, \/s 10. 44 045 "--, 1 U-. 1.91 572.2821 573.3249 -. op v k) x x 2 CH, U X W VoNSstclJ] ? 1045 H3C X3 o'so Xs 1. 91 572. 2821 573. 3249 1047 ''"".--.-.... ......... .......... CH3 -- o x cH, X 0 _ 1047_.. ___.. ^_. __. __. __.-____...-_-. _. _. __. _., _. _... ___.. ____... ___..,.. _ __---_-____. _.. _. __. _ \ X'CH'x', F Xs ì\/a x 2 2. 04 595. 2777 696. 3219 I-lz xi CH 3 HO X6 cil --C H x 588. 3231 589. 3849 Cti_. __-_-___. _.... _... _. _. _.. ____... _.. _. __... __.. _.. ____ _.--_ 1050 CH, N, X5 zu cl xi \-\-cl, 1051 x2 \/ CH 1051 xz' xiCH, X6 .... v X2 ------......, sj ;, ____ ___ _ 1. 78 582. 357 583. 4 136 1052 x N, /- \/-CH xi xp lic\0 _.-_..- r w <r y-x o a _ zu po 1053 HC' e o 1054 HaC' _. _. _. _ __. _...-__ . _.... _ _................... _ I I, 95 539. 3. 40 540 3422 cor b-cl I 055 HaC' 2. 1 579. 3'61 580. 37A3 X7 0: : r xi xp tic'b x /\ H/\ 10561.97 1056 ti'C xs 1. g7 545, 3042 546. 3319 __,/X _ _ ___ _ _,,. __.,,. _, ___ E ï Icu __ I g xt o, l d _ 1057 _________ H3C. __ _ _.... _. _ _. _ _ __. _. _ CH, 1. 81 511. 3|99_ 512. 3505 o 1058 H, C Xs 2. 04 551. 3512 552. 3825 S 7 19x SX0v5" 1 X X) 2. 04 651. 3512 552, 3825 ~ * - .-----. ^. . . . .--. S. l - x I I - 1059 0 N X, 1059 HC X3 o N °o Xa 1. 93 606. 2665 607. 3164 __-/. . \. _ xt __. _ X _-. __ . _... __...... _.. ___. ____. _.... .. _. __......-__. 1060 HC xa o Nti, Xs 1. 91 528. 2889 529. 3276 , __. __..,.- / x/ i / si F 1062 3 1 _. _...., _ __-_. _. _ XZ_____-.. _ _. _. _. _ _ _. __. _.. _. ___.. _____. _ _. _...., _.. _. __. ___. __ _ .- Xt x2 - r i \ 1062 H'C X o"Sct,, Xe . 1.98 527.2971 528.3281 /1 w 1063 HC X os. a, Xe r 2.09 61.28i4 562.3568 I v X, x _ o x H 3C !Y' x t OG4 Ho X o ___ _.... _ __. _. _. __. _.. X° Nn'1. 87 608. 2457 609. 2976 '"""/'0''"""""""'/" xs CFf - 1 2 ell3 1066 X, 1065 io6, 6_ ___. ti'C x f', J_yfn, x'1. 9 572. 2821 573. 3206 X, x oil f X ! Xa | X54 ! nSi ; ß | X /' 1 ' lOG7 HC X o=io HC"X ''"' '. 9M. J t-1. 9 650. 2563 65). 3D43 .-.. __.. __ _. . __ ___. _____. a-xi 2 X3 X, 1069 X. _. _/ .. \ i ,. o : o x. f0. 2569 _. ___. _. _.. _. cr, 0 . 1 i 1 0. v _ i oo i x, 1.9 650.2563 651.2313 x X2 xo 0 ° 1071 Fi'C x, pJ CH Hr hN 1. 96 520. 2838 521. 3221 '2/\<. ° \/' X, x . ? \== ( 1, 88 602. 2927 603, 33A2 xi X, X, 'y-cn, 0' / i, c x xi C"3 X, cit, 1. 93 631. 3192 632. 3643 . X x __. __.,.. cn'. __.. _. ___. __. _. _, __. ____- _--_______. _... __. _.. ____ cna H C x, /1 01/ ;-l C11 O 1075 N C. _ 1. 9 582. 32D6 583. 3616 xi X2 X, X, I i /, \ cl x'o -o CH 1076 195 534. 2995 535. 3 5 . x'i 1 / 'NCII 7 ftC, N YN' , ° x° 1. 99 571. 3311 512. 3079 XZ " CI1 x, C', X, 1078 1. 75 674. 2976 575. 2846 \ n u t08079' "". '1. 97 6. 329 6) 5. 3) 32 Cr"/'"Q'"''"" X . CIL 1080 FIC X x'oy 1. 97 587. 2784 580. 2736 lo x l g lXS f lxi $x f I I _., __ Iw vU \ ll<x l ? 19 I lX'liX x no ( xi xi-0 O Xz i/\ X3 --.... ... .. .. . _ _ t'- O Xi /X r 1083 H3c 0 CH3 1. 97 525.2991 526.2742 __ | cti I H C t _ _ _ __ _ __ | |xX I $X °TV P Q O I X' H3c x3 X, o HC-" " Xi Xi w, CH 1 1085"° 1. 82 588. 313A 509. 3 f 52 -..---.--.-.- J! 0 x, tOBG H'C E, c CH, 1. 93 511. 3199 512. 2905 H, 0 X cl 1087 HJC oll 2 06 565. 2496 566. 2386 x 0-Tic xi r oaa" H3 c xp 2. 07 559.2835 560. 2629 . _. _ ß H, X2-----------------» ---------------. _. 1~ _. __ e ? nJ () w X2 'X i - o, 1089 1. 99 659. 2835 560. 2698 _ _ _. .. . . __ ___... _.. ___ _. _. _. _.. _. __. _ _ ___, _. _.. _____ ____..-.-_ _... _. i J090 'J ! * 2. 02 628. 3447 29. 3398 xi x 2 =0 / o i 1091 HG X'x cn 2 593. 2348 694. 21 t7 rf' fi J (ff°'' HC" ? H, c r . ---..-.. -.......-..-.... OH X, X=/% OH _ X--o x, tri 3c i 093 " 2. 02 893. 2445 594. 2274 IX2 Cil, xz r"xr- 1094 2. 03 573. 2991 574. 271 ""'"''<r'""''"-.-"----------,-. ----- 1 1'j S"'1X 1. 71 607. 26t7608.2644 -- --.-"----"-"-Y. - c, x X XZ v _C 1 x./-a. OaiCy xi xz D xt 1Q96'2. 11 629. 325A 630. 3112 xi X, \ Xi. Xi _ 1 Xe cr xi xz oil HC) ; CH 2. 11 595. 34t 596, 3187 HC f CM <097-'"-'2. < 595.3') < 596.3) 87 xix off X 109809a "° ° 1. 89 545. 2678 546. 2605 x. x,''-"---, . T 099 ,.-"°°). 9S 579.2289 580.2228 (j r L r sC\ x' CI 1. 97 559. 2835 560. 2682 NC 1 f'lXA N 1f'IX<="I 1 0 1 10o HC no o y, g7 559.2835 560.26B ? zur v C H n A J x/-Lo r n H f F" 1 I O 1 Ei'C \ 1. 94 573. 2628574.2623 X, X2 \ i., \ 1102"H __-. _. _. _.. ____...... __. _______ __^___. _ 1. 83 558. 3029 559_2951. zu cr 1103 H 3c 1. 87 531. 2886 532. 2817 xi xi zizi J c)"r HC J 1. 93 565. 2496 56G. 240 . % ' r )) V°"- X., x/ /X \ I i 1105<05" j S45. 3042 546. 2653 xi xz xs X, r-- HC . I io6 H3c 1. 89 545. 3042 546. 2955 _....... I. _. X.. _... ______ X. ___. _.. _. _ r I"on.... __... _. _.... __... _.. _.... x, i x r oH M H 3 1. 98 551. 3512 552. 3348 | Cx I ß I x, C _ o 1108 1. 83 594. 2301 595. 2273 j +- ~-w -s z 6 -@ * | ¢S I H Cf I x< l | zA °H 1 l07 X 1. 98 551. 3512 552. 3348 09 iC 13d q 1 °+= ? ìlo g. 83 1 1. 2391S5952273| H3C s X, <1 wOH <xe x, -/\ W X3 HC'X$ CI CH 1 109 2, 01 531, 2653 532. 2531 113C X, Oil x, x tUO''-* 1. 0 497. 3042 490. 2937 113C, _ X, x x I 7 1 xp X-0 x 1 1 1 1/H'C'X H'1. 96 525. 299 i 526. 2787 I I t I2 {CS S H, c S sI i z. o4 is5. 249s BFG 24 ! 2 \ '/ x 1 1. 12,/H'C X5 C I 2. 04 565. 2496 566. 2412 e o i i 1 13/flC - . -..,..-......... . ...... ..... . . ....- ^I-IC X ? ! O, tJfl= X 'N'I x x 1. 89 594. 2665 595. 256 xt X,....... X Xz p Clla _ '.s X _.. _ //\/ Zion 1115, NC X'o GH'1. 97 526. Z99t 526. 292 1116 cl HC X/-o"\u Z. o-SN11 C d $ 1. 87 560. 2821 1 561. 2739 7 X | H, C 1 XX \ o=°rt H T < I C s¢) X g 4 X l I X, < r $X I 110 HJC XJ OSNll, CH, 1. 88 560. 2821 561. 2753 ""u. P P ' , x,-J (- xp Nil, H, C C H __,.... __. __ ____..-.-.. _,..-___. _.. ___....... _........ _..... _. __. _ _.. n_. ____. _. .... ___... _. _...... __. _.. . _____. . r- ^_. _8 _. _. ''0_2821_... r'. 6. 1. 276G, H X2 x X, 0 Up- 1110 Fi' o cit X, si Nla i 1 19 o'CH 1. 89524.3151 525. 3075 xi ''O X x 0 11200 xi OH C o o xr/x,/I. oFl te \ si X je 0 X o X, j'o 0 2. 01 fi31. 3046 G32. 2967 x i razz xi W 0 o 1123 1. 89 644. 3362 645. 35 w 1_i 23 _ _... -_-.. _.- _. _. _.-... _ _ ___, _. _. _.. _. _ _. __... _.. __. _. _ ___. _. __. _. ____ __.... __...... _....... x X o Xz Q t) 2<)'° 2. 0) G3). ZG02 G32. 2C25 _........ . _. _.. Xi_..... _ I'xn n r « t . n I X.. f _ ( 11. H. 1 t. l x 3 - I _ _. _-__.. _, _I... __. _ _-. _. _. _. ___, _____ X-. ___. -I ocu, x "r O X f v 'i 0 2. 01 617. 289 618. 2725 xi xs if, 1 \ X X/I Xs e i cH, O 3C O 1. 9 630. 3206 631. 3359 ri'' . r° r'' X", j' HO oo 1128 V43C 2. 07 627. 2709 628. 2573 xi x2 x l C 1129 ri'C _ ___. _.. _ ? , _. 2. 02 573. 299) 57A. 2791_ 1129 1 i, c 2. 02 573. 2991 574. 2791 xi X, c, a o X, X3 HC xi X2 1 130 H3C ('., 1. 92 58G. 3307 587. 3427 x''/ a r x JL J L 1131 14 Oll xt X, X, x X10 xk3 - j k. 1132 oH all 1. 87 561. 2991 562. 3006 C N S SxX xz a 1z133 OII ON xz ° x 1 C 1 ß xX I Ix. < ci o ' ci I 0 1135 Uli U--j x X2 X, cit, 1136OH x XS X' \ xi __-__. - _-O f' r fT° J' ! cl'_ 1138 H c x Oil xi \ 1 137 ... _. _ ^-U - _____ _.. ____.. . ___. _... v-__.. _. __ - _. __. _ __ _.-.. _-___. _ xll_a ,, 1138 X i i CI1/ x x 1140 HC x 558. 3359 1 X2 Xi \ U 1141 O O ho,,/ 1. 96 G03. 2369 GOA. 2373 /olj--. _...-_.- __..... . __ Ha cor m z o'o o. _../ 1142 0 HO. J [j} 6) 1. 95 609. 2031 610. 2124 X, X ? X \ \. I x w r r 3 1143 _____ c 2. 02 6t3. 2552 614. 2456 k C I f z t Xz aV l \ o oCHz 1 144 H3C X to o 1. 96_ 559. 2535 5GO 2794 1 145 HJC llO o 1. 8G 572. S t5 1 | 5 ? 3 : 3293 xi x2 x , b Ito 0 1. 96 559. 2835 1144H3 c 560. 2794 i"cEa i /\ f i x i J (i) (i p-CII 1. 98 603. 2733 604. 278 lvX t ? S-cz I I<CK C/- .. j 2. 05 575. 3148 &76. 3073 . . . @ P . f \ X x/ i xi X2 a X v Ii 2. 04 539.3148 540. 3035 x I X2 _' x'i/l _. cv ; _ - j I/) o x \) o ca, 0 2, p 63 I. 3046632.2966 i CIO i. "50" o'""' 9) 508. 3202 509. 323 lyc oil Xe C", xi fr c mst Xe 1152 HaC x'' /ll80x _____ __-_. _. _ zon xi t) 52 - 2.07 52). 3't06 522.34J2 1153 H3C xb w oa X, cor xi _--_-.- /ou 1 154 fiC - _--. _ _. cn, an oit 575. 31A0 576. 30J8 CHEZ r Cff / IJrJ HJ'X IIC CII 1155 H3c 2 X, cil, ltc cil, on xi x r:) 09.3406 1. 86 495. 325 49. 3272 113 lil"' (J N-ti5 I N-115 D2 fi tafia i i n . 11G7 x x2 x C! I -. -.. ............. ........ . X, 9 I ? Iri. lirne CRTIP. M (JSS x pli .1 ia.. _. __ X., X" t) rr. X, \===/\Lj X-------A2§. 2031 486. 3753 _.. _.. x'. _. _. z_o 515. 293 sm. ; r2 1159 _. 1 GU_ X'_-. __ X. 11 v"-Y \== nr"5 \ .-'. JL-'"'"', j, 529. 2093 630. 32 .. ex 1, ...-............. ......................... ....... ..... X, / 11 GJ i X? xn 13r _ °-mr, 2. 11 593. 2U42 591. 33 9.Y, 2 I. ./\ Y/__.. 1 1166 xi fill ylj 1166 xi , } 1 w X t t_-3 Ce A w1 ; X, I V 4, Zqg 1/ 116. 4 *-* S-.--+.-* S---.. > oX 1169 -, : ,, 1170 cul _ a. tYri. s3r. jrts' . _ 1 t67 W4 o.. m, . tt, C X."""'""'""''=--.-. SL'Y.. l. l « til-'fW l x. _ l : , t ! J J.. t ' . _ // ; . rv Is. l9 ! l,) 6rf 116v c ; "t j ! ., \/- (b< . . 1/. Sx. 3SJ, 117U -. l" 1171 cil, jxt I l"--AX, 0 Y [ -.--v. S-S x 1172 _ ___... _ , . t G 5 3i' !'1 G, (lyP X-c ; t l"s I173 i Gt X2 Si 1176 X.. 1174 ) t7 "t"."..-....-J... J.--. X./--'\ y-., , ,. 117G x X _'-, , c, ll,. - 9 \ b S' f ----Ct i t/-. x n, a- \ 117G x i t 7 J u, t; v, -- xtn .........-. .,.-.- a 1179 t Iltl _. _. .'. _. _. ___.. __... _ ' __. _.. ____. _ °_ _. _. _.. :, aT GIG, 2030 G10 ; AO ; t xr- () \/ x---° \ '\ "-\ - Jm.'" J". J\ "' 2. 12 M1. : M06 M5M x X r--. _/\ 2, 11 ! 319. 2001 rj20. 4012. - J.'0'''' 2J< St9.2Ml!; 20. 0 ----- I I C/v r t. l 02_, X-=-_./\- X - _. ! JOi.. ''=/<7 59. 3) 74 5C0. 4'124 - ...................... ........ zu si 1 to3 x _.- r I --- __ Ru xi > >a _" __.. _ xi --_. __. __. _.. ___. __ __.. ) 105 Xy. !, __.. _ . ______.. _. _ x'--'\ ...... 1. 95... _ 495. 325 496, 4399 1186 / . § /\ .. _.. _. 11ti7 X'/wx---_/ 5L. 199 560. 4452 Cl X6 69 cu. _. ' " 1 ad_ X' 1/X j_i ° 519. 2208 520. 3397 15 CI / \ l lti9 c i tt 7 \ 1 1 7U XI x L x5 2. J JJ3.2CJ JJ. 32O X j [xt-0 i : l x' 1191 x xz 2. 2G 559. 252t 5GU. 3GOt3 _ __ ___. __ ___., I __. __. _ __ _ _. _.... _, _.. _. _ _ __.,. __. ___ __. _ _.. ~ ___. _... _ _.. / o / , 1193...... , 2 1. a5 511. 3199 512. 4327 '-x. \-/" s X,? C= t l, t: r r r xy.--ci y 119A s'-. 2. 04 575. 3148 57G. 4352 - V"i--)) C r. x ! n,, , ;, _C'\ X,, ----Cf i '. \% X n_. rr r r jf \ fL'"-f (Y !2. 09 551. 3512 552. 4756 _}) _ _, __ _,, _^,,,,, _.,,,...,. (15, ~ __,,,., _ 2. 09 551. 35 t2 S5Z 4758 1 /v 119b x , ; T : a, 1. J 1 811. 31 J9 512. 42U 1 Jj9/J ""'" . ? 5 5-) 5. 3042 MG. 4t7R --t _ V i /r \J.'''"'"''--, -"------ X-<J \- .. <<)-"' J 2. 05 575. 3148 576. 4329 X2 1199 X. 551. 35. 12 552.. 4684 -æ-----O-.---«. s- w-*------+ ( Ii J 1 A j Xx IXb X I {f"X I 209 d L SX ; Xe Ur 2. 11 563. 1936 564. 32 1201 O w. xi 2. 11 593. 204-9 594'. 34 1202 12U2 x'_... _. ... __... ___. _.... ___.... _. _. _ _... _ °. ___... _2. 1 t, 593. 2042 594. 31 1203 _ (/X ti C/ I w l _ '.). \==/"'\ 1204 469, 2693 470. 3277 / s 1201 x'^. . _... __...... _. _...... __... cn,. _... __. _. _. z.. _..'9. 2 (i93 470. 3277 _... r. r.. 1 \/ X2 Xs 1/I G/ I Ç03. 2737 b01. 3101 j)/-" \ "\/--\ X, . x /V z Xa ()--X 0 \ "" ' \ \ 1207 x X2 2. 06 485. 2l.-) 913 406. 3074 lip 5 - tc 1209 2. 09. 549. 2547 550. 3127 x X., 0 Y'"0 Q 12102. 19 525. 2911 526. 3676 X, (i i, c 2.% \ \ xi > > x'x2 1. 99 45. 3tf4 4G. 35a5 __. _ __ I__.-_.... __ x. X... w... _..... _. _.. _.. _. j. _. \.-___. _.. _.. _... _. ___. _... __.... _. _. x /f iC- 1 } 2 § J e I Xs r ; s -. _...-.. _. _..... __. _. _. ____.. _. _.... __.. ____...... _.. 1213 I C - 121 x ci, 1214 xi 1214 x, Ct, 2. 19 505. S457 506. 4U02 x 9c" Y"'o ( \J' 121 2. 04 i79. 33 it30. 3 (37G . Ç, l3cvx2 X3b sVe WN .-t i3c T/ /\ x i'./ a _ o_/\ . /\ y 12) 7 itc 2. 13 543. 325 544. 3829 __, __. _ __. _. _ l-_ ___ ____.- __.... __ _ _.. __. _. _. _ _. _. _. _ _ _. ___ ___ __ ___ ___. _ _ _ xa X S x xt A . X y" ( o \/ t2! U '""."2.22 5) 9.3G<3 520. 305 S...--- " ? \ ° S 1219 481. 3093 402. 3635 Ç"jc<x2 X3 N Stt Xz' Xa /IIC / Y, 1220 X 4 2.0 5t5.293G 51G. 3GG0 11 C Xz p/ _. lXs- w 0 122)-I,--2.'05 545. 30'42 546. 36'96 fi \"-y', CO/0--/. i fi3°/v v Xi 1223 X2 1. 97 495, 325 496. 3076 Ç {IJC<X2 X3 X-\ SX6 1224 2. 09 629. 3093 530. 3716 1225 2. 08 559. 3199 560. 3892 1226 x, 17 535. 3563 536. 4433 r -aC/\ ? b1 . V *r"-t)) C f/-" . cV l iC / fS/-' ". -\ X. " Q \ . X.. _. __..... _.. 1221 X, 2. 0r, 523. 3563, 524. 43951 m1T ß V x |Xs o-6)--} A X, xc, J22S" "- ?... S7-. 3''9S 55G; 4227 228 xi 2. 1 7 G57. 3406 558. 4227 x _.... _..... _ i c/\ 1229 2. 16.-..-507. 3512 506. 4426 . _____. _. x _...-_.... ___. _.. _. __. __. _. _ _. _... 1230 xi v_, _/ -- 2. 26 563. 3875 564. 49. 06 15 ! XJ l/| li 1231 x, 2 C1 1, 2.00 519. 2DGf 520. 3GJ1 _. r_. x K. _. _. ___ ...--_.. ___... _. _.. _..... \ X6 9 13C<X2 X3t)) F W6 1232 X, 9 tt3c<X2 X3b X 1 tt, r---.-_. ___. _... _ _.. _ /. xx a o_/\ 4 /tlC / r x r/i 2. 08 503. 2811 584. 3691 - _ _ %.. _. _. __. __. _... __.... __.. _ _ \--y r r X rr\ r 1234 2. 17 659. 3174 560. 4126 X3 fr /IIG \_/s H. s 1235 2. 07 493. 3457 494. 42ra - y x V J2. 17 1 527. 3301152B. 41031 ... t, l3cAx2-X3t N. 0'l (\o S \, X _. _ 11 ( : _ _ X O. _ Xs 2 J ', "'""'.""""""""/"\/==\/''" _.. _ __.--' t i CXZ 1239 x, 16 561. 3144 562. 409 4.. % . X., . 1239 VX'. _...... _ _. ___. _. _.. .. _... _. _. ... .... _ c .. _.... _. _. _. . 11. _ 527. 3301 52a. A 1 3 t r... _ _, __. 1242Xz. Xa. Xc 1 'Eic _.. .94 495. 2806 496. 3611 .. X, X30 X ; X6 y 113C w -s s--- l--- Soa w » . _.. _. _. _.. _. _ \/ X2 Xa Xs iiC jr ... / 'x \=-/ ) 23"'"ex, J d9S ; 20G6 49G. 36) t U s I IC/ lti/v X/\ O f 1244 10 r59. 2035 5G0. 3G97 12 2. 4 l} 245 t CX'IX3t I N 1"'3-°- t2'15 "o"2, M 559.2035 560.3C97 Ç, t3cvx2-xAt xl t-o-xs 0 (J IIC /\ \).. r/ 12AG' 2. 13 535. 3193 53G. 4U42 ... _. __. _.. ___,'i. __. _. ___. .. _ X _..,.. _..... _... _...... _... _ J \... _... ....... _ _. _.. ___... _... __ _.. _. _.. _......,. _. /'\ (", Xs jM6 \. °"-A3 35. 3) 99 53G. 4042 xr- /113C' 1249 2. 04 573. 2991 574. 3901 ) 7'"'--" L.-S09. 3M2 5) 0. 3796 ,. 'xz 1251 xi X, 1249 x-. 04 r73. 2J91 574. 3J01 J .. _. _...-...... .. _....-. _. __. _.,....... _ fl -/'X \"'\/\ X - t _-i 12''x. r. 3JJ JJO. IZIJ U 2. i3 4J. 3 r x CII r 2. 1 543. 325 544. 4181 1 75J _ Z xß l H, | X3t N I PX | Ec 1 82 I 541, 3S94 1 54z 4191 1 f C c. _ ! t)/-" \ "\/-\ X, 'L'C <Q \/ "'rut : t x. 1253 X, cil, 1. 82 541. 3304 542. 4101 Viz 1 « _ n . o .., o-'" c t2G''""", c2.02 575.3) 40 576.4094 ., Z r. i,, c IQ 1. 97 605. 3254 606. 4261 X2 . 0 -., 0"" 0- ', _. xe _ __.. _ _. _____.. _ x ^''S n, d ! \--=/ r c , J257'25 597. 3719 590. 063 ! _ r x r r GJ x y IZ57. _ _w _, 225_ 597 3719 598. 48G9 125D t'| WX, SX, $ I i ; s 2. 04 1 57. S405 55545001 n_/a_J 1259 2. 15 621. 3355 622. 450 X, _--.- yc/\, 1259 x,-.) 215 621 3355 G22. 458 1261 xi Gil, I i I. aC '-=' 2. 02 587. 3512 588. 4437 xi 12G1 x X= cn 2. U2 5t37. 512 6Ut3. 4437 ft)/-" ? \-- -\/\ (/IIC x ?/\ _/ , _ 1263 2. 16 627. 3025, 628. 4063 X, Il/IIC tfG/-0 1265 X2 X,, XCI vs 126ß| x, l H, C SX U | "|----- 1 1 1, I Y3 I ? 1267 Y., xi x °-1a _ i2_... _. ____... ____ __.-. ___. _..... _.... __.. a _. _ _......... .' _. _... __.... _. _.. _. _. __.. __... _ _. __........ _. 1268 X, fp., c -. Q'- X3 -............,......... Q S P T \==/") o' ( . ff" '\/\/ Flc'X I IlC-O n s 1269 X n, cn 1.91 G i 1.3 t J9 512.400J 11 c x. yc a v yS j? 7Q x \ 2. OA A5.30h2 5AG. 3f5 (31 _1271____. _. __ _.... __. _... __. >..... __ ---C I wX y,. r 1271Xnt 2. 03 57. 314D 7. IUH1 27)''"" 2 ; 03 575. 3)/0 5. 7C.'1p9) .. /-'1 , p- \ (L 1 ru 122'va4 2. Z rJ . 3J I2 JJZ. 4dO'I . - g t X34)-ll,'s Ay - o 511. 3199 512. 394 w w w. ! » . .. z tO . . ^t. . w IaC/ /'Z--/ . c i, 1. 99 545.3042 54G. 3782 1274------- ! ?, o \ ) \/" ia i, X 1275 1. 97575.30 576. 4000 x hic 1276 ifr lp 2.07 551. 3512 552. 4422 X3 y 9/e.-0- \ X 1270 -- .-.-......- X2 // N : _ -\.. X 1/Xs f '-\ (\ \ (\-y 9 FtV X3 o ecl 1} 3Cx n X 129 4 2. 00 5Gfi. 3257 5G7. 41t3 ,......................... .. .... -- cul zo 1 Zf30 X 2. 5 530. 2449 531. 33G 1 : 1T 1Wn 143 I lC, to J 120s] wl \ b Q x °'_ 120) <>'° n, 2.05 GJ1.2397 J: IJ. 3 xi \ '. \-/\o"' () No 1282 X, 2. 12 570. 2762 571. 3751 76 2 x r. o .......... -...... .. _ _. _ I--} ' x lyc , __. _. _. ___. _. __.. / XI au 1285 X2 2. 14 513. 3144 514., 9954 XZ CI xs J205 -.. . f4 513. 3< 5) 4. 3954 _, y : ic-. _.. _....... _. _.. w.... 1'_/\ x t ; i--./ _ .--CIl 1/X - i'-'' "'"'"''' ........ ,........,.............. v \ b -\ 1288 X, 2. 05 491. 2799 480. 3539 1289 X7 2. 06 521. 2643 522. 3414 fiv J289"'--F".-"2. 06 52J. 2643 522. 3414 ... .... -.............. ..... . r22.3414 X x ^s -n rr r r 1290 x 2. 05 651. 2746 552. 3583. .-S- \ l 1291 XS 2. 14 627. 3112 528. 4017 * * -eb. - e ~ e R.. *.. P e 6 e e 1292 X, 13 \ 2. 14 519. 2208 520. 312 xi // / 2. 13 563. 2157 504. 3151 Ç 1tV Xat3 > f ( l \ cl x, c 9 \ h 1295 X, X, r X'cl E. w w b -j. ~ e Y I IC _. fl _" \J r Ic X.,--/X6 126 X'F 2.1 1 G51.2Ga4 652.379fi /i laC Xz _r r i 297 X r'' i r / z9a X,' r r", z. oa na. 2ms noc. azo 113C 1299 1 r 2. 05 1521. 26431522. 34411 | | c~x I x t j I r I 1 2. 05 1 ALl xi- 13\ X ? a o. _/. _/x. / X3 lX6 1301__., _ X _....... /"x2. XJ s xR x cri c s 302 ' " 2. ! 4 5) 9. 2200 520. 3009 Xi Y" ( Q-' /'^i X2/\ ip/t '' :' v__ 9 tl3W X3t u S , 1305_. Xy. _ . _ _..... _.. _.. _. _ _.. __..... _.. _.-. _'. 5 Ct,..-___. 2 : 4 _ 519_220U 520. 3U32 _.. __ \ _. i--. x _Ci.. _. _ _.. _ _. ___ X : 2, I3 JJa9. 2OJI JJA. 9U3 . 1UG_ _'. _. _. _. ... _. _. __-... __2.. __. _.. __. __.. _.... _. _... _. __. c. X.. _. . _... _.. __.. _. _.. _.. CI-ry--..... __.. _..... __n r r (37_ X'_. _ _. _..... __. __..... _. _. _.. ___ .. _ __..'... _.. _. 2_13_ 5a3. 217 U4. 3UG9 t3UO"'c< Y-y , v _--, t co X, ci xs Il / X X-= s Clt r r ....-.-.-. ........................ v \ c X2 1, 2. 11 503. 2504 504. : 1281 I Ir X., ci C---, l l _i x cl ...-__ I \. ___ _ ii5.. ___, _. ___.. _. x1.. _...... _ _ _.. _. _... _. _...... _ __... ___.. _ _.... __ __... _. _.. _.. X X2 x. r r X, cul V \ f"\ zu x, x =_. r r. 2799 c. 3,, 1313 a. oa o. 2ss on. 3 1, q rX I t I Cs 1314 r 2. 05 521. 2643 522. 3368 _... . _. _- ; i___-__. __.. X3..... _.... _.. __.. _...., _.. r. _-.. _-__.,... __ . .... _... 1 \ i 1= xs c 1316 X r °'" 2. OG 551. 2740 JrJ2. 3JJ7 .... .........,.............. ... .......... XCI X 131G x r 52.16 1527. 3112 528. 3931 __-_. __. . . _. ___-. __.... _.. _... _-... _.., _...... _... _....., .... ...,. _. _.... ..-.. _. -_, _.--.. _... _,. r........ .... _.. __. _..,.. _. _. _...... _ \ Fia F x. 1317 x X'r x ; r, 2. 07 4a7. 27JJ 4uo. 34JJ x \ I i l_ l X r r . 1310_ x'__. _. _____. _. X t3 M) X i Xz F Xs -cn, 2. OG 551. 274t3 552. 35GG I IC F , __ H-_.....-_. __. _.. X.. \ . Jt32U, ' 'r -/ .' 527. 32 B20. 3930 .-2)"'. L "'2. 06 ) n7. 2799 00. 3520 r-. /\ r 1321 x x2.... _. _. _. _.... _.. Gt'__. ____.. _ _2__'17. 279 400 ; 320 ___.. _,. __ \. _. __.. _..-'', __ _. ....... X7. _... _ _ __.. _. _..... x 1322 l132 X3 r-/>\ { 1322 ? _ _...... __.. _.... __. _.... . __. ___. 2. a. '_. 2_. ^..... __., _... _ _ _. _ _.. __-... __. _. __ _ _ __.. _... _ __, _ (' fizz r- 9 \ b Q x Xz 'cn, 2. 0 551. 27A0 552. 95J9 1323 W W tD FWA b r l 2. 17 527. 3112 520. 3907 1324 si . \/ _ 1325 cri \ ? Cz a. Xo ,, I IC r 1326 xi 2. 12 569. 2654 57D. 3573 F 5. 8 psi X 1/Xn >9x, l /FIC r / (R 9 -J 0 x I EI C 1320. 2. 19-... 575, 3124 576. 4 () r) 5 F -e- , x1 _.. __. 1 . I v 2. 01 517. 2$) 05 510. 3644 1329 xi x ~ + * * * # , f FI, G .. V) f. r-. tic X, X, 1332 2. 12 557. 3210 558. 4104 r - o_ x ' 'y c C'' _ _ te /lICX ? _/. /IiaC ) 33 ''2--5G9. 2M4 670. 3599 tic X, ye 1335 2. 11 599. 2759 600. 3765 x xc, /I1Cx ? % __. \ __ s r y 0. '-- '2.) P H75. 3) 24 576. 4045 x '337 X2 CIO, 206 487 2799 480. 3532 "37 I Kb 1-,,, | X, &3 E \ r | Cll, 1 2 Oß 57 779D 1402 3s32 t \ "Xz Xs xs -Xs I. IsC/ \. __. r C\/ ... J0..... -.. ''2-.. S2). 2G3 522. : M42 _ __ x iy, c _ _.. _.. \/ Xa o_=/-/xs li, c rr ( JJz. 3J " /'==\/' \ _/'V X X. xs. _. Xs. / 2. 16 527. 3 112 520. 3904 j 9 d§ {, C X SXt f vG I I I //\: \.,. \, xi x *-- -- o~ --* s *- *-* w--o-- - *--v Ç l43cwxf2 Xoe X, cl SXt v X r. 732 1.142 2. 1 537. 2347 530-3232 X., ,/'x, _ o_ \ fol ) : 143 2. 1 567. 2452 SOB. 3386 12144 0-/xe _ /lliC /"'ci l; iA1 I Ic x ruz ) 365 X2 2. 09 13i5 X X?-/k, c% n 2. OJ 537.27G7 3D. 3fi2 . __. X X-_..... _... 4,'G X. 1346 si F 1316 x r r . 2. OJ 671. 2fi t 572. 35 t 7 -... _ _... _ .... _-__. _. _. _,... X x,. __... _ % _. _. _. __. _.... __., _ ___. _. _.. __. r 13A7 x r. 2. 00 GO1. 271G 02. 36J l 3nG 1-----I-; ;, c~x,-S x---j r-? So xs 2. 16 577. 300 578. 4044 i-, c i O/ .. : _ B _ X.'. ___.... _ -_ _. __. __. _.. _.. _ __ __.. _ _ ....... _... __. ____. _ _. . 2. i _., 77. 34U r70. 4044 ___...-\. _ __. . _... __. ____... ___.... i \ xi- ' \==/.,/ \ xi xi 1352 _ \ l-n O 35) '" *"2. < C).) 9'tH 02. 3 ft)/-"X, \"'"\/\ X, Y" 0 0-. \J , EIaC - \ i--o 9 \ h" 'y \==/" \ C 132 X y'2.1 J 507.23 I 1 59f3.34 8f !. M3 "''2. 05 559. 290 5G0. 3< --.---- I J ! i4 r624. 31 1355 2. 08 j23. 2147 0--/ 3JJ x n, c 2. OD fi23.21i7 G2S. 31 13, ri6 xi ;, 3 : ( xt n, n \/'--- r \/-\ ", o , x 1357 X, X2 Gil, 2. 02 509. 3406 510. 4212 _, 357, x,, __,,, __ 2,,,,.,,,,,.....,,., C,',,.. _ 202, _,. 509. 3406 5 ! 0. 4, 2 ! 2, X x X -w-~ e b-*-. o_ ~ _ * _ __ o _ _ X _ j"b _ b _ 2.13 573, 3355 574. 433G X,Il, c :..... _.. _... __ . a' _. _ _.. _. _.. _... __. _.. __... /IiC/ x / Xa y i. 136U ' « \ - i, c ; . V X ;-.. X X C ! 1 r "t ..'L/'' ..--X _ % ..... _.. _.,. _...... X /F1C/ 162 °' 2,19 511.3457 542.4t3 xi ß II, CX IX tD í Ic x X" . .. y X ;-.' /v" \/- v H t X- \/=-\./\ /113G, \/. cn . h ! M \""''"\., x, i !, t-_ _, ruz 1. *) 65 X2 499. 2999 500. 366 | 9 t"GX2 | tD 14 Sxs /i 1C j 533. _. x l ; lC6 Sr 2. 05 533. 2012 6J4. 3GG ll C --w »-o * w------6 6 f-5s /*X 1\ \/--\ v /1 iaC .. _r,. 1 ; St /-" / x, r 1'169 y"3C 1. 07 423. 2675 424. 3203 X. 16 4 x. yc, -v \--/"-C '/U - J. 93 37. 203) 30. 3402 /\ \/-1 x, ' ;'7t "''""'L97 5L29C7 <t52. 3C79 X2 J/v Q---\ X, I x dur 1.173 xt X, 2.08 515.1936 516.27 x r xs IIC 1.375 441. 250 442. 3157 0 - s » + v s v s t- « . l ^1 X X = tir xs cn 1 2 1.) 76 xi 2. 01 455. 2737 45C). 33.'jG rus t, 17 -'r'r- X __. _..... _........ Xi / X, 11c : l. l7G.. ^_.... ___... _. _. __. _. _ _.-. __. __. _.. ?. Ot_, d55. 2137 45G. J ! iG 1_....... _ x5 ci i \ ''- \-/r \ 1 Xo cri-j 9 \ b-' 1 ; ! 70 '-- 2. 02 457. 2205 450. 3003 x c, i X5 i i, c, v \ -X \=/C) 'C . _ ) \ /- s ! '\/ \ X, X2 2. 11 1405. 2590 486, 320 : 1 g t XJ) WoR} K, l ilUU x,... _ cl X5'... _ Z. 11 485. 7598 4UG 370'1 r rc x., xs n, c-.- 113G- 1381 X, t3aj '"* '==/). 97 37. 203) <130. 3'15t . li (' . _ X.. °-. _... _..... _.. _.....-_.., _ _.. _. __ _. __ _..... _ _.. _. _. /i___\ _ \ / , _13t12.. x! __ _ xt cl l3n2 x, X2 Cl l Xs} C p,s y xi '\)- '\ 1. 85 407. 2937 400. 3646 - -. _. _. _... _. __..... _. _. _.. _. _. _... __. _.. _.. ___..... _.... _.... _........ _. x , 13 1. 88 481. 3093 402. 31153 ", C""."'".--...................... 1305 X,-1-. F Vs . 1305 _ . __. _- ___-x.. _ _ 1386 X, X. ° x II, ' f "A / \. 130G X y4 r-__/J X e lI385 ? Xt3 l Ir ; & X 93J402-39S31 I. 6 I x, I Vx f x b 1 2. 94 1 4 1. 2G40 1 492. 3259/. 1387 xi r_. _/ -.--2. 11 519. 2861 520. 37 Y \ 0'-h''- s \ i i, c .. 3Da x xi o_/\ a 1,, X. l-Xt--04 J 07. 293 !} 459. 35477 1-, X, . \ b -C 13 (19/ 009''"', ). 9) 01. 3093') 02. 3042 IRNYOt X IX'."C -FF -T 495. 325 496. 405, 1 __.. _. _... ___.. _.... _..... _. _ 1. 9G 4J5. 32 4JG. 105t . __. _.. Y'\ t) \ \ 1.1' 1 xi Xz (: 1 Ks ...... ............................. ''\ ' \--L/ \ .. _. _... _. _.... _.. _ CI1 -519. 2. 200 52. 0. 31. 35 x . e 1393 Y2 1197. 3042 490. 3747 lxi X2 10 ... 3.. , x 5. 1. 1.. 3199. 5. 12. 40011 _ ; ^.... _...... ___. _.. _.. _.. ____. l. Of 497. 3042 4J (3. 3747 cil, _--\ X, _1394__ x x,.-o \ c . _) _...... _. __. _... ; : _..... X.. __. _... _... _.. : __ 1. 1. 31 J 512. 4oUn e cul 1, 1320 L ! --. 2. 01 50tJ779 502JG9 i C l . 17) 1, x xz c Ci l 1 J) U x. __ f3r _.. 2. OI JOI. 177J JUZ. IO94 /ìyc _ _x- '_ x i ? zea I y 11 C~ Xz 3 ! I F X2 t3 r Y S tD' . iy X, ci 1, 21<---------X, 1------.------. ~ . ? _. 455 Z ? 3/_45G. 28 tH X 4 X-- S ItIU3 X, Xu.-. :--X 9 1, 101 F i . t : noz X x, x/ _-. __ r II, C I Ig, c-I-1--1----. I. ! 9, 1-4 72, 33 ! 433. 2925| X, X2 I-Xr. 2. 03 469. 2093 470 113C Xi-A n :,. ,, i --/ X. --.'. _. __... ___. _... X... _... _.... _..... _.... _..... ___. _. ___. 1. 0 437. 2031 430. 2925 - _.. _....... _ _........ 8 1.1U5 x x _. xs/ lü7'... _ r F ..., _. _........ 2 491. Z548 492. 2G83 _. __. _,... _ xs. xf. _ _... _... _. _.. _..... __ r _/ na 1 I 7 cri ! ICf X fox s MUO"' -p r g 505. 2705 506. 20 x r 1xi 2. 00 519. 21361 520, 295r) _... _ _. X _. _. __.. __... ___. _. __.. __.. _.. _ =.... x. X. ___. ____. _ _... _.. _ __. _... T \/"-o , -o zizi it il3CX 1410 si '--v \=='") t, C 1411 1. 95 467. 2937 468. 144G 1412 X, 1. 98 481. 3093 402. 2171 X6 , C--U 1413 X, cl 2 457. 2285 458. 1470 9 tz3c<X2 X3e HX5 X< /fC/ CI i. 1413 X Cl 2 457.22U5 450.1470 X 113C 1414 xi CI 2. 04 471. 24i 1 A72. 171 1 1 1415 | X, Q XX, [X, t |Cl'S Cli I g : 99 G. gG99 j499. ! 973| /\ X : i 1415 X2 ci Cif, 2. 09 405. 2598 486. 1973 f) \/\ ' ,'lIC C14 * ksi XE- Girl, -1416 2.05 __, _515.2936,516.23041 xi Y, t --O XI -. ----.--'------- 9 113C <x7 X3 49 Frf °X~x xß nC} t3 _ . _ ___-____. .. _. ____.. _. __,....... _ _ iyc j , ci x 2 503. 2304 504. 2027 y Ç 113 X3e FV Xy sXt ! ) 9 '., 2 5032304 50'L2027 r I / a 1 ly ( : H, n''"x,''"'"""","."'""'."''""""" -r '. \/''"< IU 1421 2. 08 531. 2697 532. 24911 1422,, 1. 9G 48 ?. 1 G23 488. 1573 "r' 0 0 M22 '\,.. . J.-9S/a7.) G23/) 00.) 573 I CX2 . tFoS9G AD7. 1G23 it3F3. 1"a7 ------....... r \ f''-) s _ y. G CI ! a Iz3 x. _ _... ____. _____.... ___ ___... _. _-. __. _... _ a. a. _ sot. t77 oz. t7a7 2.04 5i5.193G IG. tJ'lG ............... . ........... v \ o "\. 11r.. _. _ \_ t<12 !) '"""'. 2. 09 529. 2093 530. 2) Xa 1426 X, x CII _ 1 12G 0 \ -0 'y ==='"jC 1 121 _. x XZ x5 . _.. ___. __.. .. _.. 9 \ b -\ ... __. _... _.. ___........ 112Q_. ci i M29 \ 90 457. 2205 45S. 237P fiC - C-/XS .. ( : i ( 147. 9 /) J'-\ c : l--.//-X"-...... _. _.-_ . 5 f JC _.. _.... _... _...... _. _.. __. _ ___.. _...... .. __.. _... _. _2. 03_. 471.. 2441 472. 2G11 X2 1432 X, X3b _437. 2831 430. 29, 31 x -,--1433 1. 94 451. 2987 452. 3127 Cil 132 xi f. 90 46) 5 1i1 ; 3., Xz"s 0 '" i '-x-" ....... 1434 x Xi xs 1.9 (3 4G5.3144 4fiG. 33GG 437. 2031 430. 2971 J r X 14j f' t/- CH, ° w-1. 9 437. 2 (i31 430. 2J71 1 1,1G x. _ Xa. 99 465. 31'4'4 466*. 3413 y Xt 1437 X x s xi 1439 f ) o t nso x x? _ ...... 1. 81 453. 270 454. 3067 1440 X, X2 IIJC xi /IIC --.... Jx' ( : I I y, _144J x, X2 111 (» , t' _ % x ___.. _.... _. _.. __.. 1442 1. 87 467. 2937 460. 3278 14, 13 .... _. _.... ___... ___ , i W. J- xi Xs -...-........ ... .. (P \ "- "\ x"X. \== :/' x/' Z I I, c. -- t. fl3 4f31.3093 402.3i01 T"3'-T- 9"3', X, . _. = x, -. » _. _X'__... ______. _... ____ ?.... _.. ___. _.... w'1. 95 495. 325 496. 3608 M '" ". 1. 95 95. 325 9G. 3GOO 1 1 1. 15 1. 97 495. 325 496. 3746 1417 1 x, ylCrXx2 XXa _ I I 1 293, 1 9D349G |519-40 ! D} 14-17 X2 2. 03 509. 3406 510. 4019 1411 . _ _.. __.... _. __. _ _ _.... _ _.. 1. J7 A95. 325 4J. 374G .... 523. 3563 52-4.-4.. 143 _l"\_. i X i', J x X, X2 f \ - ''0-... "'205 S23. 3563 52 H3 14 ! i I X, b \ X, XI xi -. _F'. __... _.. _... _ x,. _ __.. __.. _....... _ __. _...... __... _... 14., 2 9 \ "' f xi " Q 2 ; OJ JOJ. 27UJ JUG. 3I99 r- l \ r \__ , Dz = ^s . 14.'il /I IC Clf "1.97 4G5.3114 46.3GG2 _ _ ___ Xa I I C lac r xi 1453 X, FI..... _ _ ......... 2. 03 479. 33 400. 31138 '--2. U3 479. 33 400. 3 (130 zu 1454 xi XS y _. _. _.. __. .. cn 2. U7. 93. 3A57 A9l. A073 -X, /'0""' X, \0/ 1455 , J ., 3 p _. ___. __... _. _... __.... _.... s \ zig _.. _ _.. __ __. °° t. tl 453. 2A I G 454. 2ti23 , CI-I 14; i7 X o _. __ _...,. 1. 03 4G7. 2573 4G0. 2JJ1 _... _ __. _. .. _. e . r X O s . _.-. ___ _ I IC X, -0 cl zu 1 nb9 x x o - ______. _. _.... _.... __.... cn 1. 9A 4J5. 2a0G 49f. 33G1 S-=J CII , 1 AGU xt IIC -1.. Bg 495. 28ggj. 496. 3342 - j,. _ __ Xe ' r v _o '""""""-x ; """-<r). - """'"" J". C" CH, /1 iC j c l5 1462x, X cll, 1. 93 509. 3042 510. 3551 1 C X/t X | I C N i ;, ; I I t ) ces. "a 9 \ d' ! 5. ' "3 2; OC M3,32G 5; 3920 _.....2 515, 2936 516. 3542 t y'. _. _____.. _. _.. X' x l ' 2. Ut3 JA.. ZJ 544. 3J2t3 2. 03 543. 325 544. 3920 x 1465 X, X2 S llzcvx2 XJT C X6n IC ci 9 \ b"o x W X thi \ S 1461 X, X7 IInC Z. 02 543 325 544. 3B7 --wl, _- ! 6& '-"'2. 05 57 : 3406 550. 409) X, . I 1IC gX-'\/7 573. 3355 574. 39aG 1469 X2 1. 97 573. 3355 674. 3906 "r-\ - (" x x C - z. ot 507, 3512 saa. oz ma ----- 1471% _t-X343 (3) 8Fo S , : . i, _ * - » » *. --S » - H-s ¢2 t X303 Il, eJ ß k SX" /-n k 1473 X, ì473 1 x x EX 43 1 r, | $CI ; r,- x. X, ---u i, c i i, c : x x. x 30 ic_o 0 1475 IIJ 91 511. 3199 512. 3705 X., 11 3c ; l474 x, 4 W, B | c 1. 87 497. 3042 498. 347 1 ic-o o x' . ) \ \-/". c-o' ( g c-o 1476 X, X7 z cl 1, 1. 85 51 1. 3199 51 Z. 3G7 /n 4A n X59 HXG 1. 93 437. 2831 438. 3286 _-____ ___. ___ _ 1478 XX Cì IJ wX3 X I IsC 2. 01 465. 3144 4G6. 3688 , 1 IC---i Cil, 1470. _. __.. _. __. ___ _. ____. _-_'..... _.. _. .. _..... __. __ __.. _. _.. _. _.-______ 2_a_. ! s. 3tt. ___...... r r r rr 2 2. 09 515. 1936 516, 2552 / X J' X 1I n 4o <\ C)/xs > 14t10 cl, a C x \ cv i, x 2 -.-L.. '".... .."...'="" \ ". i 2 455, 2737''50. 3'35 1402 Gil, __ Gil'J. (. I i 1483"C - y ."_ _ _...... .... X2 XI-0 cl 1, cil, .. __ . \-'__.. _.. _ _.. _. __ _.. _.. __. _. _... _.. _. _..... . _./ __ci x / i40 cn . _ _..... __... _. _. _ _...... _...... _.. c1'2. 0 471. 24A1 472. 29fi5 .... _. ... _.. _.... _... _.-.. _ ___ _. _..... _... __ _.... x \ 1 1487 X, O-Xl Xi c W 1 u na' ........ 1. 84 407. 2937 460. 3300 ci 1, Gt' X. ° l ! 433-lXiX-F \ \ \c"N S a N X-f 1489 ci 1,--x r --------. 2. 07 505. 2705 506, 284 --- C_13.--/ X'cy'_ _.. __.. _... __. _. ex Xt /y. X IIaC-../ moo 3 \_/ 481. 3093 482. 3268 xi Xi /V w t X 1 2 609. 3406 510. 3073 38 XzCI-I/1 w _",, X 4 n a, 1492 497. 3042 490. 3'. 5B ....... _....-.. cl I-X'i "''""\c''r'"-.. .-. ---.-.--. x a-y ; _ v n. n-n y ~---** »-xsof xs x ,. _..., __, _.. _. _. _ _ _/~\ Xan ~XO 0 I. tJG 497.3U42 490.3; 13 X / s S CJ x ° a 525.335 52G, 3023 x ,-r IIC w------R *- x§n Sxe 2 *b--------S w-------6 n-F-~N. 1491 1. 95 451. 2987 452 : 13412 i I G--- CI I 'X. \-c ; n, ;, ', 1. 9 451. 29t37 A52. 3412 1A97 . __.. _ _.. _....., _ _. _.. __.. __. _... _.... --x X, Cil H30 XrJ CH, \-'--X. (", C- Ci 1 1 _l" HC--i xa, n f. 85 4G7.2J37 4GU. 3324 1199__.. _... __ _--.. .. __. _.. . _.... __... __... _ :.. _.. _ ^.... _.. _. _....... ___. _. _..-. .-. _. _..... __. _. ___.. ___... __... ! IC--- 150U Cn' X. __.. _.-. _......... ___.. _____.. __. __.... 2. 02_ 495. 325. 49G. 37 ? 0 X2 xi cri -. _.. _. _-.. _ 1 Xi 1 : 1 ........ _. _ _..... ___... __.. _.. _.... _.. _ ___f___.. ___. _...... ____. _____.... -X- cfy "Z. U5 J 15.1 J3G 1 G. 24 - , , c'r- cul 1 a (13 _ _, cr r X/ (' f t C-- X2< A} xV rl Xa 1. 95 455. 2737 456. 315 _-. _.. _. _ _ _.. _. _ _ _.. _ __.. ____......... 1. 95, 455. 2737 45G. 315 - Y r XI 1. _-_--....-..... _. . _... 1 JOJ,. CI I X Xz _. _j... 1........ _... _... ___ _.... _ _ __ ___. _. x__ _ 2. 04. 403. 305 401. 3472 1506 r xi r CII X. _. _.. _./_.. __... _. _... °'_.. _.. ___.. __.... r. x__ 2. 04__. 7. 244) 472. 29D7 cul r Xy (w J07 _. CI I J X s 1 499. 2754 500. 3232 \-Cl 1, xe _.. _ __. _. _ _. _. __..-_.. _.-. _____X__ 1. 9f_ 451. 29f37 452. 312 r X 8. 1. 93 437. 2031 430. 3264 ...... 2. 03 _. 479. 33 480. 3817 1 : D. It-'-1 I 19 1 xs I 9 1-9 ? 3 l4soso ! r X ;''J _/,-./Xo iit X . _ _.. _ _ rr, c-/ ..,, O-X 1. 94 437. 2031 430. 3310 Y2 x cl3 XI-0 r xi Clf \/ _.... _.. - 1 A 113 a J X a I 13C--/ 1513 X. Gil 3 I in O-X 1514 ... IIrC y ( I Gl t-. - - '\ X , 0'-x LJL, 9. c-y IIC--r r X \ CII /) -CH, Q.--/ X-S'-./"-X'-". C-' , Xz _ i I, C-- ! xs x Gil 3 481. 3093 482. 350 CI 13-. K __ I 1C----i 1619, t vr I _ I ct ; ! a I-]--1---2 I G934GG] GIoG97l0 xrJ en, /x v", c- xi-0 3 x V -y y R C 15-'. J".'1'JL.., ..'. .. L. . ........ ...... y **\ V Cll \ X"_ IIC---. \/-. y .-/- li C--i 15.'21 X \ CII, f4/X a 1522 x Y2\ Xe 2. 12 633. 3018 534. 3504 } 5"Sx, <1 i. < |<x, 1 1. 2, 2 l5330, 815 5 1 . _ _ . _ x __ . _ _.. _ ____. _.... _. W r I X: 1 v S . _ . /Xf-_. _,.,. r. _...... _. _.. rr -X-. a 4LV. r m 2. 04 179. 33 4DO. L30J x u _ _ _ _ _ _ __ _ Iwa r r GI 1526 1 I. BB 467. 2573 46B. 29flO x : _,. n II-r./ r . X. C 1527 x) a lzzz, z I lc-/ 1525 4bu. 2720 4B2. 3157 ---- {} x 152B ci 1CII' . i \-Cl xo . % _.... _ __. ___... _ __. ____.. ____. --CII 1 ° l ~--b----+- 1530 xj---o ci 1, X. 1 1. 89 495. 2006 490. 3308 xo X CII . X IIC r CII a 1531 523. 3199 524. 3652 vis 1532 --x X. 1533 _. _. _. X __ _.. __ _ _.. __. r X c" x 1534 ci 1, X. 1 10 '535-\"'1. 9 S25. 3355 526. 30 !") x/ X W. _.. \. I C---i CI t _ a 1535 cul - ---/.. _.. ... _. _.. _ _. __. _ __.. _.. _.. __... _ r r Xt . X C. rr, (vCr'-^-i : 1.9 525.3355 52G. f154 \ llat. X xi cl 1, 8 1537_1 485. 2598 486. 306 137 ) 537 1533 z rt X, t I I p ! 5-1, 332536 4434 327, 1 1530 1 in > S 'cl%""' I fa (Xj .. _ _ _... _. _.... _......... _..... _...',,,, _, _ gt 5Z9. 20 ? 3 530, 27 ,A9 X, 511. 319g 512. 3699 _ x _- ( ? C ' C'" CII 1541 ber 9 \ b P. -.-__. _ ; _. _. _... _. __..... _.. _X. _.. _.. _..-. __. _. __... _. _.... I e ' . \. 27 X, " ) jy " girl, 8 X 1543 1J11 x2 ( : IIC xi y x , xz 1545 xi X F 2. 04 469. 2093 470. 3302 "','"''""'/=='---'- I. l_ \ i S ! I, C I I C r r 1547 2 465. 3144 466. 3680 9 \ & P si s 15R1 x 'C cn, 2 45. 3144 4GG. 3G00 __.. _ _. _ _ __ ^X2_ X,.. _... __.. _........ _.' .. o_ _.... __.. _ _.... _... ___-_.. si 13C 0 X i 2. 01 A91. 2540 A92. 3076 .. _. _ i-_..... __.. _. X1..... __.. _. __... __... _.. __ _.. _ _ _. _. _. _. _. _ ___, __. _ _.. r i , c I5Q9 x rr r 2. 0 05. 2T0 50. 3239 > > X2 xz n N xOm \ Hs (' Xs r r x. y 113C b Gi 13 1540 X, F F 2. 01 491. 2548 492. S076 t) /-" \ /E C I IC-O 121 H3t % n X (S, Y t d/) n d 1550 x, X2 \=D WM ns cg 1, 2. 09 51 9. 28G 1 52U. 3427 A/X2 XJ m X, X6m (INJ {t3c t=D íJC-o) \X c§3 1. 80 453. 276 454. 32 > X ~ ~ j * . . . s 6 w l x §lIC-°'II1C I I, C xz 1. 95 467. 2937 4fi0. 3404 X, 6 XS ''-J/\ IIC-p rr X c: ll r 1553 9 401. 3093 482. 3591 ílc-o s 1 553 X, X2 \-.. {. 1 1, I. 90 48 1. 3093 482, 359 z - _ X-- -fuzz x 1. 99 457. 2205 450. 2709 iic X2 X6 JJJ X x. 25 I2. C - _.... ___. __-__ _....... C 2. 05 471. 2441 472. 2914 ? \ b P JJG X X - J.. . ' "'2. 09 J85. 2598 OG. 3070 1-'---'--1---'-'-I t) I I I C------I ? ? 9 l485g5991499 ? 97 e 0--0 . ................ V "') r X 10 n, r __ _ __. ____-2. U5 51 G. 193fi 51 fi. 25 1558 xt X2 ils _... zu x5 t559 '... '-" 29 529. 2093 530. 2775 H, C'----...............-. ........... .,. r X _-x ' yC 1. 97 455. 2737 456. 3232 .......................... . ... F - ... '.... . ........ '.'.'.......... 2.... J690g3'<70. 303 _... _. ", c"" - "d ", C) 13 r X JGZ ci 1, 2 469. 2893 470. 3403 1-1 X s ...--.................. --,--- \ b i/- CI s 0 \ '- * * 4 xi 2. 07 485. 2590 406-3040 X3 y Y >), % W) x t. a 5v. za x. a u \ y"o _ cet cl 1, . __ _ _ _ x- n, r _ Jx XR. _....... ____ ... _.. _.. x f465. 3144 460. 3705 X,, 9 \ h IIG ig'IJC<X2 X3e 10 x, X<c1<3 1567 x, 1. 94 451. Z907 452. 3482 __.. _-i X'Iy _-. _, _. __....... _. I. < \J ze, c . 1G). _'_.. _.. __.. __.. ___.. .. _... _. _.. _.. _ _. _. _.........'. _ _. _ _. _ _ 2. 04 _ _479, 33. 1 (3U. 3U40 v / C/ / CI 1 r X 1570 1. 0 1 453. 270 464. 3195 e t-b - » --- »- » 6 * f o o . j -- ' \=/" r x x . 9} |3C<X2 Xlt | Ox, 4<CI13 1 57 {) x, 10 1 453. z7n 454. 3 1 95 15/1 1. 08 407. 2937 408. 3429 - -p ; xv 1572 '. y \=/\ /"Q A x X yrt''\/ x8-..-..... __ _. __. ___. _. zig 173 x U 1. 87 467. 2937 460. 3413 5/xJb l---] ~ ~x--. ° ?. I4 72S37l4ns34l ? _ X2 1. 96 495. 325 496. 3B3 ... _... _ __... __....-.. : _......... _ _.. _. ___- _. "----"'° 1. 92 4f11. 3093 I02. 3GA6 ,,- , _ G. 307C - J !'.-. -..-... ..... : \"''J. 8S 495. 325 496 ; 3a3 1. 96 495. 325 4JG. 3n3 r )'" x __.. __. _. i.. _"'C 2. 03 rU9. 340 510. 31 . .) LC X...,./--\---- . _yin 113C xo-\ 1500 ci, ' \==/'", c r X 170 X, yc 9 \ b". ---""' 2. 05 508. 2705 G06. 330G r - xi t50 « ). 9Q 4C5. 3N4 4CB. 3G7G w 15U 1.9U ? G5.3IA4 4Gfi, 3G7fi X3b I"I--X. 168) X, X2 x. 1 3c Y, .",, S 101 x. ° - _. _'. _-. . ___-___' ...... Gil, - X, iaz x x X, \. \/% tt 0\ t '-\ . . _Cr. i Jlf. f X X ''"'"", ,''7"' / -C =\/-/ X- JX f"aC- si ,-x, 'CII w y/=-t X*- .... _. _... _. _, _ nJ' ( _. _. ____.... _ _...."t : l l 2. 07 52fi. 20 G27. 32 \ \ 2. 03 451 / ") ( t'X--. cis, ci 1, X, 2. 05 465. 3144 466. 3634 °'2. U0 54. 2UJ3 555. 3G30 ..... -....". ___... _.. _. _... __. _..... __.. cil, 1 Ob'X. ! I C--i .. _.. _. _. _,.. _. __.. _ .. _.' ' ... ___ S 2. 03 451. 2907 4523538 ___. __. _.. _... _... ____..... __. _ __... ___.. _.. ___... _ __.. . X! I C11 r r x / II \/ 1 0 X 2.03 473.2G43 474.2Jg2 IJS () CII X. 159 () xi C) ci 1, i --CII 1 x c xs xo l593 l cllß-xa cl-SS llac 15Vd IXX !'X Cl., _ ? IS | ? 3g3GS15v34 ? 019 2. 11 505. 2051 506. 2584 /1 a Xe _ 1592 x' CI 1 (J c- I i C--- 633. 2365 534. 3019 J. 2 1 5U_204 -169. 4 c : i 2. 08 409. 2347 490. 2B56 ....... 2. 1 D 533. 23G5 53. 3U i J - x-_.... _.... _... __... __..... _.... _. _. _... _.. _.. cri Cl 13 1 G94 X \ X. '1 I. C-- fi cil xr" "'-/'x ", c- . 3057 i xi cl FQ C113 , , xr\ en, -, ", c-- 2 : Oa 4a9. 2347 490. 2t35G '< : i IJ9G CII'X. F' . __.... _.. __ ____.. _-.. ___. ___. _ _ _ _. _. ___...... -/' __.. _... __ \1 J _ x_.. ________ _. _ _.. ____. _. _... __ 2 : tt s t zc s ma m ,. x ; \CI I w 91 J X. .. _... _. _.. t 5yo G , x 2.1 501.295G 502.3344 2 445.232J 44fi. 2716 f t ccxWJ x. i i c_../ 2. U5 473.2G43 474.3U71 X2 Xo lU2.. _X X' 16U2 Xi-O c11, 2. 1 5Ui. 295G 5U2. 3315 6no _1 (J _ C X. ..-_ ___. _ _-_. _ _."'_ 113C AIS. 2329 446. 2750 1. 9D 446. 2329 446. 2750 _'x. __. _ __... 16 () 5 X. ... _ y,,, A/"". X. cri, --2. 03 485. 2042 406. 3231 1601 X-0 --...-........... X-s \"-x""' X---O xe 1600 six, /\ CH, '.., / r -_ _... _... __.... __... _ _. _ . _. _. . _. _'. _2. 03 495. 2042 4Ufi. 3231 . .. "', .. » l. _ cn C X. - _.. _. _.... _. _____.. .. ___ _....... _..... _ _. CI1 ..... _. __ __....... 2. 0 G13. 315t3 514. 3G23 . X.-. __... __ _. __... 'e . _. _. __. __, x : ", IlC--i. _.-. __ lGlo X ,. ai w 1 \ CII _1G11. _ _. _.. _. _. __.... ,, 115C .-. ! '...,.......... . ............ .."-' : . 48A2937 4CO ; 3< ! 23 1. 92 IG12 QX J o i 1.92 4Dt. 30J3 402.35G0 X) un IG13 x'\ i w 2 1. 89 §. !. t. 3199... 512. 3646 x,, o-------- . y x'_ _... _... _ _ e I. G I ! i,, X :... _.. __... ... _. __. _. _ I IC---. ../tu l 62u r x^ ? _ 1- ! 5Ig5 |4993752| - _ _... ____. __ _...... !. 6 ! ... cn x. \-Cl I x 1610 X-0 a )'2 402. 3 (SO7 _- _..... _... __. _.. _. _. 162U x cri 1, -'' T'-'""'. '. 2. 07 523. 3563 52. 20't . 1. 621 ci 13 tp x cy =\ \ '"'''"'/x. A 162--x 2 ci 1, .. 161 (f _ x'W. X. .. ___. __. _. ___. ____ _, t 1, I I ( :--/ oit, __Gl) x CII X 1621 I G1. a a c: i CI1 2.09 AOJ. 2347 4D0.2097 V.-) (-- ) 624 0--X, o-cl,'xs. 1. 87 525. 3355 52fr. 3t33 _. iG.. b c ; ii Q X. -xi x 11, c 1. 87 525. 3355 526. 3B39 1 6to 1 Xfs _CIIa, 85, _l ?. 1_319SSI ? 371Sß _./'Xe Ci i. x x2L, Cll CS Fe-xs x$S 16 : ?/ 1 citi L,,,Xa.. _.... _ _....... __ x ) 6 ;) 3 " """""-07 3525 <<9G. 3700 ci3 x. --x ". c- , i i, ; Xe 1 G.. 9_ Ci I, X - _. __. __. _.-. ___ _.. ct '1. t15 511. 3199 512. 371fl 16 : 10 Cil 3.... _ m : n_ X__ ci y X ,, X-- ex _. __ _.. __.. _ _ ° ° C i l. 9fi 5G 1. 199 t 562. 2G 13 _...,... __. _.. _... y. X.... __. _. __ __.. _... _ __. _..... _. _. X'\ l t\ \ m ___... _. Xi _... G : tl c ; n, i X :, . _. _.. _. _. __. . _ __.. _ __... _... «, n CI1 2 ; 03 50J. 230 590. 2J _. ., __../ _... _ _ _.. Xs __ X _. ___. ___. __. _.-. _ _ _ _......... II . lu : f2,. _. _... . __ ____.. _.. __ ____...... __. _... crl CI1 1. 00 47. 2937 16U. 3345 _..... _. _.. ___.. _... _... Xs... Xs.. _. _____. _. _- x'\ I \/1 \ \/_. ___. ___. __. _.. . IG ; 17 c ; it X . __ __.-.. _... _ cm CI1 1.97 4J5.32b 4J6.3700 J 1.77 45. 270 454.3150 163511t' xe- ci 1, Xi I CII'w i/ 1G X _____. _ _-__.. ___.- ___. _.. _.. _ _.... _...'', 1636 ci -...... _. _. _ x. _.... _. _. _..... __-,. __ . __. _. ___... __....... _. -cu, 1637.-- 1.\/w o X2\ Gil xo 163B X--O 3 X. 1 1. 77 453. 270 454. 3210 X2 xi 1639 O-X lac-/ e xi X /'"-cn, . _ - X-'-\ X 1641 O-X jL//"3 \ \L -'=". ttr---/ Gil3 xe 1642 xl__ \, O/ v ft V 3 / \-CH, ( \\/=\/--' 1643 1 f 3 .---CII xr- en, (3-x ""'''- ___ :, __-.. _^____...-__.... _". 1. U 4G7.2937 4t30.3422 .. enu C x , 1.2 401.3UJ3 402.3GUU 1641 CI I X n, I1 / - m 1: 73 439.2G24 440.30J5 1613 x \ w . _ " I 1 C-. J 1.77 453.270 464.3231 CI 1 w w 1. 77 453. 278 454. 3231 a i. IJD 4JJ. 32S 4JG, 3U5 Xe 13iql X. \) b)), ) 646 2 ; 1L. S03J703 SG't. 29 Xi 0 0"\ . _ xi c f, XI X2 xz -- ;-'. ______.... XJ....... _.... _.... _....... _...... _.. _. ____..... _.. .. _. __. _. __ ___.. _. _ I//\ /_.-_ __..... Xa x x2"\ r-"s IC C) 1649 cri u \ o-\ 1650 xi X2 ci JM9 '' C) t, _.. ...... ___.. _.... _.. _. __. ' xi was iGSU I//\ \ _.---,. _ _. _...... ----i, 1650,Cl cit ci 1, Xf x/x 5 xo 0 1652 /cl )) C F 2. 01 495. 325 496. 3744 Ila ( X ;-_.... _..,-_-_ __. _.. _.... _... __ _ _-..-.. _--_. _.... __ _bof i i, c-o cl IG ; iI_ x. _. _... _. ________ __.. __. _. _. _...... _.. _. _-_ CII. _ _. 2 4J9. 29J9 500. 344 T L \===/""/ /\ X3 te X X2 X3 ilc--o xi 0 /v _ v s xi ° Q \ h-. x \ \ ° x xz ci 'iWn'c c, 9 1 k, _1 65U.. _ X2 Cl C} J xi X2 1658 13 /v --, x 1 G ; i9 x Xs'i _.. __ ___\_-'-y_... _____.. X...... _. __....... __.. _ _.. _ __.. __. ____. __.... ___. C'..''___. i 16 gogo i9 X" CI 16 (, 0, Cl cll 16ou xi } ß X S Vx ß x t x-j----I I ß xi X, , i ruz X3. III ". bn, x 2 . x, x2 IGG2 CI .-___. _. __.. ___-_-.. 0 \ o-\ ( v \/ \ X, Xx O 1 GG3 I 1C CI-13 2. 't 509.340G 510.4029 lm7 F7 X2 s c c ; i i lGb4 y ("I :-0 xi X2 16G5 /'CI- ; i X X, nX, |"ç X,. _,,, _, G ? _ I, l ? ! G9 G ! 2, 3715 cl elf, " si 52 ! i. 335 ! i X3 xi X2 1668 te cl tell, .. _.. _..... _.... _. __. _..... _.... 1. D0 G25. 33G ; /Ctt ". H x -..,............. 9 \ ). - % \ Xe 4. 4324 x xz o ) v"/ X.'0 \ CH, '66'2.06 553.3G68 55. 32 - _ 67 lt . __.... _.... _ _. _n, '. __... _. _... _. __.... ____ ____. _........ _... e cri x6 ifs si 1672 x xZ-o, xi x X2 ../ X30 xi X2 1674 F ci 1, ,,C.........../\/==\ -- S. 167g ! x, ! | Ar !- !- !-''-'-E'''J'-'---1'''-: ) v \ ( __... _.. _.... __ _.. ,, _ 9 - x, F cn, 167Zi xi ) 675 'J xi Xa TT X,'\ \ x, xz )), c 167G I Ic CI I .... . ............... --.--- 1677 si 13 in- 1670 xi X2 1. 97 627. 2940 526. 3601 \ ". X2 ' H. X, 1 G70__ r ; i, . __.. __.. _ x, _ _. _.. ____ _.. _..... __...... __. ___.. _- : ?. _ &27. 2340 52Q. 3 (301 HC" xe , o vs 1681 xi X2 X36 ci, 9 '' x X2 16t) 2 *' tGOI X ° 1G (1Z _. c; l cn, ,u, l x . J \ \ 0--xi 1 G0 f _ _. _ x ______-. ____ ___. _ x ? __ C : I \/CI I r)"i \"'-<\/" __.. ____.-.. _.-.... _. _. __... _ 160. 1 ci-I _o XZ i, c O , 'M /==\,/t 9 - '"X----\ H \ n c_ x, xa Ibt!! i _. _. CI nr 16B ! i ci ci 1,, _.. __. __-. _. __ _.. _. y-V, ../cl, x X2 1 0 \ " i c- ks ) x \ C _529. 3105 530 : 3 *705 Xz 0 0 \ /v , 'IGUU x z ci X3 xa n-N 5 16 I gel xi __... _\_. __. _. ____.. IJ (......... _. __ x., __... ___ _.. _...... X'... __... f,'. _.... _. __.. __. __.... __.... w_. __. _..... if « si lG9o x'2 c X'Xa. _- r) O'_ xs 1-1 c i, l 1693ct, , 694 I x I (9x2 IX3t I I b Rx. E (c¢l ; I | I I¢S llgeX Ix, I i A x 2 ti 1G92 H3 X3 X, Y 2 /_. X2 " x u x. X. C) <\ C)), /\ 0 Cl \ Ira xi / ci x5 gui Y 2 Ct) x X2 ci c 1 2. 15 553. 1010 554. 32 xi xi X2 r tic ci y x ci 1, . .... 9 \ I i _v il X2 X."'-C) . X, CH, J6'... .... . Ct s C C: i Xs C11, -.-.- I {'J7 1 1 | llirx, | X3t j j Cl. I c ; 1 2w19 \ 93. 191G I G54. 3t 1 ow-o »---e 6-6 v 6 + xz -_ i 16') Y X, I l, rXx, X. _ i 2 GS G9. g7G5 li8G. 32G ? X2 i - _. : :... 17C.,.. c.. 5 cy 17t1t3 ) x -\ \ 1701 xi cl X., cl ct a i 17U1 ) 702L"" x X2 ci \ j'X ci i 17t 12 C) I 1 5' xa nr i xi X2 1703 cl 1, Uu--jHa XaX-----, r 1704 xi X2 F 113C al I cil, 'xi X3 te v".''r en ; 70<t'JL-05. g ; 20M sgq. qsM -. . ... ................... .......- J te , xi X2 1705 ____..-_ _ ___ oit fri"'"V" -cil- lit - 170'°""..-----.-. x cil, 1'707 ol I H. X3 X F cl 1, __. ___. _. ___. _ __. _ m s . t--.'h « _. I K)- U4,.... x_. __... _ _. _. ___ __... ___....... cly .. (-, 1 f-. _. _ _... _ _...... _.... _ __ _ ______-. 1. 07 529. 3 I 05 53U. 3fi7J t oo" xz ci i, " x"/. ß13 (v x dito C CI 1, 17101. 09 513. 315 514. 3G7r } 7} Xz SX't 3x5S} c, ; 1 1 V y 1-x Cl aC 3 CI 1 oil .. _. _ \ _... ; i.. _. _. __,. r__.. _ . __ _.. __ __.. _.... _. _.... _, _.. __xP_>>. _. __ _. _. ___. ___. ,/ vo- cita xz n I, c /CI I 1712 l. Ufi 525. 3355 526. 3flEt7 113f,. 1 / 1 K ?- _ x I l lC s CI 1 i io-/ X 'r X 2 C11 1714F 1. 60 499. 2999 500. 3502 ~ 8 o s o v a » X X2 Gil, 1715 xi ci roi, c y X2 X, cri 1 : 1 110 \ _ IIC " I 1 C CI ; s í, IarXxz x t f X ; D : \ ta (-C ! 1 1717 xi X2 I XS X., x4 1717 x XZ II, C \ - gril, xi 9 X . _... _. _2 _.. ___.. _.. I. _. _.. _... _..... _ ',..-.. _..... _.. _. _.. __. ___-. _____.--_. __... _. _..... X3 x 1719 x X2 110 xs _ __ _ CII 1. 89 497. 3042 408. 3563 I I ('--... _-..... _.. __..... _.. __... __.... _ _. _. __. ___- __... _. __... ___. __. 9 \ b P xz c 172p"'"'"'-- 7 ?" '" (no t./c)), \/ X x2 ^ U (IO a. I i ( CI I i721 Q \ J /, \ ^s s m t z3 X' r ci i, Z xi OG 5 (5. 29't0 5) 0. 3523 Xt-n 1724 xi X2 ' 1 K1 2A xl"z .-'7.. '.. .. .... .....,................. ...........' ; -.-.,-..-,--......... 1 if-/ Xz r c1 , X'F '3 1725 xi X2 r 05. 2042 406. 3419 1. 03 4 X, X6 r v x2.. r- 726.... -. - L? 97: 30f! 2 J? S: 3G29 y"I, x2 xi 0 1726 l, ( 498. 3629 X : s e. CI1 1727 xi "3 x xe v i, r,-o X F CI la 1720U3 515. 294a 51 G. 355 1729 xi X2 Y, xa y cul \ 1 i ( :-O 177. 9 X, \ Yn Cli 17302. 04 519. 2452 52U. 3127 I f lltrWx jX4>t= I Scil ; 1 2-94 1 9. 245z a20. 31 : S illrXx SX, ; t= X X Nx C T T I I C X Xe ''no-\/ f / cri 1732 si x xi GI r 172 x , 0ic_o x C-ou i i, c xi 0 n-c t. n 671. 341 b72. A04Z It3 ( X, I 13c X x, i f, C 1734 xi Xs 1731_ _. _.. X.. ___. _.- _. _____ __. __ _. ___. _. _.. _. _.. _ ___... _.. _... __.. _. _. _. _. _ _.. _. __. _.. __..- _ _ _.-_. r.. _. __. _.... _. " "/==\/' i , c ca, X, X2 C, 1 1 f3 1736- ri, a xi p \ '../cl, 1731 xi------t_j4 4 38 17 , _ 1 C ° "r \-<"' < '', :"'"o), t/3/'). 9Q 543.32G) S') . 38) 7 -----.- / J s x \/" ( x. "-.," Y-". X, n, ; _. _-_ _ _ _... _ - ". o p i i, c T L \-/"' o'/ _ X, ) 739 <-S2J555. 3'tp) 550. 3902 , "39 X, OCH,'-"--,, ". 1741 2 c 1, 1. 13C , x .-... __. 1142 2 cri 113 Dz 1743 xi X2 ci 113 X3 y xi 1744 si 2 ciel, ) \ \ X C)',, . cri ) 7'C) c r, \ I 1 (. Xa _ xe 0 v i Q Xz Wiz 1746 x X2 174G l747 1Vi IlkrXxX Ex-#I I Ir Ç ) 740 cl 1, 17A7 x r, ii, <746 *. \ rx°-\ i r _-- C) CI i » non fTi"''t"'\ \ <''* 9 \ -, J7' X WX 6 3 i749 e * S-- --4 4 6 z z w y 1750 x x 2 ci Cif, t750 r.. t XJ-.. ___...... _... _.. _.. _. _ _ __... ___.. _... _.... _.....-. _ X5 1751 xi X I i, ; Xe X / Ur a 'x, X2 r ci ci y I lc X, X3 0- X CI1 I i cJ ) 7G3 2. 07.. 509 : 230') 500. 3)) ! __r.... __ \.-Ia Xa lo _/-i1. e y X2 X2 r ( : II. r _ _.. __... X2 o-\/ / ci cn, ) r "\ fj ". c \ X X2 Ci if I-I C "., c J756 2 M-5') 0.'<099 I 1 r x o \ b"" ci ! 757' t751 .'W x, !'"'/-x, " , a cf'... _. 1/50 . 637. 3710. r) 30. 4346 xi b". _ o 1 l59 x' r1 a i, R3 NI ( RIl H NR4 R2 R5 TABLE 3 CMP # R1 R2 R3 R4 R5'Rtn. Time Ctnp. Mass 11 + lon Obs. ... \ Xr'x /O.. I H3 I 1 into 1800 XII xs 1.9 531. 2158 532. 2805 xi X2 GN3 /i . o X 1801ci xi z o clii c3 X 1002 3 X3 X4 oti 1. 98 565, 2 132 566. 2751 xt/ 0 1803'1. 99 515. 2573 516. 3182 X /° X. CH a X 19G 59. 2471 5G0. 3 ? _51 cl-if ! C3 1 Eto5 X'°'- X 1. t37 401. 2729 402. 34 CH ! r') i i i x 1806 on s 0 521. 2234 522. 2003 y y CH3 W cul3 CH3 1807 X'on X 1. 91 4U7. 239 4Df3. 3032 x, / i' cEi3 w w FDE X O OII) (r. 2.07 JfJ. 2J7 51G. ZQOJ R3 Ruz R5 R2 R6 I I R2 R6 i i3E 4 CMP Rt R2 R3andR4 R5 R6 Rtn. Timo Cmp. Mnss ttottObs xi X, x, o. J l \ soslt, c X4 2. 04 493. 2729 4'94. 330T xiX, X/ol' osa, 9 x/) =< f 1810 4 cl ... X o _ x. ¢D | H C f xi X xg xz vu, e .. o- x, I \ Xt z X3 J b 1812 /H C-' 1813 oil X n Xe tu, c c H, C 1813 x S _ ti c" 1814 2. 01 485. 2234 486. 3 xi xi Xz 1815 Xz 1815 tal5 _. _ _.. r ______ __. _.. _. _ Sr K fl,, O- I Is--I S -^ I 1 2 82= 1 4-39 32F | 450, 3g | IU20 s, C N- ) ( "))- 10"' \= 2 ; M S2JJ30J2 S22J352') .... .... ..... ... // r_. -, 10 ! 0 " J°' '2. 00 jt93. 2U6 J93'<0< -.--....... . . . , -! 0! 9L ". . 02.'1595J6379 2. 00 493. 200 494-3401 1819 2. 02 459. 325 460. 37 i 9 .. .............--.--- I 020 n, c 2. 01 459. 32t ; 460. a7oo si 1821 002 a X, - ___...-_. __.. _____. _.. __. __. ____... _. _...-__. _.. 2. d5 27. 2703 G20. 3104 . ir^- y _. _. _.. _____. ___. . __. _. . _-_ _ ___... _ 1/ 4/-ar0l. 3 5. $ 3'bJt. 3 3 03 1 a22 i I, r. i 1 23 uo 1.99 487. 3199 488. 3140 J R2 ii N ' TABLE. 5 r 44-1. 2ili 440. 2516 ) 832 1033 1834 1gs 10 IX, C c ! IA'. _. _. _.-v v, :, .. v... t033"',.. ,.... J..... ; : '"''''- 1 _ 1 i 1)" C !) U ; 34 '.. .. . . i f31. Cif 2. 3r, 433. 2042 434,'-552 . ln36 I. < s'134 2sos si XI 2.33 433,20A2 aSd. 2509 1 t136, CI-13 X2 3 xi 1837 X3 2.33 433.2042 434.2613 0 H xi r 1838 x3 2.22 419. 1885 420.2401 X2 y z xi 0 /x I r 1839 2. 3 505.2253 506. 2785 X3 U xi 1840 X2 2. 31 421.2042 422. 2463 xi H oh x 1841 2. 2 419. 1885 420.2424 xi - oi-3 1842 2. 27 419. 1885 420. 2401 C A xf xi w w 1843 2. 32 505, 2253 506.2746 y cn, C A ofo z xi 1844 X3 2. 3 505.2253 506.2814 1Xx, 1'W0 EX i 0 1845 X3 2. 27 421. 1678 422.2155 x'1 1846 X3 2. 4 427. 193G 428.2449 X, 0 f i st o o--J 2. 33 413.1991 414.240G I \/_O X3. x 0 x, w o i i xZ 1848 2. 25 465.1576 466.216 \ H3 X-_ X, Nci 1, i 1849xz 2. 12 420.2202 421.262 I i x/I O/X3. w f, \ O/ , BJO 2. 33 489.1552 490.2146 1 851 r xF X1 - x, / 1851 r F xZ \ 2. 46 495.181 496.2438 9 7 X x, I F3JZ r O o _l x3 2.37 401.1aG5 4Q2.2155 (. II X 1 3 /N CH 1853 48t3. 2076 4f39. 2776 1854 r sF Xz - x, / 2. 4 471. 1Ei1 472.2344 W \ va \/ x,/ II C (/ 1855 xz X, 2. 49 457. 2042 458. 2641 ou c So J 185G/i'c \ o o-J X3 443. 2097 444. 2538 AA tt ru 1857 3 i 'o xi 2. 42 433. 2042 434. 2522 xi. _.. 8J"C X3 N X, X, . i rix i/F N X, 1859 cn, Xa I \ \ i N x, 'F 18G0 xz N N/O v 1 L . J NS-xe X 851 M X3 ! X 1861 2. 17 490.2369 491.2785 N X2 C H3 xi N/ ci-I 1862 x3 1862 2u1 479. 2321 480.2817 i N x r. xi N 183 cft, Xa N X, F xi N 1864 C"3 X3 Xv N w I Nxr N N ey X3 1 E365 1'crn, X' , x : F/ F XI 1866 X3 2. 15 485. 2027 486. 248 _..... ri i/ X, i 1 Fi67 f F X' 18672. 29 472. 1762 473. 2223 1867 \ C X, | | 2, 29 | 472. 17S2 2 473. 222 | 1858X2 ( zozo 1868 1. 78 411.1583 412.1952 si '/ f I % /xz 1 BG9 X3 2. 44 443.1111 444.1614 s x2 i s x2 18 70 2. 4 423. 1657 424. 1971 1 xi. Nix t , c 1871 1871 x3 2. 11 504. 2577 505. 2372 i xi w Nx I \ X-" r 1872 \ X/ 2. 08 508. 2326 509. 2144 i XZ _ _ w I 1 X w c I F I 1873 \ \/x3 w---2. 21 524. 2031 525. 1942 i XZ-..... \ I N X F FF I-_F s x 2. 4 558. 2294 559. 21 A-x ! 0 nx9l ! 2. 4 155 :. 229l59 ! 21 X2 \ I NX 1 1875 \ \ X 1875 X2 xi 2. 01 490.242 491. 2217 XI F . _ 1876 c X 2. 11 524.2031 525.1987 X2 w -x \ F 1877 F . X3 1877 x3 2. 04 508. 2326 5092227 0 A. R2 I TABLE CMP R1 R2 R3 ntn. Tfme Cmp. Mass H-t-Ion Obs / x XZ i . w i tyc 1a78 , x. ..... 3 2. 43 417.2093 418.29 i x Xz.. w 1879 X2 c I f, 2. 42 417. 2093 418. 2941 x I I, c 2 1880 1880 2. 4 417. 2093 418. 2959 x Xz i 18a1 2. 35 421.1842 422. 275 n, x, Xz yc t cH, 1882 cil, 2. 53 411.2562 412.3455 x, I. w X2! IC/ 1883 x3 2. 57 423. 2562 424. 35319 x Xz ci . 1 af34 x '2. 42 437.1546 438. 1642 /I X Xz/ \//l \ X 1885 2. 37 417.2093 418. 2095 xi 1886 as6 X2 x, 2. 41 417. 2093 418. 2095 I w Xz 1 x 1 BS7 x, 2. 42 431.2249 432. 2221 I x Xz/' /// cEi x 1888 _ CH, x3 2. 4B 517.0903 518. 1107 _... / \ Cii3 1889 X' XZ/ 2. A6 429.2093 430.2187 x3 \ 1890 xi X2 2. 48 429.2093 430.2192 -fie s \/. I. 2. 41 433. 1842 434.2012 C3 r X, 2. f 1i392 ( X 2. 16 4G9. 1041 470. 13 /\ fc X3 cl-C 2. 21 549.1182 550.13 X I. ICwS I oui 1894 2 2. 49 393.2126 394.2145 if, c, 0 3 cru 1895 x'cn, Xz cí 2. 39 407. 246 408. 2388 0 cl X2 n, c v ci-'- oui F4 ; A Ks x3 2. 75 477.1837 478.2005 'K3 oui 1897 2 x x 3 1 F39f3 x, rtc. 1898 2. 6 525.1529 526. 1517 x, \ 78ss X'XZ C_ 1899 xi X2 2. 47 409.2406 410. 246 H 3c x 2 Xz X3 1900'"r 19002. 58 437. 2719 438. 2745 x'Xz i I 1901"' 2. 38 433. 2042 434. 2162 yc,/\ x Xi, 0 I w tc 1902 'x '2. 44 4'l3. 2355 4'14. 2371 H, C X2 1903 i y x 1903 cli, X, 2. 42 413. 2355414.239 fl, c,/\ x Xz soa 1904 X3 2. 39 413.2355 414.2406 143 si U 1905 xi 0 C"3 XI 2. 27 401-1991 402. 2076 IIC/ 'Cll 1 1906 " \==/x, 401. 1991402.2055 z q \cE r r 2. 3 421. 1445 422. 163 Xz \ 190F3 2ZF3 411. 141G 412. 9578 1908.. _. _ 2. 28 411. 144G 4 412. 1578 1 i I CL-CL ici 2. 47 1'407. 246 408. 2634 0, 1910 '1 O CFt I I lsto ! 2. 45 407. 246 40B. 2503 xi I I I ; F , i x,, F ; i F 1911: 2. 46 11 415.2123 416.2204 X2 ci N I r 3 1Q19 x, HaC '""-2. 16 508. 2281509.2342 x 2 19i3 x, CI 1913 S24. 2231 525. 2272 i N X3 m i i N I X 1914 ''2. 19 528. 1735 529.1874 r F x2 N X3 N 1915 x, CI 2. 3n 5G2. 1999 563. 214 c I C1 XZO 1916 1917 X x, t F xi W XZ 1917 v i, c N X, 191a 2. 13 494. 24E32495.2661 H C CH.. HC. _.. j \ x'. zon N 3-9" xi N 1919 xt F FIC i \ N"3 N I-N / 1920 2. 13 449.2216 450. 2522 0. 'JO" C [i3 N 9-X, 9 '-N Xz 2. 11 467.2121 468.2447 Xa N N 1922 X, F 2.14 467.2121 4G8. 2424 tic N X, N l=N U 1923 2.11 479.2321 480.2583 .... 9xi i/ 0 1924 2. 52 400.2515 401.2748 In-nô 1925 \==/2. 52 412. 2515413.2005 X2 va N x \/\ 1926 Gil, 2. 28346.2045 347. 2321 X2 1\0., X'. _.-./l \ Xa Xz 1927 2. 25 366.1732 367.2062 ific 113C xi ", c C113 H'C Cli \/ zu 1928". c"° 2.11 531. 3097 532.3127 xi Cit. X3 /o/' u, ca i I-IC---. ry=N S-CH 1929 3 X, 1. 96 503. 2243 504. 2599 6----~ * o + @- ciel, o 1930 r, c-o x, 2 517.2399 518.2G93 ti, c i , c i cn, \ N o lic 113C 1. 9G 519. 2534 52O. ZJ34 _ 1 cn, U cul 3 N 3 zon 1932 X' ... 2. 02 505.2132 506. 2226 o-o-x, lf3C ii c cii N o x, 1933 il, c-o X3 2. 05 529.2941 530.2949 0 1 in I I, c Fit, cil, x,X, --- 2. 03 529.2941 530.2936 / ". c N 935 cn zozo O .- H, Co... X3 1. 9Z 531.2733 532.2859 HC-p.. I w Xa Hc X3 I C _ x'\ o fisc C) 'en 1936 cui 3 1. 91 531.2733 532.2828 n n X3.. i N i N -. X 1937 ci CII 3 2. 27 520.203 521.2229 i i N X, cif3 193F3''C cl 2.25 520. 203 521. 2301 n, c XZ 1939 1939 ci 2. 32 534. 2186535.2426 I lié w III cm - IIC-p xr 1940 113C c 1 X3 2. 19 540. 1695 541. 1906 "''w x, ber \ N 2. 23 560. 0978561.14 B r zon zu \---X."-/H, C W t-IC . c'2. 23 560.0978 561.14 xi Ion zu er J \/ ci 2. 28 574. 1135 575. 16 W à N : 01) X i' /-.'-J'\ cri 1 / si_) \ zu N 1945\/I. IC 1945 2. 19 497.1982 498. 2381 il, c x, J-N- 1946 cl X, 2. 26 511. 2139 512, 2437 jT N N N 947 \ cfi 1947 ci CFI, 2. 25 511.2139 512. 2531 JO \ xa r N CI 1948"' ci i, 520, 203 521. 2333 X, N cri ci - w---w 2. 25 497. 1982 498.2341 X R N ciel \ x x N/\ CH 1950 ''"-i l C a 2. 25 497. 1982 498. 2305 Q-. ."' x,/) ci H t J 1 2. 3 511.2139 512.2459 <0 jr <' \----- cl ii, c. \ IC-_ (. y 2. 07 504. 2577 505. 2820 X, X3 il, c ii, c \ r- 1953 Xz 2. 07 504. 2577 505. 2755 -/ X _ \/ /\ r 1954 N'C XZ J1. 2577 JOJ. 27JJ F 1955 F XZ X, X3 2. 05 508. 2326 509.2624 1 956 X2 /v w \/ J 1956Xi 2. 03 520. 2526521.2831 x, ci CRI/ F 1957 Xz X, X3 \ l il, c S"CxX 4 A t a iXI 1958 X2 2. 05 486. 2671 487. 2196 Sa-t ri, c X2 1959 2. 06 486. 2671 487.2379 .. _ X3. _ o \/"-" i, c-o Y 1960 2. 02 402. 262 503.2366 X3 ti 3c f i3C 0 0 C vX, NH cH3 1961 2. 55 507.098 508. 09 /va xi cil cn 1 9G2. 2. 49 449. 1329450.125 F- / Cli FISC 1963 XZ C I 249 ll449., 329 N 96 (' Hic c3 sst xz ci 2. 55 463. 1485 464.155 0 "o o "P-N N zu 1965 ! 2. 5 461. 1329 462. 152 - X, y N \ 2. 13 508-115509.1421 X2 X3 si x iss 'v . _ 2. 39 437. 1546 438. 191 X, 3 1968 si 2. 1 520. 1011 521. 1198 ciel3 x'C I I3 I N I \ X 1969 1970 2. 16 4fi6. 2307 4t37. 2447 c 1-1 0 cl3 91 I u w 1970 2. 01 424. 2151 425. 2368 cl 3 I \ CH Zur N 1! \1 971 2. E3 472. 115 473. 1456 __ dz cri \/" \/ sz 2. 38 437. 1546 438. 1952 /\ 1973 x ce, 2. 37 431. 2249432.2486 1974-x f- 1974 b 1971 _ 2. 3a 37, 1546 438. 1897 ----.---- 1976 fXX z { x, 1975 XZ 2. 33 403.1936 404.224 \ x. xa Xi-I -cl xi iss 2. 36 415.1936 416.2279 xi xi go 1977 2. 3 421.1842 422.218 .. _. XZ x' 2. 29 433. 2042 434. 2361 /\ ,. /\ r Cz t, -o 2*32 447, 2198 448. 251 X'l CL c I 1980 x,"iC l. Ot3 5A7. 2026 G48. 3105 F X3 r v X r v F O 1981'1. 9 549. 2228 550. 3254 F X3 si XI F 1982 1. 97 525. 2592 526.3528 c I X' X, X,-- y0 O FIaC x IiC 1. 94577.2132 578. 3243 ci X3 , t_ iii 'O fl3C x 1984 2. du 553.2496 554.3531 "--X 0 "==-X si NON r I. IaC 1985 1. 13C 561. 229 582. 3329 ci Xi ci C. cr 1986 1. 95 551.1531 552.2697 cn ci X3 si 1987 _ x, H3C 1. 95 581.1637 582. 284B ci X3 cl ci 1988 2. 03 557.2001 558.311 Vr x ß P-xi Ber 0 Br O 1989 '1. 9 591. 1522 592.27 tx, t ? XJX /0 o 1990 xr fi'C 2.02 617.3042 618. 4236 Xx : Sxs x N O FI L 1991"'* 1. 92 639.1383 640.2621 ffl H3c\ X3 ct si 992 1. 95 607.2238 608. 3556 -Q... xi N zu N r O 1993 xs HC 1993 1. 92 621. 1627 622.29 hic x3 /x, / ber O O 1. 96 651. 1733 652. 31 ......... lo-xi foc N N O 1995 FI C J 1. 93 657.1288 658. 2678 H3c X3 . _.., N , \/ ber 'HC -- 1. 95 605. 167f3 606. 29 HC \ X3......... . x N Br NON Br 1997 x, 2. 02 581. 2042 582. 32 HaC-S..... si ci 0 ci 0 1998 t IiC w------1. 96 593.1904 594. 3127 cri \ r Fuzz F O ci X-3 si F ODIN N F F 2000 X, V'N N r 2000 2.04 591.2264 592.3466 xi t X /\ l X 1 IaC 200? 1. 93 578. 2682 579. 3848 si-I atom 2002 //x 2ooa .. . . ! _ XI N 2 Gli 2004 Cit. 1 20es C 2005'r 2005 - t, c '' a p-Git 2006 \==="2. 47 475. 25 76. 285G x3 xi 200 403. 1936 404. 2317 Ici X3 3 zoos x2 2. 42 427. 1936 428. 2387 X'l xi 2009 x2 2. 42 427. 1936 428. 2307 2009 SX X < JX | 2. 43 437.1546 438.2044 xi XA SX3. X x- x2 . 2. 39 433.15 434. 1996 xi X3 r- 201 1 XZ 2. 39 445.1842 446.226 , _ , F 2012 xi ! 0. 2 jIX,, t CIeJXz - 2. 41 455. 1452 456. 196 \S/XZ/\.. q-x 2013 2. 41 433. 15 434. 1984 s xi xi 2014Xi 2. 42 443. 1111444.1632 cri cl X3 x, /\ xi ... 2. 47 443. 1111 444. 1649 cl xi s Zo? s XZ 2. 53 477. 0721478.137 X x zo xi s CH3 I x3 R3 R4 H NEZ N--R5 RI R2 R6 TABLE 6 CMP # R1 or R1 and R2 R3 R4 R5 R6 Rtn. time Cmp. Mass 14 1-lon Obs. X cta3 J ' o xi X, 1.91 424.2151 425. 2364 ... _ o. _..... _.... X3'-0 X" X2 0 X, 4 CI-13 0 . xZ X'. xcfi3 I v 1 X3 Xi o X5 1827 2. 09 508.2362 509.2629 XlX XX A 1Cf- /\ o ( Xi xi 1828 2. 1 464. 2464 465.2729 o ci Oil I <0 X-IDa X6 2. 04 514. 2023 515. 2661 1829 X3 X4 X5 CH 3 ? (5 CrH3 'Cr \ XG 1830 1. 98 436.2281 437. 2896 1830 " Y"6 //CI \ ci HC \ Xe 1831 01 1 2. 05 470.2125 471.2745 F \ H Cx2 X4 X5 _--- 3 727 xi 0 _zo __. _'oJ F, /X/- s\ jL u /- \ 728 si zozo T'-' 2. 08 493.3105 494.3472 ""f''""'-CHg -.-..-..- ,, o 729 2. 06 465. 2791 466. 3023 cli 8 3C- f'3c 1 2 so'-J ... _.... _ _. ___. _.. _. _ _. _. _ __ _.. _... __..... _. 2. 08 165. 2791 466. 3028 ...... _X^. XS...... _........ _. __.. ___. __.. _.. __.... _....... 0 730-1- . _ 731 __. J . __.. ____-_.. _. __. _. _. __. _. _... _... _. _. __... __.. _.. ___.-1. 99 477. 2791 478. 30G2 jfLjr'\/\ X 732 v \ ... 70. ... A08'<65,2791 466.3028 V (f x \ J 731 9.. 791 478.3062 2. 07 477. 2791 478. 3031 : Y"h HJC ut F V"--..-.-..-....-..-..-.-. CX ? '\ 734 0 1. 99 471. 2322 472. 2518 F y l r ' -cil3 * s # w » F H 3c 2 X4 x 5 QY X / d H3C I V 3 ~eFisC / . CH3 I H3C xJ 1.99 489.2228 490.2399 X2 X 4 xs 3_. _ 3 1-IaC /CHa caf-13 X GH3 li3c 2-ci 1, Y CH,"A 740 X, 0 2. 05 499. 2635 500.2832 . _. 741 xi CH3 2.14 461.3206 462.3372 Hc X, CH. 741CH3 2. 14 461. 3206 1G2. 3372 F Hc H3C- (--/x4x5 i/_../ 2. 04 499. 2635 500. 2898 __.. ___... __r. _.. _. _ _____ _H.. Cx2... _... _... X X--. \ CHa xi---0 X5 'Y'CH, \ 1. 9 451. 2635 d52. 2902 F Hc x x5 H3C/X ? ,, .. 0'f f/-X"X,/-\ X, 5- r."sC ()--/")- Q \X X n- {4xi 0 2. 06 477. 2791 478. 3002 l n X 2. 06 477. 2781 478. 3002 H3c/---/---x2 X5 HJ c \/==\ x, y H3c x2 i, c 2.03 5i7.2199 518.246 3 2. 08 433. 2fi93 d34. 3055 /< ll cx2 | V > 2. 08 433. 2893 43d X f' 2 X Xs )) t ur*/-"\ tU c- ..-. CH, cl ''Y) H c" <\-.-y '"\- CLJ Vj =\ CH. X | i SX4 X5 F H3c 2 x4x5 X1 X, CH. 749 2. 11 447. 305 448. 3214 -"X/--\ X, 5\ cH 3 750 X cwa 1.99 435.305 436.3263 W Han. _, X1 O H, C 751 2. 05 463. 2999 464.3266 F"-X2 X4X5 H C C 3 XI x U 752 CH3 2. 05 449. 3206 450. 3442 t--.- r=. x2 1-i3c t-. ! cl 3 Y \ HC 7 F13C 2 04 449. 3206 450.3435 H CX2.. _.. _. ___X^ X J __ _ _ 3'_"' / HC 754xi CH 3-2. 18 475. 3363 476. 3594 H 3c 11 c x 4 x 5 CH 0 ..... __.. __.. _. X^ X5... _.. _. ___. _. _.. _. ---------- H 3c cH3 J x, F H 3c x 4 x X< h 3 q 756 X oJ 1.97 515.222 516.2496 F \ H C/X2 X X5 X O 757 xi 2. 06 477. 2791478.3031 .......... x1 {s t-lc , s , s H. C p 3 1. 99 453. 2614 454. 2874 .----.-.-..-- FHaC i 759 0 2.02 517. 2199 518. 2543 X"X,/4 \ E13C. /H3C- \/ c3 760 xi CH3 CH3 2. 1 463. 3363 464.3699 S H3C vX4 X5 H3C 2 xi CH3 c3 ex 2 UT hic cil, fTS Hc r"\ c-fy 762 X, 1 1. 98531.2534 532.2854 F x4 x f-toc /\ x o 763 CH3 1. 97 53i. 2534 532. 2903 'q 'CH, zu3 0 X CH 6 X, 0-CH, t 3 1 g3 531.2534 532. 285 704-.-S. | *. F . _ _ X4 X5 _. _65. _.. X'o CI CI H3c 0 X5 549. 1427 550. 1876 f C ==/ 0 xs llr 0 x 766/',,,......... .. t.. 549. 1427 550J876 768 3, \D _ 76a _ _."' .. __.... __... __...... _...... _.. _ __-- O F ^ --.... _. _... __,. 2_03 549. 1427 50. 1867 X X X H3C |] o ' 76'7 X 1 2. 13 575. 2948 576. 329 . _. __... X^ X5 _ _. __. ___ __.... __.. _. _____... _ _.. _. _. _. ___. _. i I-13C-- 7 () _.. _. _. X'. __. _. _.. _. _.. _. _. _ 77x F \/O Xs 771 \ xt 2 CH3 x 2 H30 HJC Xs H3 C_ (CH3 3 CH3 X Xz CH3 c- ( (' x' / CH3 , 773 . ...... . .. 2. 02 65. 3144 466. 3379 X4 X5 CH3 113c-c o-w-^CH CH i xi 3 3 775 1....................................... _. 2 06 465. 3144 466 3358 . F. H CX O/\ x Xs F ßXH3C 2 ì 0 0 F F 776''1. 99 525. 2039 526. 2423 _,.... _ F... _ ___.. ___ I i s o F F 1. 99 525. 2039 526. 2429 _ F I 3 0_ \ H3c 2 5 77f3 xt ctt ---.-..--.... . X"""" F 536. 3018 H3c 5 780 x J 0 2. 07 535. 2635 536. 3018 ..... _.. _ _. ___. _ _. _. _. _. 536. 3018 H3c 1-13c X4 x5 s 0 781 T"f) 0 CH. ,. _ ________ __ __-_ /\/ - 2.09 555.2356 556.2706 H CX2 O /\ X X H3C _.. __. X1 CH3 782 H3 1. 97 531.2534 532.2892 r t X X <-CH I e X 4 X 3 % !7a3. 783 _. __--. __ __ _.. __. _ xz Ho-C 7f34 _ __..-. ___. _ _____. _... _ HaC .... __.. X X. F C-__. _-.. _...... _ _-. 471. 2453 472. 2802 y"\ 3 4 5 p Cri3 or cii, 7f35 __... __. _. __... _ ______,.-_ _____.. __. _.. _...... _ WChi3 2 523. 321 524. 354 H'c/-x2 x4 X5 I-\W-1 i/\ 786 X HC X"3 'n O 787'""1. 98 515. 2584 516. 2964 H CX2 X4 X5. __ __-. _-.. _. _. _. _.. ___. _. 3 7f37 W Cf-1 O 1.98 515.2581 516.29G4 -jx4 x 5 H 3c 0-0 0-1 V F/'X. Xn Xs 2 7BBCt-13 0 1. 98 515. 2584 516. 2967 A H3C<x2 eX4 X5< HgC/-. / WCI-13 W X VoJ° H 3c / w 9 0 oJ _7g1 _.. _____. _. ___ ____. _... _. __. _..... _...... __...... _.. __..... _ 1. : 9$. _ 515. 2584 516. 33i5 __ _.. F ^X Xa Xs v 2 / 1 I -X,/ X. _ X Xn. Xs w H3C 2/ V r 793 x'r 2.05 563.1584 564.26 F . i 3/\/ "3C x s 0 2. 03 531. 2356 532. 3217 F, g H 3c 2 X4 x x s 0 3- 3 2. 02 531. 2356 532. 3212 X4 x 5-------- x x 2 s 797 cl 13 C'H 2. 03 561. 245 562. 3386 _ 797 _. _. _-_.. _-_. __ _.. ___. _... _- cl I3 O t X v/ ! t ... _.. ___.. : x4 X5.. ___.. _-.-. __ _. ____. _-. _... __-__. xi CH 3 N ) tu N 79B I-13C 1.74 136.3002 437.3F36 F. XZ X'Xs xi IN H. C 1. 88 462. 3159 463.4108 * *- *-.- *--. - . \//" ( 3 NHZ IX'1. 87 462. 3159 463. 4136 800 _ _.,,, _ g _ _ _.-.,. __,....... _, _ _..,. ~ _1. 87 462 3159 463. 4136 OU 1'HaC 1 xY \ F 7\\ Y 801 x, O 1. 97 507.2133 508.3045 -"X, n-/ "\/S-CH, 0- T 802 X, 2. 01 517. 2199 518-3113 Q H3C<x2 g>x4 X5es_CH3 A 0 X4 803 x 2. 02 555. 21 a5 556. 3143 F H3c 0-\) X4 F /\ X xs F )/-0 0 X5 hic r f//Xg Y== D-'\/s ) J HsC fir \ 805 2. 06 563. 1584 564. 27 Q Hscvx2 Xk wX5 805 x,,. elZc O Z. 06 563. 1584 564. 27 H3c-X2 X4 X, Hic s O 806 CF13 2. 06 551. 181 552. 2875 806 ___ __. _.. H.........., |_ 206 551_181 552. 2875 "X2 X4 X5 {d H2C f O L H3c 0 2. 03 521. 2479 522.3456 11 3c 0-X4 x Bos xl 2. 09 559. 2635 560. 3663 808 xi po f308 X'\/2. 09 559. 2635 560. 3663 _. _... _. _. _ _. ___.. _..... _.. X. _ ..... _. X XS. _.... _.. _.. ScH. __. ___ _. __ _-____... ____ i HJC 809 x, 2. 03 473. 2301 474.313 s--~HJC F H3Cx2'X, $ X5eSoCHa H3C ' \\ 2. 02 517. 2199518.3132 -/-"X, /X, s-, o _ /HsC \ o CH3 cH3 X o 501. 2558 502. 358 X HaC X4 X5W /3 Ci/ 3 cri 0 CH3 O \ CH <"3C 822. 09 527. 2715 528. 3815 .-. 0 813 xi 2. 05 521, 2479 522. 3471 F x4 x ! i w % CH 3 /CH3 X CH3 4 H3Cx2 X4X o xs LJ CH, \ t-iC i_I C- Xz-0-X5 Cf-13 ___. CH3,. _ 2.09... _ 455.2504 45G. 3523 6 X, Gl Gll O 2. 07 519. 2089520.3145 , s 1 _.... _ __ a _ _ _ _ __ X4 x5 ci- {3 817 0 1. 85 449. 2842 450. 3776 F. y/ X Xe*'-\ H3c 0 x, n 818'1. 95 513. 2428 514. 3442 F H3C 2 x4 819 0 f3 i 9, _.. X'_____ ___ __. _... __. _ _. _ _ _... _.... J 2. 04 475. 29 2 X,. __F_.......... _ _. ____. _.. _. __.. _. ____.. __. _....... _ _.. ____99 476_40_. 3 X, 0 F''-- O-- a2 x O . _ _.. _F ____. _... ____. _... _... _. ___.. _ _...... __ _. _.. _.. __. _1 _98_ 537. 2239 538. 3297 .... ..... _- _ CH3Wiz CH3 x, A . fi21___ ____-___ __. __e... __ _.. _.... __... _ 2. 04 457. 2893 458. 3844 I S I H3C f J SÄ | X5< /3 H3C CH3 /I X 822 CH3 H3Crx2 X4 X5 _ x, 623 CH3 hic 3 o 824 xi 0 1. 96 513.2428 514.345 - -w- X1 B25 r....... _2. 04 475. 29,, 9 9. 476. 3996 ' ( X 113C Ä X C b cul13 F 826 F 1. 97 473. 2654 474. 3578 . __. ____.. __ xi 827 F 2. 08 499. 281 600. 39, 29 CH, H3C--- ( 828 Cil3 CH 3 F Xz H3C'- C!-13 /I X'2 , CH3 x2 _ X. Xs H'C 3c 0 829 x 1 2. 08 577.274 578. 3961 a29 XX F Xa Xs . HaC /\ ! \ _ 830 xi 2 503. 2384 504. 3399 ----------- f'3C/ 831 0 Q \<X X2 X rcll3 xH . __. __. _. _..... r-.-\... _. _. __.... __. _.... _. _ _. __....... CH3......... X _. _. _ .. o __.. __ _r. _.. __ _.... ___.. _......... __. _.. _ _.. _. _. r-j-0 ca3 X 2. 03 529. 274 530. 3805 __. _. _. _F__.. __.. _. _. H CX2 r _ X, X5... _... _.. __......... ___. _. __. ___ 833 xi 0 ----. 833 x' 2. 03 563. 15fl4 564. 2842 .. __. _ __.. _. __.. _. _______ _____.. X2 _.. _..'jC_O _. _ X4.. X5... _.. _______, _. _.... ___. __. _ ___. ___ HC -CI-I f134 X 1.98 545.269 546.380F3 y HaC F 1-13C-0 < 1 iac X, \nr 835 xi 1.97 545. 269 54G. 371 X H9CX3 IIJC-ßf 4 XS 3 X o' 836 F 1. 98 545. 269 Q "" ' ''"==< ? 0 0 O- 1. 92 t337 X'y- J i Xt n, '-° _ o H3c 0-. 838 xi 0 2 A 5..-. zu _ 839 )/V. \ y Xr-t rt-y JL//X r)-<'/ \/\ 7-CH, -X4-r\-Cil' bzw 840 X, _... ___. _. _F ___.. _. _... _. __. __ __. ___. ___. _.. _.. __. _. ca, 2. 04 592. 285 593. 4103 . _ __..... _ _. _... __.. _. _. ____. /\/ a41 H3c 0-X4 H2c 0 x s N x, .. 842___ __... __-... _. ___.. _.. ____. _. __... __... __.. _.... _.... _ _2. 0... 5d4. 2308 545. 3511 0 :) IX2 0 X5 (JX \ _'O X4 () DIX2 x5 0 844 1-13C x2 // s X a Q) IX2 x5 1. 97 525. 2592 526. 3528 -X x. r 2/ _,, o Xz- Xs x,ci dix2 F0 86""1. 94 577.2132 578. 3243 X^ CI } Ç 0 ° i z 0 H. C O H3C 847 F13 c 2. 01 553.2496 554.3531 ilsX2 848-laC F 1. 92 581. 229 582.3329 _ _ . r' X2/ Xs \ l x o 849 Cl 1. 95 551. 1531 552. 2697 xs t x o x4X-ck o-- (/_-. x2 \ I/ Xs. 0 cri 1. 95 581. 1637 582. 2848 X, CI - " o a51 Cl 2. 03 557. 2001 558. 311 X xi O f352 X yC Br l, g 591.1522 592.27 x4 X5 /X2 \/'o )) C \/ Ç XX2 X4 4 5 | I l 853 2. 02 617. 3042 61 a. 4236 ODIX 2 - x i o 2 O 1. 92 639. 13f33640.2621 w * o + x4 3 \ 0 X5 x, o i o 0 3 3 1. 95 6fl7. 2238 608. 3556 855 I'i C _. _. H C.. _.... _.. . ____......... _ _... _... i XZ v o O 1. 92 621. 1627 622. 29 X4 hic X, \ \ 0 Vs \ X B o O X. C H. C 8571. 96 651.1733 652. 31 F 5 X XX2 IX 858. __ _.. _.. 1-ß3C.-----------1. 93 _ _571 288 658. 2678 jI-13C Xi11. 3c 'p \ 0 o 0 1. 95 605. 1 G78 60G. 29 1 X L I | ° I i 0 :), x2 X5 \/ 0 X2 xi ber F3b0 2. 02 581. 2042 582. 32 861 x I 1., c p ci 1. 96 593. 1904 594. 3127 l i i/\ x5, xi o 0 . x. CI X 2 0 x4 ci F F 2 0 CI X4 X5 - \ rio F 863 xi 2. 04 591.2264 592. 3466 X5 u XZ -O 0 X N I abn t-i3c X 864 J 1. 93 578.2682 579. 3848 R3 R4 R1'_N H NRS N R4 RIEN TABLA 2 Cp : _. 1 =-_. . _-"__. R -=-^___. _. _.. 3_. _.. __... _ _.. '.. ___.. ___.. _. _. __. _. _ 5-. ___. _.. ________. R Rtn. Trrno Cmd. Mnss 1 t lan obs table. 2. CMP R3 900 X2 Xs 1. 99 453. 1779 456. 2343 ---> -------------. *-.---.--.--F---------------. c ""7'- -CH, Xi-13__ X2 X c I C H3 X, / \ 1. 98 451. 2987 452, 3564 903 __. _ --~ _ s _ Xe 1. 98 451. 2987 45 3564 xil H3 X3-C113/==\ X, ; -cm 3 --C H . __ 90A_. _ xz X x H3c------- xi cl /', i Xa CH 905 dz X Y 2. OB 515. 2703 516. 3389 .-.-.--. Cf 906ci 2. 02 501. 2647 502. 3203 0 cri 907 ? vs 2.05 535. 239 536. 3062 r"'F"f '°\ "itch X/ 1. 95 495. 2886 496. 338 " L C \-CH, /-' 909 x x. 909 x 2 1. 95 509. 3042 510, 349 CX | V P X, < I 0 X, t S / _ 91 O. __. _. _. _ _. _. __r. ______ _....... _.. _..... __ __.. ___ _.. __.. __. ___. _ _. T. 2. 06 543. 2886 544_3537 xi x X, N \/ 2. 06 529. 2729 530. 3288 xi CH, X3 _,, i Xz X. 2 : 06 527. 2936 528. 3539 lC1 2S IXD xX J { [ 911 X2 x 2. 06 529. 27Z9 530. 3288 J C'C V xJ xs 9 1 2 X2 Xt 2 : 06 527. 2936 528. 3539 si O 6 _- 913 1. 91 493. 3093 494. 3662 .. ___ ....,. _.. _____. [o __... _. _. . ____.. _. _. __-_-_-.. _____.. _ 914 dz 1. 98 501-278502.3292 '"'"""'''""------- X'Cli, ci a CH \ 95 " OH 2. 04 481.286 482.3375 xt H, C / city 916 CH3 x 916 _ _____.. CH oo Xe .-____-... _ _.... _... _... _____.. __. _. __. _____ . __. ___.-__ _ ___ X3Sf o o I XOH CH ! \ X, [/XCFI ..3 0,-, o X, ci \ x 113C H3cCH3 0 z < f ° . L. H3 x xC, , ... 918 _. __. _ H'o. v. o Xs CI 2.01 559.2602 560,3214 3 W . _. 919__ Ca XS I X S H, C y Xa 1 2. 07 C < ! \ 920 HaC X 2. 07 515.2936 5) 6. 356) - X, X", -CH3 C HO 1. 8 467. 2937 468. 3449 x cti, ci X, ==N \/... C H3 "'--'-'x w 5 1. 97 486. 255 487. 3133 "Z x ci x cl x 2 X, 923 ___. r__.. _ __ _____.. _.. __ _.... _... _ _ S 1.96 520.2394 521.3087 y. Cli X \ _. __... __.. ____.. _.. _... _,. _. __. _____. __ _..-.-. _-_. _ _. _-, __ _-... _ Zon cr \/ 924 Xi 1. 77 521. 3519 522. 4169, si-x s 9ZJ x2 ------- 1. 79 555. 3362 556. 421 . CH, '''''"'"\"\/==\ 0 cri c o I 926 XZ CH 2. 06 665. 2496 566. 3239 ................., S -" 927 xz 1.76 545.3155 546.309 x x I x 6 MHz o /--C H cl) I I 928_, _"__. _ Xz., xs 2. 02 531. 2653 532. 3318 A 28 I X 1 X XXsX-CH, I--------202 |) 1. 2653 | 532. 3318 J 1//-- cl 929. xi' __. _. _-.. ___ x.. X "/ 1 930 x \/-MHz ZON 930 Xx' _.,. _. \ _X .-___. _... _____. _ _...... _ _ _..... ___. ___. _ . ___ 4.... _. ___. ____... -, 1. 95-_ 525_2991 526. 368& _-Flou V xs--. __.. __. r__ / cor 931 xi xi_.. ___ r. ___. ____ I--'l- C---y) C Y {F, o R {x, I I Fs 299l |_s26235S6 ß FXe 133.x2 9" C lui dito cr X6 ?. 3. 3...... ..... ' 93 470573 xz 934 Xz X5 . 1 f X, no ! () 935 2. 05 653. 2296 SS-t. 3043 xiCH3 X, 936 XZ _. _..... _... _.. _.. _. . _. _. _ _. _. ________. _.. _-. _ 1. 97 513. 2782 514. 3508 XX X/1. 97 513. 2792 514. 3508 I F 937 x= _ _'___, _. _____^,- x_. _., _-___ _ 2. 06 547. 2635 548_3326 X2 x. ! 2. 06 547. 2635 548. 3326 oE, --. ctl, 0 . ! « - ~ 8 l sS t ¢> i T i Xs 0 t \ CH,] x X. X, 1. ¢y \ ! c"' 938 '1. 71 483. 26B6 484. 3469 xi X2 x H3 "\".) S\ ! N Xa J Xa 940 1. 94 458. 2504 A59. 2958 fTT'\/"\ " X'U X s N 941 HC 1. 93 492. 2348 493. 2848 Ho xi / s42. _.--____^ x ___.. _ x5 1. 74 467. 3049 468. 3629 X,---'\,, C H :, o--x3 943 x5 9431. 92 437. 2831 438. 2847 xi xi ZON \/ 944 xz 944"'1. 77 495. 3362 496. 4057 , N X- . _r N cl3 945 X2 \ S __ zu -C H we xr" 947 ''. 93 482729 4B2. 3) 88 X 0 po ___... ____ _ ____. _.. _. _ _. _.. _.. __. __... ____..... _.. ___. __. __.. _ ____.. _... ___- t : sa at. z7zs aa2. aies . _.. ___... __ ___. __. 948 Hi 948 HC Xa x H/ 5 2.01 501.278 502,3374 xi X2 I X X Hc xr 4 9 H, C 1. 99 501. 278 502. 3323 xi X, r r ON x OH CH OH 950 H,1. 88 467. 2937 468.3544 __ \ _-X ; x, ______ _. _ _. \.. _ ___ __ _... __. _. _. __.-___ _. _\ _ oH x- / - H C x XS CH, 951''1. 88 467. 2937 468. 352 '---------------.---..----- o' H r"'- . 353.... 1...................... 2. 03 S09. 3042 5<0. 364 X. J HC'\/ 953 H'C N'2. 03 509. 3042 5f0. 364 __.. _.. _., \ __. X'_. ___ _X __., _. _. _..... _ __ _. __...... __ _...... ___. __. ___ ____.. ____... ^ _..-.. _.. ____ zu x. . x5/ 954 95493 536. 294 537. 3635 x X2 Xe / H C x' '''9. 94 502. 3097 503. 3694 xi X2 X, x xs 2. 05 542.3409 543. 4108 --. * - + -.------.-H o .- « *- -Cti Xs xiX2 xa xi X Xs 957H3C 3 CH3 1. 92 48|. 3093 482. 3674 __ ____. ___.... ______.. ____ _.. _ _. ___ X _-- - X ! \ OH (Xe xi X2 xe fl ' < 958 5 1. 99 529.2729 530. 3309 XI X2 oll ruz 959 HC x5 1. 97 495. 2886 496.3324 xi X2 OH xe 1 | x, | xS 9G0 H'C xs 2. 08 535. 3199 536. 3663 Np xp-N xi X 961 H'C CH'1, 93 502. 3U97 503. 3532 fT't/\/\/ =N fiC X'X 962 2. 06 542. 3409 543. 387 x xiCH3 X3 963xz 1. 77 559. 3311 560. 4 x 1T tx3< g X'<I N h 964 2 wß 1. 77 529. 3206 30. 373 W g H X X 965N 964 xZ" 1. 77 529. 32a6 530. 373 529. 3206 530. 373 xi X2 xe .. .... ".... .. ... ........... . . . J....... ... N-CFI e /\ H3c xp Cr p "' HC v/CH, 967 ..': 1.83 494.3409 495.392) 966 H' x5 i. 94 528. 3253 529. 3721 967 H 3c xp X-P CH, 1J-ClI . 1. 88 494. 3409 495. 3921 . . X X1 _ ___ _... __. __. _-_. ___. _.. _.. ____.. _ __ Xe _-_ - CH X6 968 HG xs 2. 05 53d. 3723 535. 431 W ta 1. 77, 491. 3049, 4923542 xi X, X, s /\ xJ bX xi _ X __. _. _. _-_vX r____. _. _.... . ..... _... _... __... __... ___. _. _. __... _. ___.. _-.. _... _-yil ...-..-. ___-_-___. _-__... _ ! X X'i'1. 98 534. 2817 535, 3365 xi X2 X, xi 973 H, C /\ xi s7z ° x, c xi Cr' '' ?''''''''''J"'7 I 1. 89 508. 3202 509. 3457 xi x 2 N xp 975 _. _-_ __..-HC, ., _______ _. _. _.. _. __. ___. _. _ _ _ cH'1. 91 522, 3359 523. 3574 975 s CH, rad ci, cit, 976 x. 2. 3. 562. 3672 563. 3868 OFi X6 xi x'xs 9771. 96 515. 2936 516. 3203 ^ | .- * --. * f- * N C 1 H g xS S X 978 HC CH, 1, 86 481. 3093 482. 3423 --- + f --* .- l -- xi 0/0 cf 979H3c 2. 05 521. 3406 522. 3715 xi X2 X, i 980 H'C 2. 06 515. 2936 5t6. 3033 --'"''p''''''''""""- x cii, x, o-cEi, x 98 1 3C X 1. 89 481. 3093 482. 3204 xi xe O-city 982H3c xp 2. 12 521'. 3406 522. 3559 x X, X6 Q chu l X 983J2. 06 5t5. 2936 5) 6. 3141 I 8 3 l {H, C | XX] 2. 03 [< \ Xt Xz /, / o e _ CFI vs x7 HC CH, . gg qg, 3093 462. 3264 x X2 xe X s X3 521. 3406 522. 3597 x 13C cli H, x CH3 X, 0 Cli3 X, < Y r CH °? X 2. 03 489.3355 490.3545 xi CH ri, c. , a, zizi x, 987 CH'n, X° 1, g3461.3406 462. 3651 F ~ -. ----. t .-- - v o xi x2 z HC'x5 988 2. 1 549. 3355 550. 3556 b b -- * X @ . * 0 * S . » R-S- x X2 x xp 1.99 559. 2835 560. 3169 X2 X, ç r g < 2 X3 X, <) 2. 06 565.3304 56G. 3G08 x xp X. i vs v 992 1.82 611.3199 812,3492 . y y/-OH V 99 X tj3C,. 1. 98 545. 3042 546. 332 xiX, v ? t X, / //_ \ Xa x, 2. 05 551. 3512 552. 3806 992 H3c CH, 1. 82 511. 3199 S12. 3492 994 CH3 o N, CH, Xo 1. 91 488. 3515 489. 3748 /\ / X xs 893 2.05 551. 3512 552. 3806 * v ---» -#-- e - 0 -- - l N XI 99A ^___.... ____ __. _..... ___. _ _. ____.. ___. ____. _. __ ° _. _c_ X 1. 91 488. 3515 489. 3748 XZ oH xe 995 2. 02 546. 2631 547. 2886 v 6 l 0- - -----R * x t + _-po X 997 X j oli Xe xi \O HC x x5 xi X, Oil xp 2. 11 552. 3101 553. 335 xi X, xe H, C x 1-,xi xz X, xi oh OSi/ X cc =0 998 H'C X5 2. 02 546. 2631 547. 2888 ffi s » W ç i--. o ov * e 1/ / oa x, 13 H X A=o t ) x %-rolx g X _ I \ Xt Xa. _ ov-o _ Xe Ofi x3 f >+ 4-H H3c xp 1003 cl, _ i fr' <f'""< -. r. s ; _ Xe J x7 ................-.. ) x ty n ZOOut It3C 3 X¢S U. i. 92 592, 4141 593. 47 X. X-CH. CH.. -.- X3 1005Cfi3 °"" xs 1. 9 474. 3359 A76. 3617 xi x 2 cor x y liez 1006'1. &1 558. 2995 559. 3615 . __. _. _. ___. _. ___.. _. _. ____.-___.... _ GH _. __. x 113C CH pi3 x r-, rCH, 1. 78 460. 3566 461.4005 rV''.-. -------.----.-----.-, 7C5 O xiCI1, 1008 3 2. 03 543. 2886 544. 3141 -".--)' ?'""" xp \cil o cry, 1009 H'C CHI 1. 95 509, 3042 510. 3276 xi X, xa fizz X'll ° o cu, 1010 HC 1010 2. 08 549. 3355 550. 3668 _,. X-.-__ _.. __ _/. __. \. _... ____..... __ __. ____.. __. __ f_. \ X __.-_.-_. _. X, X, X-/1014 HJC 101 1 1. 96 515. 2936 516. 3184 I. <L ? : ; gH, C XX 2 SxQoH 1 e x, ota xp 6 1. 84 481. 3093 482. 3309 o""----.. ; . x, oa i 0 i 3 H'C i. 98 521. 3406 522. 3785 x g g [xS l SX<-°Ifl // I \, o-=o 1014 CH X ^", xa 1. 88 564. 2559 565.3013 i X2 H3 y fr 1015 CH, 3 N11, e 1. ö7 530.2715 531. 3078 . ____. . _ \... __. ____.. __. _... __... __ _.. _.. ___. _. _____ O, . v | C [g B llCx CH, S ... _. _ X.. _.. _... _.------ ! S H ß S XX zozo H3C xp Lt \/ i z' s o I/ J X 1018 H3C 1.96 523.3199 52't. 3st81 xi 0-0/cit, X 1019 H3C CH, 1. 82 489. 3355 490.3575 0vu 1020 H'C i. 9 509. 3042 51. 3383 ... __ \ X _. _ X-_ ____.. r. f _.... ;...... _..., _..... _.... _.... __.. _ ___. ___.... __,. _. ________.. ___. a.-_---___.-__ x x xs 1021 H, C X3 1. 88 495. 325 496.3488 - l ~ - i-#----S ~ # 0 * ~ xp- x 1022 HC CH t. 77 461. 3A06 4G2. 3634 -./ __\ X'-X __. __.. __... _... __ _.. __... _.. _. ___... _ _ _. _. _. _-___ ______ __ / /1 1 O o ? 2 X, 2.03 573.262B 574.2927 1024 H3c X'x'o ° 2. 03 587.2784 588.3088 H - . -- »- * <- X w. ho oh HC Xa X oH 1025'o i. 9G 573. 2628 574. 3035 .. _.... _. _.... _. ; _\_. _. _X ; ,. X ___. _. _.. . _ . _...,. _.. _.. _.,... _... _. _.... _. X_. .. ;. ______... ___. _ _ CH'_-. -_-... __. __.. . _.. __... _. _ _.. _ 1 X, x x CH,. 1026 H c 3 01 C *10 0 xi r3c xrkch, 1027 X, X, 1. 85 544. 2872 545. 3313 O-Cli,axS x FIC X H j"CH 6 o x 1028H, C xp 2. 03 5432886 544. 3122 x X, \ X P H Cg S XX I S I CH 1 029 3, 2. 03 509. 3042 5t0§3t 73 xi X2 cit, 15 o x ;-i xi 1 030 3 2. 12 549. 3355 550. 3542 xi X2 Oil 6 4/ o X 1031H Cg [XX | xi X2 Off XB H c xp x, X 1032 2. 08 535, 3199 536, 3453 x x Oil X5 X 1033 H'C 1. 97 5t5. 2936 516. 3203 1s3 ! tH, C ? [XX S 01 ou xi xi x3 t0343093.'482. 3294- y v ox y - '3 \/ ) p35 2.06 559.2835 660 Hf f*M 1035 Fi'C 2. 06 559. 2835 560. 3t 1 ......,. ....... ... HC . 7 t037 ='-2.17 565.3304 566.35 x X, X, / x X 1036CH, ll3"x S +,"40x 2. 03 525. 299f 526. 3195 xi X, Oil x__o . X 1037 HC 2. 17 565. 3304 566, 35 cr x X2 ) (P x ° l \ X, X, x 1038 . _... _. ___X __ _. ___ _.. __.- __ _. ____. __...... _... ___... _... __ _ _.... _. ot-. ___-X6 _ _-_.. ____ i xi H C X'Xs 1. 93 531. 2886 532. 3281 10b0 1.93 531.2886 532.3281